EGFR exon 19 deletion: trials, approvals and companies

Therapy	Tumour	United States	European Union
afatinib FDA, 2013 first line, metastatic, non-resistant EGFR mutations incl. exon 19 deletion / L858R Current label: first-line metastatic NSCLC with non-resistant EGFR mutations (broader than ex19del/L858R; broadened 2018), so level changed to broad. Original 2013 approval was for exon 19 deletions or exon 21 L858R. Year not checked against an FDA approval announcement (FDA's pre-2023 announcement archive was not reachable). Source EU (EMA), 2013 EGFR TKI-naive, locally advanced or metastatic with activating EGFR mutation(s) Initial MA 25/09/2013 (EGFR TKI-naive, activating EGFR mutations). Source Gilotrif, GiotrifBroader label	NSCLC	Approved 2013To verify	Approved 2013
amivantamab with carboplatin + pemetrexed FDA, 2024 locally advanced or metastatic, EGFR exon 19 deletion or exon 21 L858R, progressed on or after an EGFR TKI FDA approval 19/09/2024. Label requires progression on or after an EGFR TKI (not specifically osimertinib). Source FDA, 2025 locally advanced or metastatic, EGFR exon 19 deletion or exon 21 L858R, progressed on or after an EGFR TKI Subcutaneous amivantamab; FDA approval 17/12/2025; label 1.2. Source EU (EMA), 2024 advanced, after failure of prior therapy including an EGFR TKI II/0011, EC decision 22/08/2024. Source Rybrevant, Rybrevant Faspro	NSCLC	Approved 2024	Approved 2024
amivantamab with lazertinib FDA, 2024 first line, locally advanced or metastatic, EGFR exon 19 deletion or exon 21 L858R FDA approval 19/08/2024 (Rybrevant + Lazcluze); label 1.1. Source FDA, 2025 first line, locally advanced or metastatic, EGFR exon 19 deletion or exon 21 L858R Subcutaneous amivantamab; FDA approval 17/12/2025; label 1.1. Source EU (EMA), 2024 first line, advanced, EGFR exon 19 deletions or exon 21 L858R II/0013: CHMP opinion 14/11/2024, EC decision 19/12/2024. Lazertinib is Lazcluze in the EU (separate MA 20/01/2025, own row). Source Rybrevant, Rybrevant Faspro	NSCLC	Approved 2024	Approved 2024
dacomitinib FDA, 2018 first line, metastatic, EGFR exon 19 deletion or exon 21 L858R Current label: first-line metastatic NSCLC with exon 19 deletion or exon 21 L858R. Year not checked against an FDA approval announcement (FDA's pre-2023 announcement archive was not reachable). Source EU (EMA), 2019 first line, locally advanced or metastatic with activating EGFR mutations Initial MA 02/04/2019. Source Vizimpro	NSCLC	Approved 2018To verify	Approved 2019
datopotamab deruxtecan FDA, 2025 locally advanced or metastatic EGFR-mutated, after EGFR-directed therapy and platinum chemotherapy AA 23/06/2025; still accelerated (FDA Ongoing list, label 1.1). Label says 'EGFR-mutated' (broader than ex19del/L858R). Source EU (EMA) (no EU lung indication) No EU lung indication. A separate MAA (Datopotamab deruxtecan Daiichi Sankyo, non-squamous NSCLC, not EGFR-restricted) was withdrawn by the company on 20/12/2024; EMA's provisional view was that it could not be authorised. Datroway's EU indication is HR+/HER2- breast cancer only (MA 04/04/2025). Source Datopotamab deruxtecan Daiichi Sankyo, DatrowayBroader label	NSCLC	Approved 2025 accelerated	Not approved
erlotinib FDA, 2013 metastatic, EGFR exon 19 deletion or exon 21 L858R, first line Current label (10/2016) covers EGFR ex19del/L858R NSCLC in first-line, maintenance, or second or later line (see own row for the 2016 maintenance/later-line change). Year 2013 for first line not checked against an FDA announcement. Source FDA, 2016 metastatic, EGFR exon 19 deletion or exon 21 L858R, maintenance or second/later line after >=1 chemotherapy Label Recent Major Changes show Indications and Usage 1.1 changed 10/2016, restricting maintenance and later-line use (previously approved for unselected NSCLC) to ex19del/L858R. Date is from the label, not an FDA announcement. Source EU (EMA), 2011 first line, locally advanced or metastatic with EGFR activating mutations Tarceva authorised in the EU 2005 for unselected NSCLC; first-line EGFR-mutation indication added by II/0020, EC decision 24/08/2011. Source EU (EMA), 2016 switch maintenance, locally advanced or metastatic with EGFR activating mutations and stable disease after first-line chemotherapy Maintenance indication first authorised 27/04/2010 for unselected patients (II/0017); restricted to EGFR-activating mutations by II/0043, EC decision 25/01/2016. Source Tarceva	NSCLC	Approved 2013To verify	Approved 2011
gefitinib FDA, 2015 first line, metastatic, EGFR exon 19 deletion or exon 21 L858R Current label: first-line metastatic NSCLC with exon 19 deletions or exon 21 L858R (label 'Initial U.S. Approval: 2015'). Year not checked against an FDA approval announcement (FDA's pre-2023 announcement archive was not reachable). Source EU (EMA), 2009 locally advanced or metastatic with activating EGFR-TK mutations EU label: 'activating mutations of EGFR-TK'; restriction present since initial MA 24/06/2009. Source Iressa	NSCLC	Approved 2015To verify	Approved 2009
lazertinib with amivantamab FDA, 2024 first line, locally advanced or metastatic, EGFR exon 19 deletion or exon 21 L858R FDA approval 19/08/2024. Source EU (EMA), 2025 first line, advanced, EGFR exon 19 deletions or exon 21 L858R MA 20/01/2025 (EMA medicines data). The matching Rybrevant variation had its EC decision on 19/12/2024 (see A026). Source Lazcluze	NSCLC	Approved 2024	Approved 2025
osimertinib FDA, 2018 first line, metastatic, EGFR exon 19 deletion or exon 21 L858R Label 1.3 first-line metastatic ex19del/L858R. First FDA approval 2015 was for T790M (AA 13/11/2015, converted 30/03/2017). Year not checked against an FDA approval announcement (FDA's pre-2023 announcement archive was not reachable). Source FDA, 2020 adjuvant after resection, EGFR exon 19 deletion or exon 21 L858R Label 1.1 adjuvant after tumour resection, ex19del/L858R. Year not checked against an FDA approval announcement (FDA's pre-2023 announcement archive was not reachable). Source FDA, 2024 locally advanced unresectable stage III, no progression after platinum chemoradiation FDA approval 25/09/2024; label 1.2. Source EU (EMA), 2018 first line, locally advanced or metastatic with activating EGFR mutations Tagrisso first EU MA 01/02/2016 (conditional, T790M), switched to full MA 24/04/2017. First-line activating-EGFR indication added by II/0019, EC decision 07/06/2018. Source EU (EMA), 2021 adjuvant after complete resection, stage IB-IIIA, exon 19 deletions or exon 21 L858R II/0039/G, EC decision 21/05/2021. Source EU (EMA), 2024 unresectable locally advanced, no progression after platinum chemoradiation, exon 19 deletions or exon 21 L858R II/0056: CHMP opinion 14/11/2024, EC decision 19/12/2024. Source Tagrisso	NSCLC	Approved 2018To verify	Approved 2018
osimertinib with pemetrexed + platinum chemotherapy FDA, 2024 first line, locally advanced or metastatic, EGFR exon 19 deletion or exon 21 L858R FDA approval 16/02/2024; label 1.4. Source EU (EMA), 2024 first line, advanced, exon 19 deletions or exon 21 L858R II/0053, EC decision 28/06/2024. EU wording: exon 19 deletions or exon 21 L858R. Source Tagrisso	NSCLC	Approved 2024	Approved 2024
ramucirumab with erlotinib FDA, 2020 first line, metastatic, EGFR exon 19 deletion or exon 21 L858R Label 1.2: with erlotinib, first-line metastatic NSCLC with ex19del or L858R. Year not checked against an FDA approval announcement (FDA's pre-2023 announcement archive was not reachable). Source EU (EMA), 2020 first line, metastatic with activating EGFR mutations II/0033, EC decision 23/01/2020. The EPAR web page indication list omits this NSCLC bullet; date and wording taken from the procedural-steps document. Source Cyramza	NSCLC	Approved 2020To verify	Approved 2020
aumolertinib EU (EMA), 2026 first line, advanced, EGFR exon 19 deletions or exon 21 L858R MA 12/02/2026 (CHMP opinion 11/12/2025). EMA medicines data (updated 05/10/2026) show status 'Revoked' dated 25/09/2026, but the EPAR page (last updated 27/02/2026) still says 'Authorised'. Status set to withdrawn based on the newer EMA data; reason not published. Also authorised for T790M (not tracked here). Source Aumseqa	NSCLC	Not approved	Withdrawn approved 2026

A Clinical Trial on the Outcomes of Comprehensive Enhanced Prophylaxis Management (CEPM) in Chinese Patients With EGFR-Mutated Advanced NSCLC Receiving Amivantamab-Based Regimens

Not yet recruiting Phase 4 Shanghai Pulmonary Hospital, Shanghai, China Started 2026 NCT07469488

Enhanced dermatologic managementEnhanced IRR ProphylaxisEnhanced VTE Prophylaxis (Cohort 1 only)

EGFR mutation must be an Ex19del or Ex21 L858R substitution.

NSCLC (Advanced Non-small Cell Lung Cancer), VTE (Venous Thromboembolism), Rash Due to Epidermal Growth Factor Receptor Inhibitors, Infusion Reaction

Osimertinib Combined With Chemotherapy in Patients Who Had Distant Recurrence After Adjuvant Osimertinib for EGFRm Resectable SIB-IIIA NSCLC.

Recruiting Phase 4 AstraZeneca Started 2026 NCT07279935

Osimertinib+cisplatin or carboplatin + pemetrexed Edit FDA EU

EGFR mutation (Exon 19del/Exon 21 L858R)-reconfirmed for study entry (mandatory undergo NGS by plasma, and tissue i…

Non-small Cell Lung Cancer

Firmonertinib Combined With Intrathecal Injection for the Treatment of EGFR Mutant NSCLC With Leptomeningeal Metastases

Recruiting Phase 4 Union Hospital, Tongji Medical College, Huazhong University of Science and Technology Started 2025 NCT07092202

FirmonertinibIntrathecal injection of pemetrexed

…ed by histological or cytological specimens tested in the central laboratory to have EGFR exon 19 deletion mutation (19DEL) or exon 21 L858R point mutation (L858R), which can exist alone or in com…

Leptomeningeal Metastasis, NSCLC, Intrathecal Chemotherapy, Tyrosine Kinase Inhibitor

Osimertinib With or Without Primary Lung Tumor Resection for EGFR-Mutant Oligometastatic Non-Small Cell Lung Cancer

Recruiting Phase 3 National Taiwan University Hospital Started 2026 NCT07738172

Osimertinib FDA EU

EGFR sensitizing mutation limited to exon 19 deletion or exon 21 L858R.

Lung Neoplasms, Non-Small Cell Lung Cancer

Pivotal Study to Evaluate YL202 Versus Docetaxel in Patients With Locally Advanced or Metastatic EGFR Sensitive Mutation Non-Squamous Non-Small Cell Lung Cancer

Recruiting Phase 3 MediLink Therapeutics (Suzhou) Started 2026 NCT07416994

YL202Docetaxel

…vanced or metastatic non-squamous non-small cell lung cancer (NSCLC) with documented EGFR Exon 19 deletion or Exon21 L858R mutation.

Non-Small Cell Lung Cancer

A Phase Ⅲ Clinical Study of SYS6010 in Combination With Osimertinib in Patients With Locally Advanced or Metastatic NSCLC

Not yet recruiting Phase 3 CSPC Started 2026 NCT07376382

SYS6010Osimertinib FDA EUplatinum-pemetrexed

Carry at least one EGFR-sensitive mutation (ex19del or L858R, which can be combined with other EGFR mutations).

NSCLC

ASKC202 Plus Limertinib as the First-line Therapy for Patients With EGFRm+/MET+ Locally Advanced or Metastatic NSCLC

Not yet recruiting Phase 3 Jiangsu Aosaikang Pharmaceutical Started 2026 NCT07897188

ASKC202ASKC202 placeboosimertinib placebo FDA EUosimertinib FDA EUpemetrexedcisplatin or carboplatin

The tumor harbors EGFR sensitizing mutation (Ex19Del or L858R).

EGFR Activating Mutation, Non-Squamous Non-Small Cell Lung Cancer (NSCLC), MET Positive

Study of Izalontamab Brengitecan (BMS-986507) in Combination With Osimertinib Versus Osimertinib Monotherapy or Osimertinib in Combination With Platinum-based Chemotherapy for EGFRmt Non-small Cell Lung Cancer (IZABRIGHT-Lung02)

Recruiting Phase 3 Bristol Myers Squibb Started 2026 NCT07680790

Iza-brenOsimertinib FDA EUPemetrexedCarboplatinCisplatin

Participants must have documented EGFR-TKI-sensitizing mutation (exon 19 deletion or exon 21 L858R substitution)

Non-Small Cell Lung Cancer

Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations

Recruiting Phase 3 AstraZeneca Started 2025 NCT07291037

Datopotamab deruxtecan (Dato-DXd) FDADocetaxel

Participants must have documented negative test results for EGFR (eg, exon 19 deletion or exon 21 L858R, exon 21 L861Q, exon 18 G719X, or exon 20 S768I mutation), ALK, and ROS1…

Non-small Cell Lung Cancer (NSCLC)

A Study to Assess Adverse Events, Change in Disease Activity of Intravenous Telisotuzumab Adizutecan in Combination With Osimertinib as First-Line Treatment in Adult Participants With Locally Advanced Unresectable or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer

Recruiting Phase 2/3 AbbVie Started 2025 NCT07005102

Telisotuzumab AdizutecanOsimertinib (Osi) FDA EUCisplatinCarboplatinPemetrexed

…d metastatic/locally advanced non-squamous NSCLC with documented classical EGFR mutation (Exon 19 Del or Exon 21 L858R) either alone or in combination with other EGFR mutations as detected by…

Non-Squamous Non-Small Cell Lung Cancer, c-MET

A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Telisotuzumab Adizutecan, Monotherapy or in Combination With Osimertinib, Compared to Standard of Care in Adult Participants With Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer

Recruiting Phase 2/3 AbbVie Started 2025 NCT07155187

Telisotuzumab AdizutecanOsimertinib FDA EU

…vanced or metastatic non-squamous non-small cell lung cancer (NSCLC) with documented EGFR Exon 19 deletion or Exon21 L858R mutation.

Non-Small Cell Lung Cancer, c-MET

Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)

Recruiting Phase 2/3 Bristol Myers Squibb Started 2025 NCT07100080

Iza-brenCarboplatinCisplatinPemetrexed

Documented evidence of EGFR mutation (exon 19 deletion, L858R mutation).

Non-Small Cell Lung Cancer

A Study Evaluating Furmonertinib Plus Platinum-based Doublet Chemotherapy Versus Osimertinib in Patients With Epidermal Growth Factor Receptor (EGFR) Sensitizing Mutation-Positive Non-squamous Non-Small Cell Lung Cancer (NSCLC) and Brain Metastases

Recruiting Phase 3 Allist Pharmaceuticals Started 2024 NCT06970639

Furmonertinib Mesilate TabletsCarboplatin InjectionCisplatin for injectionPemetrexed Disodium for InjectionOsimertinib Mesylate Tablets FDA EU

Confirmed EGFR sensitizing mutations (ex19del or L858R) via tumor tissue/cytology/blood testing;

NSCLC Patients With Brain Metastasis

Adjuvant Target Therapy Guided by ctDNA-MRD in Patients With EGFR-mutant II-IIIA Non-small Cell Lung Cancer (ECTOP-1022)

Not yet recruiting Phase 3 Fudan University Started 2024 NCT06323148

Osimertinib FDA EUNo adjuvant therapy

…lar testing (such as ARMS-PCR or high-throughput sequencing), specifically with mutations 19del or 21L858R.

Status may be outdated, last updated 2024-03-21Lung Cancer, EGFR Gene Mutation, Minimal Residual Disease

Furmonertinib 160mg as First-line Treatment in Locally Advanced or Metastatic NSCLC With EGFR Classical Mutations

Recruiting Phase 3 Peking Union Medical College Hospital Started 2024 NCT06674343

Furmonertinib

…ents have been confirmed by local laboratory to have one of the following EGFR mutations: 19Del or L858R (single or compound)

Advanced or Metastatic Non-small Cell Lung Cancer

A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Active, not recruiting Phase 3 AstraZeneca Started 2024 NCT06417814

Dato-DXdOsimertinib FDA EUPemetrexedCarboplatinCisplatin

…pidermal growth factor receptor \[EGFR\] tyrosine kinase inhibitor \[TKis\] sensitivity \[Ex19del, L858R, G719X, S768I, or L861Q\], either alone or in combination with other EGFR mutation…

Metastatic Non-small Cell Lung Cancer

Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell Lung Cancer

Recruiting Phase 3 AstraZeneca Started 2024 NCT06350097

Osimertinib FDA EUDatopotamab Deruxtecan FDA

… least 1 of the 2 common EGFR mutations known to be associated with EGFR-TKI sensitivity (Ex19del or L858R), either alone or in combination with other genomic alterations, which may inclu…

Non-small Cell Lung Cancer

YK-029A as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations

Not yet recruiting Phase 3 Suzhou Puhe Pharmaceutical Technology Started 2023 NCT05767892

YK-209A tabletPemetrexed+carboplatin/Cisplatin

…mutations for which there are approved anti-EGFR tyrosine kinase inhibitors \[TKIs\] (ie, exon 19 del, L858R, T790M, L861Q, G719X, or S768I, where X is any other amino acid).

Status may be outdated, last updated 2023-04-05Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)

Phase III Study of AK112 for NSCLC Patients

Active, not recruiting Phase 3 Summit Therapeutics Started 2023 NCT06396065

AK112 Injection

…tumor histology or cytology or blood test before enrollment (eg, exon 18 point mutations, exon 19 deletions, exon 20 point mutations, and exon 21 point mutations).

Non-Squamous Non-small Cell Lung Cancer

Armatinib Alone or in Combination With SRT for Brain Metastases EGFR-mutated Non-small Cell Lung Cancer

Recruiting Phase 3 Shanghai Cancer Hospital, China Started 2023 NCT05800223

Almonertinib

5. epidermal growth factor receptor (EGFR) exon 19 deletion or exon 21 (L858R) substitution mutation (alone or in combination with other EGFR mutatio…

Status may be outdated, last updated 2023-04-05Non-small Cell Lung Cancer Metastatic

Early or Delayed Intervention of Brain Radiotherapy Combined With Almonertinib in EGFR Mutated NSCLC With Brain Metastases

Recruiting Phase 3 Sun Yat-sen University Started 2023 NCT05768490

Almonertinib

EGFR sensitivity mutation (exon19del or exon21 L858R);

Status may be outdated, last updated 2023-03-14Brain Metastases, Radiotherapy, EGFR Activating Mutation

SH-1028 Tablets Versus Placebo as Adjuvant Therapy in Resected Stage II-IIIB NSCLC With Sensitizing EGFR Mutations

Recruiting Phase 3 Nanjing Sanhome Pharmaceutical Started 2023 NCT06080776

SH-1028 tablets

Patients must harbor one of the two common sensitizing EGFR mutations (Ex19del, L858R), either alone or in combination with other EGFR mutations including T790M, the mu…

Status may be outdated, last updated 2023-10-12Non-small Cell Lung Cancer

Adjuvant Befotertinib in Stage IB-IIIB Non-small Cell Lung Cancer With Positive EGFR Sensitive Mutations

Recruiting Phase 3 Betta Pharmaceuticals Started 2023 NCT06041776

Befotertinib + Icotinib placeboIcotinib + Befotertinib placebo

…bors one of the 2 common EGFR mutations known to be associated with EGFR-TKI sensitivity (Ex19del, L858R).

Status may be outdated, last updated 2023-09-22Non-Small Cell Lung Cancer, EGFR Sensitive Mutation, Adjuvant Therapy

A Global Study to Assess the Effects of Osimertinib in Participants With EGFRm Stage IA2-IA3 NSCLC Following Complete Tumour Resection

Active, not recruiting Phase 3 AstraZeneca Started 2022 NCT05120349

Osimertinib FDA EU

A tumour which harbours one of the 2 EGFR mutations (Ex19del, L858R) by cobas® EGFR Mutation Test v2 (Roche Diagnostics) or FoundationOne® test.

Non-Small Cell Lung Cancer

MDT-bridged Radical Therapy After Aumolertinib With MRD-guided Maintenance in EGFRm+ Unresectable Stage III NSCLC (APPROACH)

Active, not recruiting Phase 3 Guangdong Association of Clinical Trials Started 2022 NCT04841811

Almonertinib

…es effusions, and pericardial effusions are confirmed to be EGFR sensitive mutations (ie, exon 19 deletion or L858R, alone or coexisting, Or with other EGFR mutations, but patients with EGFR20 exo…

Lung Cancer

HERTHENA-Lung02: A Study of Patritumab Deruxtecan Versus Platinum-based Chemotherapy in Metastatic or Locally Advanced EGFRm NSCLC After Failure of EGFR TKI Therapy

Active, not recruiting Phase 3 Daiichi Sankyo Started 2022 NCT05338970

Patritumab DeruxtecanPlatinum-based chemotherapy

… documentation of an EGFR-activating mutation detected from tumor tissue or blood sample: exon 19 deletion or L858R at diagnosis or thereafter.

Nonsquamous Non-small Cell Lung Cancer, EGFR L858R, EGFR Exon 19 Deletion

Savolitinib Plus Osimertinib Versus Platinum-based Doublet Chemotherapy in Participants With Non-Small Cell Lung Cancer Who Have Progressed on Osimertinib Treatment

Active, not recruiting Phase 3 AstraZeneca Started 2022 NCT05261399

SavolitinibOsimertinib FDA EUPemetrexedCisplatinCarboplatin

Must have at least one documented sensitising EGFR mutation: exon19 deletion, L858R mutation, and/or T790M.

Carcinoma, Non-Small-Cell Lung

A Study of Lazertinib With Subcutaneous Amivantamab Compared With Intravenous Amivantamab in Participants With Epidermal Growth Factor Receptor (EGFR)-Mutated Advanced or Metastatic Non-small Cell Lung Cancer

Active, not recruiting Phase 3 Johnson & Johnson Started 2022 NCT05388669

Lazertinib FDA EUAmivantamab Subcutaneous and Co-Formulated with Recombinant Human Hyaluronidase (SC CF) FDA EUAmivantamab Intravenous FDA EU

…cell lung cancer (NSCLC), characterized by either epidermal growth factor receptor (EGFR) Exon 19 deletion (Exon 19del) or Exon 21 leucine 858 to arginine substitution (Exon 21 L858R) mutation by …

Advanced or Metastatic Non-small Cell Lung Cancer

A Study to Evaluate Chemotherapy Plus Osimertinib Against Chemotherapy Plus Placebo in Patients With Non-small Cell Lung Cancer (NSCLC)

Active, not recruiting Phase 3 AstraZeneca Started 2021 NCT04765059

Osimertinib (AZD9291) pemetrexed cisplatin or carboplatin FDA EU

…) mutations known to be associated with EGFR tyrosine kinase inhibitor (TKI) sensitivity (Ex19del or L858R), either alone or in combination with other EGFR mutations, which may include T7…

Non-small Cell Lung Cancer

A Study of Amivantamab and Lazertinib in Combination With Platinum-Based Chemotherapy Compared With Platinum-Based Chemotherapy in Patients With Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non- Small Cell Lung Cancer After Osimertinib Failure

Active, not recruiting Phase 3 Johnson & Johnson Started 2021 NCT04988295

Lazertinib FDA EUAmivantamab FDA EUPemetrexedCarboplatin

…dvanced or metastatic disease diagnosis by either epidermal growth factor receptor (EGFR) Exon 19del or Exon 21 L858R mutation

Carcinoma, Non-Small-Cell Lung

Aumolertinib with or Without Chemotherapy As 1st Line Treatment in Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Sensitizing EGFR Mutations

Active, not recruiting Phase 3 Hansoh Pharma Started 2021 NCT04923906

Aumolertinib

…arbors 1 of the 2 common EGFR mutations known to be associated with EGFR-TKI sensitivity (Ex19del, L858R), either alone or in combination with other EGFR mutations assessed by central tes…

Non-small Cell Lung Cancer

To Assess the Efficacy and Safety of Furmonertinib Versus Placebo, in Patients With Epidermal Growth Factor Receptor Mutation Positive Stage II-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy

Recruiting Phase 3 Allist Pharmaceuticals Started 2021 NCT04853342

Drug: Furmonertinib 80 mgFurmonertinib 80 mg placebo

…bors one of the 2 common EGFR mutations known to be associated with EGFR-TKI sensitivity (Ex19del, L858R), either alone or in combination with other EGFR mutations including T790M.

Non-small Cell Lung Carcinoma

Osimertinib Monotherapy or Combination With Chemotherapy for Advanced NSCLC Concurrent EGFR and TP53 Mutations

Active, not recruiting Phase 3 Li Zhang, MD Started 2021 NCT04695925

Osimertinib FDA EUPemetrexedCarboplatin

…V or recurrent non-squamous non-small cell lung carcinoma with activating EGFR mutations (exon 19 deletion or exon 21 L858R point mutation) and concurrent TP53 mutations;

Non-small Cell Carcinoma, EGFR Gene Mutation

Clinical Study on Savolitinib + Osimertinib in Treatment of EGFRm+/MET+ Locally Advanced or Metastatic NSCLC

Active, not recruiting Phase 3 HUTCHMED Started 2021 NCT05009836

SavolitinibOsimertinib FDA EU

…arrying two common EGFR mutations clearly related with the sensitivity to EGFR-TKI (i.e., exon 19 deletion, and L858R) and c-MET overexpression

Non-small Cell Lung Cancer

Almonertinib Versus Placebo as Adjuvant Therapy in Resected Stage II-IIIB Non-Small Cell Lung Cancer With EGFR-sensitive Mutations

Active, not recruiting Phase 3 Hansoh Pharma Started 2021 NCT04687241

Almonertinib

…bors one of the 2 common EGFR mutations known to be associated with EGFR-TKI sensitivity (Ex19del, L858R), either alone or in combination with other EGFR mutations including T790M.

Non-small Cell Lung Cancer

A Phase III Study to Assess the Effects of Almonertinib Following Chemoradiation in Patients With Stage III Unresectable Non-small Cell Lung Cancer

Recruiting Phase 3 Hansoh Pharma Started 2021 NCT04951635

Almonertinib

…rs one of the two common EGFR mutations known to be associated with EGFR-TKI sensitivity (Ex19Del, L858R), either alone or in combination with other EGFR mutations including T790M, assess…

Status may be outdated, last updated 2022-06-16Non-small Cell Lung Cancer

Efficacy and Safety of Almonertinib Combined With or Without Chemotherapy as an Adjuvant Treatment for Stage II-IIIA Non-small Cell Lung Carcinoma Following Complete Tumour Resection

Enrolling by invitation Phase 3 Chinese Academy of Medical Sciences Started 2021 NCT04762459

AlmonertinibPemetrexedCisplatin

…ours one of the 2 common EGFR mutations known to be associated with EGFR-TKI sensitivity (Ex19del, L858R), either alone or in combination with other EGFR mutations including T790M.

Status may be outdated, last updated 2022-02-24Non-small Cell Lung Carcinoma

A Study of Osimertinib With or Without Chemotherapy Versus Chemotherapy Alone as Neoadjuvant Therapy for Patients With EGFRm Positive Resectable Non-Small Cell Lung Cancer

Active, not recruiting Phase 3 AstraZeneca Started 2020 NCT04351555

Osimertinib FDA EUCisplatinCarboplatinPemetrexed

…ours one of the 2 common EGFR mutations known to be associated with EGFR-TKI sensitivity (Ex19del, L858R), either alone or in combination with other EGFR mutations (eg., T790M, G719X, Exo…

Non-Small Cell Lung Cancer

Alflutinib Mesylate Versus Gefitinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer （FLAG）

Active, not recruiting Phase 3 Allist Pharmaceuticals Started 2019 NCT03787992

Alflutinib Mesylate (AST2818) 80mg//40 mg+ placeboGefitinib 250 mg FDA EU

…ours one of the 2 common EGFR mutations known to be associated with EGFR-TKI sensitivity (Ex19del, L858R).

Locally Advanced or Metastatic EGFR Sensitising Mutation Positive Non-small Cell Lung Cancer

A Study of Osimertinib With or Without Chemotherapy as 1st Line Treatment in Patients With Mutated Epidermal Growth Factor Receptor Non-Small Cell Lung Cancer (FLAURA2)

Active, not recruiting Phase 3 AstraZeneca Started 2019 NCT04035486

Osimertinib FDA EUPemetrexed/CarboplatinPemetrexed/Cisplatin

… with Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKI) sensitivity (Ex19del or L858R), either alone or in combination with other epidermal growth factor receptor (EG…

Non-Small Cell Lung Cancer

A Global Study to Assess the Effects of Osimertinib Following Chemoradiation in Patients With Stage III Unresectable Non-small Cell Lung Cancer (LAURA)

Active, not recruiting Phase 3 AstraZeneca Started 2018 NCT03521154

Osimertinib 80mg/40mg FDA EU

…rs one of the two common EGFR mutations known to be associated with EGFR-TKI sensitivity (Ex19del, L858R), either alone or in combination with other EGFR mutations, assessed by cobas® EGF…

Non Small Cell Lung Cancer (Stage III)

A Study of Ramucirumab (LY3009806) in Combination With Erlotinib in Previously Untreated Participants With EGFR Mutation-Positive Metastatic NSCLC (RELAY)

Active, not recruiting Phase 3 Eli Lilly Started 2015 NCT02411448

Ramucirumab FDA EUErlotinib FDA EUGefitinib FDA EUOsimertinib FDA EU

…h erlotinib based on documented evidence of tumor harboring an activating EGFR mutation \[exon 19 deletion or exon 21 (L858R) substitution mutation\].

Metastatic Non-Small Cell Lung Cancer

Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial)

Active, not recruiting Phase 3 National Cancer Institute (NCI) Started 2015 NCT02193282

Erlotinib Hydrochloride FDA EU

Previously registered to A151216, with the result of lung cancer harboring an EGFR exon 19 deletion or L858R mutation

Lung Non-Squamous Non-Small Cell Carcinoma, Stage IB Lung Non-Small Cell Carcinoma AJCC v7, Stage II Lung Non-Small Cell Cancer AJCC v7, Stage IIA Lung Non-Small Cell Carcinoma AJCC v7

AZD9291 Versus Placebo in Patients With Stage IB-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy.

Active, not recruiting Phase 3 AstraZeneca Started 2015 NCT02511106

AZD9291 80 mg/40 mgOpen-label AZD9291 80 mg/40 mg

…ours one of the 2 common EGFR mutations known to be associated with EGFR-TKI sensitivity (Ex19del, L858R), either alone or in combination with other EGFR mutations including T790M.

Stage IB-IIIA Non-small Cell Lung Carcinoma

Consolidative Stereotactic Radiotherapy for Oligo-Residual Advanced EGFR-Mutant NSCLC After First-Line Third-Generation EGFR-TKI Plus Chemotherapy

Not yet recruiting Phase 2 Fudan University Started 2026 NCT07822984

Third-generation EGFR tyrosine kinase inhibitorPlatinum plus pemetrexed chemotherapyPemetrexed maintenance therapy

Sensitizing EGFR mutation: EGFR exon 19 deletion or EGFR L858R.

EGFR-mutant Non-small Cell Lung Cancer, SBRT, NSCLC (Advanced Non-small Cell Lung Cancer)

A Phase II Study of Sacituzumab Tirumotecan in Combination With Furmonertinib in Patients With Non-squamous Non-Small Cell Lung Cancer Who Have Progressed After EGFR-TKI and Platinum-Based Chemotherapy

Recruiting Phase 2 Tianjin Medical University Cancer Institute and Hospital Started 2026 NCT07548060

sacituzumab tirumotecan

…er (AJCC)\], with tissue or blood-based genetic testing showing EGFR-sensitive mutations (19del and L858R).

NSCLC Stage IV, EGFR Gene Mutation

Vebreltinib Plus Furmonertinib in Patients With EGFR-mutated Advanced Non-small Cell Lung Cancer and High PD-L1 Expression

Recruiting Phase 1/2 Second Affiliated Hospital of Nanchang University Started 2026 NCT07655622

VebreltinibFurmonertinib 80mg

…ed/metastatic disease Histologically or cytologically confirmed EGFR-sensitive mutations (exon 19 deletion or exon 21 L858R point mutation)

Non-Small-Cell Lung Cancer

Local Ablative Therapy to Oligoresidual Metastasis in EGFR Mutated Non-small Cell Lung Cancer

Recruiting Phase 2 Chinese University of Hong Kong Started 2026 NCT07379476

Osimertinib alone FDA EU

Positive for EGFR exon 19 deletion or EGFR exon 21 L858R mutation (either by tissue or plasma testing)

Lung Cancer (NSCLC)

Ivonescimab Alone And With Carboplatin/Pemetrexed For NSCLC

Recruiting Phase 2 Massachusetts General Hospital Started 2026 NCT07405190

Ivonescimabcarboplatinpemetrexed

…vonescimab monotherapy: Tumor harboring classical EGFR sensitizing mutation (i.e., L858R, exon 19 deletion), or ALK, ROS1, RET, or NTRK1-3 fusion, per local testing.

Lung Cancer (NSCLC), Lung Cancer Non-Small Cell Cancer (NSCLC), Lung Cancer (Non-Small Cell), Lung Cancer - Non Small Cell

Osimertinib Induction and Maintenance for Chemo-ineligible Stage III Unresectable EGFR+ NSCLC: Single-arm Study

Recruiting Phase 2 AstraZeneca Started 2026 NCT07295821

Osimertinib FDA EU

…arbors 1 of the 2 common EGFR mutations known to be associated with EGFR-TKI sensitivity (Ex19del, L858R), either alone or in combination with other EGFR mutations including de novo T790M

Lung Cancer

EGFR-TKIs Plus PD-1 in EGFR-Mutant Advanced NSCLC

Recruiting Phase 2 Nanfang Hospital, Southern Medical University Started 2026 NCT07637448

EGFR-TKIs Combined with PD-1 Monoclonal Antibody

…atients with histologically or cytologically confirmed, previously untreated EGFR-mutant (19del/L858R) locally advanced or metastatic (stage IIIB/IIIC or IV) non-small cell lung cancer …

Lung Cancer Non-Small Cell Cancer (NSCLC), EGFR Activating Mutation, PD-1 Antibody

Limertinib Plus Radiotherapy for EGFR-Mutant NSCLC With Brain Metastases

Not yet recruiting Phase 2 The First Affiliated Hospital of Guangzhou Medical University Started 2026 NCT07413952

Limertinib Plus Radiotherapy

… or third-party testing institutions confirming the presence of EGFR classical mutations (19Del \& 21L858R).

NSCLC

PHOENIX: QL1706 Plus Chemotherapy and Bevacizumab in AGA-Resistant, PD-L1 ≥50% Non-Squamous NSCLC

Recruiting Phase 2 Guangdong Association of Clinical Trials Started 2026 NCT07416058

QL1706 (bispecific antibody targeting PD-1 and CLTA-4)

these mutations are stratified as follows: EGFR (19del, L858R)

Lung Adenocarcinoma

Firmonertinib 160 mg in Patients With EGFR-Mutant Advanced NSCLC Demonstrating SD After 8 Week Induction With Firmonertinib 80 mg

Not yet recruiting Phase 2 Peking University Cancer Hospital & Institute Started 2026 NCT07298148

Firmonertinib 160mg

Documented EGFR 19del or L858R mutation.

NSCLC Stage IV, EGFR Positive Non-small Cell Lung Cancer, EGFR-TKI Sensitizing Mutation

Telisotuzumab Vedotin and Osimertinib for the Treatment of Progressive, Incurable, Non Small Cell Lung Cancer

Recruiting Phase 2 Jonsson Comprehensive Cancer Center Started 2026 NCT07323641

Osimertinib FDA EUTelisotuzumab Vedotin

Enrollment of patients with mutations other than exon 19 deletion and the L858R point mutation require literature supporting sensitivity to osimertinib.

Lung Non-Small Cell Carcinoma

Limertinib Plus Carboplatin and Etoposide for EGFR-mutant NSCLC With SCLC Transformation After EGFR-TKI Progression

Not yet recruiting Phase 2 Hunan Province Tumor Hospital Started 2026 NCT07001995

limertinibetoposide and carboplatin

…ologically confirmed non-small cell lung cancer (NSCLC) with a sensitizing EGFR mutation (exon 19 deletion or L858R, with or without concurrent mutations).

Small Cell Lung Cancer, Non Small Cell Lung Cancer, Non Small Cell Lung Cancer NSCLC

Study of IBI3005 Combination Therapy in Participants With Unresectable, Locally Advanced or Metastatic Solid Tumors

Not yet recruiting Phase 1/2 Innovent Biologics Started 2026 NCT07612137

IBI3005SintilimabBevacizumab biosimilarLimertinibOsimertinib FDA EUCarboplatin

Tumor harboring EGFR-sensitive mutations (Ex19del or L858R, with or without other EGFR mutations) confirmed via histology or cytology speci…

Solid Tumor

Firmonertinib in Perioperative Treatment of Resectable Stage II-IIIB EGFR-mutated Lung Adenocarcinoma

Recruiting Phase 2 Peking University Cancer Hospital & Institute Started 2026 NCT07622706

Firmonertinib 80mg qd oral for 8 weeks.Firmonertinib 160mg qd oral for 8 weeks.Firmonertinib 80mg qd oral for 16 weeks.firmonertinib adjuvant therapy

5.EGFR mutation-positive (19Del and/or L858R, with or without T790M) as determined by NGS testing of tumor tissue or bloo…

NSCLC, EGFR Positive Non-small Cell Lung Cancer, Neoadjuvant Therapy

Zorifertinib Plus Intra-Ommaya CSF Chemotherapy for Leptomeningeal Progression in NSCLC After Third-Generation EGFR-TKI

Not yet recruiting Phase 2 Cancer Institute and Hospital, Chinese Academy of Medical Sciences Started 2026 NCT07551414

Zorifertinib Plus Intra-Ommaya CSF Chemotherapy

…all cell lung cancer (NSCLC) and test positive for EGFR-sensitive mutations (L858R and/or Exon 19Del).

NSCLC (Non-small Cell Lung Carcinoma), Leptomeningeal Metastasis, EGFR-TKI Sensitizing Mutation, Zorifertinib

Comparative ¹⁸F-FDG and ⁶⁸Ga-MY6349 PET/CT Imaging for Assessing TROP2 ADC Therapeutic Efficacy in EGFR-TKI Resistant Advanced NSCLC

Not yet recruiting Phase 2 Zhou Chengzhi Started 2026 NCT07685197

Presence of EGFR sensitizing mutations (exon 19 deletion or exon 21 L858R point mutation).

NSCLC, EGFR Activating Mutation, EGFR-TKI-resistant Non-Small Cell Lung Cancer, Trop2

JS212 Plus JS111 in EGFR-Mutant Advanced NSCLC: A Phase II Study

Recruiting Phase 2 Shanghai Junshi Bioscience Started 2026 NCT07518160

JS212 for Injection＋JS111 capsules (AP-L1898)

Exon 19 deletion or L858R mutation,Either alone or in combination with other EGFR mutations, Including tho…

Locally Advanced, Metastatic, or Recurrent Non-small Cell Lung Cancer (NSCLC) Harboring Epidermal Growth Factor Receptor (EGFR) Mutations

A Randomized Study to Evaluate the Efficacy of a Reduced Starting Dose of Lazertinib (Leclaza) and Preemtive Magnesium Supplementation to Prevent Lazertinib(Leclaza)-Induced Peripheral Neuropathy

Recruiting Phase 2 Samsung Medical Center Started 2026 NCT07774520

Supplementation of magnesium lactateDose reduction of lezertinib

Patient with a confirmed EGFR mutation of Exon 19 deletion or L858R.

Non-small Cell Lung Cancer(NSCLC), EGFR Mutant

Furmonertinib Plus Radiotherapy for EGFR+ NSCLC With Pleural Effusion

Not yet recruiting Phase 2 Jiangmen Central Hospital Started 2026 NCT07482605

Furmonertinib

Positive for EGFR-sensitive mutations (exon 19 deletion or exon 21 L858R).

Lung Cancer (NSCLC), Malignant Pleural Effusions (Mpe)- Pleurodesis

ctDNA Monitoring Guides the Treatment of NSCLC With Befotertinib Combined With Radiotherapy

Not yet recruiting Phase 2 Hebei Medical University Fourth Hospital Started 2026 NCT07410611

Befotertinib

Presence of an EGFR sensitizing mutation (19Del or 21L858R);

Patients With Advanced Oligometastatic Non-small Cell Lung Cancer (NSCLC) Who Have Tested Positive for EGFR Mutations Confirmed by Histopathological Examination

Befotertinib Plus Chemotherapy With an MRD-guided Adaptive Strategy for Treatment Escalation and Response Optimization in EGFR-mutated NSCLC Patients

Not yet recruiting Phase 2 Guangzhou University of Traditional Chinese Medicine Started 2026 NCT07709585

BefotinibPemetrexed + Cisplatin /Carboplatin

Confirmed EGFR exon 19 deletion or exon 21 (L858R) substitution mutation by central laboratory or site-validated testing …

Advanced Non-small Cell Lung Cancer (NSCLC), EGFR Exon 19 Deletion Mutation, EGFR Exon 21 Mutation, EGFR Exon 21 L858R Mutation

Osimertinib and Cyclosporine A to Enhance Antitumor Efficacy in NSCLC

Recruiting Phase 2 NYU Langone Health Started 2026 NCT07874490

Osimertinib FDA EUCyclosporine A (CsA)

Somatic activating mutation in EGFR exon 19 deletion or EGFR L858R in pre-treatment tumor biopsy or cytology from pleural fluid or cfDNA as de…

Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor

Collaborative Clinical-translational Cohort of Amivantamab Plus Lazertinib and Amivantamab Plus Chemotherapy in Patients With EGFR-mutant, Locally Advanced or Metastatic/Recurrent Non-Small Cell Lung Cancer (INSTAR Study)

Not yet recruiting Phase 2 Yonsei University Started 2026 NCT07507188

Amivantamab SC + Lazertinib PO FDA EUAmivantamab SC + Chemotherapy (Carboplatin IV & Pemetrexed IV) FDA EU

Documented activating EGFR mutation (Exon 19 deletion or L858R)

Non Small Cell Lung Cancer

Osimertinib Plus Capivasertib in NSCLC With PIK3CA/AKT1/PTEN Alterations Following Prior 1L Osimertinib

Not yet recruiting Phase 1/2 Shanxi Province Cancer Hospital Started 2026 NCT07486648

Capivasertib in combination with Osimertinib FDA EU

Documented EGFR sensitive mutations (exon19 deletion, L858R mutation) prior to the first-line EGFR-TKI therapy.

Lung Cancer (NSCLC), Lung Cancer (Non-Small Cell), Advanced Non-small-cell Lung Cancer

Neoadjuvant Chemotherapy Sequentially Combined with Sintilimab in Resectable EGFR-Mutant NSCLC

Not yet recruiting Phase 2 Shanghai Chest Hospital Started 2025 NCT06688656

Pemetrexed 500 mg/m2carboplatinSintilimab

…ically, cytologically, or hematologically confirmed presence of EGFR-sensitive mutations (Ex19del, L858R), with co-existing driver mutations allowed;

Lung Cancer

A Study of Osimertinib-based Adaptive Treatment Guided by ctDNA EGFRm+ Monitoring in NSCLC

Recruiting Phase 2 Shanghai Chest Hospital Started 2025 NCT07058519

Osimertinib-based adaptive treatment FDA EUOsimertinib 80 MG FDA EU

…dvanced or metastatic non-squamous NSCLC with sensitizing EGFR mutations positive (either Exon 19 deletion or 21 L858R, confirmed by histology or cytology), and classified as stage IIIB, IIIC, IV …

Locally Advanced or Metastatic EGFRm Non-small Cell Lung Cancer (NSCLC)

High-Dose Firmonertinib Combined With Bevacizumab and Intrathecal Pemetrexed in the Treatment of EGFR-Mutated Non-Small Cell Lung Cancer With Leptomeningeal Metastasis

Not yet recruiting Phase 2 Qiming Wang Started 2025 NCT06971406

Combination therapy prospective cohort

EGFR mutations confirmed by genetic testing (EGFR Ex19del/L858R/Ex20ins/PACC/L861Q).

Non Small Cell Lung Cancer, EGFR Mutation, Leptomeningeal Metastases, Targeted Therapy

A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors

Recruiting Phase 1/2 BioNTech Started 2025 NCT07070232

BNT326PumitamigItraconazoleParoxetine

…est results for an EGFR-sensitizing mutation (EGFR-sensitizing mutation Exon 21-L858R and 19del).

Advanced Solid Tumor

Phase Ib/II Study of Vebreltinib With Furmonertinib in NSCLC Patients With c-Met Amplification After EGFR-TKI Failure

Recruiting Phase 1/2 Peking University Cancer Hospital & Institute Started 2025 NCT07087223

Vebreltinib combined with FurmonertinibVebreltinib combined with FurmonertinibVebreltinib combined with Furmonertinib

Documented EGFR sensitive mutations (exon 19 deletion or exon 21 L858R mutation).

Non Small Cell Lung Cancer NSCLC

A Clinical Study on the Efficacy and Safety of the Combination of Limertinib and Bevacizumab Versus Limertinib as First-line Treatment for NSCLC.

Not yet recruiting Phase 2 Shanghai Chest Hospital Started 2025 NCT06982924

Limertinib+bevacizumabLimertinib

Confirmed EGFR - sensitive mutations (Ex19del, L858R) in tumor histology or cytology or in hematology.

EGFR Mutation Positive Advanced Non Small Cell Lung Cancer, PD-L1 Positive

ORIENT-31 Regimen in Combination With SBRT for EGFR-mutant Metastatic NSCLC After First-line Third-generation EGFR-TKIs

Recruiting Phase 2 Fudan University Started 2025 NCT06775743

ORIENT-31 regimen

EGFR-sensitive mutations (L858R, 19del);

NSCLC (Advanced Non-small Cell Lung Cancer), EGFR Mutation Positive Advanced Non Small Cell Lung Cancer

Bolstering Outcomes After Induction With Osimertinib Plus Chemotherapy Through Optimized Site-Directed Primary Tumor Therapy (BOOST Trial)

Recruiting Phase 2 Pusan National University Hospital Started 2025 NCT07073365

Presence of activating EGFR mutation (exon 19 deletion or L858R).

Non-Small Cell Lung Cancer, Epidermal Growth Factor Receptor

A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors

Recruiting Phase 1/2 Bristol Myers Squibb Started 2025 NCT06618287

BMS-986507Osimertinib FDA EUPembrolizumabNivolumabPumitamig

…ants must have pathologically confirmed locally advanced or metastatic NSCLC with an EGFR exon 19 deletion or L858R mutation in exon 21, either alone or in combination with other EGFR mutations, w…

Lung Cancer, Breast Cancer

JS111 in Patients With Advanced NSCLC Harboring EGFR Mutations

Active, not recruiting Phase 1/2 Suzhou Junjing BioSciences Started 2025 NCT06940401

JS111 capsules (AP-L1898)

Confirmed presence of EGFR-sensitizing mutations (exon 19 deletion or L858R mutation), either alone or co-occurring with other EGFR mutations (including T79…

NSCLC

Firmonertinib Combined With Chemotherapy as Neoadjuvant Therapy for Resectable Stage Ⅱ-ⅢB EGFR Sensitive Mutanted NSCLC

Not yet recruiting Phase 2 Tianjin Medical University Cancer Institute and Hospital Started 2025 NCT06890182

Firmonertinib combined with Carboplatin/Cisplatin and Pemetrexed

EGFR mutation positive (exon 19 deletions or exon 21 L858R, with or without other EGFR mutations)

Non-small Cell Lung Cancer

Sequential Chemotherapy With Befotertinib in Non-Small Cell Lung Cancer (NSCLC) Patients With Resistance to Third-Generation EGFR-TKI

Recruiting Phase 2 Betta Pharmaceuticals Started 2025 NCT07181499

BefotertinibPemetrexed + Carboplatin

…FR TKIs, with EGFR-sensitive mutations confirmed via tissue or blood samples (defined as: 19 Del or 21 L858R);

NSCLC, Adjuvant Drug Therapy, EGFR

Postoperative EGFR-TKI Therapy forContralateral Pulmonary Nodules in Patients With EGFR-Mutant NSCLC（ARMOR2501）

Recruiting Phase 2 Sun Yat-sen University Started 2025 NCT06924398

Postoperative EGFR-TKI Therapy

…ide of the lung, with pathology confirming adenocarcinoma and an EGFR-sensitive mutation (exon 19 deletion or exon 21 L858R point mutation).

Lung Cancer (NSCLC)

Furmonertinib Combined With Intrathecal Chemotherapy and Stereotactic Radiotherapy (SRT) for EGFR-Mutated NSCLC Patients With Brain Parenchymal and Leptomeningeal Metastases

Recruiting Phase 2 Tianjin Medical University Cancer Institute and Hospital Started 2025 NCT07304739

FurmonertinibIntrathecal chemotherapy

… patient was confirmed by a local laboratory to have one of the following EGFR mutations :19Del or L858R;

Non Small Cell Lung Cancer

Sacituzumab Tirumotecan in Combination With Furmonertinib as Second-line Treatment for EGFR-mutant Advanced or Metastatic NSCLC After Failure of First-line Third-generation EGFR-TKI Therapy

Not yet recruiting Phase 2 Fudan University Started 2025 NCT07193160

Sacituzumab TirumotecanFurmonertinib

…ious EGFR mutation test results (known presence of EGFR mutations sensitive to EGFR-TKI \[Ex19del, L858R\], which may exist alone or concurrently with other EGFR mutations, possibly inclu…

NSCLC (Non-small Cell Lung Cancer)

Real-world Experience With Combination Chemotherapy and Osimertinib in Poor Prognostic Group of Metastatic EGFR-mutated Lung Adenocarcinoma

Not yet recruiting Phase 2 The University of Hong Kong Started 2025 NCT06918782

Osimertinib plus platinum doublet chemotherapy FDA EU

Confirmed EGFR common sensitizing mutations (exon 21 L858R or exon 19 del) by locally approved molecular testing methods (allele-specific PCR or NGS) based on tumo…

Lung Cancer (NSCLC)

Intrathecal Pemetrexed for Leptomeningeal Metastasis From Lung Adenocarcinoma That Progressed After Osimertinib.

Recruiting Phase 2 Guangzhou Medical University Started 2025 NCT06296745

Pemetrexed

…ytologically confirmed diagnosis of NSCLC with single activating EGFR mutations (L858R or Exon19Del).

Leptomeningeal Metastasis

A Phase Ⅱ Study of RC108 in Combination With Furmonertinib for the First-line Treatment of EGFR-Mutated Combined MET-Positive Unresectable Locally Advanced or Recurrent Metastatic NSCLC

Recruiting Phase 2 RemeGen Started 2025 NCT06962865

RC108Furmonertinib Mesilate Tablets Monotherapy

Carring 1 of 2 common EGFR mutations clearly associated with EGFR-TKI sensitivity (i.e., exon 19 deletion or L858R) and MET positivity;

Non-Small Cell Lung Cancer

Study of Oral EGFR Inhibitor DZD6008 Combined With Sunvozertinib in Patients Who Have Advanced NSCLC With EGFR Mutations (TIAN-SHAN8)

Recruiting Phase 1/2 Dizal Pharmaceuticals Started 2025 NCT07079475

DZD6008SunvozertinibOsimertinib FDA EU

Part B: EGFR sensitizing mutations (Exon19del and/or L858R) with or without T790M/C797S resistance mutations.

Non-Small Cell Lung Cancer

Clinical Trial for Safety and Effectiveness Evaluation of Tarlatamab (AMG757) With Etoposide, Carboplatin and Atezolizumab in Transformed Small Cell Lung Cancer Patients From Adenocarcinoma After EGFR TKI Treatment

Recruiting Phase 2 Sehhoon Park Started 2025 NCT06830694

Atezolizumab, Etoposide, Carboplatin, Tarlatamab

Patient initially diagnosed with activating EGFR mutation (L858R, Del 19) and treated with any kind of EGFR TKI.

Small Cell Carcinoma of Lung

Study of MCLA-129 in the Treatment of Advanced Non-small Cell Lung Cancer with AGA and MET Amplification.

Not yet recruiting Phase 2 Betta Pharmaceuticals Started 2025 NCT06885840

MCLA-129

…Cohort 2: Patients with advanced NSCLC with previously detected EGFR-sensitive mutations (exon 19 deletion or exon 21 L858R mutation) who have progressed after prior standard treatment which inclu…

Non-Small Cell Lung Cancer

Sacituzumab Tirumotecan (Sac-TMT) Plus Bevacizumab in 3rd Generation EGFR-TKI Treated Advanced EGFR-mutant Nonsquamous NSCLC With Brain Metastasis

Not yet recruiting Phase 2 Li-kun Chen Started 2025 NCT07197008

Sacituzumab tirumotecan (Sac-TMT) plus bevacizumab

Histologically or cytologically confirmed nonsquamous NSCLC with EGFR-sensitive mutation (exon 19 deletion or exon 21 L858R mutation).

Lung Cancer

A Clinical Trial to Test if an Investigational Combination Therapy With BNT326 and BNT327 is Safe and Potentially Beneficial for People With Advanced Non-small Cell Lung Cancer (NSCLC)

Recruiting Phase 1/2 BioNTech Started 2025 NCT07111520

BNT326Pumitamig

…est results for an EGFR-sensitizing mutation (EGFR-sensitizing mutation Exon 21-L858R and 19del).

Non-small Cell Lung Cancer

A ctDNA-guided Phase II Trial of Osimertinib in Combination With Sacituzumab Tirumotecan in EGFR-mutated Advanced NSCLC Patients With Positive ctDNA After lead-in Osimertinib Monotherapy

Recruiting Phase 2 Guangdong Association of Clinical Trials Started 2025 NCT07375316

Osimertinib + Sacituzumab Tirumotecan FDA EUOsimertinib FDA EU

Presence of sensitizing EGFR mutation (exon 19 deletion and/or L858R);

Non Small Cell Lung Cancer

A Study of IBI363 Combination Therapy in Participants With Advanced Solid Tumors

Not yet recruiting Phase 2 Innovent Biologics Started 2025 NCT07124793

IBI363+IBI305

Documented EGFR mutation (ex19del or L858R) detected in tumor tissue or blood samples;

EGFR Mutant NSCLC and Platinum Resistant Ovarian Cancer

Aumolertinib Versus Osimertinib As First-line Therapy for Patients with EGFR Mutated Locally Advanced or Metastatic Non-small-cell Lung Cancer

Not yet recruiting Phase 2 Peking Union Medical College Hospital Started 2024 NCT06752408

AumolertinibOsimertinib FDA EU

… effusion, ascites, cerebrospinal fluid) with at least one sensitizing mutation (L858R or 19Del).

Non Small Cell Lung Cancer

Bronchoscopic Cryoablation Combined With Chemo-Immunotherapy in NSCLC With Central Airway Obstruction

Not yet recruiting Phase 2 Hunan Province Tumor Hospital Started 2024 NCT06604351

Sintilimab, Nab-Paclitaxel, and Carboplatin

…all cell lung cancer (NSCLC) without prior systemic therapy and EGFR-sensitive mutations (19del, L858R and T790M).

Status may be outdated, last updated 2024-09-19Non-Small Cell Lung Cancer

Neoadjuvant Almonertinib Followed by Chemo-immunotherapy in II-IIIB EGFR-mutant NSCLC

Active, not recruiting Phase 2 Guangdong Provincial People's Hospital Started 2024 NCT06300424

almonertinibCarboplatinNab paclitaxel

6. harboring EGFR mutation: Ex19del, L858R, T790M, G719X, Exon20 insertions, S768I or L861Q

Non Small Cell Lung Cancer, EGFR Gene Mutation

Vebreltinib Plus PLB1004 as the First-line Therapy for Patients With EGFRm+/MET+ Locally Advanced or Metastatic NSCLC.

Recruiting Phase 2 Avistone Biotechnology Started 2024 NCT06574347

VebreltinibOsimertinib FDA EUPLB1004

Patients with previously untreated, EGFRm-positive (exon 19 deletion or L858R) and MET overexpression (IHC 3+) .

Non-Small-Cell Lung Cancer

To Evaluate the Efficacy/Safety of Osimertinib Prior to CRT and Maintenance of it With Stage III, Unresectable NSCLC With EGFR Mutations

Active, not recruiting Phase 2 AstraZeneca Started 2024 NCT06194448

Osimertinib FDA EUCisplatin or Carboplatin; Pemetrexed or PaclitaxelRadiation

…rs one of the two common EGFR mutations known to be associated with EGFR-TKI sensitivity (Ex19del, L858R), either alone or in combination with other EGFR mutations including de novo T790M

Lung Cancer

Intrathecal Pemetrexed for Leptomeningeal Metastasis in EGFR-Mutant NSCLC

Recruiting Phase 2 Taipei Veterans General Hospital, Taiwan Started 2024 NCT05805631

Pemetrexed

…ciety for Medical Oncology (EANO-ESMO) guideline. \[5\] EGFR activating mutations include exon19 deletion, T790M, L858R, G719X, L861Q, or S768I.

Carcinoma, Non-Small-Cell Lung, Epidermal Growth Factor Receptor, Leptomeningeal Metastasis

Double Dose of Third-generation EGFR-TKI Plus Intrathecal Pemetrexed Versus Double Dose of Third-generation EGFR-TKI in Patients With LM Progression Following the Treatment of Routine Dose of Third-generation EGFR-TKI

Not yet recruiting Phase 2 Fujian Cancer Hospital Started 2024 NCT06441045

Double Dose of Third-generation EGFR-TKIIntrathecal Pemetrexed

with EGFR sensitive mutation (exon 19 deletion or L858R mutation), LM progression after conventional doses of three generation EGFR targ…

Status may be outdated, last updated 2024-06-04Leptomeningeal Metastasis

Osimertinib and Etoposide as First-Line Treatment in Osimertinib-Resistant Advanced EGFR-Mutant NSCLC

Not yet recruiting Phase 2 Daping Hospital and the Research Institute of Surgery of the Third Military Medical University Started 2024 NCT06436144

Osimertinib FDA EU

Harboring an EGFR sensitizing mutation (Exon 19 deletion or L858R).

Status may be outdated, last updated 2024-05-30Non Small Cell Lung Cancer, EGFR Gene Mutation, Non Small Cell Lung Cancer Stage IIIB, Non-small Cell Lung Cancer Stage IV

A Study of VRN110755 in Patients With EGFR-Mutant Non-Small Cell Lung Cancer

Recruiting Phase 1/2 Voronoi Started 2024 NCT07699328

VRN110755

NSCLC with EGFR exon 19 deletion or L858R mutation plus a C797X resistance mutation following disease progression after fi…

EGFR-Mutant Non-Small Cell Lung Cancer

Gumarontinib Combined With 3rd EGFR-TKI in Patients With Non-small Cell Lung Cancer.

Not yet recruiting Phase 2 Cancer Institute and Hospital, Chinese Academy of Medical Sciences Started 2024 NCT06452433

gumarontinibthird-generation EGFR-TKI (Osimertinib, Almonertinib or Furmonertinib) FDA EU

Patients with EGFR mutations known to be associated with drug sensitivity (i.e., exon 19 deletion or L858R mutation).

Status may be outdated, last updated 2024-06-11Non-small Cell Lung Cancer

Clinical Study of Trop2 CAR-NK in the Treatment of Relapsed/Refractory Non-Small Cell Lung Cancer (NSCLC)

Not yet recruiting Phase 1/2 Henan Cancer Hospital Started 2024 NCT06454890

Anti-Trop2 CAR-NK cell

For patients with EGFR-sensitive mutations (19del, 21L858R, 18exonG719X, 20exonS768I, 21exonL861Q), they must meet one of the following req…

Status may be outdated, last updated 2024-06-12Non-Small Cell Lung Cancer NSCLC

Evaluation of the Efficacy and Safety of Befotertinib Combined With Bevacizumab as First-Line Treatment for EGFR-Positive Non-Small Cell Lung Cancer With Brain Metastases: A Single-Arm, Open-Label, Prospective Phase II Clinical Study

Active, not recruiting Phase 2 Li-kun Chen Started 2024 NCT06728865

The treatment regimen is Befotertinib combined with Bevacizumab.

Baseline evaluation confirming the presence of EGFR-sensitizing mutations (19del/L858R) via first- or second-generation sequencing.

Non-small Cell Lung Cancer (NSCLC), EGFR Mutation-Positive Lung Cancer, Brain Metastases, Leptomeningeal Metastases

A Phase 2 Clinical Study of Combination Therapy With ABSK043 and Firmonertinib

Recruiting Phase 2 Abbisko Therapeutics Started 2024 NCT06668103

ABSK043 in combination with Firmonertinib

Documented genetic testing reports confirmed the presence of EGFR L858R or EGFR exon 19 del mutations in tumor or plasma ctDNA.

Non-Small Cell Lung Cancer With EGFR Mutation

Study of FIH of STX-241 in Locally Advanced or Metastatic NSCLC Resistant to EGFR TKIs

Recruiting Phase 1/2 Pierre Fabre Medicament Started 2024 NCT06567015

STX-241

Histological confirmation of locally advanced or metastatic, EGFR-mutant (ex19del or L858R mutations) non-small cell lung cancer (NSCLC) Stage IIIB/C or IV (AJCC 8th editi…

Non-small Cell Lung Cancer (NSCLC)

Lazertinib & Tepotinib for EGFR Mutant NSCLC in MET Overexpressed or Amplified Who Progressed After Lazertinib Treatment

Recruiting Phase 2 Sehhoon Park Started 2024 NCT06106802

Lazertinib FDA EUTepotinib

Confirmed EGFR mutations (exon 19 deletion, L858R) with acquired resistance after first-line lazertinib treatment (either partial re…

Non-Small Cell Lung Cancer Metastatic

Neoadjuvant Furmonertinib and Cisplatin/Pemetrexed as in EGFR Mutated Stage IIA-IIIB Resectable NSCLC (FORESEE)

Active, not recruiting Phase 2 Tang-Du Hospital Started 2023 NCT05430802

Furmonertinib+cisplating/pemetrexed

EGFR mutation positive (exon 19 deletions or exon 21 L858R, with or without other EGFR mutations)

Non-small Cell Lung Cancer

Safety and Efficacy of Aumolertinib Combined With Anlotinib as 1st Line Treatment in Advanced Lung Cancer EGFR Mutation With TP53 Co-Mutation

Not yet recruiting Phase 2 Tianjin Medical University Cancer Institute and Hospital Started 2023 NCT05778149

Aumolertinib,Anlotinib

Locally advanced or metastatic NSCLC EGFR sensitive mutations (19del and L858R) and TP53 co-mutation;

Status may be outdated, last updated 2023-03-21Aumolertinib, Anlotinib, TP53, NSCLC

A Study of Zipalertinib in Patients With Advanced Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions or Other Uncommon Mutation.

Recruiting Phase 2 Taiho Oncology Started 2023 NCT05967689

TAS6417CYP CocktailTransporter Cocktail

common EGFRmt (eg, ex19del or L858R)

Advanced or Metastatic NSCLC Harboring Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion (ex20ins) Mutations

A Study of Combination Therapy With Amivantamab and Cetrelimab in Participants With Metastatic Non-small Cell Lung Cancer

Active, not recruiting Phase 1/2 Johnson & Johnson Started 2023 NCT05908734

CetrelimabAmivantamab FDA EU

Cohort A: Participant's tumor must have an EGFR exon19del or L858R mutation, as determined by local molecular testing, Cohort B: Participants must …

Carcinoma, Non-Small-Cell Lung

SRS for NSCLC With Oligo-residual Intracranial Disease After First-line 3rd Generation EGFR-TKI

Active, not recruiting Phase 2 Fudan University Started 2023 NCT06020066

EGFR-TK Inhibitor

EGFR mutations: EGFR L858R, EGFR exon 19 deletion;

Brain Metastases, Non-small Cell Lung Cancer

Study of Furmonertinib as Neoadjuvant Therapy for Resectable Stage Ⅱ-ⅢB EGFR Sensitive Mutant NSCLC

Recruiting Phase 2 Shanghai Zhongshan Hospital Started 2023 NCT05987826

Furmonertinib

7）EGFR mutation positive (exon 19 deletions or exon 21 L858R, with or without other EGFR mutations)

Non-Small Cell Lung Cancer

Premedication to Reduce Amivantamab Associated Infusion Related Reactions

Active, not recruiting Phase 2 Johnson & Johnson Started 2023 NCT05663866

DexamethasoneMontelukastMethotrexateAmivantamab FDA EULazertinib FDA EU

Previously identified EGFR-mutated non-small cell lung cancer (NSCLC) (EGFR Exon19 deletion or L858R) (identified locally in a Clinical Laboratory Improvement Amendments \[CLIA\]-ce…

Carcinoma, Non-Small-Cell Lung

First-in-Human Study of BBT-207 in Advanced Non-Small Cell Lung Cancer Harboring EGFR Mutation After Treatment With EGFR TKI

Active, not recruiting Phase 1/2 Bridge Biotherapeutics Started 2023 NCT05920135

BBT-207

…that the tumor harbors an EGFR mutation known to be associated with EGFR TKI sensitivity (exon 19 deletion or L858R).

EGFR Mutant Advanced Non-Small Cell Lung Cancer

A Randomized Phase II Study of LAZE rtiNib Alone Versus Lazertinib Plus bevaCizumab for NSCLC With EGFR + & Smoker

Recruiting Phase 2 National Cancer Center, Korea Started 2023 NCT06156527

Lazertinib FDA EUBevacizumab Injectable Product

Patients with institutionalized EGFR mutation (exon 19 deletion or L858R)

Status may be outdated, last updated 2023-12-05Lazertinib

A Study of 5 Years of Adjuvant Osimertinib in Completely Resected Epidermal Growth Factor Receptor Mutation (EGFRm) Non-small Cell Lung Carcinoma (NSCLC)

Active, not recruiting Phase 2 AstraZeneca Started 2023 NCT05526755

Osimertinib 80 mg/40 mg FDA EU

…on by the local laboratory that the tumour harbours one of the two common EGFR mutations (Ex19del, L858R), either alone or in combination with other EGFR mutations including de novo EGFR …

Stage II-IIIB Non-small Cell Lung Carcinoma

Neoadjuvant Lazertinib With or Without Chemotherapy for Patients With EGFR-mutated Resectable Non-small Cell Lung Cancer

Active, not recruiting Phase 2 Yonsei University Started 2022 NCT06268210

Lazertinib+Pemetrexed+Carboplatin FDA EULazertinib FDA EU

Documented presence of EGFR activating mutations (EGFR exon 19 deletion or L858R mutation).

Non-small Cell Lung Cancer

To Evaluate OBI-833/OBI-821 in Combination With First-Line Erlotinib in Patients With EGFR-Mutated, Globo H-Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Recruiting Phase 2 OBI Pharma Started 2022 NCT05442060

30 μg OBI-833/100 μg OBI-821Erlotinib (150 mg daily) FDA EU

The tumor harbors an exon 19 deletion or exon 21 L858R mutation in EGFR, confirmed locally.

Non-small Cell Lung Cancer

Neoadjuvant Icotinib With Chemotherapy for Epidermal Growth Factor Receptor(EGFR)-Mutated Resectable Lung Adenocarcinoma

Not yet recruiting Phase 2 Liaoning Cancer Hospital & Institute Started 2022 NCT05132985

IcotinibCisplatinCarboplatinPemetrexed

A tumor which harbors either Ex19del or L858R EGFR-TKI-sensitizing mutations, either alone

Status may be outdated, last updated 2021-12-10NSCLC, EGF-R Positive Non-Small Cell Lung Cancer

Osimertinib to Suppress the Progression of GGN(EGFR Mutation-positive)

Recruiting Phase 2 Samsung Medical Center Started 2022 NCT04591002

Osimertinib 80 MG FDA EU

…ed lung adenocarcinoma should have actionable EGFR mutation, which is limited to L858R or exon 19 deletion.

Lung Cancer

Furmonertinib Monotherapy and Combination Therapy in Advanced EGFR Mutant NSCLC With Uncleared ctDNA

Recruiting Phase 2 Sun Yat-sen University Started 2022 NCT05334277

FurmonertinibFurmonertinibFurmonertinib/Pemetrexed/CarboplatinFurmonertinib/Pemetrexed/Carboplatin/Bevacizumab

Patient with EGFR 19Del or L858R mutation diagnosed histologically or cytologically and confirmed by ctDNA, the r…

Status may be outdated, last updated 2022-08-31Non-small Cell Lung Cancer

Adjuvant Treatment Based on MRD for EGFR Mutant NSCLC

Recruiting Phase 2 Guangdong Association of Clinical Trials Started 2022 NCT05536505

Adjuvant treatment for MRD positivity

Target population is completely resected pathological stage IB-IIIB NSCLC with EGFR exon 19 deletions, L861Q mutation, G719X mutation and exon 21 L858R activating mutation.

Status may be outdated, last updated 2022-09-14MRD

Osimertinib to Suppress the Progression of Remaining GGN for EGFR Mutation-positive Stage IB-IIIA Lung Adenocarcinoma

Recruiting Phase 2 Samsung Medical Center Started 2022 NCT05528458

Osimertinib 80Mg Tab FDA EU

…ed lung adenocarcinoma should have actionable EGFR mutation, which is limited to L858R or exon 19 deletion.

Lung Adenocarcinoma

First-line Treatment With Dacomitinib Plus Anlotinib for Patients With Advanced NSCLC With EGFR 21L858R Mutations

Recruiting Phase 1/2 Shanghai Chest Hospital Started 2022 NCT05271916

Dacomitinib+Anlotinib FDA EUDacomitinib FDA EU

It is acceptable for subjects with the presence of EGFR activating mutation (exon 19 deletion and the L858R mutation in exon 21) to be included in this Phase I study

Status may be outdated, last updated 2023-04-19Non-Small Cell Lung Cancer (NSCLC)

Osimertinib Therapy After Resection in High-risk Stage I EGFRm NSCLC (OSTAR)

Recruiting Phase 2 Tianjin Medical University Cancer Institute and Hospital Started 2022 NCT05686434

Osimertinib FDA EU

…ns one of the two common EGFR mutations known to be associated with EGFR-TKI sensitivity (Ex19del, L858R), alone or in conjunction with other EGFR mutations, including T790M;

Status may be outdated, last updated 2023-01-17NSCLC, Stage I

A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer

Recruiting Phase 2 Johnson & Johnson Started 2022 NCT05498428

Amivantamab FDA EULazertinib FDA EUCarboplatinPemetrexedDirect Oral Anticoagulant (DOAC)Low Molecular Weight Heparin (LMWH)

…quirements include: Cohorts 1, 3, 3b, 5, 6 and 7: epidermal growth factor receptor (EGFR) exon 19 deletion (Exon19del) or Exon 21 L858R mutation

Carcinoma, Non-small-Cell Lung

Necitumumab and Trastuzumab in Combination With Osimertinib for the Treatment of Refractory Epidermal Growth Factor Receptor (EGFR)-Mutated Stage IV Non-small Cell Lung Cancer

Active, not recruiting Phase 1/2 Jonsson Comprehensive Cancer Center Started 2021 NCT04285671

NecitumumabOsimertinib FDA EUTrastuzumab

Enrollment of patients with mutations other than exon 19 deletion and the L858R point mutation require literature supporting sensitivity to EGFR tyrosine k…

Metastatic Lung Non-Small Cell Carcinoma, Refractory Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer American Joint Committee on Cancer (AJCC) v8, Stage IVA Lung Cancer AJCC v8

A Study of Icotinib With Chemotherapy as Neoadjuvant Therapy for Patients With EGFRm Positive Resectable Non-Small Cell Lung Cancer

Recruiting Phase 2 Peking University Cancer Hospital & Institute Started 2021 NCT05104788

IcotinibCisplatinCarboplatinPemetrexed

…d with EGFR-TKI （epidermal growth factor receptor tyrosine kinase inhibitors）sensitivity (Ex19del, L858R).

Status may be outdated, last updated 2021-11-03Non-Small Cell Lung Cancer

HERTHENA-Lung01: Patritumab Deruxtecan in Subjects With Metastatic or Locally Advanced EGFR-mutated Non-Small Cell Lung Cancer

Active, not recruiting Phase 2 Daiichi Sankyo Started 2021 NCT04619004

Patritumab Deruxtecan (Fixed dose)Patritumab Deruxtecan (Up-Titration)

Documentation of an EGFR-activating mutation detected from tumor tissue or blood sample: exon 19 deletion or L858R.

Non-Small Cell Lung Cancer Metastatic, Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor

Additional Chemotherapy for EGFRm Patients with the Continued Presence of Plasma CtDNA EGFRm At Week 3 After Start of Osimertinib 1st-line Treatment (PACE-LUNG)

Recruiting Phase 2 Goethe University Started 2021 NCT05281406

Osimertinib FDA EUPemetrexedCisplatinCarboplatin

Tumor positive for Ex19del or L858R EGFR mutation assessed according to local standard.

NSCLC Stage IIIB, NSCLC Stage IV

Neoadjuvant Osimertinib + Chemotherapy for EGFR-mutant Stage III NSCLC

Recruiting Phase 2 Sun Yat-sen University Started 2021 NCT05011487

Osimertinib FDA EUCisplatinPemetrexed

…ours one of the 2 common EGFR mutations known to be associated with EGFR-TKI sensitivity (Ex19del, L858R), either alone or in combination with other EGFR mutations (ie, T790M, G719X, Exon…

Status may be outdated, last updated 2024-01-16Non-Small Cell Lung Cancer

A Study to Evaluate Pembrolizumab Plus Lenvatinib in PD-L1 Positive TKI Resistant NSCLC Patients

Active, not recruiting Phase 2 Shanghai Chest Hospital Started 2021 NCT05078931

PembrolizumabLenvatinib

Have confirmation with sensitizing EGFR mutations, either DEL19 or L858R

NSCLC

Primary Tumor Resection With EGFR TKI for Stage IV NSCLC

Recruiting Phase 2 National Taiwan University Hospital Started 2021 NCT05215548

Afatinib FDA EU

Patients must have one of the following:NSCLC which harbors EGFR exon 19 deletion or L858R mutation.

NSCLC Stage IV

Study to Evaluate VT3989 in Patients With Metastatic Solid Tumors

Recruiting Phase 1/2 Vivace Therapeutics Started 2021 NCT04665206

VT3989Nivolumab & IpilimumabOsimertinib FDA EUPemetrexed/Carboplatin

… diagnosed incurable locally advanced (inoperable or recurrent), or metastatic NSCLC with exon 19 deletions or exon 21 L858R mutations, with or without prior treatment with Osimertinib.

Solid Tumor, Adult, Mesothelioma, NSCLC

Telaglenastat Hydrochloride and Osimertinib in Treating Patients With EGFR-Mutated Stage IV Non-small Cell Lung Cancer

Active, not recruiting Phase 1/2 National Cancer Institute (NCI) Started 2020 NCT03831932

Osimertinib FDA EUTelaglenastat Hydrochloride

Activating mutation present in the EGFR gene (L858R or exon 19 deletion, alone or in combination with other EGFR mutations) as per local assessment of a tissue b…

Advanced Lung Non-Small Cell Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8

Dacomitinib in Lung Cancer With Uncommon EGFR Mutations

Active, not recruiting Phase 2 Shanghai Chest Hospital Started 2020 NCT04504071

Dacomitinib FDA EU

Uncommon EGFR mutations were defined as mutations in exon 18-21 but except for 19del, 21L858R and well-established drug resistant type (20 insertion, 20T790M, 19L747S, 19L747…

Non-small Cell Lung Cancer Metastatic, EGF-R Positive Non-Small Cell Lung Cancer

Osimertinib and Abemaciclib in EGFR Mutant Non-Small Cell Lung Cancer After Osimertinib Resistance

Active, not recruiting Phase 2 University of California, San Diego Started 2020 NCT04545710

AbemaciclibOsimertinib FDA EU

Tumor must harbor an EGFR activating mutation (Exon 21 L858R, Exon 19 deletion, Exon 18 G719X, Exon 21 L861Q).

Status may be outdated, last updated 2024-08-05Lung Cancer

Study of Osimertinib + SRS vs Osimertinib Alone for Brain Metastases in EGFR Positive Patients With NSCLC

Active, not recruiting Phase 2 British Columbia Cancer Agency Started 2019 NCT03769103

Osimertinib FDA EU

Epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations (either alone or in combination with other EGF…

Lung Cancer Non-small Cell Stage IV, Brain Metastases

Phase 2 Study of Dacomitinib in NSCLC

Active, not recruiting Phase 2 National Cancer Centre, Singapore Started 2019 NCT04027647

Dacomitinib FDA EU

The presence of an EGFR activating mutation (exon 19 deletion or the L858R mutation in exon 21) in tumor specimen determined by the local laboratory;

NSCLC Stage IIIB, NSCLC Stage IIIC, NSCLC Stage IV, Recurrent NSCLC

Study of Osimertinib With and Without Ramucirumab in Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

Active, not recruiting Phase 2 Xiuning Le Started 2019 NCT03909334

Osimertinib FDA EURamucirumab FDA EU

NSCLC which harbours EGFR Exon 19 deletion.

Non Small Cell Lung Cancer, EGFR Gene Mutation, Advanced Cancer, Metastatic Cancer

A Phase 2 Study of Osimertinib in Combination With Selumetinib in EGFR Inhibitor naïve Advanced EGFR Mutant Lung Cancer

Active, not recruiting Phase 2 Dana-Farber Cancer Institute Started 2018 NCT03392246

Osimertinib FDA EUSelumetinib

…e histologically confirmed stage IV NSCLC (per AJCC 7th edition) with either the L858R or exon 19 deletion activating EGFR mutation as identified in a CLIA-approved laboratory.

Non-small Cell Lung Cancer

Testing Afatinib as Potentially Targeted Treatment in Cancers With EGFR Genetic Changes (MATCH - Subprotocol A)

Active, not recruiting Phase 2 National Cancer Institute (NCI) Started 2018 NCT06385483

Afatinib FDA EU

Activating mutations of EGFR (del 19, L858R) OR

Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Refractory Lymphoma, Refractory Malignant Solid Neoplasm

Osimertinib in Treating Participants With Stage I-IIIA EGFR-mutant Non-small Cell Lung Cancer Before Surgery

Active, not recruiting Phase 2 University of California, San Francisco Started 2018 NCT03433469

Osimertinib FDA EU

Documented activating EGFR mutation (Exon 19 deletion, T790M, or L858R) on tumor samples by Clinical Laboratory Clinical Laboratory Improvement…

Stage I Non-Small Cell Lung Cancer, Stage IA Non-Small Cell Lung Cancer, Stage IB Non-Small Cell Lung Cancer, Stage II Non-Small Cell Lung Cancer

Osimertinib, Surgery, and Radiation Therapy in Treating Patients With Stage IIIB or IV Non-small Cell Lung Cancer With EGFR Mutations, NORTHSTAR Study

Active, not recruiting Phase 2 M.D. Anderson Cancer Center Started 2018 NCT03410043

Osimertinib FDA EU

NSCLC which harbors EGFR exon 19 deletion or L858R mutation.

Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage IIIB Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8

Osimertinib In EGFR Mutant Lung Cancer

Active, not recruiting Phase 2 Dana-Farber Cancer Institute Started 2018 NCT03586453

Osimertinib FDA EU

…e histologically confirmed stage IV NSCLC (per AJCC 7th edition) with either the L858R or exon 19 deletion activating EGFR mutation as identified in a CLIA-approved laboratory from tumor tissue.

Carcinoma, Non-Small-Cell Lung

Osimertinib With or Without Bevacizumab in Treating Patients With EGFR Positive Non-small Cell Lung Cancer and Brain Metastases

Active, not recruiting Phase 2 National Cancer Institute (NCI) Started 2018 NCT02971501

BevacizumabOsimertinib FDA EU

Non-small cell lung cancer (NSCLC) with an activating EGFR mutation (exon 19 deletion, L858R point mutation, or any other mutation known to be associated with EGFR TKI sensiti…

Metastatic Lung Non-Small Cell Carcinoma, Metastatic Malignant Neoplasm in the Brain, Stage IV Lung Cancer AJCC v8

Osimertinib and Gefitinib in EGFR Inhibitor naïve Advanced EGFR Mutant Lung Cancer

Active, not recruiting Phase 1/2 Dana-Farber Cancer Institute Started 2017 NCT03122717

Gefitinib FDA EUOsimertinib FDA EU

…e histologically confirmed stage IV NSCLC (per AJCC 7th edition) with either the L858R or exon 19 deletion activating EGFR mutation as identified in a CLIA-approved laboratory.

Non-Small Cell Lung Cancer

Phase I Study of Single-Agent KGX105 in Patients With Advanced or Metastatic Solid Tumors

Not yet recruiting Phase 1 Kangabio AUSTRALIA LTD PTY Started 2026 NCT07702955

KGX105 injection

Driver genes primarily include: EGFR exon 19 deletion, L858R mutation, or exon 20 insertion mutation.

Advanced or Metastatic Solid Tumors

JIN-A02 Plus Amivantamab in EGFR-Mutant NSCLC After Third-Generation EGFR-TKI Failure

Not yet recruiting Phase 1 Yonsei University Started 2026 NCT07798921

JIN-A02 in Combination with Amivantamab FDA EU

Subjects with advanced and/or metastatic NSCLC harboring an activating EGFR mutation (Ex19del or L858R), as confirmed by testing of tissue or blood samples, whose disease has progress…

Carcinoma, Non-Small-Cell Lung

JH021 in Patients With Advanced Solid Tumors or EGFR-Mutant NSCLC

Not yet recruiting Phase 1 Biotech Pharmaceutical Started 2026 NCT07582822

JH021

…nced or metastatic non-small cell lung cancer (NSCLC) with EGFR-sensitive mutations (EGFR exon 19 deletion or exon 21 L858R) detected in tumor tissue or plasma ctDNA, who are resistant to third-ge…

Advanced Solid Tumor

OBSERVE: A Pilot Study Of Omission Of Brain Metastasis Stereotactic Radiosurgery Following Resection With CNS-Active Systemic Therapy

Recruiting Phase 1 M.D. Anderson Cancer Center Started 2026 NCT07655583

Exon 19 deletion

Brain Metastasis, Stereotactic Radiosurgery, Resection, Systemic Therapy

A Multinational Study Assessing an Oral EGFR Inhibitor, DZD6008 in Patients Who Have Advanced NSCLC With EGFR Mutations (TIAN-SHAN1)

Recruiting Phase 1 Dizal Pharmaceuticals Started 2025 NCT06905197

DZD6008Sunvozertinib

For Part A monotherapy cohorts and all cohorts of Part B, EGFR sensitizing mutations (Exon19del and/or L858R) are required.

Non Small Cell Lung Cancer

A Study Evaluating the Effect of Aumolertinib on the Pharmacokinetics of Midazolam in Patients With NSCLC

Recruiting Phase 1 Hansoh Pharma Started 2025 NCT06926413

Aumolertinib；midazolam

…nti-tumor systemic therapy, and the tumor must harbor at least one of the EGFR mutations (ex19del or L858R, single mutation or combined with other EGFR mutations are both acceptable).

Non Small Cell Lung Cancer

Osimertinib, Cetuximab, and Tucatinib for the Treatment of EGFR-Mutant Stage IV or Recurrent Non-small Lung Cell Cancer

Not yet recruiting Phase 1 Jonathan Riess Started 2024 NCT06067776

CetuximabOsimertinib FDA EUTucatinib

NSCLC must harbor at least one of the following EGFR activating mutations: Exon 21 L858R, Exon 19 deletion, Exon 18 G719X, Exon 21 L861Q, Exon 20 S768I.

Status may be outdated, last updated 2023-10-05Metastatic Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8

A Study of Aumolertinib in European Participants With Non-Small Cell Lung Cancer

Recruiting Phase 1 Hansoh Pharma Started 2024 NCT07130916

Aumolertinib

…nti-tumor systemic therapy, and the tumor must harbor at least one of the EGFR mutations (ex19del or L858R).

Non-Small Cell Lung Cancer

Assessing an Oral EGFR Inhibitor, DZD6008 in Patients Who Have Advanced NSCLC With EGFR Mutations (TIAN-SHAN2)

Recruiting Phase 1 Dizal Pharmaceuticals Started 2024 NCT06813365

DZD6008

Documentation of EGFR sensitizing mutation (Exon19del and/or L858R) from a local CLIA-certified laboratory (or equivalent).

Nonsmall-cell Lung Cancer

Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors

Recruiting Phase 1 Baili-Bio / SystImmune Started 2023 NCT05983432

BL-B01D1

a) Evidence of documented EGFR TKI-sensitizing deletion mutation in EGFR Exon 19 (ex19del) or leucin-arginine substitution point mutation in EGFR Exon 21 (ex21L858R), the serine-i…

Non Small Cell Lung Cancer, Esophageal Cancer, Small Cell Lung Cancer, Nasopharyngeal Cancer

Study of MCLA-129 Combined With Befotertinib in the Treatment of Advanced Non-small Cell Lung Cancer With EGFR Sensitive Mutation

Not yet recruiting Phase 1 Betta Pharmaceuticals Started 2023 NCT06015568

MCLA-129: 1500mg or 2000mg IV Q2WBefotertinib: 75 mg or 100 mg Po QD

…astatic NSCLC that is not suitable for radical surgery or radiotherapy, and harbored EGFR exon 19 deletion or exon 21 L858R mutation( either alone or in combination with other EGFR mutations) in N…

Status may be outdated, last updated 2023-08-29Non-Small Cell Lung Cancer、EGFR Sensitive Mutation

A Phase Ib Study to Evaluate the Safety and Preliminary Efficacy of IL6-receptor Antibody Sarilumab in Combination With antiPD1 Antibody Cemiplimab for Patients With Non-small Cell Lung Cancer.

Active, not recruiting Phase 1 M.D. Anderson Cancer Center Started 2023 NCT05704634

CemiplimabKevzara (Sarilumab)

NSCLC which harbours EGFR Exon 19 deletion.

Lung Cancer

A Study of YL202 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer and Breast Cancer

Active, not recruiting Phase 1 MediLink Therapeutics (Suzhou) Started 2022 NCT05653752

YL202

Have a documentation of an EGFR-activating mutation (exon 19 deletion or L858R) detected from tumor tissue at diagnosis or thereafter.

Non Small Cell Lung Cancer, Breast Cancer

Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer

Recruiting Phase 1 BioNTech Started 2022 NCT05142189

BNT116CemiplimabDocetaxelCarboplatinPaclitaxelBNT316

Participants' NSCLC must have classical EGFR mutations, i.e., ex19Del or L858R.

Non-Small Cell Lung Cancer

A Study of NX-019 in Patients with Advanced, Epidermal Growth Factor Receptor (EGFR) Mutant Cancer

Active, not recruiting Phase 1 Nalo Therapeutics Started 2022 NCT05514496

NX-019

Patients with NSCLC with EGFR exon 19 deletions or exon 21 L858R mutations who have progressed on or after prior EGFR TKI therapy.

EGFR Mutation-Related Tumors

Minnelide and Osimertinib for the Treatment of Advanced EGFR Mutated Non-Small Cell Lung Cancer

Active, not recruiting Phase 1 City of Hope Medical Center Started 2022 NCT05166616

Osimertinib FDA EUTriptolide Analog

… with epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKI) sensitivity (Ex19del or L858R), either alone or in combination with other epidermal growth factor receptor (EG…

Advanced Lung Non-Small Cell Carcinoma, Locally Advanced Lung Non-Small Cell Carcinoma, Stage III Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8

Osimertinib and Tegavivint as First-Line Therapy for the Treatment of Metastatic EGFR-Mutant Non-small Cell Lung Cancer

Recruiting Phase 1 Ohio State University Comprehensive Cancer Center Started 2022 NCT04780568

Osimertinib FDA EUTegavivint

A common activating mutation must be present in the EGFR gene, i.e., exon 19 deletion or L858R.

Metastatic Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8

Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumor Activity of ASKC202 With or Without ASK120067

Recruiting Phase 1 Jiangsu Aosaikang Pharmaceutical Started 2022 NCT05306132

ASKC202ASK120067

…ocally advanced or metastatic NSCLC;b)Histologically confirmed EGFR sensitizing mutation (Ex19del or L858R).；c)Disease progression following treatment with a third-generation EGFR TKI, or…

Advanced Solid Tumor

Intrathecal Double Checkpoint Inhibition

Active, not recruiting Phase 1 University of Zurich Started 2022 NCT05598853

intrathecal nivolumab and intrathecal ipilimumab

…ncogenic driver alteration: sensitising Epidermal Growth Factor Receptor (EGFR) mutation (exon 19-del and 21-L858R), anaplastic lymphoma kinase (ALK) or ROS proto-oncogene-1 (ROS1) rearrangem…

Leptomeningeal Metastasis, Non-small Cell Lung Cancer Stage IV, Melanoma Stage IV

HER3-DXd (Patritumab Deruxtecan; U3-1402) in Combination With Osimertinib in Subjects With Locally Advanced or Metastatic EGFR-mutated Non-Small Cell Lung Cancer

Active, not recruiting Phase 1 Daiichi Sankyo Started 2021 NCT04676477

HER3-DXdHER3-DXdOsimertinib FDA EUOsimertinib FDA EUHER3-DXdHER3-DXd

Documentation of EGFR exon 19 deletion or L858R mutation detected from tumor tissue

Non-Small Cell Lung Cancer (NSCLC)

A Study of Mobocertinib in Japanese Adults With Non-Small Cell Lung Cancer

Active, not recruiting Phase 1 Takeda Started 2019 NCT03807778

Mobocertinib

…r alone or in combination with other EGFR or HER2 mutations except EGFR common mutations (exon 19 del or L858R).

Non-Small Cell Lung Cancer

A Study of Lazertinib as Monotherapy or in Combination With Amivantamab in Participants With Advanced Non-small Cell Lung Cancer

Active, not recruiting Phase 1 Johnson & Johnson Started 2019 NCT04077463

Lazertinib FDA EUAmivantamab FDA EUCarboplatinPemetrexed

…Cohort D, E, and F: Participant must have advanced or metastatic EGFR-mutated NSCLC (EGFR Exon19 deletion or L858R) that has progressed on prior treatment with osimertinib in the first or second …

Carcinoma, Non-Small-Cell Lung

Study of EGF816 in Combination With Selected Targeted Agents in EGFR-mutant NSCLC

Active, not recruiting Phase 1 Novartis Started 2018 NCT03333343

EGF816trametinibribociclibLXH254INC280gefitinib FDA EU

…tologically confirmed locally advanced (stage IIIB) or metastatic (stage IV) EGFR mutant (ex19del, L858R) NSCLC.

EGFR-mutant Non-small Cell Lung Cancer

Testing the Combination of MLN0128 (TAK-228) and AZD9291 in Advanced EGFR (Epidermal Growth Factor Receptor) Mutation Positive Non-small Cell Lung Cancer

Active, not recruiting Phase 1 National Cancer Institute (NCI) Started 2017 NCT02503722

Osimertinib FDA EUSapanisertib

NSCLC must harbor an EGFR activating mutation (Exon 21 L858R, Exon 19 deletion)

Metastatic Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage III Lung Non-Small Cell Cancer AJCC v7, Stage IIIA Lung Non-Small Cell Cancer AJCC v7

Osimertinib and Necitumumab in Treating Patients With EGFR-Mutant Stage IV or Recurrent Non-small Cell Lung Cancer Who Have Progressed on a Previous EGFR Tyrosine Kinase Inhibitor

Active, not recruiting Phase 1 National Cancer Institute (NCI) Started 2016 NCT02496663

NecitumumabOsimertinib FDA EU

NSCLC must harbor at least one of the following EGFR activating mutations: Exon 21 L858R, Exon 19 deletion, Exon 18 G719X, Exon 21 L861Q or for EGFR Exon 20 insertion expansion cohort D, NSCLC mus…

Metastatic Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8

Study of Amivantamab, a Human Bispecific EGFR and cMet Antibody, in Participants With Advanced Non-Small Cell Lung Cancer

Active, not recruiting Phase 1 Johnson & Johnson Started 2016 NCT02609776

Amivantamab FDA EUAmivantamab FDA EULazertinib FDA EUCarboplatinPemetrexed

…ion Dose Escalation with lazertinib only: Participants must have been diagnosed with EGFR Exon 19del or L858R activating mutation and (a) be treatment naïve for metastatic disease, without a…

Non-Small-Cell Lung Cancer

A Study Evaluating the Safety, Pharmacokinetics (PK), and Preliminary Efficacy of ABBV-399 in Participants With Advanced Solid Tumors

Active, not recruiting Phase 1 AbbVie Started 2014 NCT02099058

Osimertinib FDA EUNivolumabTelisotuzumab vedotinTelisotuzumab vedotinErlotinib FDA EU

…ced nonsquamous NSCLC with documented Epidermal Growth Factor Receptor (EGFR) mutation(s) del19 or L858R, with or without T790M mutation, and none of the EGFR mutations known to be resi…

Advanced Solid Tumors Cancer

Therapy for Advanced NSCLC With EGFR 19delins Mutation

Not yet recruiting Early Phase 1 Fuzhou General Hospital Started 2026 NCT07458919

Icotinib/Gefitinib FDA EU

Epidermal growth factor receptor (EGFR) exon 19 deletion-insertion mutation (19delins) documented by testing of tumor tissue or plasma samples usi…

Lung Cancer

Pulsatile High-dose Furmonertinib in EGFR-mutant NSCLC With Leptomeningeal Metastasis

Recruiting No phase Guangzhou University of Traditional Chinese Medicine Started 2026 NCT07348965

Furmonertinib 320mg qod poFurmonertinib 160mg qd po

Patients with EGFR exon 19 deletion or exon 21 L858R mutation

NSCLC (Advanced Non-small Cell Lung Cancer), Leptomeningeal Metastasis, Furmonertinib, EGFR Activating Mutation

JS212 in Combination With JS111 as First-Line Treatment in EGFR-Mutant Advanced NSCLC

Not yet recruiting No phase Huan Zhou Started 2026 NCT07714304

JS212 for InjectionJS111 capsules (AP-L1898)

Confirmed EGFR-sensitizing mutation, defined as an exon 19 deletion or L858R mutation, either occurring alone or together with other EGFR mutations, includin…

NSCLC Harboring EGFR Mutations

MRD-Guided Aumolertinib-Based Adjuvant Therapy for Resected EGFR-Mutant NSCLC

Not yet recruiting No phase Peking University People's Hospital Started 2026 NCT07873086

AumolertinibPemetrexedCarboplatin

EGFR exon 19 deletion and/or exon 21 L858R mutation detected by histological or cytological testing.

Non-Small Cell Lung Cancer

Double-Dose Third-Generation EGFR-TKI Plus Bevacizumab and Intrathecal Chemotherapy for Refractory Leptomeningeal Metastatic NSCLC: A Phase II Study

Recruiting No phase Second Affiliated Hospital of Nanchang University Started 2026 NCT07398599

a combined regimen consisting of double-dose third-generation EGFR-TKI, bevacizumab, and intrathecal chemotherapy in patients

Presence of EGFR-sensitive mutations (exon 19 deletion or exon 21 L858R mutation).

Leptomeningeal Metastasis, Lung Neoplasms, Non-Small Cell Lung Cancer

MWA With or Without Furmonertinib for Early-Stage Non-Small Cell Lung Cancer

Not yet recruiting No phase Shanghai Chest Hospital Started 2025 NCT06969781

TKI

EGFR exon 19 deletion or exon 21 L858R mutation.

Lung Cancer (NSCLC)

Intra-pemetrexed Plus Third-generation Small Molecule TKI Drugs (e.g. 'Osimertinib') Versus Third-generation Small Molecule TKI Drugs Alone for Leptomeningeal Metastasis From Epidermal Growth Factor Receptor Mutation-Positive Non-Small-cell Lung Cancer

Recruiting No phase Guangzhou Medical University Started 2024 NCT06304441

Osimertinib FDA EUPemetrexed

…ytologically confirmed diagnosis of NSCLC with single activating EGFR mutations (L858R or Exon19Del).

Leptomeningeal Metastasis

A Prospective Cohort Study to Evaluate Molecular pRognostic Factors and Resistance Mechanisms to Osimertinib in Adjuvant Treatment of Completely Resected pIB-IIIA Non-small Cell Lung Carcinoma With Common EGFR Mutations (L858R and Del19)

Recruiting No phase Intergroupe Francophone de Cancerologie Thoracique Started 2024 NCT06053099

Presence of a common EGFR mutation (Del19 or L858R).

Status may be outdated, last updated 2024-03-08Non Small Cell Lung Cancer, EGFR Activating Mutation, EGFR DEL19, EGFR L858R

The Feasibility of Dynamic Liquid Biopsy Monitoring During Neoadjuvant Treatment for EGFR-mutated NSCLC

Not yet recruiting No phase Zhejiang University Started 2024 NCT06287593

Patients with EGFR 19del or L858R mutations.

Status may be outdated, last updated 2024-04-24EGF-R Positive Non-Small Cell Lung Cancer

Study to Evaluate SBRT for EGFR Mutant NSCLC Patients Receiving Osimertinib (CULTRO)

Not yet recruiting No phase Centro de Tratamiento e Investigación sobre Cáncer, Luis Carlos Sarmiento Angulo Started 2023 NCT05998993

Have confirmation of the presence of common EGFR mutations (exon 19 deletion, L858R/exon 21, or G719X) through any locally and internationally accepted standard tests…

Status may be outdated, last updated 2023-08-21EGF-R Positive Non-Small Cell Lung Cancer, Non Small Cell Lung Cancer, EGFR Exon 19 Deletion, EGFR Exon 21 Mutation

A Study to Evaluate the Efficacy of Osimertinib With Early Intervention SRS Treatment Compared to the Continuation of Osimertinib Alone, in Patients With EGFR Mutated NSCLC and Asymptomatic Brain Metastases

Recruiting No phase Hadassah Medical Organization Started 2021 NCT05033691

…ince the initial diagnosis of NSCLC) known to be sensitive to Osimertinib - These include exon 19 del

Status may be outdated, last updated 2021-09-05NSCLC, EGFR Gene Mutation, EGF-R Positive Non-Small Cell Lung Cancer, Non-small Cell Lung Cancer

Whole Genomic Landscape of Advanced EGFR-mutant NSCLC

Active, not recruiting No phase Seoul National University Hospital Started 2019 NCT03969823

Tagrisso FDA EU

…diotherapy with local confirmation of the presence of EGFR TKI-sensitizing mutation (EGFR exon 19 deletion or L858R mutation), either alone or in combination with other EGFR mutations excluding EG…

Locally Advanced or Metastatic NSCLC

An Open-label, Single-arm Study of Prophylaxis for Datopotamab Deruxtecan (Dato-DXd) -Related Stomatitis in Eligible Patients With Metastatic or Inoperable Locally Recurrent Breast Cancer or Locally Advanced or Metastatic Epidermal Growth Factor Receptor-Mutated Non-small Cell Lung Cancer.

Recruiting Phase 4 AstraZeneca Started 2026 NCT07357597

Dexamethasone mouthwashDatopotamab Deruxtecan (Dato-DXd) FDA

Patients with locally advanced or metastatic EGFRm NSCLC who have received prior EGFR-directed therapy and platinum-based chemotherapy.

Broad match: EGFR mutation (unspecified)Stomatitis

Tarlatamab and Durvalumab vs. Durvalumab Alone for Limited-Stage-Small Cell Lung Cancer

Not yet recruiting Phase 3 PrECOG Starts 2027 NCT07637513

TarlatamabDurvalumab

…previous diagnosis of non-small cell lung cancer (e.g., Epidermal Growth Factor Receptor (EGFR)-mutant non-small cell lung cancer (NSCLC) with SCLC transformation).

Broad match: EGFR mutation (unspecified)Limited Stage Small-Cell Lung Cancer

A Study Comparing BL-B01D1 in Combination With Osimertinib Versus Osimertinib Alone in Patients With Locally Advanced, Unresectable EGFR-mutated Non-small Cell Lung Cancer(Stage III) Whose Disease Has Not Progressed Following Definitive Platinum-based Chemoradiation Therapy(PANKU-Lung08)

Recruiting Phase 3 Baili-Bio / SystImmune Started 2026 NCT07640789

BL-B01D1Osimertinib FDA EU

…With Osimertinib Versus Osimertinib Alone in Patients With Locally Advanced, Unresectable EGFR-mutated Non-small Cell Lung Cancer(Stage III) Whose Disease Has Not Progressed Following Definiti…

Broad match: EGFR mutation (unspecified)Non-small Cell Lung Cancer Stage III

A Study of BL-B01D1 in Combination With Osimertinib as Perioperative Therapy in Patients With EGFR-mutated Resectable Non-small Cell Lung Cancer(PANKU-Lung09)

Recruiting Phase 2/3 Baili-Bio / SystImmune Started 2026 NCT07642024

BL-B01D1Osimertinib FDA EUCarboplatinPemetrexedCisplatin

…udy of BL-B01D1 in Combination With Osimertinib as Perioperative Therapy in Patients With EGFR-mutated Resectable Non-small Cell Lung Cancer(PANKU-Lung09)

Broad match: EGFR mutation (unspecified)Non-small Cell Lung Cancer

Study of Becotatug Vedotin Added to Standard Treatment for Advanced Bile Duct Cancer With EGFR Mutations

Not yet recruiting Phase 2/3 Sir Run Run Shaw Hospital Started 2026 NCT07598318

Becotatug VedotinPucotenlimabGemcitabineCisplatin

Study of Becotatug Vedotin Added to Standard Treatment for Advanced Bile Duct Cancer With EGFR Mutations

Broad match: EGFR mutation (unspecified)Cholangiocarcinoma

SYS6010 Versus Docetaxel for Previously Treated EGFR Wild-type NSCLC: Phase Ⅲ

Not yet recruiting Phase 3 CSPC Started 2026 NCT07442565

SYS6010Docetaxel

EGFR mutations (currently approved by regulatory authorities for targeted therapy) must be confirmed neg…

Broad match: EGFR mutation (unspecified)Non-Small Cell Lung Cancer

ASKC202 Combined With Limertinib Versus Platinum-based Chemotherapy in Treatment of Locally Advanced or Metastatic NSCLC With MET Amplification/Overexpression After Failure of EGFR-TKI Therapy

Recruiting Phase 3 Jiangsu Aosaikang Pharmaceutical Started 2025 NCT07109531

ASKC202+ LimertinibPemetrexed + Cisplatin /Carboplatin

EGFR mutation with MET amplification/Overexpression by a central laboratory;

Broad match: EGFR mutation (unspecified)Locally Advanced or Metastatic NSCLC

Umbrella Trial of Adjuvant Therapy in Completely Resected High-risk Stage IA-IB NSCLC: Focus on Driver Mutations

Not yet recruiting Phase 3 The First Affiliated Hospital of Guangzhou Medical University Started 2025 NCT06955325

IcotinibRezivertinibEnsartinibBenmelstobart

Documented driver gene status (EGFR mutation, ALK/ROS1 fusion, or wild-type) via postoperative tumor sample.

Broad match: EGFR mutation (unspecified)Non-Small Cell Lung Cancer

Phase III Trial of SYS6010 Versus Platinum-based Chemotherapy for EGFR-mutated NSCLC（SYNSTAR01）

Recruiting Phase 3 CSPC Started 2025 NCT06927986

SYS6010PemetrexedCisplatinCarboplatin

Phase III Trial of SYS6010 Versus Platinum-based Chemotherapy for EGFR-mutated NSCLC（SYNSTAR01）

Broad match: EGFR mutation (unspecified)EGFR-mutated Locally Advanced or Metastatic NSCLC

A Study of BL-B01D1 in Combination With Osimertinib Versus Osimertinib as First-Line Treatment in Patients With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer(PANKU-Lung04)

Recruiting Phase 3 Baili-Bio / SystImmune Started 2025 NCT06838273

BL-B01D1Osimertinib FDA EUOsimertinib FDA EU

…sue samples of primary or metastatic lesions at or after diagnosis for testing, including EGFR mutation type;

Broad match: EGFR mutation (unspecified)Non-small Cell Lung Cancer

A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)

Recruiting Phase 3 Pfizer Started 2025 NCT07144280

PF-08046054Docetaxel monotherapy

Participants with known AGAs (eg, EGFR mutations, ALK translocations, or other relevant actionable mutations) must fulfill the following c…

Broad match: EGFR mutation (unspecified)Non-small Cell Carcinoma, Non-Small Cell Lung Cancer Metastatic, Non-Small Cell Lung Carcinoma

A Study to Assess Zipalertinib Versus Placebo in Participants With Early Stage NSCLC With Uncommon EGFR Mutations, Following Complete Tumor Resection

Recruiting Phase 3 Taiho Oncology Started 2025 NCT07128199

TAS6417Zipalertinib Matching-placebo

…Study to Assess Zipalertinib Versus Placebo in Participants With Early Stage NSCLC With Uncommon EGFR Mutations, Following Complete Tumor Resection

Broad match: EGFR sensitizing mutationLung Cancer, Adjuvant, Post-surgical, EGFR

Glumetinib Combined With Osimertinib Treatment for Non-Small Cell Lung Cancer Patients

Not yet recruiting Phase 2/3 Shanghai JMT-Bio Started 2025 NCT06908772

Glumetinib TabletsOsimertinib Mesylate Tablets FDA EUGlumetinib Tablets Placebo

…ined With Osimertinib as First-Line Treatment in Non-Small Cell Lung Cancer Patients With Classical EGFR Mutations Accompanied by MET Amplification or Overexpression

Broad match: EGFR sensitizing mutationRecurrent or Metastatic NSCLC Patients With Classical EGFR Mutations Accompanied by MET Amplification or Overexpression

Vebreltinib Plus PLB1004 Versus Platinum-based Doublet Chemotherapy in Patients With EGFRm, MET+, Locally Advanced or Metastatic NSCLC Following EGFR-TKI Failure

Not yet recruiting Phase 3 Avistone Biotechnology Started 2025 NCT06970782

VebreltinibPLB1004Pemetrexed plus Carboplatin or Cisplatin

Vebreltinib Plus PLB1004 Versus Platinum-based Doublet Chemotherapy in Patients With EGFRm, MET+, Locally Advanced or Metastatic NSCLC Following EGFR-TKI Failure

Broad match: EGFR mutation (unspecified)Non-Small-Cell Lung Cancer

A Study of SHR-A2009 Combined With Aumolertinib Versus Aumolertinib for First-line Treatment in EGFR-mutated, Advanced or Metastatic NSCLC

Active, not recruiting Phase 3 Jiangsu Hengrui Started 2025 NCT07183189

SHR-A2009 ; AumolertinibAumolertinib

…lly confirmed locally advanced, metastatic, or recurrent non-small cell lung cancer, with EGFR mutations confirmed by tissue or blood specimens.

Broad match: EGFR mutation (unspecified)Non-small Cell Lung Cancer

A Study of SKB264 in Combination With Osimertinib Versus Osimertinib in Patients With Epidermal Growth Factor Receptor (EGFR) Mutations, Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer

Active, not recruiting Phase 3 Kelun-Biotech Started 2024 NCT06670196

SKB264Osimertinib FDA EU

…on With Osimertinib Versus Osimertinib in Patients With Epidermal Growth Factor Receptor (EGFR) Mutations, Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer

Broad match: EGFR mutation (unspecified)Non-Small Cell Lung Cancer

A Study of SHR-A2009 Versus Platinum-based Chemotherapy in EGFR-mutated, Advanced or Metastatic NSCLC

Active, not recruiting Phase 3 Jiangsu Hengrui Started 2024 NCT06671379

SHR-A2009 monotherapyplatinum-based dual-agent chemotherapy

A Study of SHR-A2009 Versus Platinum-based Chemotherapy in EGFR-mutated, Advanced or Metastatic NSCLC

Broad match: EGFR mutation (unspecified)Non-small Cell Lung Cancer

Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors (MK-2870-009)

Active, not recruiting Phase 3 MSD (Merck & Co.) Started 2024 NCT06305754

Sacituzumab tirumotecanPemetrexedCarboplatinH1 Receptor AntagonistH2 Receptor AntagonistAcetaminophen (or equivalent)

…etrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Prior EGF…

Broad match: EGFR mutation (unspecified)Non-small Cell Lung Cancer (NSCLC)

A Study Comparing BL-B01D1 With Platinum Based Chemotherapy in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer(PANKU-Lung01)

Active, not recruiting Phase 3 Baili-Bio / SystImmune Started 2024 NCT06382116

BL-B01D1Pemetrexed+Cisplatin or Carboplatin

Documented classical EGFR mutations detected from tumor tissue or blood samples;

Broad match: EGFR sensitizing mutationNon-small Cell Lung Cancer

Almonertinib Combined With Anlotinib as First-line Treatment for Advanced Non-small Cell Lung Cance

Recruiting Phase 3 Qianfoshan Hospital Started 2023 NCT06043973

almonertinib

Patients with EGFR mutation and TP53 mutation advanced Non-squamous NSCLC.

Broad match: EGFR mutation (unspecified)Status may be outdated, last updated 2023-09-21Advanced Non-small Cell Lung Cancer

Sacituzumab Tirumotecan (MK-2870) Versus Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations (MK-2870-004)

Active, not recruiting Phase 3 MSD (Merck & Co.) Started 2023 NCT06074588

Sacituzumab tirumotecanDocetaxelPemetrexed

…iously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations (MK-2870-004)

Broad match: EGFR mutation (unspecified)Non-small Cell Lung Cancer (NSCLC)

Maintenance Pembrolizumab at Usual or Low doSE in Non-squamous Lung Cancer: a Non-inferiority Study

Recruiting Phase 3 Gustave Roussy, Cancer Campus, Grand Paris Started 2023 NCT05692999

Pembrolizumab 200 mg Q6WPemetrexed 500 mg/m^2 Q3WPembrolizumab 200 mg Q3W or 400 mg Q6W

In the presence of an EGFR mutation, an ALK or ROS1 rearrangement the patient must have received at least one specific target…

Broad match: EGFR mutation (unspecified)Metastatic Non-squamous Lung Cancer

A Phase III Study of SKB264 for EGFR Mutant NSCLC Patients

Active, not recruiting Phase 3 Kelun-Biotech Started 2023 NCT05870319

SKB264PemetrexedCarboplatinCisplatin

A Phase III Study of SKB264 for EGFR Mutant NSCLC Patients

Broad match: EGFR mutation (unspecified)Non-small Cell Lung Cancer

REZILIENT3 (REsearching ZIpaLertinib In Egfr Non-small Cell Lung Cancer Tumors)

Active, not recruiting Phase 3 Taiho Oncology Started 2023 NCT05973773

TAS6417

Part A: EGFR ex20ins or other uncommon single or compound EGFR mutation

Broad match: EGFR mutation (unspecified)Advanced or Metastatic NSCLS With Exon 20 Insertion Mutation

Phase 3 Clinical Study of AK112 for NSCLC Patients

Active, not recruiting Phase 3 Akeso Started 2022 NCT05184712

Ivonescimab (SMT112 or AK112) Injection

The tumor histology, cytology or hematology confirmed the presence of EGFR activating mutations before enrollment

Broad match: EGFR sensitizing mutationNon-Squamous Non-small Cell Lung Cancer

Phase III Study of TY-9591 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (FLETEO)

Recruiting Phase 3 TYK Medicines Started 2022 NCT05382728

TY-9591Osimertinib FDA EU

Presence of an activating EGFR-sensitive mutations (including exon 19 deletions, L858R, the above mentioned mutations alone or co-existed with other EGFR-mutated sites)…

Broad match: EGFR exon 19 deletionStatus may be outdated, last updated 2024-01-30NSCLC, EGFR Activating Mutation

EGFR-mutated Lung Cancer in Randomized Investigator-Initiated Study

Recruiting Phase 3 Region Skane Started 2022 NCT06486142

Afatinib/Dacomitinib FDA EUOsimertinib FDA EU

EGFR-mutation in tumor (in cases where tumor tissue is not available for mutation analysis, circulating…

Broad match: EGFR mutation (unspecified)Non-Small Cell Lung Cancer

Metformin Plus Tyrosine Kinase Inhibitors for Treatment of Patients With Non-small Cell Lung Cancer With EGFR Mutations

Recruiting Phase 3 Instituto Nacional de Cancerologia de Mexico Started 2021 NCT05445791

Metformin Hydrochloride

Patients with non-small cell lung cancer and a documented EGFR sensitizing mutation.

Broad match: EGFR sensitizing mutationNon Small Cell Lung Cancer

FHND9041 Versus Afatinib for Non-small Cell Lung Cancer

Enrolling by invitation Phase 3 Jiangsu Chia Tai Fenghai Pharmaceutical Started 2021 NCT06759857

FHND9041Afatinib FDA EU

…nce of a confirmed EGFR-positive gene mutation sensitive to EGFR-TKI treatment, including exon 19 deletion or L858R mutation.

Broad match: EGFR exon 19 deletionNon Small Cell Lung Cancer

A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Active, not recruiting Phase 3 Johnson & Johnson Started 2020 NCT04487080

Amivantamab FDA EUOsimertinib FDA EULazertinib FDA EU

The tumor harbors exon 19 deletions (Exon 19del) or Exon 21 L858R substitution, as detected by an food and drug administrati…

Broad match: EGFR exon 19 deletionCarcinoma, Non-Small-Cell Lung

PD-1 Inhibitor and Chemotherapy With Concurrent Irradiation at Varied Tumour Sites in Advanced Non-small Cell Lung Cancer

Active, not recruiting Phase 3 UNICANCER Started 2018 NCT03774732

PembrolizumabChemotherapy

Non-squamous NSCLC with targetable tumor mutations, activating EGFR mutations or ALK translocation Note: documentation of these mutation for non-squamous histology is …

Broad match: EGFR sensitizing mutationNon Small Cell Lung Cancer, Non Small Cell Lung Cancer Metastatic, Non-Small Cell Carcinoma of Lung, TNM Stage 4

Zipalertinib With Carboplatin and Pemetrexed for the Treatment of Resectable, Stage II-IIIB, Non-Small Cell Lung Cancer

Not yet recruiting Phase 2 Jonsson Comprehensive Cancer Center Starts 2027 NCT07229339

CarboplatinPemetrexedZipalertinib

…llment with EGFR Ex20Ins-mutated (addition of 1 or more amino acids) or uncommon/compound EGFR mutations (E709X, G719X, L747X, S758I, and/or L861Q) in tumor tissue or blood

Broad match: EGFR mutation (unspecified)Lung Non-Squamous Non-Small Cell Carcinoma

Lurbinectedin With Osimertinib in Transformed Small Cell Lung Cancer

Recruiting Phase 1/2 Misty Shields Starts 2027 NCT07153055

LurbinectedinOsimertinib FDA EU

Must have an initial diagnosis of EGFR altered (EGFR-mutated) non-small cell lung cancer and received EGFR targeted therapy (TKI) osimer…

Broad match: EGFR mutation (unspecified)Small Cell Lung Cancer ( SCLC ), Transformed Small Cell Lung Cancer

A Prospective Study of Firmonertinib as First-line Adaptive Therapy Guided by Dynamic ctDNA (MRD) Changes in Locally Advanced or Metastatic EGFR-mutated Non-small Cell Lung Cancer

Not yet recruiting Phase 2 Anhui Provincial Cancer Hospital Started 2026 NCT07661173

FirmonertinibFirmonertinib/pemetrexed/CarboplatinFirmonertinib/pemetrexed/Carboplatin/Bevacizumab

Confirmed presence of EGFR mutation-positive by tumor histology, cytology, or hematology;

Broad match: EGFR mutation (unspecified)Non Small Cell Lung Cancer

Phase II Study of Sacituzumab Tirumotecan in Combination With Osimertinib for Neoadjuvant Treatment in Patients With Resectable Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer

Recruiting Phase 2 Kelun-Biotech Started 2026 NCT07329322

Sacituzumab TirumotecanOsimertinib FDA EU

Confirmed by tumor histology, or cytology to have EGFR sensitizing mutations.

Broad match: EGFR sensitizing mutationNon-Small Cell Lung Cancer

Furmonertinib 160mg vs 80mg + Chemotherapy in EGFR-Mutated NSCLC With Brain Metastases: Efficacy and Safety Study

Not yet recruiting Phase 2 Tianjin Medical University Cancer Institute and Hospital Started 2026 NCT07365410

FurmonertinibFurmonertinibcarboplatinpemetrexed

Furmonertinib 160mg vs 80mg + Chemotherapy in EGFR-Mutated NSCLC With Brain Metastases: Efficacy and Safety Study

Broad match: EGFR mutation (unspecified)Non-small Cell Lung Cancer (NSCLC), Brain Metastases, Furmonertinib, EGFR Mutation

Tislelizumab in Combination With Bevacizumab and Capecitabine in Advanced Solid Tumors With Evaluation in Immunotherapy-Resistant and Central Nervous System Disease

Not yet recruiting Phase 1/2 National University Hospital, Singapore Started 2026 NCT07681297

Tislelizumab + Bevacizumab + Capecitabine

Patients with driver mutations (e.g., EGFR-mutant or ALK-rearranged NSCLC, HER2+ metastatic breast cancer) must have received at least one …

Broad match: EGFR mutation (unspecified)Advanced Solid Tumor Cancer, Triple-Negative Breast Cancer (TNBC), CNS Disease, Breast Cancer

Sacituzumab Tirumotecan Plus Third-Generation TKI With/Without Radiotherapy for EGFR-Mutant NSCLC Brain Metastases

Not yet recruiting Phase 2 Zhejiang Cancer Hospital Started 2026 NCT07343479

sac-TMT plus EGFR-TKI

Confirmed EGFR sensitizing mutation including exon 19 deletion (19-Del) or exon 21 point mutation (L858R);

Broad match: EGFR sensitizing mutationNSCLC (Advanced Non-small Cell Lung Cancer), EGFR Gene Mutations, Brain Metastasis

Fecal Microbiota Transplant(FMT) Combination With Tislelizumab in Advanced or Metastatic NSCLC

Not yet recruiting Phase 2 Se-Hoon Lee Started 2026 NCT07432984

Tislelizumab

…perienced disease progression after prior immunotherapy (However, patients with confirmed EGFR or ALK mutations must have shown progression after approved targeted therapies.)

Broad match: EGFR mutation (unspecified)Non Small Cell Lung Cancer

A Phase II Clinical Trial of Ivonescimab Plus Third-generation EGFR-TKIs in Advanced Non-small Cell Lung Cancer With Gradual or Potential Progression After EGFR-TKIs Treatment

Active, not recruiting Phase 2 Shandong Cancer Hospital and Institute Started 2026 NCT07669051

ivonescimab plus EGFR-TKI.

…confirmed by tumor histology, cytology or hematology testing before enrollment, including exon 19 deletion (19Del) and exon 21 point mutation (L858R)

Broad match: EGFR exon 19 deletionNSCLC (Advanced Non-small Cell Lung Cancer)

A Study to Investigate ANS02 in Participants With EGFR Mutation-Positive Non-Small Cell Lung Cancer

Recruiting Phase 1/2 Avistone Biotechnology Started 2026 NCT07538804

ANS02

With documentation of EGFR alteration

Broad match: EGFR mutation (unspecified)Non-Small Cell Lung Cancer

AMT-116 in Combination With AK112 in Patients With Lung Cancer

Recruiting Phase 1/2 Multitude Therapeutics Started 2026 NCT07590531

AMT-116AK112

…ort 3: Histologically or cytologically diagnosed with non-squamous NSCLC and harboring an EGFR mutation.

Broad match: EGFR mutation (unspecified)Advanced Non-small Cell Lung Cancer (NSCLC)

Hippocampus-Protective Radiotherapy Combined With Osimertinib for Symptomatic Brain Metastases in EGFR-Mutated Lung Cancer

Recruiting Phase 2 Tianjin Medical University Cancer Institute and Hospital Started 2026 NCT07505173

Hippocampus-Protective Radiotherapy Combined With Osimertinib for Symptomatic Brain Metastases in EGFR-classic Mutated Lung Cancer FDA EU

EGFR gene test confirmed EGFR sensitive mutations, including exon 19 deletion (19del) and exon 21 L858R mutation (verified and confirmed by investigators at the respec…

Broad match: EGFR exon 19 deletionNaive Advanced Non-small Cell Lung Cancer With EGFR-sensitive Mutations (EGFR Exon 19 Deletion and Exon 21 L858R Mutation) and Symptomatic Brain Metastases

Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII

Recruiting Phase 2 Black Diamond Therapeutics Started 2026 NCT07326566

silevertinib in combination with temozolomidetemozolomide (TMZ)

For Part 1 (Safety Lead-in) ONLY: EGFR alterations.

Broad match: EGFR mutation (unspecified)Glioblastoma (GBM), Newly Diagnosed Glioblastoma, GBM, Glioblastoma Multiforme (GBM)

BPI-361175 Tablets in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)

Not yet recruiting Phase 1/2 Xcovery Holdings Started 2026 NCT05393466

BPI-361175

…lly confirmed diagnosis of inoperable locally advanced or recurrent/metastatic NSCLC with EGFR mutations.

Broad match: EGFR mutation (unspecified)Non-small Cell Lung Carcinoma

Sacituzumab Tirumotecan（Sac-TMT） and Brain Radotherapy for EGFR+ NSCLC With Brain Mets

Not yet recruiting Phase 2 Xiaorong Dong Started 2026 NCT07789444

Sacituzumab Tirumotecan (Sac-TMT)

Presence of EGFR-sensitizing mutations, including exon 19 deletion or exon 21 L858R point mutation.

Broad match: EGFR exon 19 deletionNon-Small Cell Lung Cancer, Brain Metastases From Non-small Cell Lung Cancer (NSCLC), EGFR Mutation Positive Advanced Non-Small Cell Lung Cancer

Intestinal Low-Dose Radiotherapy Combined With Immune Checkpoint Inhibitors in Solid Tumors With Liver Metastases

Not yet recruiting Phase 2 Bing Xia Started 2026 NCT07875465

PD-1/PD-L1 inhibitorsCombined Chemotherapy

Cohort B: Advanced NSCLC with positive driver genes (EGFR/ALK/ROS1), disease progression during first-line targeted therapy.

Broad match: EGFR mutation (unspecified)Liver Metastases, Non-Small Cell Lung Cancer, Colorectal Cancer (Diagnosis), Pancreatic Cancer Metastatic

Amivantamab Combined With Intrathecal Pemetrexed for LM From EGFR-Mutated Lung Adenocarcinoma

Recruiting Phase 1/2 Second Affiliated Hospital, Zhejiang University, School of Medicine Started 2026 NCT07744529

Amivantamab+ systemic/ intrathecal Pemetrexed FDA EU

Patients with EGFR-mutated lung adenocarcinoma with leptomeningeal metastasis diagnosed according to the EANO-ESMO g…

Broad match: EGFR mutation (unspecified)Leptomeningeal Metastasis From Lung Cancer

A Phase 2 Study of ABSK043 Combined With Osimertinib

Not yet recruiting Phase 2 Abbisko Therapeutics Started 2026 NCT07710612

ABSK043 in combination with Osimertinib FDA EU

Documented genetic testing report confirms the presence of EGFR alteration(s) in tumor or plasma.

Broad match: EGFR mutation (unspecified)Non-Small Cell Lung Cancer With EGFR-mutated and PD-L1 Positive

Symbiotic-Lung-14: A Study to Learn About the Study Medicine Called PF08634404 in Combination With Chemotherapy in Adult Participants With Transformed Small Cell Lung Cancer

Recruiting Phase 2 Pfizer Started 2026 NCT07476287

PF-08634404Chemotherapy

Participant must have had a prior diagnosis of NSCLC with EGFR mutation which transformed to SCLC following the treatment with TKI(s).

Broad match: EGFR mutation (unspecified)Small Cell Lung Cancer, Small Cell Lung Cancer ( SCLC ), Transformed Small Cell Lung Cancer, Lung Neoplasms

Temozolomide, With or Without WSD0922-FU, for the Treatment of EGFR-Mutant, IDH-Wildtype Glioblastoma

Recruiting Phase 2 Mayo Clinic Started 2026 NCT07708961

EGFR/EGFRvIII Inhibitor WSD0922-FUTemozolomide

Glioblastomas must have a pathogenic EGFR mutation, with or without EGFR amplification, detected by Clinical Laboratory Improvement Act (CLI…

Broad match: EGFR mutation (unspecified)Glioblastoma, IDH-Wildtype

A Study to Evaluate ANS014004 in Combination With EGFR-TKI in Non-Small Cell Lung Cancer

Not yet recruiting Phase 1/2 Beijing Pearl Biotechnology Limited Liability Company Started 2026 NCT07285148

ANS014004 + PLB1004ANS014004 + Osimertinib FDA EU

Have a documented EGFR positive mutation (EGFR classic mutations including ex19del and ex21 L858R, uncommon mutations and ex20 insertion mutations) in tumor tissue samples …

Broad match: EGFR exon 19 deletionNon-Small Cell Lung Cancer, EGFR Mutation, Metastatic Lung Cancer, MET Alteration

Boosting Osimertinib Blood Brain Barrier Penetration

Recruiting Phase 2 Maastricht University Medical Center Started 2026 NCT07485452

Osimertinib & febuxostat FDA EU

The patient has metastatic EGFR-mutated NSCLC and is treated with osimertinib as part of regular care with CT-confirmed stable di…

Broad match: EGFR mutation (unspecified)Non-Small Cell Lung Cancer

First-line Therapy With Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor(EGFR-TKI) Combined With Trastuzumab Rezetecan for Advanced Non-small Cell Lung Cancer(NSCLC) Harboring EGFR Mutations Concomitant With Human Epidermal Growth Factor Receptor 2(HER2) Alterations

Not yet recruiting Phase 2 Yongsheng Wang Started 2026 NCT07699952

AlmonertinibTrastuzumab Rezetecan

Confirmed EGFR mutations via genetic testing, including Exon 19 deletion or L858R point mutation;

Broad match: EGFR exon 19 deletionLung Cancer (NSCLC), EGFR Activating Mutation, HER2

Neoadjuvant Sacituzumab Tirumotecan and Limertinib for Potentially Resectable Stage Ⅲ EGFR-mutant Non-small Cell Lung Cancer

Recruiting Phase 2 Shanghai Pulmonary Hospital, Shanghai, China Started 2026 NCT07323056

Sacituzumab Tirumotecan and Limertinib

Patients with non-small cell lung cancer (NSCLC) with EGFR mutation confirmed by pathology

Broad match: EGFR mutation (unspecified)EGFR-mutant Non-small Cell Lung Cancer, Potentially Resectable

A Study of Ivonescimab in Combination With Dato-DXd or Osimertinib in People With Non-Small Cell Lung Cancer

Recruiting Phase 1/2 Memorial Sloan Kettering Cancer Center Started 2026 NCT07535437

IvonescimabDato-DXdOsimertinib FDA EU

A Phase 1/2 Trial of Ivonescimab With Dato-DXd or Osimertinib in Patients With Metastatic EGFR-mutant Non-small Cell Lung Cancer That Progressed on EGFR TKI Therapy

Broad match: EGFR mutation (unspecified)Non-Small Cell Lung Cancer

The Study Of Andamertinib Plus Anlotinib In Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Not yet recruiting Phase 2 Fudan University Started 2026 NCT07780578

AndamertinibAnlotinib

Harboring EGFR mutations (including exon19 deletions and exon21 L858R mutation), with documented disease progressed following only one prior …

Broad match: EGFR exon 19 deletionNon-Small Cell Lung Cancer (NSCLC, Locally Advanced or Metastatic, Second-line

A Phase II Study of SKB264 + SKB118 in Nsq-NSCLC After EGFR-TKI Failure

Not yet recruiting Phase 2 Kelun-Biotech Started 2026 NCT07854509

SKB264+SKB118

Confirmed EGFR-sensitizing mutations.

Broad match: EGFR sensitizing mutationNon-Squamous Non-Small Cell Lung Cancer

Andamertinib With or Without Platinum-doublet Chemotherapy Versus Platinum-doublet Chemotherapy in Patients With NSCLC Harboring Atypical EGFR Mutations

Recruiting Phase 2 Avistone Biotechnology Started 2026 NCT07336732

PLB1004

…ublet Chemotherapy Versus Platinum-doublet Chemotherapy in Patients With NSCLC Harboring Atypical EGFR Mutations

Broad match: EGFR sensitizing mutationNon-Small-Cell Lung Cancer

Neoadjuvant Therapy With Firmonertinib Combined With Anlotinib and Platinum-Based Doublet Chemotherapy for Resectable EGFR-Mutated NSCLC

Not yet recruiting Phase 2 Hubei Cancer Hospital Started 2026 NCT07807722

Firmonertinib combined anlotinib and chemotehrapy

EGFR mutation positive non-small cell lung cancer (including 19Del and 21L858R) confirmed by biopsy

Broad match: EGFR exon 19 deletionNSCLC (Non-small Cell Lung Cancer), EGFR, Neoadjuvant Therapy

A Clinical Study for the Efficacy and Safety of BL0020 Injection in Patients With Small Cell Lung Cancer Transformed From Non-Small Cell Lung Cancer Following EGFR TKI Therapy

Not yet recruiting Phase 1/2 Shanghai Best-Link Bioscience Started 2026 NCT07414927

BL0020

Patients with initial diagnosis of EGFR-mutated NSCLC and histologically or cytologically confirmed transformation to SCLC following trea…

Broad match: EGFR mutation (unspecified)Small Cell Carcinoma of Lung

Safety and Efficacy Study in Adults With Advanced Solid Tumors Receiving REGN13089-M404-M2980, an Antibody-drug Conjugate That Targets MET Protein on Tumors

Not yet recruiting Phase 1/2 Regeneron Started 2026 NCT07863024

REGN13089-M404-M2980

Histologically confirmed cancer (non-small cell lung cancer (epidermal growth factor receptor mutant type or epidermal growth factor receptor mutant type), colorectal cancer, gastric/gastroe…

Broad match: EGFR mutation (unspecified)Advanced Solid Tumors

DZD6008 Combination Therapy in Patients With Locally Advanced or Metastatic NSCLC With EGFR Mutation (TIAN-SHAN7)

Recruiting Phase 1/2 Dizal Pharmaceuticals Started 2025 NCT07070440

DZD6008PemetrexedCarboplatinDocetaxel

Documentation of EGFR sensitizing mutation confirmed by local laboratory.

Broad match: EGFR sensitizing mutationNon Small Cell Lung Cancer

A Phase 1/2 Clinical Trial to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HMBD-501 in Patients With HER3-Expressing Solid Tumors

Recruiting Phase 1/2 Hummingbird Bioscience Started 2025 NCT06956690

ENV-501

Locally advanced or metastatic mutated EGFR (mEGFR) NSCLC (HER3+)

Broad match: EGFR mutation (unspecified)Melanoma (Skin), Non Small Cell Lung Cancer, Breast Cancer

Immunochemotherapy, Surgery or Chemoradiation, and Durvalumab for Stage IIIA/B NSCLC

Recruiting Phase 2 University Hospital, Bonn Started 2025 NCT06810609

Immunotherapy

Histologically and / or cytologically proven NSCLC (EGFRm-, ALK-). 8.

Broad match: EGFR mutation (unspecified)Lung Cancer Non-Small Cell Cancer (NSCLC)

Cerebrospinal Fluid Cytology-guided Intrathecal Chemo-holiday Therapy for EGFR-positive NSCLC Leptomeningeal Metastases

Not yet recruiting Phase 2 Zhejiang Cancer Hospital Started 2025 NCT06861218

pemetrexedvometinib

Histologically or cytologically confirmed diagnosis of NSCLC with EGFR mutations.

Broad match: EGFR mutation (unspecified)Leptomeningeal Metastases

Trilaciclib in Combination With Docetaxel for Second-Line and Beyond Treatment of Locally Advanced or Metastatic NSCLC

Recruiting Phase 2 The First Affiliated Hospital of Xiamen University Started 2025 NCT06929936

Trilaciclib combined with Docetaxel

Definition of driver genes: EGFR (including 19del, L858R, S768I, L861Q, and/or G719X), BRAF V600E, NTRK, MET14 exon skipping mutation, RET,…

Broad match: EGFR exon 19 deletionNon-Small Cell Lung Cancer, Myelosuppression

A Study of YL201 and Ivonescimab (AK112) in Advanced Solid Tumors

Recruiting Phase 1/2 MediLink Therapeutics (Suzhou) Started 2025 NCT07208773

YL201Ivonescimab

Phase 2: Extensive-stage SCLC, Non-AGA NSCLC, EGFR mutation NSCLC.

Broad match: EGFR mutation (unspecified)Advanced Solid Tumors, Non Small Cell Lung Cancer, Small Cell Lung Cancer

A Study of SYS6010 Combined With Osimertinib Versus Osimertinib Alone as Neoadjuvant Therapy for Patients With EGFR Mutation-positive Resectable Non-squamous Non-small Cell Lung Cancer

Not yet recruiting Phase 2 CSPC Started 2025 NCT07256509

SYS6010Osimertinib FDA EUPemetrexedCisplatinCarboplatin

…mbined With Osimertinib Versus Osimertinib Alone as Neoadjuvant Therapy for Patients With EGFR Mutation-positive Resectable Non-squamous Non-small Cell Lung Cancer

Broad match: EGFR mutation (unspecified)Non-Small Cell Lung Cancer

Primary Tumor Resection Plus Osimertinib in Advanced EGFR-mutant Non-small Cell Lung Cancer

Not yet recruiting Phase 2 Jianxing He Started 2025 NCT07177092

Osimertinib FDA EU

Presence of EGFR exon 19 deletion (19Del) or L858R mutation, confirmed by ARMS-PCR, NGS, or other validated methods.

Broad match: EGFR exon 19 deletionNon-Small Cell Lung Cancer, EGFR

Phase I/II Study of PLB1004 Combined With Platinum-based Doublet Chemotherapy in Patients With EGFR Mutation-positive

Not yet recruiting Phase 1/2 Avistone Pharmaceutical（Ningbo）Co. Started 2025 NCT07063329

PLB1004 80mg/160mg/240mg oral once daily Combined with Platinum-Based ChemotherapyPLB1004 80mg/160mg/240mg oral once daily Combined with Platinum-Based ChemotherapyRP2D of PLB1004 oral once daily Combined with Platinum-Based ChemotherapyRP2D of PLB1004 oral once daily Combined with Platinum-Based Chemotherapy

Patients with other EGFR mutations such as EGFR exon 20 insertion: They must have received platinum-based chemotherapy.

Broad match: EGFR mutation (unspecified)NSCLC (Non-small Cell Lung Cancer)

A Study of BL-B01D1 and Almonertinib in Patients With Resectable EGFR+ Stage II-IIIB NSCLC

Recruiting Phase 2 Sichuan University Started 2025 NCT06951464

BL-B01D1Almonertinib

…B01D1 in Combination With Almonertinib Followed by Adjuvant Almonertinib in Patients With Epidermal Growth Factor Receptor Mutation Positive Stage II-IIIB Resectable Non-Small Cell Lung Cancer

Broad match: EGFR mutation (unspecified)Non-Small Cell Lung Cancer

A Study of BH-30643 in Subjects With Locally Advanced or Metastatic NSCLC Harboring EGFR and/or HER2 Mutations

Recruiting Phase 1/2 BlossomHill Therapeutics Started 2025 NCT06706076

BH-30643BH-30643 combo therapy with Carboplatin/PemetrexedBH-30643

Pathologically confirmed diagnosis of locally advanced or metastatic NSCLC with EGFR or HER2 mutations in the kinase domain of exons 18, 19, 20, or 21.

Broad match: EGFR mutation (unspecified)NSCLC (Advanced Non-small Cell Lung Cancer)

A Phase Ⅰ/Ⅱa Clinical Study of GEN-725 in Combination With Dositinib

Recruiting Phase 1/2 Henan Genuine Biotech Started 2025 NCT07362940

GEN-725 tablets + Dositinib mesylate tablets

Patients with a positive EGFR mutation. (For patients with prior third-generation EGFR-TKI therapy, post-progression EGFR mutati…

Broad match: EGFR mutation (unspecified)Non-Small Cell Lung Cancer

CVL006 Combination Therapy in Advanced Solid Tumors

Not yet recruiting Phase 1/2 Convalife (Shanghai) Started 2025 NCT07157956

CVL006 combined with pemetrexed and carboplatinCVL006 in combination with SKB264CVL006 in combination with DS-8201CVL006 in combination with Enfortumab Vedotin

…rm2.1, Arm2.2, Arm2.5 and Arm2.7: For NSCLC Arm2.1: Non-squamous, wild-type NSCLC Arm2.2: EGFRm nsqNSCLC Arm2.3: Malignant pleural mesothelioma Arm2.4: triple-negative breast cancer Arm…

Broad match: EGFR mutation (unspecified)Advanced Solid Tumor

Osimertinib Combined With Savolitinib in the Treatment of NSCLC With Low Copy Number MET Amplification

Recruiting Phase 2 Qingdao Central Hospital Started 2025 NCT07322783

• Drug: Savolitinib • Drug: Osimertinib Mesylate Tablets FDA EU

Osimertinib Combined With Savolitinib in the Treatment of EGFR Mutated Osimertinib Resistant NSCLC With Low Copy Number MET Amplification

Broad match: EGFR mutation (unspecified)EGFR Positive Non-small Cell Lung Cancer, MET Amplification

Trilaciclib in Patients Receiving Sacituzumab Tirumotecan for EGFR-mutated, Advanced Non-Small Cell Lung Cancer (NSCLC)

Recruiting Phase 2 The First Affiliated Hospital of Xiamen University Started 2025 NCT06992739

Trilaciclib and Sacituzumab Tirumotecan

Patients with locally advanced or metastatic EGFR mutant non-small cell lung cancer diagnosed by histological or cytological examination, who have…

Broad match: EGFR mutation (unspecified)NSCLC (Advanced Non-small Cell Lung Cancer), EGFR, Myelosuppression

Targeted Induction Therapy for Stage III Unresectable EGFR Mutant Positive NSCLC

Recruiting Phase 2 Peng Zhang Started 2025 NCT07742332

Fumetinib combined platinum-based double chemotherapyConcurrent Radiochemotherapy

Targeted Induction Therapy for Stage III Unresectable EGFR Mutant Positive NSCLC

Broad match: EGFR mutation (unspecified)EGFR, NSCLC (Non-small Cell Lung Cancer), Locally Advanced Non-Small Cell Lung Cancer, Radiotherapy

A Study of TY-9591 With Chemotherapy as 1st Line Treatment in Patients With Mutated Epidermal Growth Factor Receptor NSCLC

Not yet recruiting Phase 2 TYK Medicines Started 2025 NCT06672068

TY-9591 80mg QD+pemetrexed+Cisplatin/CarboplatinTY-9591 160mg QD+pemetrexed+Cisplatin/Carboplatin

Tissue or blood samples tested positive for EGFR sensitive mutations (including exon 19 deletion, exon 21 L858R mutation, alone or in combination with other EGFR mutations) by central la…

Broad match: EGFR exon 19 deletionNSCLC

A Multicenter Phase II Randomized Trial of Limertinib Followed by Sintilimab and Chemotherapy vs. Limertinib Followed by Limertinib and Chemotherapy as Neoadjuvant Therapy in Resectable Stage II-IIIB EGFR-Mutant NSCLC

Not yet recruiting Phase 2 Wen-zhao ZHONG Started 2025 NCT07038460

Limertinib+sintilimab+chemotherapyLimertinib+chemotherapyOsimertinib FDA EU

…ollowed by Limertinib and Chemotherapy as Neoadjuvant Therapy in Resectable Stage II-IIIB EGFR-Mutant NSCLC

Broad match: EGFR mutation (unspecified)Resectable Non-small Cell Lung Cancer

Study of Anti-CEACAM5 ADC M9140 in Participants With Advanced Solid Tumors (PROCEADE PanTumor)

Active, not recruiting Phase 1/2 Merck KGaA Started 2025 NCT06710132

M9140

…essing EGFR tumors (including participants with any driver genomic alterations other than EGFR mutations

Broad match: EGFR mutation (unspecified)Solid Tumors, Gastric Cancer, Non-Small Cell Lung Cancer (NSCLC), Pancreatic Cancer

A Phase II Clinical Study to Evaluate HLX43 in Subjects With Advanced Non-small Cell Lung Cancer (NSCLC)

Recruiting Phase 2 Henlius Started 2025 NCT06907615

HLX43 DOSE 1 (2.0 mg/kg)HLX43 DOSE 2 (2.5 mg/kg)

Subjects with non-squamous NSCLC must have documented negative test results for EGFR and ALK alterations.

Broad match: EGFR mutation (unspecified)Non Small Cell Lung Cancer

High-Dose Firmonertinib Plus Bevacizumab as Neoadjuvant Therapy for Resectable EGFRm Stage II-IIIB NSCLC

Not yet recruiting Phase 2 Peking University Cancer Hospital & Institute Started 2025 NCT07182708

Firmonertinib Mesilate TabletsBevacizumab injection

EGFR mutation-positive confirmed by local laboratory testing of tissue or blood samples.

Broad match: EGFR mutation (unspecified)NSCLC (Non-small Cell Lung Cancer), EGFR Activating Mutation, Resectable Lung Non-Small Cell Carcinoma

Whole Body HER3 Quantification With Radiolabelled Patritumab Deruxtecan (HER3-DXd) PET/CT

Recruiting Phase 2 The Netherlands Cancer Institute Started 2025 NCT06222489

89Zr-Patritumab deruxtecan

Have a histologically or cytologically confirmed diagnosis of (locally) advanced stage EGFR mutation positive NSCLC, not amenable for curative intent treatment.

Broad match: EGFR mutation (unspecified)Non-Small Cell Lung Carcinoma, Advanced Non-Small Cell Squamous Lung Cancer, EGFR Gene Mutation

A Study to Assess the Efficacy of WSD0922-FU in Patients With C797S+ Advanced Non-small Cell Lung Cancer

Recruiting Phase 2 Wayshine Biopharm Started 2025 NCT06868485

WSD0922-FU Tablets, Dose level AWSD0922-FU Tablets, Dose level B

Documented EGFR mutation .

Broad match: EGFR mutation (unspecified)Non Small Cell Lung Cancer

A Phase Ib/II Clinical Study to Evaluate HLX43 in Combination With Serplulimab in Patients With Advanced/Metastatic Solid Tumors

Recruiting Phase 1/2 Henlius Started 2025 NCT06848699

HLX43 dose 1HLX43 dose 2HLX43 dose 3HLX43 dose 4HLX43 dose 5Serplulimab

… /metastatic NSCLC subjects confirmed by histology or cytology, requiring the presence of EGFR mutation and failure or intolerance to EGFR-TKI or/and platinum-based chemotherapy.

Broad match: EGFR mutation (unspecified)Solid Tumor Cancer, Non Small Cell Lung Cancer

A Phase Ib/II Clinical Study of GH21 Capsules Combined With Osimertinib Mesylate Tablets in Patients With NSCLC

Recruiting Phase 1/2 Suzhou Genhouse Bio Started 2024 NCT06306456

GH21Tagrisso

Advanced NSCLC patients with EGFR mutations confirmed by cytological or histological assessments, and meet the following requirement:

Broad match: EGFR mutation (unspecified)Status may be outdated, last updated 2024-07-08Non-Small Cell Lung Cancer With EGFR Mutation

A Study to Evaluate LB1410 in Combination With LB4330 in Patients With Advanced or Metastatic Solid Tumors

Recruiting Phase 1/2 L & L Bio Co., Ltd., Ningbo, China Started 2024 NCT06468358

LB1410LB4330

1. non-squamous NSCLC must have documented test results of EGFR mutation, ALK fusion and ROS1 fusions, and the above driver genes must be wild type;

Broad match: EGFR mutation (unspecified)Solid Tumor

A Study to Evaluate the Efficacy and Safety of the Combination of Glumetinib and Docetaxel（Albumin Bound）Verse Docetaxel for the Treatment of MET-overexpressed Non-small Cell Lung Cancer

Not yet recruiting Phase 2 CSPC Started 2024 NCT06525350

Glumetinib tabletsHB1801 (docetaxel, albumin-bound）Docetaxel

Driver genes alterations must be negative (including EGFR mutations, ALK fusion, ROS1 rearrangement fusion, BRAF V600 mutation, NTRK fusion, MET 14 exon skip…

Broad match: EGFR mutation (unspecified)Status may be outdated, last updated 2024-07-29Locally Advanced/Recurrent or Distant Metastasized Non-small Cell Lung Cancer With MET Overexpression

High-dose Furmonertinib or Combined With Chemotherapy in EGFR-mutant Advanced NSCLC After Disease Progression on Third-generation EGFR-TKI

Recruiting Phase 2 Jialei Wang Started 2024 NCT06652048

Furmonertinib 160mg QDFurmonertinib 240mg QDFurmonertinib 160mg QD plus Chemotherapy

High-dose Furmonertinib or Combined With Chemotherapy in EGFR-mutant Advanced NSCLC After Disease Progression on Third-generation EGFR-TKI

Broad match: EGFR mutation (unspecified)Non-Small Cell Lung Cancer

Study of BEBT-109 in Subjects With Non-Small Cell Lung Cancer Carrying EGFR Exon 20 Insertion Mutations

Recruiting Phase 2 BeBetter Med Started 2024 NCT06514027

BEBT-109 CapsulesPemetrexed Disodium for InjectionCarboplatin InjectionCisplatin Injection

Patients may have only EGFR exon 20 insertion mutations or may also have other EGFR or HER2 mutations;

Broad match: EGFR mutation (unspecified)Non Small Cell Lung Cancer

A Clinical Trial of Furmonertinib Combination Therapy As Neoadjuvant Treatment in Resectable EGFR-Mutated NSCLC

Not yet recruiting Phase 2 Shanghai Pulmonary Hospital, Shanghai, China Started 2024 NCT06585644

Furmonertinib in combination with Anrotinib and chemotherapy

Inclusion Criteria: 1) EGFR mutation-positive (including 19Del and 21L858R) non-small cell lung cancer (NSCLC) confirmed by biopsy

Broad match: EGFR exon 19 deletionStatus may be outdated, last updated 2024-09-05Lung Cancer (NSCLC)

A Study of Combining Cabozantinib and Atezolizumab for Advanced/Metastatic NSCLC (Cabatezo-1)

Not yet recruiting Phase 2 Jun Zhang, MD, PhD Started 2024 NCT05859217

CabozantinibAtezolizumab

…ates who are qualified for upfront FDA-approved targeted therapy (e.g. having sensitizing mutations in EGFR, ALK and BRAF, etc.), treatment must have failed and received at least one line of ONLY F…

Broad match: EGFR mutation (unspecified)Status may be outdated, last updated 2024-05-08Lung Cancer, NSCLC Stage IV, Metastatic NSCLC - Non-Small Cell Lung Cancer, Advanced NSCLC

Neoadjuvant Targeted Therapy in Patients With Resectable EGFR-mutated Lung Squamous Cell Carcinoma

Recruiting Phase 2 The First Affiliated Hospital of Guangzhou Medical University Started 2024 NCT06383728

Osimertinib FDA EU

Gene text confirmed EGFR mutation;

Broad match: EGFR mutation (unspecified)Status may be outdated, last updated 2024-05-09Lung Cancer, Carcinoma, Squamous Cell

A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

Recruiting Phase 2 Johnson & Johnson Started 2024 NCT06667076

Amivantamab FDA EULazertinib FDA EUChemotherapy: PemetrexedChemotherapy: Carboplatin

…Amivantamab in Combination With Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Broad match: EGFR sensitizing mutationCarcinoma, Non-Small-Cell Lung

Enhanced Dermatological Care to Reduce Rash and Paronychia in Epidermal Growth Factor Receptor (EGRF)-Mutated Non-Small Cell Lung Cancer (NSCLC) Treated First-line With Amivantamab Plus Lazertinib

Active, not recruiting Phase 2 Johnson & Johnson Started 2024 NCT06120140

Amivantamab IV FDA EUAmivantamab SC FDA EULazertinib FDA EUDoxycyclineMinocyclineClindamycin

Have a tumor that harbors an epidermal growth factor receptor (EGFR) Exon 19del or Exon 21 L858R substitution, as detected by an Food and Drug Administration (FDA)-appro…

Broad match: EGFR exon 19 deletionCarcinoma, Non-Small-Cell Lung

Neoadjuvant Toripalimab for Clinically Stage II-IIIB Resectable Non-small Cell Lung Cancer with EGFR Mutation and PD-L1 Positive Expression

Recruiting Phase 2 Ruijin Hospital Started 2024 NCT06269211

Toripalimab

Confirmation by the central laboratory that the tumor harbors EGFR mutations either sensitive mutations, uncommon mutations or complex mutations.

Broad match: EGFR mutation (unspecified)Carcinoma, Non-Small-Cell Lung

A Phase 1/2, Open-label, Multicenter, FIH Study to Evaluate Safety, Tolerability, PK and Anti-tumor Activity of YH42946

Recruiting Phase 1/2 Yuhan Started 2024 NCT06616766

YH42946

…ssue in quantity sufficient to allow for retrospective confirmation of HER2 aberration or EGFR mutation

Broad match: EGFR mutation (unspecified)NSCLC (Non-small Cell Lung Cancer), Solid Tumor

A Study of Sunvozertinib Combined With Anlotinib in Local Advanced or Metastatic Non-small Cell Lung Cancer

Not yet recruiting Phase 2 Shanghai Zhongshan Hospital Started 2024 NCT06182761

Sunvozertinib combination with Anlotinib

EGFR sensitive mutations confirmed by accredited local laboratories， including 19del、L858R and T790M。

Broad match: EGFR exon 19 deletionStatus may be outdated, last updated 2023-12-27NSCLC

A Study to Evaluate the Safety and Efficacy of HB0025 Injection in Patients With Advanced Solid Tumor

Recruiting Phase 1/2 Huabo Biopharm Started 2024 NCT06758557

HB0025PemetrexedPaclitaxelCarboplatin

3.1.3 Patients with tyrosine kinase inhibitor (TKI) drug sensitivity mutations of epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) translocation, who have experienced disease progres…

Broad match: EGFR mutation (unspecified)Advanced NSCLC, Advanced Endometrial Cancer

Furmonertinib Combined With Anlotinib in Lung Adenocarcinoma Patients With EGFR Mutations and Brain Metastases

Not yet recruiting Phase 2 Cancer Institute and Hospital, Chinese Academy of Medical Sciences Started 2024 NCT06483672

FurmonertinibAnlotinib

Tumor tissue samples or blood samples are confirmed to be EGFR mutations;

Broad match: EGFR mutation (unspecified)Status may be outdated, last updated 2024-07-03Adenocarcinoma of Lung Metastatic to Brain

Thoracic Radiotherapy for Patients With Metastatic (Stage IV) Non-Small Cell Lung Cancer at High Risk of Symptomatic Progression Within the Thorax

Recruiting Phase 2 University of Rochester Started 2024 NCT06262321

…of Non-Small Cell Lung Cancer (NSCLC) without targetable/oncogene driven mutations (i.e., EGFR mutations, ALK-rearrangement, ROS1 rearrangement).

Broad match: EGFR mutation (unspecified)Stage 4 NSCLC, Radiotherapy

Efficacy and Resistance Mechanisms of IP in NSCLC With Leptomeningeal Metastases

Recruiting Phase 2 Hunan Province Tumor Hospital Started 2024 NCT06440954

Intrathecal pemetrexed

EGFR mutant, ALK fusion, ROS1 fusion, and other oncogenic alterations including RET fusion, BRAF muta…

Broad match: EGFR mutation (unspecified)Status may be outdated, last updated 2024-06-04Non-Small Cell Lung Cancer

Sunvozertinib Plus Anlotinib as 1L Treatment in EGFR-Sensitive Mutations Combined With Co-Mutations Advanced NSCLC

Recruiting Phase 2 Hunan Province Tumor Hospital Started 2024 NCT06348927

sunvozertinib in combination with Anlotinib

EGFR-sensitive mutations confirmed by an accredited local laboratory, including exon 19 deletions, exon 21 L858R point mutations, and T790M mutations, combined with co-mutations, includi…

Broad match: EGFR exon 19 deletionStatus may be outdated, last updated 2024-09-19Non-Small Cell Lung Cancer

Phase II Clinical Study of Befotertinib in EGFR Non-classical Mutant NSCLC

Recruiting Phase 2 Second Affiliated Hospital, Zhejiang University, School of Medicine Started 2024 NCT06863506

befotertinib

Documented EGFR mutations: Cohort 1 (G719X/L861Q/S768I) or Cohort 2 (exon 20 insertion)

Broad match: EGFR mutation (unspecified)NSCLC (Non-small Cell Lung Cancer)

A Study of Stereotactic Radiosurgery (SRS) and Standard Treatment in People With Lung Cancer That Has Spread to the Brain

Recruiting Phase 2 Memorial Sloan Kettering Cancer Center Started 2024 NCT06741085

osimertinib FDA EU

Non-small cell lung cancer (NSCLC) with somatic activating mutation in EGFR diagnosis, confirmed at enrolling institution

Broad match: EGFR mutation (unspecified)Non Small Cell Lung Cancer Metastatic

Sunvozertinib Plus Anlotinib as 1L Treatment in EGFR Mutant Advanced NSCLC-RW

Recruiting Phase 2 Hunan Province Tumor Hospital Started 2024 NCT06355609

sunvozertinib in combination with Anlotinib

EGFR-sensitive mutations confirmed by an accredited local laboratory, including exon 19 deletions, exon 21 L858R point mutations, and T790M mutations, combined with co-mutations, includi…

Broad match: EGFR exon 19 deletionStatus may be outdated, last updated 2024-09-20Non-small Cell Lung Cancer

Neoadjuvant Befotertinib Combined Bevacizumab or Platinum-based Double Chemotherapy for Resectable Locally-advanced EGFR Mutation-positive Non-Small Cell Lung Cancer

Recruiting Phase 2 Peng Zhang Started 2024 NCT06755684

Befotertinib combined BevacizumabBefotertinib combined platinum-based double chemotherapy

…ombined Bevacizumab or Platinum-based Double Chemotherapy for Resectable Locally-advanced EGFR Mutation-positive Non-Small Cell Lung Cancer

Broad match: EGFR mutation (unspecified)EGFR, Non-Small Cell Lung Cancer, Locally Advanced Non-Small Cell Lung Cancer, Pemetrexed

A Study of AZD3470, a PRMT5 Inhibitor, Given as Monotherapy and in Combination in Patients With MTAP Deficient Advanced/Metastatic Solid Tumors

Recruiting Phase 1/2 AstraZeneca Started 2024 NCT06130553

AZD3470Datopotamab deruxtecan FDA

…defined criteria) and the participant has received prior systemic therapy appropriate for EGFR-altered advanced/metastatic NSCLC (per protocol), OR Tumor is negative for EGFR alterations eligi…

Broad match: EGFR mutation (unspecified)Advanced Solid Tumors That Are MTAP Deficient

A Study to Assess the Efficacy and Safety of WSD0922-FU in Patients With EGFRm+ Advanced Non-small Cell Lung Cancer

Recruiting Phase 1/2 Wayshine Biopharm Started 2024 NCT06631989

WSD0922-FU

A Study to Assess the Efficacy and Safety of WSD0922-FU in Patients With EGFRm+ Advanced Non-small Cell Lung Cancer

Broad match: EGFR mutation (unspecified)EGFR Mutation Positive Advanced Non-Small Cell Lung Cancer

Nintedanib Plus EGFR TKI In EGFR-mutated Non-small Cell Lung Cancer Patients

Recruiting Phase 1/2 China Medical University Hospital Started 2024 NCT06071013

Nintedanib, gefitinib, erlotinib, afatinib, osimertinib FDA EU

Positive EGFR mutations are diagenesis.

Broad match: EGFR mutation (unspecified)Non-small Cell Lung Cancer, EGFR Gene Mutation, EGFR-TKI Resistant Mutation

Sunvozertinib Combined With Chemotherapy for EGFRm After EGFR-TKI Treatment Failure：Phase I/II

Recruiting Phase 1/2 Sichuan University Started 2024 NCT06195189

SunvozertinibChemotherapy

EGFR-sensitive mutations including exon 19 deletion and exon 21 L858R mutated, and exon 20 T790M mutated.

Broad match: EGFR exon 19 deletionNon Small Cell Lung Cancer

Osimertinib Plus Dalpiciclib in Patients With EGFR-mutant, CDK4/6 Pathway Aberrant, Advanced Non-small Cell Lung Cancer Following Acquired Resistance to Third-generation EGFR TKI: a Phase II Trial

Recruiting Phase 2 Tianjin Medical University Cancer Institute and Hospital Started 2024 NCT06363734

Osimertinib plus Dalpiciclib FDA EU

Osimertinib Plus Dalpiciclib in Patients With EGFR-mutant, CDK4/6 Pathway Aberrant, Advanced Non-small Cell Lung Cancer Following Acquired Resistan…

Broad match: EGFR mutation (unspecified)Status may be outdated, last updated 2024-04-16Non-small Cell Lung Cancer, EGFR Activating Mutation, Cell Cycle Deregulation, EGFR-TKI Resistant Mutation

High-dose Furmonertinib Versus Osimertinib in Advanced EGFRm NSCLC Patients With Brain Metastases

Not yet recruiting Phase 2 Taizhou Hospital Started 2024 NCT06319950

FurmonertinibOsimertinib FDA EU

The tissue or blood sample is determined to be EGFR positive (including rare EGFR mutations) by testing by a tertiary Class A hospital or a qualified testing institution, and the ti…

Broad match: EGFR mutation (unspecified)Status may be outdated, last updated 2024-03-20Lung Cancer, Nonsmall Cell

Befotertinib and Icotinib for NSCLC With Uncommon EGFR Mutations

Recruiting Phase 2 Sun Yat-sen University Started 2024 NCT06517953

IcotinibBefotertinib

Befotertinib and Icotinib for NSCLC With Uncommon EGFR Mutations

Broad match: EGFR sensitizing mutationStatus may be outdated, last updated 2024-07-25Non-small Cell Lung Cancer Metastatic, EGFR G719X, EGFR L861Q, EGFR S768I

A Phase 1/2 Study to Evaluate the Safety, Tolerability and PK of JIN-A02 in Patients With EGFR Mutant Advanced NSCLC

Recruiting Phase 1/2 J Ints Bio Started 2023 NCT05394831

JIN-A02

…thologically confirmed and finally diagnosed advanced and/or metastatic NSCLC with active EGFR mutant

Broad match: EGFR mutation (unspecified)EGFR Mutant Advanced Non-small Cell Lung Cancer

A Study to Evaluate the Efficacy and Safety of Sutetinib Maleate Capsule in Locally Advanced or Metastatic NSCLC

Recruiting Phase 2 Teligene US Started 2023 NCT06010329

Sutetinib Maleate Capsule

…ficacy and Safety of Sutetinib Maleate Capsule in Locally Advanced or Metastatic NSCLC (Uncommon EGFR Mutations Only)

Broad match: EGFR sensitizing mutationNon-small Cell Lung Cancer

Anti-PD-1 Antibody Therapies of Camrelizumab in Combination With Pemetrexed and Carboplatin as First-line Treatment in Patients With Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer

Recruiting Phase 2 CrystalGenomics Started 2023 NCT05841472

Camrelizumab (SHR-1210), Pemetrexed, and Carboplatin

The site must provide documented information on EGFR mutation and ALK translocation and both must be negative.

Broad match: EGFR mutation (unspecified)Status may be outdated, last updated 2023-08-30Non Squamous Non Small Cell Lung Cancer

Vebreltinib Plus PLB1004 in EGFR-mutated, Advanced NSCLC With MET Amplification or MET Overexpression Following EGFR-TKI

Recruiting Phase 1/2 Avistone Biotechnology Started 2023 NCT06343064

VebreltinibPLB1004

EGFR mutations, including exon 19 deletion and exon 21 L858R.

Broad match: EGFR exon 19 deletionNon-Small-Cell Lung Cancer

A Study to Investigate Safety and Efficacy of Osimertinib and Amivantamab in Participants With Non-small Cell Lung Cancer With Common Epidermal Growth Factor Receptor Mutations

Active, not recruiting Phase 2 AstraZeneca Started 2023 NCT05801029

Osimertinib FDA EUAmivantamab FDA EU

…icacy of Osimertinib and Amivantamab in Participants With Non-small Cell Lung Cancer With Common Epidermal Growth Factor Receptor Mutations

Broad match: EGFR sensitizing mutationNon-Small Cell Lung Cancer (NSCLC)

A Phase 2 Study of Osimertinib and S-1 in Treatment Resistant EGFR Mutant NSCLC

Active, not recruiting Phase 2 National Cancer Centre, Singapore Started 2023 NCT05773092

Oral S-1 + Oral Osimertinib FDA EU

Patients must have histologically or cytologically confirmed EGFR mutant NSCLC.

Broad match: EGFR mutation (unspecified)NSCLC

XTX301 in Patients With Advanced Solid Tumors

Recruiting Phase 1/2 Xilio Development Started 2023 NCT05684965

XTX301

ROS1 fusion, NTRK fusion, BRAF V600E mutation, EGFR mutation, or ALK fusion) must have been previously treated with relevant targeted therapy per loca…

Broad match: EGFR mutation (unspecified)Advanced Solid Tumor

A Study to Investigate the Safety, Pharmacokinetics, and Clinical Activity of AP203 in Patients with Locally Advanced or Metastatic Solid Tumors, and Expansion to Selected Malignancies

Recruiting Phase 1/2 AP Biosciences Started 2023 NCT05473156

AP203AP203

No sensitive epidermal growth factor receptor (EGFR) mutation and anaplastic lymphoma kinase (ALK) rearrangement.

Broad match: EGFR mutation (unspecified)Locally Advanced or Metastatic Solid Tumors, Non Small Cell Lung Cancer (NSCLC), Head and Neck Squamous Cell Carcinoma (HNSCC), Esophageal Squamous Cell Carcinoma (ESCC)

A Study of SKB264 (MK-2870; Sac-TMT) for the Treatment of Participants With Advanced or Metastatic Non-small Cell Lung Cancer (SKB264-II-04) (MK-2870-003)

Active, not recruiting Phase 2 Klus Pharma Started 2023 NCT05816252

SKB264PembrolizumabCarboplatinOsimertinib FDA EU

or confirmed to harbor EGFR mutation;

Broad match: EGFR mutation (unspecified)Non-small Cell Lung Cancer

The Efficacy and Safety of IBI363 in Solid Tumors

Recruiting Phase 1/2 Hunan Province Tumor Hospital Started 2023 NCT06081907

IBI363IBI363IBI363IBI363IBI363

…F: Patients with histological or cytological confirmation of advanced NSCLC who harboring EGFR mutation and failed standard treatment.

Broad match: EGFR mutation (unspecified)Status may be outdated, last updated 2024-05-30Advanced Solid Tumor

IN10018 Combination Therapy in Advanced EGFR Mutation-positive NSCLC

Recruiting Phase 1/2 InxMed (Shanghai) Started 2023 NCT05994131

IN10018Furmonertinib

Documented EGFR mutations known to be associated with EGFR-TKI sensitivity, including Ex19del or L858R.

Broad match: EGFR exon 19 deletionNSCLC

Amivantamab, Lazertinib and Bevacizumab in Patients With EGFR-mutant Advanced Non-small Cell Lung Cancer With Progression on Previous Third-generation EGFR-TKI

Active, not recruiting Phase 2 ETOP IBCSG Partners Foundation Started 2023 NCT05601973

Amivantamab FDA EULazertinib FDA EUZirabev

Amivantamab, Lazertinib and Bevacizumab in Patients With EGFR-mutant Advanced Non-small Cell Lung Cancer With Progression on Previous Third-generation EGFR-TK…

Broad match: EGFR mutation (unspecified)Non Small Cell Lung Cancer

Safety and Efficacy Evaluation of Serplulimab Plus Chemo in SCLC Transformed From EGFR-mutated NSCLC After Treatment

Active, not recruiting Phase 2 Guangdong Association of Clinical Trials Started 2023 NCT05957510

SerplulimabSOC

…on, and the reports clearly indicate that they were non-small cell lung cancer containing EGFR mutations before transformation.

Broad match: EGFR mutation (unspecified)Small-cell Lung Cancer

Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)

Recruiting Phase 2 SWOG Cancer Research Network Started 2023 NCT05642572

CapmatinibOsimertinib FDA EURamucirumab FDA EU

Participants must have documentation of NSCLC with a sensitizing EGFR mutation and have radiologically or clinically progressed (in the opinion of the treating physicia…

Broad match: EGFR sensitizing mutationRecurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8

TY-9591 in the Patients With EGFR Mutations in Advanced NSCLC With Brain Metastases

Recruiting Phase 2 TYK Medicines Started 2023 NCT05948813

TY-9591Osimertinib FDA EU

Presence of an activating EGFR-sensitive mutations (including exon 19 deletions, L858R, the above mentioned mutations alone or co-existed with other EGFR-mutated sites)…

Broad match: EGFR exon 19 deletionNSCLC, EGFR Activating Mutation, Brain Metastases

To Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetic Profile of ABN401 in Patients With Advanced Solid Tumors Harboring c-MET Dysregulation

Recruiting Phase 2 Abion Started 2023 NCT05541822

VabametkibLazertinib FDA EU

EGFR mutation-positive including exon 19 deletions or exon 21 L858R as detected by an FDA-approved or other validated test in a CLIA certif…

Broad match: EGFR exon 19 deletionAdvanced Solid Tumors

Neoadjuvant Furmonertinib Plus Bevacizumab or Furmonertinib Monotherapy for Resectable and Potentially Resectable Stage III-IVA EGFR Mutation-Positive Lung Adenocarcinoma

Recruiting Phase 2 Shanghai Pulmonary Hospital, Shanghai, China Started 2022 NCT05503667

FurmonertinibBevacizumab

…umab or Furmonertinib Monotherapy for Resectable and Potentially Resectable Stage III-IVA EGFR Mutation-Positive Lung Adenocarcinoma

Broad match: EGFR mutation (unspecified)Status may be outdated, last updated 2022-08-17Lung Adenocarcinoma Stage III, Lung Adenocarcinoma Stage IV, EGFR Gene Mutation

Neoadjuvant Lazertinib Therapy in EGFR-Mutation Positive Lung Adenocarcinoma Detected by BALF Liquid Biopsy

Recruiting Phase 2 Konkuk University Medical Center Started 2022 NCT05469022

Neoadjuvant lazertinib FDA EU

Patients with the following EGFR gene mutations in the test on bronchoalveolar lavage fluid: E19Del, L858R alone or concurrent rare EGFR …

Broad match: EGFR mutation (unspecified)Status may be outdated, last updated 2022-07-21Non Small Cell Lung Cancer

Study to Evaluate Sutetinib Maleate Capsule in Locally Advanced or Metastatic Non-small Cell Lung Cancer

Recruiting Phase 2 Teligene US Started 2022 NCT05168566

Sutetinib Maleate Capsule

Confirmation that the tumor harbors a non-resistant uncommon EGFR mutation (tumor tissue biopsy), including one or more of L861Q, G719X and S768I mutations, excludi…

Broad match: EGFR sensitizing mutationNon-small Cell Lung Cancer

Safety and Efficacy of Combining APL-101 With Frontline Osimertinib in Patients With EGFR-mutated Metastatic Non-small Cell Lung Cancer (NSCLC)

Active, not recruiting Phase 1/2 Washington University School of Medicine Started 2022 NCT04743505

APL-101Osimertinib FDA EU

…ncer, or locally advanced disease that is not amendable for curative intent therapy, with TKI-sensitive EGFR mutation through CLIA certified lab.

Broad match: EGFR sensitizing mutationMetastatic Non Small Cell Lung Cancer

Dose Escalation/Expansion Study of Mavrostobart (PT199), an Anti-CD73 mAb, Administered Alone and in Combination With a PD-1 Inhibitor or Chemotherapy (the MORNINGSTAR Study)

Recruiting Phase 1/2 Phanes Therapeutics Started 2022 NCT05431270

Mavrostobart (PT199)TislelizumabGemcitabine + nab-PaclitaxelDocetaxelPemetrexedGemcitabine

…ically confirmed diagnosis of NSCLC without actionable genomic alterations (AGAs) such as EGFR or ALK mutations and radiological documentation of disease progression on prior treatments, which may inc…

Broad match: EGFR mutation (unspecified)Non Small Cell Lung Cancer, Pancreatic Ductal Adenocarcinoma

Study of ORIC-114 in Patients With Advanced Solid Tumors Harboring an EGFR or HER2 Alteration

Recruiting Phase 1/2 ORIC Pharmaceuticals Started 2022 NCT05315700

ORIC-114Chemotherapy drug

…d or metastatic solid tumor with a documented EGFR or HER2 exon 20 insertion mutation or atypical EGFR mutation as determined by any nucleic acid-based diagnostic testing method, or HER2 amplification/…

Broad match: EGFR sensitizing mutationSolid Tumors

Phase Ib/II Study of Almonertinib Combined With SHR-1701 in the Treatment of Relapsed or Advanced Non-small Cell Lung Cancer

Not yet recruiting Phase 1/2 Jiangsu Hengrui Started 2022 NCT05503888

Almonertinib combined with SHR-1701Almonertinib

…Innovative Drugs in the Treatment of Relapsed or Advanced Non-small Cell Lung Cancer With EGFR Mutation

Broad match: EGFR mutation (unspecified)Status may be outdated, last updated 2022-08-17Relapsed or Advanced Non-small Cell Lung Cancer

Surufatinib Combined With Toripalimab and Chemotherapy in the Treatment of Non-Small Cell Lung Cancer

Active, not recruiting Phase 2 Li Zhang, MD Started 2022 NCT05003037

Surufatinib, Toripalimab, Pemetrexed, Carboplatin/Cisplatin

EGFR mutation cases are not expected to exceed 50% of all enrolled patients in Cohort 2.

Broad match: EGFR mutation (unspecified)Non Small Cell Lung Cancer

Radiation During Osimertinib Treatment: a Safety and Efficacy Cohort Study

Active, not recruiting Phase 2 AIO-Studien-gGmbH Started 2022 NCT05089916

Osimertinib FDA EU

…ding to marketing authorization (first line treatment of tumor positive for a common or uncommon EGFR mutation, or later line treatment of tumor positive for EGFR T790M mutation, assessed according to…

Broad match: EGFR sensitizing mutationNSCLC, EGFR Positive Non-small Cell Lung Cancer, Oligoprogression

Phase 1/2 Study of Silevertinib (BDTX-1535) in Patients With Glioblastoma or Non-Small Cell Lung Cancer With EGFR Mutations

Active, not recruiting Phase 1/2 Black Diamond Therapeutics Started 2022 NCT05256290

silevertinib (BDTX-1535) monotherapy

…ed resistance C797S cohort): Advanced/metastatic NSCLC with the acquired resistance C797S EGFR mutation following up to 2 lines of therapy, including only one EGFR TKI, which must be a third ge…

Broad match: EGFR mutation (unspecified)Non-Small Cell Lung Cancer, Advanced Non-Small Cell Squamous Lung Cancer, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Lung Cancer

A Dose-escalation and Dose-expansion Phase I/Phase II Clinical Study of Dositinib Mesylate Tablets (90-1408) in the Treatment of Locally Advanced or Metastatic Non-small Cell Lung Cancer With Positive EGFR Mutation

Recruiting Phase 1/2 Henan Genuine Biotech Started 2022 NCT07231068

Dositinib mesylate tablets

Patients with confirmed EGFR activating mutations that are sensitive to EGFR TKI at any time after initial diagnosis, in dose escalation p…

Broad match: EGFR sensitizing mutationNon-Small Cell Lung Cancer

Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)

Recruiting Phase 1/2 Genmab Started 2022 NCT05579366

Rina-SCarboplatinBevacizumabPembrolizumabErythromycinItraconazole

…ncer, or fallopian tube cancer), endometrial cancer, non-small cell lung cancer (Part A), EGFR-mutated NSCLC (Part B), breast cancer (hormone receptor positive, HER2-negative and triple-negati…

Broad match: EGFR mutation (unspecified)High Grade Epithelial Ovarian Cancer, High Grade Serous Ovarian Cancer, Primary Peritoneal Carcinoma, Fallopian Tube Cancer

Study of MCLA-129, a Human Bispecific EGFR and cMet Antibody, in Patients With Advanced NSCLC and Other Solid Tumors

Recruiting Phase 1/2 Betta Pharmaceuticals Started 2021 NCT04930432

MCLA-129

For patients with advanced NSCLC, EGFR positive is defined as: EGFR mutation or EGFR amplification.

Broad match: EGFR mutation (unspecified)Solid Tumor, Non-Small Cell Lung Cancer, Head and Neck Cancer, Colorectal Cancer

Neoadjuvant HS-10296 (Almonertinib) Therapy for Potential Resectable Stage III EGFR Mutation-Positive Non-small Cell Lung Cancer

Active, not recruiting Phase 2 Shanghai Pulmonary Hospital, Shanghai, China Started 2021 NCT04685070

HS-10296 (Almonertinib)

Neoadjuvant HS-10296 (Almonertinib) Therapy for Potential Resectable Stage III EGFR Mutation-Positive Non-small Cell Lung Cancer

Broad match: EGFR mutation (unspecified)Status may be outdated, last updated 2024-08-14Non-small Cell Lung Cancer Stage III

JMT101 Combined With Osimertinib in Patients With Stage Ⅲb-Ⅳ Non-small Cell Lung Cancer (NSCLC) Characterized by Epithermal Growth Factor Receptor (EGFR) Common Mutations

Active, not recruiting Phase 2 Shanghai JMT-Bio Started 2021 NCT06391944

JMT101 InjectionOsimertinib tablet FDA EU

… to the 8th edition of the AJCC TNM staging criteria) or metastatic (Stage IV) harbouring EGFR common mutation with tumour tissue/blood sample.

Broad match: EGFR sensitizing mutationStatus may be outdated, last updated 2024-04-30Local Advanced or Metastatic NSCLC, Harboring EGFR Common Mutation

The Study of NC318 Alone or in Combination With Pembrolizumab in Patients With Advanced Non-small Cell Lung Cancer

Active, not recruiting Phase 2 Yale University Started 2021 NCT04699123

NC318 800 mgNC318 400 mgPembrolizumab

Patients with NSCLC known to harbor an ALK rearrangement, ROS1 rearrangement, EGFR mutation or BRAF mutation known to be sensitive to FDA approved tyrosine kinase inhibitors (TKI), …

Broad match: EGFR mutation (unspecified)Advanced Non-small Cell Lung Cancer

Verteporfin for the Treatment of Recurrent High Grade EGFR-Mutated Glioblastoma

Recruiting Phase 1/2 Emory University Started 2021 NCT04590664

Verteporfin

…hase 1 / 2 Study of Visudyne (Liposomal Verteporfin) in Persons with Recurrent High Grade EGFR-Mutated Glioblastoma

Broad match: EGFR mutation (unspecified)Glioblastoma, Recurrent Glioblastoma

Osimertinib Then Chemotherapy in EGFR-mutated Lung Cancer with Osimertinib Third-line Rechallenge

Recruiting Phase 2 Mark Vincent Started 2021 NCT04335292

Osimertinib First-Line FDA EUPlatinum + Pemetrexed Chemotherapy Second-LineOsimertinib Third-Line FDA EU

Patients must have a known activating Epidermal Growth Factor Receptor (EGFR) mutation.

Broad match: EGFR mutation (unspecified)Status may be outdated, last updated 2024-10-22Non-Small Cell Lung Cancer

Tiragolumab With Atezolizumab Plus Bevacizumab in Previously-Treated Advanced Non-squamous NSCLC

Active, not recruiting Phase 2 Georgetown University Started 2021 NCT04958811

TiragolumabAtezolizumabBevacizumab

Confirmed activating alteration in EGFR (cohort B only)

Broad match: EGFR mutation (unspecified)Non-squamous Non-small-cell Lung Cancer

Quaratusugene Ozeplasmid (Reqorsa) and Osimertinib in Patients With Advanced Lung Cancer Who Progressed on Osimertinib

Recruiting Phase 1/2 Genprex Started 2021 NCT04486833

quaratusugene ozeplasmidosimertinib FDA EUPlatinum-Based Chemotherapy

The NSCLC must be epidermal growth factor receptor (EGFR) mutation positive-positive based on results from most recent tissue biopsy or most recent evaluati…

Broad match: EGFR mutation (unspecified)Carcinoma, Non-Small Cell Lung

Tocilizumab, Ipilimumab, and Nivolumab for the Treatment of Advanced Melanoma, Non-Small Cell Lung Cancer, or Urothelial Carcinoma

Active, not recruiting Phase 2 M.D. Anderson Cancer Center Started 2021 NCT04940299

IpilimumabNivolumabTocilizumab

…CLC with EGFR mutation known to be associated with EGFR TKI sensitivity (including G719X, exon 19 deletion, L858R, L861Q).

Broad match: EGFR exon 19 deletionClinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Locally Advanced Bladder Carcinoma, Locally Advanced Bladder Urothelial Carcinoma

Pemetrexed and Carboplatin With or Without Anlotinib Hydrochloride for Osimertinib-resistant Non-squamous NSCLC

Recruiting Phase 2 Fudan University Started 2021 NCT04136535

PemetrexedCarboplatinAnlotinib

Presence of EGFR activating mutations and previously disease progression to Osimertinib (previously treated with 1st / 2nd gen…

Broad match: EGFR sensitizing mutationNSCLC Stage IV

Targeted Treatment for RET Fusion-Positive Advanced Non-Small Cell Lung Cancer (A LUNG-MAP Treatment Trial)

Active, not recruiting Phase 2 SWOG Cancer Research Network Started 2020 NCT04268550

Selpercatinib

This includes EGFR sensitizing mutations, EGFR T790M, ALK gene fusion, ROS1 gene fusion, KRAS activating mutation, BRAF V600E mut…

Broad match: EGFR sensitizing mutationRecurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8

Osimertinib Alone or With Chemotherapy for EGFR-Mutant Lung Cancers

Recruiting Phase 2 Memorial Sloan Kettering Cancer Center Started 2020 NCT04410796

Osimertinib FDA EUCarboplatinPemetrexed

Patients with detectable plasma EGFR mutations at C2D1

Broad match: EGFR mutation (unspecified)Metastatic Non-small Cell Lung Cancer

PLATFORM Study of Precision Medicine for Rare Tumors

Recruiting Phase 2 Cancer Institute and Hospital, Chinese Academy of Medical Sciences Started 2020 NCT04423185

Almonertinib 110 MGDacomitinib 45 MG FDA EUAlectinib 150 MGCrizotinib 250 MGPyrotinib 160/80 MGImatinib 400 MG

when obtaining EGFR mutation, ALK fusion, ROS-1 fusion, C-MET amplification, C-MET mutation, BRAF mutation, BRCA1/2 mu…

Broad match: EGFR mutation (unspecified)Rare Tumor

A Study Comparing Savolitinib Plus Osimertinib vs Savolitinib Plus Placebo in Patients With EGFRm+ and MET Amplified Advanced NSCLC

Active, not recruiting Phase 2 AstraZeneca Started 2020 NCT04606771

Osimertinib + Savolitinib FDA EUSavolitinib + Placebo

…Study Comparing Savolitinib Plus Osimertinib vs Savolitinib Plus Placebo in Patients With EGFRm+ and MET Amplified Advanced NSCLC

Broad match: EGFR mutation (unspecified)Non-Small Cell Lung Cancer

Study BT8009-100 in Subjects With Nectin-4 Expressing Advanced Malignancies

Active, not recruiting Phase 1/2 BicycleTx Limited Started 2020 NCT04561362

BT8009Pembrolizumab

…ng cancer (NSCLC) with no actionable mutations, such as Epidermal Growth Factor Receptor (EGFR) mutation, anaplastic lymphoma kinase (ALK) fusion oncogene, or ROS1 that have progressed following…

Broad match: EGFR mutation (unspecified)Urinary Bladder Neoplasm, Triple Negative Breast Neoplasms, Hormone Receptor Positive, HER2-negative Neoplasms, Hormone Receptor Positive, HER2-low Neoplasms

Osimertinib Plus Savolitinib in EGFRm+/MET+ NSCLC Following Prior Osimertinib

Active, not recruiting Phase 2 AstraZeneca Started 2019 NCT03778229

osimertinib FDA EUsavolitinib

…with EGFR TKI sensitivity and permitted in the osimertinib national label (such as either exon 19 deletion and/or L858R) which is not amenable to curative therapy.

Broad match: EGFR exon 19 deletionCarcinoma

Genetic Testing in Guiding Treatment for Patients With Brain Metastases

Active, not recruiting Phase 2 Alliance for Clinical Trials in Oncology Started 2019 NCT03994796

AbemaciclibPI3K Inhibitor paxalisibEntrectinibAdagrasib

For lung cancer, EGFR mutant patients must have failed EGFR therapies

Broad match: EGFR mutation (unspecified)CDK Gene Mutation, Metastatic Malignant Neoplasm in the Brain, Metastatic Malignant Solid Neoplasm, NTRK Family Gene Mutation

Assessing an Oral EGFR Inhibitor, Sunvozertinib in Patients Who Have Advanced Non-small Cell Lung Cancer With EGFR or HER2 Mutation (WU-KONG1)

Active, not recruiting Phase 1/2 Dizal Pharmaceuticals Started 2019 NCT03974022

Sunvozertinib

…ocumented histological or cytological confirmed locally advanced or metastatic NSCLC with EGFR or HER2 mutations.

Broad match: EGFR mutation (unspecified)Non-Small Cell Lung Cancer

Phase II Randomized Trial of Carboplatin+Pemetrexed+Bevacizumab+/- Atezolizumab in Stage IV NSCLC

Active, not recruiting Phase 2 Fox Chase Cancer Center Started 2019 NCT03786692

Arm AArm B

…izumab, With or Without Atezolizumab in Stage IV Non-squamous NSCLC Patients Who Harbor a Sensitizing EGFR Mutation or Have Never Smoked

Broad match: EGFR sensitizing mutationNon-Small Cell Carcinoma of Lung, TNM Stage 4

Oleclumab (MEDI9447) Epidermal Growth Factor Receptor Mutant (EGFRm) Non-small Cell Lung Cancer (NSCLC) Novel Combination Study

Active, not recruiting Phase 1/2 AstraZeneca Started 2018 NCT03381274

OleclumabOsimertinib FDA EUAZD4635

…sed with histologically or cytologically confirmed locally advanced/metastatic NSCLC with EGFRm

Broad match: EGFR mutation (unspecified)Carcinoma, Non-Small-Cell Lung

Study of Osimertinib and Stereotactic Ablative Radiation (SABR) in EGFR Mutant NSCLC

Active, not recruiting Phase 2 University of Texas Southwestern Medical Center Started 2018 NCT03667820

Osimertinib FDA EU

EGFR mutations may be demonstrated by standard, clinically accepted methods, including direct gene seque…

Broad match: EGFR mutation (unspecified)Non-small Cell Lung Cancer (NSCLC)

Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change

Recruiting Phase 2 National Cancer Institute (NCI) Started 2018 NCT03191149

Osimertinib FDA EU

Phase II Study of Osimertinib (AZD9291) in Advanced NSCLC Patients With Exon 20 Insertion Mutations in EGFR

Broad match: EGFR mutation (unspecified)Advanced Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage IIIB Lung Non-Small Cell Cancer AJCC v7, Stage IV Lung Non-Small Cell Cancer AJCC v7

Testing AZD9291 as Potentially Targeted Treatment in Cancers With EGFR Genetic Changes (MATCH-Subprotocol E)

Active, not recruiting Phase 2 National Cancer Institute (NCI) Started 2016 NCT06303167

Osimertinib FDA EU

…mertinib (AZD9291) in Patients With Tumors Having EGFR T790M Mutations or Rare Activating Mutations of EGFR

Broad match: EGFR mutation (unspecified)Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphoid Cell Neoplasm, Refractory Lymphoma

A Study of TAK-788 in Adults With Non-Small Cell Lung Cancer

Active, not recruiting Phase 1/2 Takeda Started 2016 NCT02716116

TAK-788

…one of the following documented by a local test: an activating mutation in EGFR including exon 19 deletions or exon 21 L858R substitution (with or without T790M), or an uncommon activating mutatio…

Broad match: EGFR exon 19 deletionCarcinoma, Non-Small-Cell Lung

Erlotinib Hydrochloride and Cabozantinib-s-Malate Alone or in Combination as Second or Third Line Therapy in Treating Patients With Stage IV Non-small Cell Lung Cancer

Active, not recruiting Phase 2 National Cancer Institute (NCI) Started 2013 NCT01708954

Cabozantinib S-malateErlotinib Hydrochloride FDA EU

Tumor with a sensitizing mutation in epidermal growth factor receptor (EGFR), defined as follows:

Broad match: EGFR mutation (unspecified)Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Non-Small Cell Cancer AJCC v7

Afatinib With CT and RT for EGFR-Mutant NSCLC

Active, not recruiting Phase 2 Massachusetts General Hospital Started 2012 NCT01553942

Afatinib FDA EUCisplatinPemetrexed

Have lung cancer harboring an EGFR mutation

Broad match: EGFR mutation (unspecified)Lung Cancer

Erlotinib With or Without Hydroxychloroquine in Chemo-Naive Advanced NSCLC and (EGFR) Mutations

Active, not recruiting Phase 2 Massachusetts General Hospital Started 2009 NCT00977470

Erlotinib FDA EUHydroxychloroquine

An EGFR sensitizing mutation must be detected in tumor tissue.

Broad match: EGFR sensitizing mutationNon-small Cell Lung Cancer

CM93 Treatment in Subjects With Epidermal Growth Factor Receptor (EGFR)-Modified Recurrent Glioblastoma (rGBM)

Not yet recruiting Phase 1 Crimson Biopharm Starts 2027 NCT04933422

CM93

Archival tumor from initial or other prior surgery is documented to have EGFR mutation or EGFR amplification

Broad match: EGFR mutation (unspecified)Status may be outdated, last updated 2024-08-21Glioblastoma

Safety and Efficacy of Intrathecal Sacituzumab Tirumotecan for Leptomeningeal Metastasis in EGFR-TKI-Resistant Non-Small Cell Lung Cancer

Not yet recruiting Phase 1 Henan Cancer Hospital Started 2026 NCT07702305

Sacituzumab tirumotecan

Pathologically diagnosed as EGFR mutation-positive non-small cell lung cancer;

Broad match: EGFR mutation (unspecified)EGFR-TKI-resistant Non-small Cell Lung Cancer With Leptomeningeal Metastasis

An Open-label, Fixed-sequence Phase I Clinical Trial to Evaluate the Effect of HS-10504 on the Pharmacokinetics of Midazolam in Patients With Non-small Cell Lung Cancer

Not yet recruiting Phase 1 Hansoh Pharma Started 2026 NCT07685041

HS-10504； midazolam

Confirmed EGFR mutation positivity in participants before enrollment.

Broad match: EGFR mutation (unspecified)NSCLC

Zorifertinib With Osimertinib for NSCLC With Meningeal Progression

Recruiting Phase 1 Alpha Biopharma (Jiangsu) Started 2026 NCT07361705

Zorifertinib and Osimertinib Combination Therapy FDA EU

…riod, subjects must have a previous histological or cytological diagnosis of NSCLC with a sensitising EGFR mutation (including L858R and/or Exon19Del).

Broad match: EGFR sensitizing mutationPatients With Advanced Non-small Cell Lung Cancer With Meningeal Progression After Osimertinib Treatment

Locoregional Administration of Genetically Engineered Cells (EGFR/IL13Rα2 Pool-CAR T Cells) for the Treatment of Recurrent or Progressive High-Grade Gliomas

Recruiting Phase 1 City of Hope Medical Center Started 2026 NCT07544992

Autologous Anti-EGFR/Anti-IL13Ralpha2 CAR T-cells

EGFR gene-altered by NGS or FISH analysis

Broad match: EGFR mutation (unspecified)Recurrent Astrocytoma, IDH-Mutant, Grade 4, Recurrent Glioblastoma, IDH-Wildtype

JL19001 Injection Alone or in Combination With Standard Therapy in Patients With Advanced Solid Tumors or Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma

Recruiting Phase 1 Jecho Biopharmaceuticals Started 2026 NCT07603479

JL19001, subcutaneous injection, 1 μg/kgJL19001, subcutaneous injection, 5 μg/kgJL19001, subcutaneous injection,10 μg/kgJL19001, subcutaneous injection,15 μg/kgJL19001, subcutaneous injection,20 μg/kgJL19001, subcutaneous injection,25 μg/kg

For patients with driver alterations (e.g., EGFRmutations, ALKfusions, ROS1fusions, BRAF V600mutations, NTRKfusions, METexon 14 skipping, RETaltera…

Broad match: EGFR mutation (unspecified)Malignancies, Solid Malignant Tumor, NHL (Non-Hodgkin Lymphoma), Solid Tumor Cancer

A Phase 1 Study of EPI-326 in EGFR-mutant NSCLC and HNSCC

Recruiting Phase 1 EpiBiologics Started 2026 NCT07462377

EPI-326

o For NSCLC: the tumor harbors any documented EGFR mutation, insertion, or deletion.

Broad match: EGFR mutation (unspecified)Epidermal Growth Factor, Epidermal Growth Factor Receptor, Epidermal Growth Factor Receptor Gene Mutation, Non Small Cell

A Phase Ib Study of HS-10504 Combined Therapy in NSCLC

Not yet recruiting Phase 1 Hansoh Pharma Started 2026 NCT07414953

HS-10504SHR-A2009HS-20122HS-20117SHR-1826SHR-A2102

Cohort1:participants with EGFR mutation advanced stage NSCLC，disease progression on or after prior treatment；

Broad match: EGFR mutation (unspecified)Lung Cancer

A Clinical Study to Evaluate the Safety and Tolerability of AWT020 in Patients With Advanced Malignancies

Recruiting Phase 1 Shanghai Junshi Bioscience Started 2025 NCT06839105

TaxolCisplatin or CarboplatinPemetrexedOxaliplatinCapecitabineBevacizumab

Subjects with EGFR or ALK mutations will need to progress with prior treatment with appropriate kinase inhibitors.

Broad match: EGFR mutation (unspecified)Non-Small Cell Lung Cancer, Colorectal Cancer, Renal Cell Carcinoma, Melanoma and Other Solid Tumor

A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-159642 in Participants With Advanced Solid Tumors

Recruiting Phase 1 Vividion Therapeutics Started 2025 NCT06804824

VVD-159642SotorasibTrametinib

any solid tumor that harbors an epidermal growth factor receptor (EGFR) alteration as per local/historical testing

Broad match: EGFR mutation (unspecified)Advanced Solid Tumors

A Phase l Clinical Study to Evalute the Safety,Tolerability,Pharmacokinetic Characteristics,and Preliminary Anti-tumor Efficacy of HJ-004-02 Tablets in Patients With Non-squamous Non-small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Mutations

Recruiting Phase 1 Tongji University Started 2025 NCT07361237

HJ-004-02 tablets

Subjects must have non-squamous NSCLC with one or more positive EGFR mutations

Broad match: EGFR mutation (unspecified)NSCLC (Advanced Non-small Cell Lung Cancer)

Study of NXP900 With Osimertinib in Subjects With Advanced, EGFR-Mutated Non-Small Cell Lung Cancer

Recruiting Phase 1 Nuvectis Pharma Started 2025 NCT07315113

NXP900Osimertinib FDA EU

Unresectable, metastatic or locally advanced EGFR-mutated NSCLC.

Broad match: EGFR mutation (unspecified)EGFR Mutation Positive Non-small Cell Lung Cancer, EGFR Mutated Non-small Cell Lung Cancer Patients

A Phase I Study of CFT8919 in Patients With Advanced NSCLC

Recruiting Phase 1 Betta Pharmaceuticals Started 2024 NCT06641609

Dose-Escalation (Phase Ia) CFT8919 capsuleDose-Expansion (Phase Ib) CFT8919 capsuleCohort-Expansion (Phase Ic) CFT8919 capsule

…rienced disease progression after third-generation EGFR-TKI treatment and carry secondary EGFR mutations (such as C797S, L718Q, G724S, S768I, etc.).

Broad match: EGFR mutation (unspecified)Non-Small Cell Lung Cancer With EGFR Mutation

A Clinical Trial of SIBP-A13 Injection in the Treatment of Advanced Malignant Solid Tumor Patients.

Recruiting Phase 1 Shanghai Institute Of Biological Products Started 2024 NCT06298058

SIBP-A13 formulation for injection

…cell lung cancer (NSCLC) confirmed by histology or cytology, with disease progression and EGFR mutation during or after treatment with third generation TKI and platinum containing therapy.

Broad match: EGFR mutation (unspecified)Advanced Solid Tumor

A Study of DM001 in Patients With Advanced Solid Tumors

Active, not recruiting Phase 1 Xadcera Biopharmaceutical (Suzhou) Started 2024 NCT06475937

DM001

…e pathologically or cytologically confirmed documented metastatic/advanced breast cancer, EGFRmut or EGFRwt NSCLC, gastric cancer, gastroesophageal cancer or CRC, and have progressed on s…

Broad match: EGFR mutation (unspecified)Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Solid Carcinoma

A Study to Investigate the Safety and Efficacy of KQB198 as Monotherapy and in Combination in Participants With Advanced Solid Malignancies

Active, not recruiting Phase 1 Kumquat Biosciences Started 2024 NCT06507306

KQB198Osimertinib FDA EUAmivantamab FDA EU

… arms) and Part 2 Cohort A and Cohort B: Histologically confirmed diagnosis of NSCLC with activating EGFR mutation and progression on osimertinib

Broad match: EGFR sensitizing mutationSolid Tumor, Adult

HY1272 in Patients With Locally Advanced or Metastatic Solid Tumors or Locally Advanced or Metastatic EGFRm+ NSCLC

Not yet recruiting Phase 1 Newsoara Biopharma Started 2024 NCT06218940

HY1272

All patients must have documented EGFRm+, prior to enrolling in the combination therapy cohorts of this study.

Broad match: EGFR mutation (unspecified)Status may be outdated, last updated 2024-01-23NSCLC Stage IV

A Clinical Study of SYS6023 in Patients With Advanced Solid Tumors

Recruiting Phase 1 CSPC Started 2024 NCT07110883

SYS6023

…r (PR) ) expression for breast cancer participants, and Epidermal Growth Factor Receptor (EGFR) mutation, Anaplastic Lymphoma Kinase (ALK) fusion, ROS Proto-Oncogene 1, receptor tyrosine kinase …

Broad match: EGFR mutation (unspecified)Advanced Solid Tumor

A Study of the Oral EGFR Inhibitor PLB1004 in Non-Small Cell Lung Cancer

Recruiting Phase 1 Avistone Biotechnology Started 2024 NCT06046495

PLB1004

Have a documented EGFR mutation by a local test in tissue or plasma;

Broad match: EGFR mutation (unspecified)Non-Small Cell Lung Cancer

A Study of NPX887 for Participants With Solid Tumors Known to Express B7-H7/HHLA2

Recruiting Phase 1 NextPoint Therapeutics Started 2024 NCT06240728

NPX887

…xpansion) and Part 1c (Randomized Dose Comparison): participants who have clear cell RCC, EGFR mutant lung adenocarcinoma, or gastric/GEJ adenocarcinoma.

Broad match: EGFR mutation (unspecified)Metastatic Malignant Neoplasm

First in Human Multicenter Open Name Dose-increase, Consolidation Method to Study Safety Drug-level in Blood & Drug Metabolism Clinical Activity of Oral JBI-778 in Lung Cancer Patients With, Without Brain Metastasis IDH Mutated WHO Grade 3,4 Recurrent Glioma, Salivary Glands Tumor

Recruiting Phase 1 Jubilant Therapeutics India Limited Started 2024 NCT07755397

JBI-778

EGFR-mutated non-small cell lung cancer (NSCLC) with or without brain metastases previously treated wi…

Broad match: EGFR mutation (unspecified)NSCLC Patients With EGFR Activating Mutation, Adenoid Cystic Carcinoma Metastatic, Adenoid Cystic Carcinoma of the Head and Neck

A Phase I Clinical Study of HS-20117 in Participants With Advanced Solid Tumors

Not yet recruiting Phase 1 Hansoh Pharma Started 2023 NCT05940116

HS-20117

…a study: Participants with locally advanced or metastatic NSCLC (stage IIIB/IIIC/IV) with EGFR-activating mutations who have progressed after or are intolerant to or not available to standard of care (SoC…

Broad match: EGFR sensitizing mutationStatus may be outdated, last updated 2023-07-12Non-Small Cell Lung Cancer, Solid Tumor

Study of Osimertinib With Carotuximab in Advanced, EGFR-mutated Non-Small Cell Lung Cancer

Recruiting Phase 1 Karen Reckamp, MD, MS Started 2023 NCT05401110

Osimertinib FDA EUCarotuximab

Stage IV or recurrent/metastatic non-squamous NSCLC that harbors an EGFR activating mutation (Exon 21 L858R, Exon 19 deletion, Exon 18 G719X, Exon 21 L861Q, etc).

Broad match: EGFR sensitizing mutationNon Small Cell Lung Cancer, Lung Cancer

A Phase 1 Study of CPO301 in Adult Patients With Advanced or Metastatic Solid Tumors

Recruiting Phase 1 Conjupro Biotherapeutics Started 2023 NCT05948865

CPO301

In Part B, Cohort 1 will exclusively include NSCLC patients with documented EGFR mutations based on previous biopsy result and Cohort 2 will be patients with other cancer(s) sugges…

Broad match: EGFR mutation (unspecified)Cancer, Cancer, Lung

A Phase I Study to Evaluate the Safety, Tolerability, and PK of HLX43 in Advanced/Metastatic Solid Tumors

Enrolling by invitation Phase 1 Henlius Started 2023 NCT06115642

HLX43HLX10

The standard treatment for non-squamous NSCLC with known EGFR mutations is defined as EGFR inhibitors and platinum-containing chemotherapy.

Broad match: EGFR mutation (unspecified)Advanced/Metastatic Malignant Solid Tumors

Study of Furmonertinib in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Activating, Including Uncommon, Epidermal Growth Factor Receptor (EGFR) or Human Epidermal Growth Factor Receptor 2 (HER2) Mutations

Active, not recruiting Phase 1 ArriVent BioPharma Started 2022 NCT05364073

FurmonertinibFurmonertinibFurmonertinibFurmonertinibFurmonertinib

… results from local testing of either tumor tissue or blood confirming the presence of an EGFR activating mutation, performed at a CLIA- or equivalently certified laboratory.

Broad match: EGFR sensitizing mutationNon-Small Cell Lung Cancer (NSCLC), Metastatic Non-Small Cell Lung Cancer, Advanced Non-Small Cell Lung Cancer, HER2 Exon 20 Mutations

First in Human Study of AZD9592 in Solid Tumors

Active, not recruiting Phase 1 AstraZeneca Started 2022 NCT05647122

AZD9592Osimertinib FDA EU5-Fluorouracil (5-FU)LeucovorinBevacizumab

Histologically or cytologically confirmed metastatic or locally advanced EGFRmut., NSCLC

Broad match: EGFR mutation (unspecified)Advanced Solid Tumours, Carcinoma Non-small Cell Lung, Head and Neck Neoplasms, Colorectal Neoplasms

Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors

Active, not recruiting Phase 1 AbbVie Started 2022 NCT05599984

ABBV-706CisplatinBudigalimabCarboplatin

…euroendocrine carcinoma (LCNEC)s, SCLC transformed from epidermal growth factor receptor (EGFR) mutant non-small cell lung cancer (NSCLC), atypical lung carcinoids, and other high-grade poorly…

Broad match: EGFR mutation (unspecified)Advanced Solid Tumors

MRX-2843 and Osimertinib for the Treatment of Advanced EGFR Mutant Non-small Cell Lung Cancer

Recruiting Phase 1 Emory University Started 2021 NCT04762199

Flt3/MerTK Inhibitor MRX-2843Osimertinib FDA EU

…nts must have histologically confirmed metastatic non-small cell lung cancer (NSCLC) with activating EGFR mutation including typical and atypical mutations in egfr exons 19 and 21

Broad match: EGFR sensitizing mutationAdvanced Lung Non-Small Cell Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8

A Dose Escalation Study of SHP2 Inhibitor in Patients With Solid Tumors Harboring KRAS of EGFR Mutations

Active, not recruiting Phase 1 HUYABIO International Started 2021 NCT05163028

HBI-2376

Advanced malignant solid tumors with KRAS or EGFR mutations diagnosed by histology or cytology

Broad match: EGFR mutation (unspecified)Non Small Cell Lung Cancer, Colorectal Cancer, Pancreatic Cancer, Solid Tumor

A Study of CLN-619 Alone and in Combination With Pembrolizumab in Advanced Solid Tumors

Active, not recruiting Phase 1 Cullinan Therapeutics Started 2021 NCT05117476

CLN-619PembrolizumabPaclitaxelCarboplatin AUC 6pemetrexedDatopotamab deruxtecan-dlnk (Dato-DXd) FDA

…1: Histologically or cytologically confirmed metastatic or locally advanced, unresectable EGFRm NSCLC.

Broad match: EGFR mutation (unspecified)Advanced Solid Tumor, NSCLC

DS8201a and Pembrolizumab in Participants With Locally Advanced/Metastatic Breast or Non-Small Cell Lung Cancer

Active, not recruiting Phase 1 Daiichi Sankyo Started 2020 NCT04042701

Trastuzumab deruxtecan (DS-8201a)Trastuzumab deruxtecan (DS-8201a)Pembrolizumab

Participants who have known epidermal growth factor receptor (EGFR) mutation, anaplastic lymphoma kinase (ALK), BRAF V600E mutation, or ROS1 fusion should have diseas…

Broad match: EGFR mutation (unspecified)Breast Cancer, Non-small Cell Lung Carcinoma

Safety and Efficacy of Combination Osimertinib and Ipilimumab in Patients w EGFR Mutated NSCLC

Active, not recruiting Phase 1 University of Utah Started 2020 NCT04141644

IpilimumabOsimertinib FDA EU

Safety and Efficacy of Combination Osimertinib and Ipilimumab in Patients w EGFR Mutated NSCLC

Broad match: EGFR mutation (unspecified)Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor (Disorder)

A Study of APG-1252 Plus Osimertinib(AZD9291) in EGFR TKI Resistant NSCLC Patients

Active, not recruiting Phase 1 Ascentage Pharma Group Started 2019 NCT04001777

APG-1252Osimertinib Mesylate Tablets FDA EU

Cohort 3: Patients with advanced EGFR-mutated NSCLC not previously treated with TKI.

Broad match: EGFR mutation (unspecified)EGFR Positive Non-small Cell Lung Cancer

WSD0922-FU for Treatment of Glioblastoma, Anaplastic Astrocytoma, or Non-small Cell Lung Cancer With Central Nervous System Metastases

Active, not recruiting Phase 1 Mayo Clinic Started 2019 NCT04197934

EGFR/EGFRvIII Inhibitor WSD0922-FU

GBM/AA must either EGFR amplification and/or any activating EGFR mutation (e.g.

Broad match: EGFR sensitizing mutationAnaplastic Astrocytoma, IDH-Wildtype, Glioblastoma, IDH-Wildtype, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Malignant Neoplasm in the Central Nervous System

CCL21-Gene Modified Dendritic Cell Vaccine and Pembrolizumab in Treating Patients With Stage IV Non-small Cell Lung Cancer

Active, not recruiting Phase 1 Jonsson Comprehensive Cancer Center Started 2019 NCT03546361

Autologous Dendritic Cell-Adenovirus CCL21 VaccinePembrolizumab

Have received prior tyrosine kinase inhibitor therapy in patients with a sensitizing EGFR mutation and/or ALK gene rearrangement.

Broad match: EGFR sensitizing mutationLung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8

A Study of the Combination of Osimertinib, Platinum and Etoposide for Patients With Metastatic EGFR Mutant Lung Cancers

Active, not recruiting Phase 1 Memorial Sloan Kettering Cancer Center Started 2018 NCT03567642

Osimertinib FDA EUPlatinumEtoposide

…dy of the Combination of Osimertinib, Platinum and Etoposide for Patients With Metastatic EGFR Mutant Lung Cancers

Broad match: EGFR mutation (unspecified)Lung Cancer

U3-1402 in Metastatic or Unresectable Non-Small Cell Lung Cancer

Active, not recruiting Phase 1 Daiichi Sankyo Started 2017 NCT03260491

HER3-DXd (FL-DP)HER3-DXd (CTM-1 Lyo-DP)HER3-DXd (CTM-3 Lyo-DP)

Has documentation of EGFR-activating mutation(s) detected from tumor tissue: G719X, exon deletion 19, L858R, or L861Q.

Broad match: EGFR sensitizing mutationNon-Small Cell Lung Cancer (NSCLC)

AZD9291 in Combination With Ascending Doses of Novel Therapeutics

Active, not recruiting Phase 1 AstraZeneca Started 2014 NCT02143466

Part A - AZD9291 in combination with AZD6094 FDA EUPart A - AZD9291 in combination with continuous selumetinib (Asian subjects) FDA EUPart A - AZD9291 in combination with continuous selumetinib (non-Asian subjects) FDA EUPart A - AZD9291 in combination with intermittent selumetinib FDA EUPart A - AZD9291 in combination with MEDI4736 FDA EUPart B - AZD9291 in combination with AZD6094 FDA EU

…our harbours an EGFR mutation known to be associated with EGFR TKI sensitivity (including exon 19 deletion and L858R).

Broad match: EGFR exon 19 deletionAdvanced Non Small Cell Lung Cancer

A Phase I Study to Evaluate the Safety, Tolerability, and PK of HLX37 in Advanced/Metastatic Solid Tumors

Recruiting Early Phase 1 Henlius Started 2025 NCT07274813

HLX37

For non-squamous NSCLC subjects, there must be previous test results confirming negative EGFR and ALK gene alterations.

Broad match: EGFR mutation (unspecified)Advanced/Metastatic Solid Tumors, NSCLC

Clinical Study on the Safety and Immunogenicity of Specific Cancer Vaccines in Preventing Recurrence of Glioblastoma

Enrolling by invitation Early Phase 1 Beijing Neurosurgical Institute Started 2025 NCT07520214

mRNA vaccine: GV-907、GV-108

…torial IDH-wildtype glioblastoma located in the frontal, temporal, or occipital lobe with EGFR gene mutation

Broad match: EGFR mutation (unspecified)Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype, Glioblastom WHO Grade 4

CSF CTC-Capture-Guided EGFR-TKI and Bevacizumab Combination Therapy in EGFR-Mutant Advanced NSCLC

Not yet recruiting Early Phase 1 Second Affiliated Hospital of Nanchang University Started 2024 NCT06557096

Osimertinib 80 MG FDA EUBevacizumab

…tissue samples or blood samples are confirmed to have EGFR-sensitive mutations (including exon 19 deletions or L858R).

Broad match: EGFR exon 19 deletionStatus may be outdated, last updated 2024-08-16Non Small Cell Lung Cancer, Circulating Tumor Cell, EGF-R Positive Non-Small Cell Lung Cancer

A Phase 0/1 Study of BDTX-1535 in Recurrent High-Grade Glioma (rHGG) and Newly Diagnosed Glioblastoma (nGBM) Participants With EGFR Alterations or Fusions

Recruiting Early Phase 1 St. Joseph's Hospital and Medical Center, Phoenix Started 2023 NCT06072586

BDTX-1535BDTX-1535 combined with radiation therapyBDTX-1535 combined with temozolomide and radiation therapy

The tissue must have evidence of EGFR alterations including variants, fusion, and mutations with or without amplifications. rHGG participan…

Broad match: EGFR mutation (unspecified)High Grade Glioma, Glioblastoma

ctDNA-driven Adaptive Proton Craniospinal Irradiation in Non-Small Cell Lung Cancer With Leptomeningeal Metastasis After Resistance to Third-Generation TKIs in the Consolidation Phase

Recruiting No phase Shuanghu Yuan Started 2026 NCT07751536

Intrathecal pemetrexed

…g cancer (NSCLC) by cytology or histology, harbouring EGFR-sensitive mutations (including 19del and exon 21 L858R).

Broad match: EGFR exon 19 deletionLeptomeningeal Metastasis From Lung Cancer

Dermatological Effects and Quality of Life in Oncology Patients

Not yet recruiting No phase European Institute of Oncology Started 2026 NCT07869186

Osimertinib: Adjuvant therapy in patients with common activating EGFR mutations for Non-Small Cell Lung Cancer (NSCLC) Amivantamab for advanced or metastatic EGFR-mutate…

Broad match: EGFR sensitizing mutationBreast Cancer, Ovarian Cancer, NSCLC (Non-small Cell Lung Cancer), Melanoma (Skin Cancer)

Electroacupuncture Combined With PD-1 Inhibitor for Elderly Patients With Advanced NSCLC

Recruiting No phase Kong Fanming Started 2025 NCT07086300

…testing or other molecular biological methods, to exclude common driver mutations such as EGFR mutations and ALK rearrangements.

Broad match: EGFR mutation (unspecified)Elderly Patients (>65 Years), Non-Small Cell Lung Cancer, PD-1 Inhibitors, Electroacupuncture

Ivonescimab Combined With Chemotherapy for the Treatment of Leptomeningeal Metastases Failed to EGFR-TKIs

Not yet recruiting No phase Jiangsu Province Nanjing Brain Hospital Started 2025 NCT06766591

Ivonescimab combined with chemotherapy

EGFR mutation NSCLC

Broad match: EGFR mutation (unspecified)NSCLC, Chemotherapy, Leptomeningeal Metastases, EGFR-TKI

Evaluating High-dose Furmonertinib with Bevacizumab and Pemetrexed for EGFRm NSCLC with Leptomeningeal Metastasis

Recruiting No phase Henan Cancer Hospital Started 2024 NCT06643000

furmonertinib

Genetic testing confirming positive for classical or non-classical EGFR mutations;

Broad match: EGFR mutation (unspecified)Non-small Cell Lung Cancer, Leptomeningeal Metastasis, EGFR Gene Mutation

A Pilot Study to Understand the Impact of Therapy With Tumour Treating Fields (TTFields) in NSCLC

Not yet recruiting No phase Nir Peled Started 2023 NCT05698264

Cohort A, confirmed EGFR mutation.

Broad match: EGFR mutation (unspecified)Status may be outdated, last updated 2023-01-26Non Small Cell Lung Cancer, EGFR Gene Mutation, Immune Checkpoint Inhibitor

Nitroglycerin Plus Radiotherapy Versus Conventional Radiotherapy in Patients With Lung Cancer.

Recruiting No phase Instituto Nacional de Cancerologia de Mexico Started 2023 NCT06238882

Nitroglycerin

…ation Therapy vs Radiation Therapy Alone in Patients With Non-small Cell Lung Cancer With EGFR Mutations and Brain Metastases.

Broad match: EGFR mutation (unspecified)Non-small Cell Lung Cancer, Brain Metastases, EGFR Gene Mutation

Preoperative Sintilimab Combined With Bevacizumab and Chemotherapy for Resectable Non-Small Cell Lung Cancer

Recruiting No phase Ruijin Hospital Started 2022 NCT04973293

sintilimabbevacizumab

…table non-small cell lung cancer (stage II-IIIA, patients with squamous cell carcinoma or EGFR mutation should not be included);

Broad match: EGFR mutation (unspecified)Lung Neoplasm Malignant

CSF Analysis in EGFR Mutant Non-Small Cell Lung Cancer With Leptomeningeal Disease

Recruiting No phase British Columbia Cancer Agency Started 2022 NCT05257967

Histologically or cytologically confirmed metastatic EGFR mutant NSCLC.

Broad match: EGFR mutation (unspecified)EGFR Activating Mutation, Leptomeningeal Metastasis, Non Small Cell Lung Cancer

Assessing an Oral EGFR Inhibitor, DZD9008 in Patients With Advanced Non-small Cell Lung Cancer(NSCLC) With EGFR Mutations (WU-KONG15)

Recruiting No phase Peking Union Medical College Hospital Started 2021 NCT05559645

DZD9008DZD9008

in Cohort 5 with EGFR sensitizing mutation

Broad match: EGFR sensitizing mutationNon Small Cell Lung Cancer

Real-World Study on Gene Profile in Patients With Advanced NSCLC Who Progressed on First-Line Osimertinib Therapy(GPS).

Completed Phase 4 AstraZeneca Started 2022 NCT05219162

Gene Profile explore

…onfirmed non-small cell lung cancer (NSCLC) with documented EGFR sensitive mutation (EGFR 19del and L858R) positive before Osimertinib 1L.

Advanced NSCLC

Efficacy Study of Osimertinib in Treatment-naïve Patients With EGFR Mutant NSCLC According to TP53 Mutational Status.

Unknown status Phase 4 Fondazione Policlinico Universitario Agostino Gemelli IRCCS Started 2022 NCT05785208

Osimertinib FDA EU

…ot amenable to curative surgery or radiotherapy with confirmation of the presence of EGFR exon 19 deletion or exon 21 p.L858R.

Non Small Cell Lung Cancer

Synergistic Effect of Elemene Plus TKIs Compared With TKIs in EGFR-mutated Advanced NSCLC：Prospective Study

Unknown status Phase 4 Tian Xie Started 2020 NCT04401059

Elemene plus first or third generation EGFR-TKIsFirst or third generation EGFR-TKIs FDA EU

Patients with EGFR mutations (deletions in exon 19 and L858R in exon 21 of the EGFR gene), plan to receive First-generation EGFR-TKIs (Gefit…

Carcinoma, Non-Small-Cell Lung Cancer, Adenocarcinoma

the Clinical Trial of Gefitinib(Non - Small Cell Lung Cancer)

Unknown status Phase 4 Jiangsu Famous Medical Technology Started 2017 NCT03264794

Gefitinib Tab （CTTQ），First medication；Gefitinib Tab （CTTQ），From the 8th day of trial FDA EUGefitinib tablets (Yi Ruisha），First medication FDA EUGefitinib Tab 250 MG（CTTQ），From the 8th day of trial. FDA EU

Detection of EGFR-positive exon 19 deletion or exon 21 (L858R) mutation was performed by providing a detectable specimen (tissue or c…

Non-small Cell Lung Cancer

Afatinib in EGFR+NSCLC (Recurrent or Stage IV) - Patients With Poor Performance Status (ECOG 2 or 3)

Terminated Phase 4 Boehringer Ingelheim Started 2016 NCT02695290

Afatinib FDA EU

Evidence of common EGFR activating mutations (Del 19 and/or L858R)

Carcinoma, Non-Small-Cell Lung, ErbB Receptors

Afatinib Treatment for Patients With EGFR Mutation Positive NSCLC Who Are Age 70 or Older

Completed Phase 4 Boehringer Ingelheim Started 2015 NCT02514174

Afatinib FDA EU

Evidence of common EGFR mutation (Del 19 and/or L858R)

Carcinoma, Non-Small-Cell Lung, ErbB Receptors

Sequential Icotinib Plus Chemotherapy Versus Icotinib Alone as First-line Treatment in Stage IIIB/IV Lung Adenocarcinoma

Unknown status Phase 4 Betta Pharmaceuticals Started 2014 NCT02103257

Sequential Icotinib Plus ChemotherapyIcotinib

EGFR activating mutation (exon 19 deletion, L858R) is required

EGFR Positive Non-small Cell Lung Cancer, Adenocarcinoma

Afatinib as Second-line Therapy for Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Mutation

Completed Phase 4 Boehringer Ingelheim Started 2014 NCT02208843

Afatinib FDA EU

…ly Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Harbouring an EGFR Mutation (Del19 or L858R) Who Have Failed First-line Treatment With Platinum-based Chemotherapy

Carcinoma, Non-Small-Cell Lung

Icotinib as First-line and Maintenance Treatment in EGFR Mutated Patients With Lung Adenocarcinoma

Unknown status Phase 4 Betta Pharmaceuticals Started 2012 NCT01665417

ExperimentalChemotherapyChemotherapy

Patients must have lung cancer with a documented EGFR activating mutation (exon 19 deletion, L858R).

EGFR Positive Non-small Cell Lung Cancer, Adenocarcinoma

Study of Intravenous Telisotuzumab Vedotin in Combination Osimertinib or Standard of Care Chemotherapy to Assess Change in Disease Activity in Adult Participants With Non-Small Cell Lung Cancer That Has a Mutation in the Epidermal Growth Factor Receptor Gene and That Overexpresses the c-Met Protein

Withdrawn Phase 3 AbbVie Started 2024 NCT06093503

Telisotuzumab VedotinOsimertinib FDA EUCisplatinCarboplatinPemetrexed

…anced non-squamous NSCLC with documented epidermal growth factor receptor (EGFR) mutation del19 or L858R, with or without T790M mutation, and no identified EGFR mutations known to confe…

Non-Small Cell Lung Cancer

Aumolertinib With Chemotherapy or Alone Compared With Osimertinib in Patients With Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer

Terminated Phase 3 EQRx International Started 2022 NCT05493501

Aumolertinib monotherapyOsimertinib monotherapy FDA EUPemetrexedCisplatinCarboplatinPaclitaxel

…rbors one of the 2 common EGFR mutations known to be associated with EGFR-TKI sensitivity-ex19del or L858R-either alone or in combination with other EGFR mutations (eg, G719X, exon 20 ins…

NSCLC

JY025 is a First-line Treatment for EGFR Mutated NSCLC Phase II and III Clinical Trials of Efficacy and Safety

Unknown status Phase 2/3 Beijing Dongfang Biotech Started 2021 NCT04874844

Recombinant anti-VEGFR2 fully human monoclonal antibody (JY025)

(5) The patient has EGFR exon 19 deletion (19del) or 21 exon \[L858R\] mutation confirmed by the central laboratory (only tissue sa…

NSCLC

Study of Anlotinib Combined With Icotinib as the First-line Treatment in Patients With EGFR Concomitant Mutation NSCLC

Unknown status Phase 3 Tianjin Medical University Cancer Institute and Hospital Started 2021 NCT04797806

AnlotinibIcotinib

…rent non-squamous NSCLC（according to the 8th Edition of the AJCC Staging system）with EGFR 19 del or 21 L858R gene mutation and concomitant others.

Non Small Cell Lung Cancer

Clinical Trial of YH25448(Lazertinib) as the First-line Treatment in Patients With EGFR Mutation Positive Locally Advanced or Metastatic NSCLC (LASER301)

Completed Phase 3 Yuhan Started 2020 NCT04248829

Lazertinib 240 mg/160 mg FDA EUGefitinib 250 mg FDA EULazertinib-matching placebo 240 mg/160 mg FDA EUGefitinib-matching placebo 250 mg FDA EU

… least 1 of the 2 common EGFR mutations known to be associated with EGFR TKI sensitivity (Ex19del or L858R), either alone or in combination with other EGFR mutations

Non-Small Cell Lung Cancer

A Study of SH-1028 Tablets Versus Gefitinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer

Unknown status Phase 3 Nanjing Sanhome Pharmaceutical Started 2020 NCT04239833

SH-1028 tabletsGefitinib FDA EU

…ours one of the 2 common EGFR mutations known to be associated with EGFR-TKI sensitivity (Ex19del, L858R), either or in combination with other EGFR mutations assessed by central testing u…

Non-Small Cell Lung Cancer

TAK-788 as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations

Completed Phase 3 Takeda Started 2020 NCT04129502

TAK-788PemetrexedCisplatinCarboplatin

…mutations for which there are approved anti-EGFR tyrosine kinase inhibitors \[TKIs\] (ie, exon 19 del, L858R, T790M, L861Q, G719X, or S768I, where X is any other amino acid)

Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)

Almonertinib Plus Chemotherapy as First-line Treatment in Patients With EGFR Concomitant Non-EGFR Driver Gene Mutant, Locally Advanced or Metastatic NSCLC

Unknown status Phase 3 Cancer Institute and Hospital, Chinese Academy of Medical Sciences Started 2020 NCT04500704

AlmonertinibAlmonertinib plus carboplatin and pemetrexed

…ours one of the 2 common EGFR mutations known to be associated with EGFR-TKI sensitivity (Ex19del, L858R), in combination with non-EGFR driver genes mutations assessed by central testing …

Non Small Cell Lung Cancer

Almonertinib Plus Chemotherapy as First-line Treatment in Patients With EGFR Concomitant Tumor Suppressor Gene Mutation

Unknown status Phase 3 Cancer Institute and Hospital, Chinese Academy of Medical Sciences Started 2020 NCT04500717

AlmonertinibAlmonertinib plus carboplatin and pemetrexed

…ours one of the 2 common EGFR mutations known to be associated with EGFR-TKI sensitivity (Ex19del, L858R), in combination with tumor suppressor genes mutations assessed by central testing…

Non Small Cell Lung Cancer

Abivertinib Maleate Versus Geifitinib in Patients With Advanced Non-small Cell Lung Cancer With Sensitive EGFR Mutation

Unknown status Phase 3 Hangzhou ACEA Pharmaceutical Research Started 2019 NCT03856697

Abivertinib Maleate CapsulesGefitinib Tablets FDA EU

…umor tissue or cytopathological specimens have any of two common sensitive EGFR mutation (Ex19del or L858R) as confirmed by tests with Cobas (Roche) kit in central lab of this study, whic…

Advanced Non-small Cell Lung Cancer

D-0316 Versus Icotinib in Patients With Locally Advanced or Metastatic EGFR Sensitising Mutation Positive NSCLC

Completed Phase 2/3 Betta Pharmaceuticals Started 2019 NCT04206072

D-0316 CapsuleIcotinib Hydrochloride Tablets

…ur one of the two common EGFR mutations known to be associated with EGFR-TKI sensitivity (Ex19del, L858R), either alone or in combination with other EGFR mutations, assessed by central la…

Non-Small Cell Lung Cancer, EGFR Gene Mutation

ASK120067 Versus Gefitinib as First-line Treatment for EGFRm Locally Advanced or Metastatic NSCLC

Unknown status Phase 3 Jiangsu Aosaikang Pharmaceutical Started 2019 NCT04143607

ASK120067Gefitinib FDA EU

…ours one of the 2 common EGFR mutations known to be associated with EGFR-TKI sensitivity (Ex19del, L858R) that have been confirmed by the central laboratory testing report before enrollme…

Locally Advanced or Metastatic NSCLC

Gefitinib in Combination With Anlotinib or Placebo in Previously Untreated EGFR-mutant NSCLC

Unknown status Phase 3 Sun Yat-sen University Started 2019 NCT04028778

Gefitinib FDA EUAnlotinib Hydrochloride

5.Documented evidence of tumor harboring an activating EGFR mutation (exon19 del and L858R)

Lung Cancer, Nonsmall Cell

A Study to Evaluate Safety and Efficacy of HS-10296 as First-Line Treatment in Patients

Unknown status Phase 3 Hansoh Pharma Started 2019 NCT03849768

HS-10296Gefitinib FDA EU

…ours one of the 2 common EGFR mutations known to be associated with EGFR-TKI sensitivity (Ex19del, L858R), either or in combination with other EGFR mutations assessed by central testing u…

Non Small Cell Lung Cancer

Study of Pemetrexed + Platinum Chemotherapy With or Without Pembrolizumab (MK-3475) in Adults With Tyrosine Kinase Inhibitor- (TKI)-Resistant Epidermal Growth Factor Receptor- (EGFR)-Mutated Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-789/KEYNOTE-789)

Completed Phase 3 MSD (Merck & Co.) Started 2018 NCT03515837

pembrolizumabpemetrexedcarboplatincisplatinsaline solution

Documentation of tumor activating EGFR mutation, specifically either DEL19 or L858R.

Non-small Cell Lung Cancer

A Study to Determine the Efficiency For Brain Metastasis NSCLC Patients Treated With Icotinib Alone or Combined With Radiation Therapy

Unknown status Phase 3 Betta Pharmaceuticals Started 2018 NCT04058704

Icotinib

Positive EGFR mutation（Ex19del or 21L858R）

Non Small Cell Lung Cancer, Brain Metastases

Phase III Study of Nazartinib (EGF816) Versus Erlotinib/Gefitinib in First-line Locally Advanced / Metastatic NSCLC With EGFR Activating Mutations

Withdrawn Phase 3 Novartis Started 2018 NCT03529084

EFG816erlotinib or gefitinib FDA EU

…ic, stage IIIB/ IIIC or stage IV NSCLC with documented EGFR activating mutation (L858R or ex19del)

Carcinoma, Non-small Cell Lung

A Study of Atezolizumab Compared With a Single-Agent Chemotherapy in Treatment Naïve Participants With Locally Advanced or Recurrent or Metastatic Non-Small Cell Lung Cancer Who Are Deemed Unsuitable For Platinum-Doublet Chemotherapy

Completed Phase 3 Roche Started 2017 NCT03191786

Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibodyVinorelbineGemcitabine

No sensitizing epidermal growth factor receptor (EGFR) mutation (L858R or exon 19 deletions) or anaplastic lymphoma kinase (ALK) fusion oncogene detected

Non-Small Cell Lung Cancer

A Study of ASP8273 vs. Erlotinib or Gefitinib in First-line Treatment of Patients With Stage IIIB/IV Non-small Cell Lung Cancer Tumors With EGFR Activating Mutations

Terminated Phase 3 Astellas Started 2016 NCT02588261

naquotinib mesilateErlotinib FDA EUGefitinib FDA EU

Subject has an EGFR activating mutation (exon 19 deletion or exon 21 L858R), with or without T790M mutation, by local or central testing on examina…

Non-small Cell Lung Cancer (NSCLC)

A Study of Gefitinib With or Without Apatinib in Patients With Advanced Non-squamous Non-Small-Cell Lung Cancer Harboring EGFR Mutations

Unknown status Phase 3 Sun Yat-sen University Started 2016 NCT02824458

ApatinibGefitinib FDA EU

Documented evidence of tumor harboring an activating EGFR mutation (Example 19 del and L858R) .

EGFR Tyrosine Kinase Inhibitors Plus VEGFR Inhibitors

Clinical Study of YYJD Decoction Combined With Gefitinib in Advanced Pulmonary Adenocarcinoma

Unknown status Phase 3 Shanghai University of Traditional Chinese Medicine Started 2016 NCT02929693

gefitinib FDA EUYiqi-yangyin-jiedu decoction

With activating EGFR mutation (either exon19del or exon21L858R) and one month of gefitinib as first-line or second-line therapy without d…

Cancer

Adjuvant Erlotinib Intercalating Chemotherapy or Adjuvant Chemotherapy Alone in NSCLC With Common EGFR Mutation

Withdrawn Phase 3 Yonsei University Started 2016 NCT02795884

intercalation therapy using pemetrexed, cisplatin and erlotinib FDA EUVinorelbine, cisplatin

Confirmed with Exon 19 deletion or L858R EGFR mutation

NSCLC

Pemetrexed Combined With Synchronous Gefitinib as Adjuvent Therapy in Patient With EGFR Mutant Lung Adenocarcinoma

Unknown status Phase 3 Tang-Du Hospital Started 2015 NCT02518802

Gefitinib FDA EUPemetrexed

…arget population is completely resected pathological stage II-IIIA(N1-N2) NSCLC with EGFR exon 19 deletions and exon 21 L858R activating mutation.

Lung Neoplasms

Anticancer Activity of Nicotinamide on Lung Cancer

Unknown status Phase 2/3 Il Yeong Park, Ph.D. Started 2015 NCT02416739

Nicotinamide

EGFR mutated (exon 19 deletion or L858R mutation)

Non-Small-Cell Lung Carcinoma

S1403, Afatinib Dimaleate With or Without Cetuximab in Treating Patients With Newly Diagnosed Stage IV or Recurrent, EGFR Mutation Positive Non-small Cell Lung Cancer

Completed Phase 2/3 SWOG Cancer Research Network Started 2015 NCT02438722

Afatinib Dimaleate FDA EUCetuximab

Patients must have documented presence of an EGFR exon 19 deltion or exon 21 (L858R) substitution mutation

Recurrent Non-Small Cell Lung Carcinoma, Stage IV Non-Small Cell Lung Cancer

A Multicenter Randomized Phase III Study Comparing Second-line Treatment With Chemotherapy Associated or Not to Erlotinib in NSCLC Patients With Secondary Resistance to TKI-EGFR

Terminated Phase 3 Centre Francois Baclesse Started 2014 NCT02178397

ERLOTINIB WITH CHEMOTHERAPY FDA EUCHEMOTHERAPY ONLY

Presence of one of the EGFR activating mutations in the tumor (exon 19 deletion or L858R, G719X or L861Q)

NSCLC Patients With EGFR Activating Mutation

Comparator-Controlled Study for EGFR(+) Patients With Multiple BMs From NSCLC (BROKE) (EGFR-epidermal Growth Factor Receptor;BM-brain Metastases)

Unknown status Phase 2/3 Shanghai Chest Hospital Started 2014 NCT02338011

Gefitinib FDA EU

Sequencing EGFR mutation(primary lesion or metastases,exon 19 deletions or exon 21 L858R (EGFR mutation in exon 21, L858R point mutation) mutations;

Non-Small Cell Lung Cancer, Brain Metastases, EGFR Gene Mutation

AZD9291 Versus Gefitinib or Erlotinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer

Completed Phase 3 AstraZeneca Started 2014 NCT02296125

AZD9291 80 mg/40 mg + placeboErlotinib 150/100 mg FDA EUGefitinib 250 mg FDA EU

…ours one of the 2 common EGFR mutations known to be associated with EGFR-TKI sensitivity (Ex19del, L858R).

Locally Advanced or Metastatic EGFR Sensitising Mutation Positive Non Small Cell Lung Cancer

Erlotinib 100mg or 150mg in Treating EGFR Mutated NSCLC

Unknown status Phase 3 The First Affiliated Hospital of Guangzhou Medical University Started 2013 NCT02140333

Erlotinib FDA EU

Sensitive mutation EGFR gene (18, 19 del, 21 L858R gene mutation) (mutation detection methods:ARMS-PCR, sequence method)

NSCLC, EGFR Mutation

ARCHER1050: A Study of Dacomitinib vs. Gefitinib in 1st-Line Treatment Of Advanced NSCLC.

Completed Phase 3 Pfizer Started 2013 NCT01774721

Dacomitinib (PF-00299804) FDA EUGefitinib FDA EU

…med, advanced NSCLC (with known histology) with the presence of EGFR-activating mutation (exon 19 deletion or the L858R mutation in exon 21).

Non-small Cell Lung Cancer With EGFR-Activating Mutations

Gefitinib Versus Vinorelbine/Platinum as Adjuvant Treatment in Stage II-IIIA(N1-N2) NSCLC With EGFR Mutation

Unknown status Phase 3 Guangdong Association of Clinical Trials Started 2011 NCT01405079

Gefitinib FDA EUVinorelbine+Cisplatin

…arget population is completely resected pathological stage II-IIIA(N1-N2) NSCLC with EGFR exon 19 deletions and exon 21 L858R activating mutation.

Non-small Cell Lung Cancer

Erlotinib Versus Gemcitabine/Carboplatin in Chemo-naive Stage IIIB/IV Non-Small Cell Lung Cancer Patients With Epidermal Growth Factor Receptor (EGFR) Exon 19 or 21 Mutation

Completed Phase 3 Tongji University Started 2008 NCT00874419

erlotinib FDA EUgemcitabine/carboplatin

EGFR exon19 deletions or exon 21 L858R mutation by the DNA direct PCR sequencing using fresh tumor sample or p…

Non-small Cell Lung Cancer

Aumolertinib in EGFR-Mutant Resected Stage IB-IIIA NSCLC (AERESA).

Withdrawn Phase 2 Sun Yat-sen University Started 2024 NCT06227897

Aumolertinib

…t Aumolertinib for Completely Resected Stage IB-IIIA Non-Small-Cell Lung Cancer With EGFR Exon 19 Deletion or L858R Mutations.

Lung Cancer

Biologically Guided Radiation Therapy (BgRT) and Stereotactic Body Radiation Therapy (SBRT) to Tyrosine Kinase Inhibitor in Oligoprogressive Oncogenic Positive Non-Small Cell Lung Carcinoma

Suspended Phase 2 City of Hope Medical Center Started 2024 NCT06014827

Osimertinib FDA EU

… with epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKI) sensitivity (Ex19del or L858R), either alone or in combination with other epidermal growth factor receptor (EG…

Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8

A Study of Furmonertinib Combined With Chemotherapy in the Treatment of NSCLC With Leptomeningeal Metastasis

Unknown status Phase 2 Jiangsu Province Nanjing Brain Hospital Started 2024 NCT06339242

Furmonertinib

Patients with EGFR sensitive mutations (EGFR exon 19 deletion or EGFR exon 21 L858R mutation) without other driver genes with targeted therapy (such as…

NSCLC

Neoadjuvant Toripalimab for Non-squamous NSCLC With EGFR Mutation

Unknown status Phase 2 Peking University People's Hospital Started 2023 NCT05962021

Toripalimab plus Chemotherapy

Harboring EGFR mutation (19del or L858R);

Non Squamous Non Small Cell Lung Cancer, EGFR Positive Non-small Cell Lung Cancer

Osimertinib Combined With Aspirin Neoadjuvant Therapy for Resectable EGFR Mutated NSCLC Patients.

Unknown status Phase 2 Daping Hospital and the Research Institute of Surgery of the Third Military Medical University Started 2023 NCT06018688

Osimertinib FDA EUAspirin

Patients with EGFR sensitizing mutations (Ex19del or L858R).

Non Small Cell Lung Cancer, EGFR Gene Mutation

EMB-01 in Combination With Osimertinib in Patients With EGFR Mutant Lung Cancer

Unknown status Phase 1/2 Shanghai EpimAb Biotherapeutics Started 2023 NCT05498389

EMB-01Osimertinib FDA EU

Group 1: Patient had a documented EGFR Exon 19del or L858R activating mutation and progressed while on osimertinib as first-line therapy in…

Metastatic Lung Non-Small Cell Carcinoma, Advanced Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8

Lazertinib and Chemotherapy Combination in EGFR-mutant NSCLC Patients Without ctDNA Clearance After lead-in Lazertinib Monotherapy

Unknown status Phase 2 Yonsei University Started 2023 NCT06020989

Lazertinib+Pemetrexed+Carboplatin FDA EULazertinib FDA EULazertinib FDA EU

Presence of the sensitising EGFR-mutation (exon 19 deletion and/or L858R) detected by an accredited laboratory.

Non Small Cell Lung Cancer

Amivantamab, Lazertinib, and Pemetrexed for First-line Treatment of Recurrent/Metastatic Non-small Cell Lung Cancers With Epidermal Growth Factor Receptor Mutations

Completed Phase 2 Latin American Cooperative Oncology Group Started 2023 NCT05299125

Amivantamab FDA EULazertinib FDA EUPemetrexed 500 mg

Participant must have a tumor that was previously determined to have Exon 19del or Exon 21 L858R substitution, as detected by a validated test in accordance with site st…

Metastatic Non-small Cell Lung Cancers

High-dose Furmonertinib for First-line Treatment of EGFR Mutated NSCLC With Central Nervous System (CNS) Metastases

Unknown status Phase 2 Hunan Province Tumor Hospital Started 2022 NCT05379803

Furmonertinib

…esults from local testing of either tumor tissue or blood confirming the presence of EGFR 19del or exon 21del L858R mutation.

Non-Small Cell Lung Cancer

Aumolertinib Adjuvant Therapy of Resectable Stage I EGFRm+ NSCLC With High-grade Patterns

Unknown status Phase 2 Baohui Han Started 2022 NCT04922138

Aumolertinib

…ours one of the 2 common EGFR mutations known to be associated with EGFR-TKI sensitivity (Ex19del, L858R), either alone or in combination with other EGFR mutations including T790M.

Lung Cancer

Aurora Kinase Inhibitor LY3295668 in Combination With Osimertinib for the Treatment of Advanced or Metastatic EGFR-Mutant Non-squamous Non-small Cell Lung Cancer

Completed Phase 1/2 M.D. Anderson Cancer Center Started 2022 NCT05017025

Aurora A Kinase Inhibitor LY3295668Osimertinib FDA EU

NSCLC which harbours EGFR Exon 19 deletion.

Advanced Lung Non-Squamous Non-Small Cell Carcinoma, Metastatic Lung Non-Squamous Non-Small Cell Carcinoma, Stage III Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8

Almonertinib Plus Microwave Ablation in Advanced Non-small Cell Lung Cancer

Unknown status Phase 2 Qianfoshan Hospital Started 2022 NCT04755738

Almonertinib plus microwave ablation

EGFR Exon 19del or Exon 21 L858R mutations;

Advanced Non Small Cell Lung Cancer

Osimertinib and Locally Ablative Radiotherapy in Patients With Synchronous Oligo-metastatic EGFR Mutant NSCLC (STEREO)

Terminated Phase 2 ETOP IBCSG Partners Foundation Started 2022 NCT04908956

Osimertinib FDA EU

Presence of the sensitising EGFR-mutation (exon 19 deletion and/or exon 21 L858R) detected by an accredited laboratory.

NSCLC Stage IV, EGFR Gene Mutation

Tislelizumab +Bevacizumab+pc for Untreated EGFR+ and High PD-L1 Non-squamous NSCLC

Unknown status Phase 2 Sichuan Cancer Hospital and Research Institute Started 2022 NCT05394233

Tislelizumab Combined With Bevacizumab and Platinum Plus Pemetrexed

Patients with EGFR sensitive mutations: 19del and L858R who have not been treated with TKI for the first time, the patients need to pro…

Non-squamous Non-small Cell Lung Cancer, EGFR Gene Mutation

Salvage Surgery Following Downstaging of Advanced Non-small Cell Lung Cancer by Targeted Therapy (SDANT)

Unknown status Phase 2 Union Hospital, Tongji Medical College, Huazhong University of Science and Technology Started 2022 NCT05085054

Osimertinib Mesylate FDA EU

…ogical diagnosis of NSCLC with confirmed activation of driver gene mutation (EGFR mutant: exon 19 deletion or exon 21 L858R mutation

Non Small Cell Lung Cancer

A Multicenter Prospective Study to Assess the Effects of Adjuvant Icotinib in EGFRm Stage I NSCLC With High-risk of Disease Recurrence After Complete Resection

Unknown status Phase 2 Wu Nan Started 2022 NCT05514314

Icotinib

A tumour which harbours one of the 2 EGFR mutations (Ex19del, L858R) ,without KRAS mutation

Non-Small Cell Lung Cancer

Clinical Study of Ametinib Combined With Bevacizumab in First-line Treatment of Advanced NSCLC With EGFR-mutations.

Unknown status Phase 2 The Second Affiliated Hospital of Shandong First Medical University Started 2022 NCT05754736

Ametinib combined with bevacizumab

③ EGFR mutation positive (exon 19 deletion or exon 21 L858R mutation)

Non-small Cell Lung Cancer

Lazertinib/Pemetrexed/Carboplatin After Osimertinib Failure in NSCLC With Brain Metastases

Terminated Phase 2 Jin Hyoung Kang Started 2022 NCT05477615

Lazertinib FDA EUPemetrexedCarboplatin

Confirmed sensitizing EGFR mutation prior to administration of osimertinib (L858R, Exon 19 deletion, G719X and L861Q mutations should be confirmed as a record)

Non-small Cell Lung Cancer

Lenvatinib in Combination With Carboplatin Pemetrexed and Pembrolizumab for NSCLC With EGFR Mutations

Completed Phase 2 Juntendo University Started 2022 NCT05258279

PembrolizumabLenvatinibCarboplatinPemetrexed

Have documentation of tumor activating EGFR mutation, specifically either exon 19 deletion or exon 21 L858R.

Non-squamous Non-small-cell Lung Cancer, EGFR Activating Mutation

To Evaluate the Efficacy and Safety of Anlotinib Combined With Furmonertinib Mesylate in Lung Cancer

Completed Phase 2 Cancer Institute and Hospital, Chinese Academy of Medical Sciences Started 2021 NCT04671303

Anlotinib Hydrochloride Capsule Combined with Furmonertinib Mesylate

The previous report confirmed the presence of an EGFR gene exon 19 deletion mutation or exon 21 L858R mutation, and the investigator verified that the report reflect…

Lung Cancer

Treatment of EGFR-TKI for Residual Lesions of Multiple Synchronous Ground-glass Opacities

Unknown status Phase 2 Ruijin Hospital Started 2021 NCT04982900

furmonertinib

The pathology of the main lesion is NSCLC with sensitizing EGFR mutation positive (19del/L858R), with or without other EGFR mutations including T790M;

Multiple Primary Lung Cancers

Almonertinib Combined With Cerebral Radiation Treat Brain Metastases From EGFR Positive NSCLC

Unknown status Phase 2 Chongqing University Cancer Hospital Started 2021 NCT04905550

Almonertinib

Confirmed pathology of EGFR mutation positive（exon 19 deletion, L858R, T790M）NSCLC with brain metastases on enhanced MRI.

Non-Small Cell Lung Cancer (NSCLC)

Efficacy and Safety of Furmonertinib in EGFR-Mutant, PD-L1+ Patients With Locally Advanced or Metastatic NSCLC (FUTURE)

Unknown status Phase 2 Fudan University Started 2021 NCT05255406

Furmonertinib (160mg)

The tumour harbours one of the most common EGFR mutations (19del or L858R);

Non-Small-Cell Lung Cancer

Furmonertinib as Perioperation Therapy in Stage IIIA-IIIB (N1-N2) Resectable EGFR Mutated Lung Adenocarcinoma (FRONT)

Unknown status Phase 2 Tianjin Medical University Cancer Institute and Hospital Started 2021 NCT04965831

Furmonertinib

EGFR mutation positive (19Del or L858R, with or without T790M)

Lung Adenocarcinoma

Study of Osimertinib+Bevacizumab+Chemotherapy for EGFR+ Advanced Non-Small Cell Lung Cancer With Concurrent Mutations

Unknown status Phase 2 Tianjin Medical University Cancer Institute and Hospital Started 2021 NCT05507606

Osimertinib FDA EUBevacizumab Biosimilar IBI305CarboplatinPemetrexed

The tumor harbors epidermal growth factor receptor (EGFR) mutations(include 19del, L858R, T790M, G719X, L861Q, S768I, 20 A763-Y764ins), and at least concurrent with TP53

Non Small Cell Lung Cancer

SRT for Residual Oligometastases of NSCLC After 3rd Generation EGFR-TKIs

Completed Phase 2 Fudan University Started 2021 NCT04764214

3rd generation EGFR-TKI FDA EU

EGFR Exon19 deletion or Exon21 L858R mutation

NSCLC Stage IV, EGFR Activating Mutation

Befotertinib and Icotinib in Treatment-naive Patients With Advanced EGFR-Mutant Lung Cancer

Unknown status Phase 2 Betta Pharmaceuticals Started 2021 NCT05007938

IcotinibBefotertinib

…ur one of the two common EGFR mutations known to be associated with EGFR-TKI sensitivity (Ex19del, L858R),either alone or in combination with other EGFR mutations, excluding co-mutation o…

Non-Small Cell Lung Cancer

Neurocognition in NSCLC Patients Treated With Osimertinib or Osimertinib + WBI

Unknown status Phase 2 Sun Yat-sen University Started 2021 NCT04829019

Osimertinib FDA EU

Histologically documented that with sensitizing EGFR mutations(either L858R or Exon19del)

Neurocognitive

Adjuvant Targeted-therapy for Patients With Resected High-risk EGFR-mutant Stage IB-IIA Non-small Cell Lung Carcinoma

Unknown status Phase 2 Tongji University Started 2021 NCT05165355

Furmonertinib

The tumour harbours one of the most common EGFR mutations (19del or L858R) ;

NSCLC, EGF-R Positive Non-Small Cell Lung Cancer

Osimertinib Plus Chemotherapy vs Osimertinib in EGFRm NSCLC With Persistence Week-3 ctDNA EGFRm After 1L Osimertinib

Completed Phase 2 Beijing Cancer Prevention & Treatment Society Started 2021 NCT04769388

Osimertinib FDA EUPemetrexed/Carboplatin

History of EGFRm (exon 19 deletion or exon 21 L858R) in the plasma ctDNA by the local testing methods.

Non Small Cell Lung Cancer

Bintrafusp Alfa With Chemotherapy for Tyrosine Kinase Inhibitor-Resistant EGFR-Mutant Non-small Cell Lung Cancer

Terminated Phase 2 M.D. Anderson Cancer Center Started 2021 NCT04971187

Bintrafusp AlfaPemetrexedCarboplatinCisplatin

NSCLC which harbors EGFR Exon 19 deletion.

Locally Advanced Lung Non-Squamous Non-Small Cell Carcinoma, Metastatic Lung Non-Squamous Non-Small Cell Carcinoma, Stage III Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8

Furmonertinib Combined With Anlotinib as the First-line Treatment in Patients With EGFR Mutation-positive NSCLC

Unknown status Phase 2 Shanghai Chest Hospital Started 2021 NCT04895930

FurmonertinibAnlotinib

The tumour harbours one of the most common EGFR mutations (19del or L858R) ;

Non-Small-Cell Lung Cancer

Lazertinib in Patients With NSCLC With Asymptomatic or Mild Symptomatic Brain Metastases After Failure of EGFR TKI.

Unknown status Phase 2 Jin Hyoung Kang Started 2021 NCT05326425

lazertinib(YH25448) FDA EU

…tizing EGFR mutation prior to administration of gefitinib, erlotinib, or afatinib (L858R, Exon 19 deletion, G719X and L861Q mutations chould be confirmed as a record)

Lung Neoplasms

The Safety and Efficacy of First-line Lazertinib and Locally Ablative Radiotherapy in Patients With Synchronous Oligo-metastatic EGFR-mutant Non-small Cell Lung Cancer

Unknown status Phase 2 Yonsei University Started 2021 NCT05167851

Lazertinib , a combination group of SBRT FDA EULazertinib single administration group FDA EU

Presence of the sensitising EGFR-mutation (exon 19 deletion and/or L858R) detected by an accredited laboratory.

Non Small Cell Lung Cancer

Central Nervous System(CNS) Efficacy of Dacomitinib

Unknown status Phase 2 Samsung Medical Center Started 2020 NCT04675008

Dacomitinib FDA EU

Biopsy proven recurrent or metastatic NSCLC (adenocarcinoma) with major EGFR mutation (exon 19 deletion or Leu858Arg mutation without the Thr790Met)

Non Small Cell Lung Cancer, Brain Metastases

Almonertinib With Chemotherapy in mEGFR NSCLC

Unknown status Phase 2 Tianjin Medical University Cancer Institute and Hospital Started 2020 NCT04646824

Almonertinib Pemetrexed/Cisplatin

… with Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKI) sensitivity (Ex19del or L858R), either alone or in combination with other epidermal growth factor receptor (EG…

Non-Small Cell Lung Cancer Metastatic

A Phase II Trial of Upfront Radiotherapy Plus Almonertinib for Epidermal Growth Factor Receptor(EGFR)-Mutant Non-small-cell Lung Cancer(NSCLC) Patients With Brain Metastases

Unknown status Phase 2 First People's Hospital of Hangzhou Started 2020 NCT04643847

Almonertinib

EGFR-sensitive mutations (include 19del or L858R mutation or coexist with other types of EGFR mutation).

EGFR Positive Non-small Cell Lung Cancer, Brain Metastases

A Phase II Study of Atezolizumab in Combination With Bevacizumab, Carboplatin or Cisplatin, and Pemetrexed for EGFR-mutant Metastatic Non-small Cell Lung Cancer Patients After Failure of EGFR Tyrosine Kinase Inhibitors.

Completed Phase 2 National Taiwan University Hospital Started 2020 NCT04147351

Atezolizumab Injection; bevacizumab Injection

EGFR activating mutations include exon19 deletion, L858R, G719X, L861Q, or S768I.

NSCLC Stage IIIB~IV

Study of Osimertinib in Patients with a Lung Cancer with Brain or Leptomeningeal Metastases with EGFR Mutation

Completed Phase 2 Intergroupe Francophone de Cancerologie Thoracique Started 2020 NCT04233021

Osimertinib FDA EU

The following mutations are considered to be activating: L858R, exon 19 deletions, exon 19 insertions, L861Q, G719X.

Non Small Cell Lung Cancer Metastatic, Leptomeningeal Metastasis, Brain Metastases, EGFR Activating Mutation

An Open Label, Multicenter, Phase II Study of Dacomitinib for EGFR Mutated Non-Small Cell Lung Cancer (NSCLC) With Brain Metastases

Unknown status Phase 2 Guangdong Association of Clinical Trials Started 2020 NCT04339829

Dacomitinib FDA EU

The presence of an EGFR activating mutation (exon 19 deletion or the L858R mutation in exon 21) in tumor specimen determined by the local laboratory.

Dacomitinib for EGFR Mutated Non-Small Cell Lung Cancer (NSCLC) With Brain Metastases

Efficacy and Safety of 80mg Osimertinib in Patients With Non-small Cell Lung Cancer(NSCLC)

Completed Phase 2 Sehhoon Park Started 2020 NCT04563871

80mg Osimertinib FDA EU

Patients must have documented (only allowed for EGFRm+ \[exon 19 deletions or L858R\] in pre-treated patients) and/or confirmed central/local test result showing e…

Non-small Cell Lung Cancer (NSCLC)

Advanced Lung Tumor Treated by Osimertinib Plus Anlotinib

Completed Phase 1/2 Shanghai Chest Hospital Started 2020 NCT04770688

Osimertinib FDA EUAnlotinib

…s one of the most common EGFR mutations known to be associated with EGFR-TKI sensitivity (exon 19 deletion

Non-Small Cell Lung Cancer With EGFR Mutation, Locally Advanced Solid Tumor, Metastatic Cancer, Adenocarcinoma of Lung

A Phase 2 Trial of Almonertinib With Concurrent Radiotherapy in The Treatment of Local Advanced EGFR-mutant NSCLC

Unknown status Phase 2 First People's Hospital of Hangzhou Started 2020 NCT04636593

Almonertinib

Blood or tissue EGFR detection is Exon 19 deletion or L858R mutation;

Non Small Cell Lung Cancer, Stage III NSCLC, EGFR Activating Mutation

Gefitinib With Anlotinib in Advanced Non-squamous NSCLC Patients With Uncleared Plasma ctDNA EGFRm After First-line Treatment With Gefitinib

Unknown status Phase 2 Second Affiliated Hospital of Nanchang University Started 2020 NCT04358562

Gefitinib FDA EUAnlotinib

Histologically confirmed that EGFR sensitive mutation (ex19del or L858R mutation) in tumor tissue was detected by non-squamous NSCLC, and EGFR mutation …

Non-small Cell Lung Cancer, EGFR Gene Mutation

Study of Anlotinib Combined With Osimertinib as Second-line Treatment in Stage IIIb-IV NSCLC With Confirmed EGFRm and T790M

Unknown status Phase 2 Tianjin Medical University Cancer Institute and Hospital Started 2019 NCT04029350

Anlotinib Combined With Osimertinib FDA EU

Non-small cell lung cancer (NSCLC) with an activating EGFR mutation (exon 19 deletion, L858R point mutation, or any other mutation known to be associated with EGFR TKI sensiti…

Non Small Cell Lung Cancer

MEchanisms of Resistance in EGFR Mutated Nonpretreated Advanced Lung Cancer Receiving OSimErtib

Unknown status Phase 2 Nantes University Hospital Started 2019 NCT03865511

TAGRISSO® 80mg (Osimertinib) FDA EUTumor biopsiesctDNA analysis

…ours one of the 2 common EGFR mutations known to be associated with EGFR-TKI sensitivity (Ex19 deletions, L858R), either alone or in combination with other EGFR mutations.

Non-small Cell Lung Cancer

A Randomised Phase II Trial of Osimertinib With or Without SRS for EGFR Mutated NSCLC With Brain Metastases

Completed Phase 2 Trans Tasman Radiation Oncology Group Started 2019 NCT03497767

Osimertinib FDA EU

…ince the initial diagnosis of NSCLC) known to be sensitive to Osimertinib - These include exon 19 del

Metastatic Non Small Cell Lung Cancer

Icotinib as Neoadjuvant and Adjuvant Therapy in EGFR-mutant Stage IIIB or Oligometastasis Non-small Cell Lung Cancer

Unknown status Phase 2 Betta Pharmaceuticals Started 2018 NCT03349203

Icotinib

EGFR mutation (EGFR 19del and/or 21L858R) detected by tumor tissue biopsy of primary lesion or metastatic lesion or…

EGF-R Positive Non-Small Cell Lung Cancer

Non Small Cell Lung Cancer Trial of Durvalumab and Tremelimumab in Advanced Epidermal Growth Factor Receptor (EGFR) Mutant Disease.

Unknown status Phase 2 University of Sydney Started 2018 NCT03994393

TremelimumabDurvalumab

…/or cytologically confirmed non-squamous non-small cell lung cancer with EGFR mutation of Exon 19 deletion or Exon 21 L858R point mutation.

EGFR Mutant Advanced Non Small Cell Lung Cancer

Gefitinib and Berberine in the First-line Treatment of Lung Adenocarcinoma With EGFR Mutation

Unknown status Phase 2 Fujian Cancer Hospital Started 2018 NCT03486496

gefitinib FDA EUBerberine

Centrally confirmed EGFR exon 19 deletion (del19) or exon 21 mutation (L858R)

Lung Adenocarcinoma, EGFR Mutation

S-1 Plus Gefitinib Versus Gefitinib Monotherapy in Patients With EGFR-sensitive Mutation Advanced Non-squamous NSCLC

Unknown status Phase 2 Henan Cancer Hospital Started 2018 NCT03457337

S-1 plus Gefitinib FDA EUGefitinib FDA EU

4. exon 19 deletion or exon 21 L858R for EGFR mutation.

Advanced NSCLC With EGFR Mutation

A Study of Toripalimab+ Pemetrexed Plus Carboplatin in Patients With EGFR-mutation Positive and T790M Negative After Progression on EGFR-TKI Treatment

Completed Phase 2 Shanghai Junshi Bioscience Started 2018 NCT03513666

Drug intervention

… confirmed advanced or recurrent non-small cell lung cancer with EGFR sensitive mutation (exon 19 deletion, exon 21 L858R), and meeting the following conditions at the same time:

NSCLC

Icotinib as Neoadjuvant Therapy in EGFR-mutant Stage ⅢA-N2 Non-small Cell Lung Cancer

Unknown status Phase 2 Betta Pharmaceuticals Started 2018 NCT03749213

Icotinib

EGFR mutation (EGFR 19del and/or 21L858R) detected by tumor tissue biopsy of primary lesion or metastatic lesion or…

EGF-R Positive Non-Small Cell Lung Cancer

Icotinib as Consolidation Therapy After Chemoradiotherapy in EGFR-Mutant Stage IIIA-IIIB Non-small Cell Lung Cancer

Unknown status Phase 2 Betta Pharmaceuticals Started 2018 NCT03396185

Icotinib

…er, histology or cytology confirmed lung adenocarcinoma, pathological specimens with EGFR 19 del and/or 21 L858R gene mutation detected by amplification refractory mutation system method

EGFR Gene Mutation, Non Small Cell Lung Cancer Stage IIIA, Non Small Cell Lung Cancer Stage IIIB

Study of Anlotinib Combined With Icotinib as the First-line Treatment in Patients With EGFR Mutation-positive NSCLC

Completed Phase 2 Tianjin Medical University Cancer Institute and Hospital Started 2018 NCT03736837

Anlotinib Plus Icotinib

…rent non-squamous NSCLC（according to the 8th Edition of the AJCC Staging system）with EGFR 19 del and/or 21 L858R gene mutation

Non Small Cell Lung Cancer

Efficiency of Icotinib in Plasma ctDNA EGFR Mutation-positive Patients Diagnosed With Lung Cancer

Unknown status Phase 2 Betta Pharmaceuticals Started 2017 NCT03346811

Icotinib

Plasma EGFR mutations (EGFR 19del and/or 21L858R) positive (simultaneously detected by Super-ARMS, ddPCR and NGS，any positi…

Plasma EGFR Mutation-positive Lung Cancer

EGFR Mutation Positive NSCLC Patients With Gefitinib and Thalidomide

Unknown status Phase 2 Fujian Cancer Hospital Started 2017 NCT03341494

Thalidomide

Locally diagnosed sensitive EGFR mutation positive (Exon 19 deletion or L858R)

NSCLC Stage IV, Chemotherapy Effect

Bevacizumab and Erlotinib in Lung Cancer With Brain Metastases, a Phase II Trial

Unknown status Phase 2 National Taiwan University Hospital Started 2017 NCT02655536

Bevacizumab plus erlotinib FDA EUErlotinib FDA EU

A tumor harboring an EGFR mutation known to be associated with erlotinib sensitivity (exon 19 deletion and L858R)

Carcinoma, Non-Small-Cell Lung, Brain Neoplasms

Osimertinib and Bevacizumab Versus Osimertinib Alone as Second-line Treatment in Stage IIIb-IVb NSCLC With Confirmed EGFRm and T790M

Completed Phase 2 ETOP IBCSG Partners Foundation Started 2017 NCT03133546

Osimertinib FDA EUBevacizumab

Histological or cytological confirmation of EGFRm (exon 19 deletion or exon 21L858R);

Non Small Cell Lung Cancer Metastatic

Phase II Study of AZD9291 in Advanced Stage NSCLC With EGFR and T790M Mutations Detected in Plasma Ct-DNA

Unknown status Phase 2 National University Hospital, Singapore Started 2017 NCT02811354

AZD9291 FDA EU

Documentation of activating EGFR mutations (exon 19 deletions or exon 21 L858R substitution mutations) at the time of initial diagnosis

Carcinoma, Non-Small-Cell Lung

Gefitinib With Chemotherapy or Anti-angiogenesis in NSCLC Patients With Bim Deletion or Low EGFR Mutation Abundance

Unknown status Phase 2 Qilu Pharmaceutical Started 2017 NCT03267654

gefitinib combined with chemotherapy FDA EUgefitinib combined with apatinib FDA EUgefitinib single agent FDA EU

EGFR mutation (exon 19 deletion or exon 21 L858R) with Bim deletion or low abundance for EGFR mutation.

Non-small-cell Lung Cancer

A Study of Tarceva vs. Avastin+Tarceva for Advanced NSCLC With EGFR m(+)

Unknown status Phase 2 National Cancer Center, Korea Started 2016 NCT03126799

Erlotinib plus Bevacizumab FDA EUErlotinib FDA EU

Locally diagnosed sensitive EGFR mutation positive (Exon 19 deletion or L858R)

EGFR Positive Non-small Cell Lung Cancer

A Phase 1b/2 Study of Safety and Efficacy of Rociletinib in Combination With MPDL3280A in Patients With Advanced or Metastatic EGFR-mutant NSCLC

Terminated Phase 1/2 Clovis Oncology Started 2016 NCT02630186

RociletinibMPDL3280A

…cally advanced or metastatic NSCLC, with one or more activating EGFR mutation (eg, G719X, exon 19 deletion, L858R, L861Q) and absence of exon 20 insertion

Non-small Cell Lung Cancer

A Study of Hypofractionated Radiotherapy for Limited Metastatic NSCLC Harboring Sensitizing EGFR Mutations After First Line TKI Therapy

Unknown status Phase 2 First People's Hospital of Hangzhou Started 2016 NCT02788058

EGFR-TKI FDA EU

…wly diagnosed metastatic lung adenocarcinoma harboring sensitizing EGFR mutations (L858R, exon 19 deletion), and became oligometastatic disease after 3 months TKI, evaluated by PET/CT scan, brain …

Lung Adenocarcinoma, EGFR Positive Non-small Cell Lung Cancer

Osimertinib in First and Second Line Treatment of NSCLC Harboring EGFR Mutations From Circulating Tumor DNA

Completed Phase 2 Chonnam National University Hospital Started 2016 NCT02769286

Osimertinib FDA EU

Activating EGFR mutation (G719X, exon 19 deletion, L858R, L861Q) detected from circulating tumor DNA either by PANA mutyper® or Cobas® EGFR…

Lung Neoplasms, EGFR Gene Mutations

Gefitinib Combined With Chemotherapy or Antiangiogensis in Patients With Bim Deletion or Low EGFR Mutation Abundance

Unknown status Phase 2 Caicun Zhou Started 2016 NCT02930954

Gefitinib FDA EUpemetrexed or gemcitabine plus carboplatin,bevacizumab

EGFR exon 19 deletion or exon 21 L858R.

Non-small-cell Lung Cancer

Afatinib in Lung Cancer With EGFR Mutation From Circulating Tumor DNA

Completed Phase 2 Chonnam National University Hospital Started 2016 NCT02629523

Afatinib FDA EU

Activating EGFR mutation (G719X, exon 19 deletion, L858R, L861Q) detected from circulating DNA

Lung Neoplasms, EGFR Gene Mutation

An Open-Label Phase 1/2 Study of Itacitinib in Combination With Osimertinib in Subjects With Non-Small Cell Lung Cancer

Completed Phase 1/2 Incyte Started 2016 NCT02917993

ItacitinibOsimertinib FDA EU

Documented evidence of somatic activating mutation in EGFR (eg, G719X, exon 19 deletion, L858R, L861Q) in a tumor tissue sample.

Lung Cancer

Dasatinib and Osimertinib (AZD9291) in Advanced Non-Small Cell Lung Cancer With EGFR Mutations

Terminated Phase 1/2 Chul Kim Started 2016 NCT02954523

DasatinibOsimertinib FDA EU

Presence of sensitizing EGFR mutations (deletion in exon 19, L858R in exon 21, G719X, and L861Q).

EGFR Gene Mutation, Nonsmall Cell Lung Cancer

Radiotherapy Combined With Thymosin for Metastatic NSCLC Patients Who Showed Stable Disease After First Line TKI Therapy

Unknown status Phase 2 First People's Hospital of Hangzhou Started 2016 NCT02787447

TKI FDA EUThymosin Alpha 1

…wly diagnosed metastatic lung adenocarcinoma harboring sensitizing EGFR mutations (L858R, exon 19 deletion), and showed stable disease after 3 months TKI, evaluated twice by PET/CT scan, brain MRI…

Lung Adenocarcinoma

Chemotherapy Plus Gefitinib for Advanced Lung Adenocarcinoma and Sensitive EGFR Mutations: a Randomized Controlled Trial

Unknown status Phase 2 Shanghai Chest Hospital Started 2016 NCT02951637

Pemetrexed plus carboplatin combined with gefitinib FDA EUGefitinib FDA EU

Sensitive EGFR mutations (19del, 21L858R);

Lung Adenocarcinoma

High Dose Icotinib With Sequential SRS For NSCLC Patients Harboring EGFR Mutation With Brain Metastases

Unknown status Phase 2 Betta Pharmaceuticals Started 2016 NCT02726568

Icotinib

Positive EGFR mutation（Ex19del or 21L858R）.

Non-small Cell Lung Cancer, Brain Metastases

Uncommon EGFR AZD9291

Unknown status Phase 2 Samsung Medical Center Started 2016 NCT03424759

AZD9291

…confirmed metastatic or recurrent stage IV NSCLC with activating EGFR mutation other than deletion in exon 19, L858R, T790M and insertion in exon 20

Non Small Cell Lung Cancer

The Role of Icotinib in the Perioperative Treatment of IIIA - IIIB NSCLC Patients With EGFR Mutation

Unknown status Phase 2 Beijing Haidian Hospital Started 2016 NCT02820116

Icotinib

Pathologically confirmed non-small cell lung cancer with EGFR exon 19 deletion or exon 21 L858 mutation.

Non-small Cell Lung Cancer(NSCLC)

Erlotinib Hydrochloride and Onalespib Lactate in Treating Patients With Recurrent or Metastatic EGFR-Mutant Non-small Cell Lung Cancer

Completed Phase 1/2 National Cancer Institute (NCI) Started 2016 NCT02535338

Erlotinib Hydrochloride FDA EUOnalespib Lactate

…, histologically confirmed NSCLC that harbors an EGFR activating mutation (exon 21 L858R, exon 19 deletion, exon 18 G719X, exon 21 L861Q) with progressive disease by RECIST 1.1 on a previous EGFR-…

Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Non-Small Cell Cancer AJCC v7

Combination of Cetuximab With Afatinib for Patient With EGFR Mutated Lung Cancer

Completed Phase 2 Intergroupe Francophone de Cancerologie Thoracique Started 2016 NCT02716311

Afatinib FDA EUCetuximab

EGFR mutation (exon 19 deletion, L858R mutation, G719X , L861Q or S768I mutations or exon 19 insertion)

Non Small Cell Lung Cancer

Liquid Biopsy as a Tool to Evaluate Resistance to First and Third (AZD9291) (EGFR) (TKIs) in (EGFR) Mutant NSCLC

Unknown status Phase 2 Hellenic Oncology Research Group Started 2016 NCT02771314

AZD9291 FDA EU

Presence of EGFR activating mutations (exon 19 deletion or L858R in exon 21)

Non Small Cell Lung Cancer

EGFR-TKI Combined With Concurrent or Sequential Chemotherapy for Patients of Gradual Progression

Completed Phase 2 Shanghai Chest Hospital Started 2015 NCT03544814

icotinib combined with pemetrexed plus cisplatinfirst icotinib and then pemetrexed plus cisplatin

Sensitive EGFR mutations (exon 19 deletion or L858R mutation in exon 21)

Lung Adenocarcinoma, EGFR Activating Mutation

Phase 2 Study of Study of Tesevatinib in Subjects With NSCLC and Brain or Leptomeningeal Metastases

Completed Phase 2 Kadmon Corporation Started 2015 NCT02616393

Tesevatinib

History of NSCLC with EGFR mutation (either exon 19 deletion or L858R mutation) or, if previously treated, history of an activating EGFR mutation that…

Non-Small Cell Lung Cancer, Leptomeningeal Metastases, Brain Metastases

A Study For Patients With EGFRm (Epidermal Growth Factor Receptor Mutant) Lung Cancer

Withdrawn Phase 2 Pfizer Started 2015 NCT02297425

PF-06459988

…istological or cytologically confirmed diagnosis of locally advanced or metastatic EGFRm (del19 or L858R) NSCLC that is resistant to standard therapy.

Advanced EGFRm (Del 19 or L858R +/- T790M) NSCLC

Study of Safety and Efficacy of EGFR-TKI EGF816 in Combination With cMET Inhibitor INC280 in Adult Patients With EGFR Mutated Non Small Cell Lung Cancer.

Terminated Phase 1/2 Novartis Started 2015 NCT02335944

CapmatinibNazartinib

…nts in Phase Ib and Phase II Groups 1 to 4: locally documented EGFR mutation L858R and/or ex19del, or a characterized de novo EGFR T790M mutation (or other rare activating mutations that …

Non Small Cell Lung Cancer

A Study of ASP8273 in Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor-Naïve Patients With Non-Small Cell Lung Cancer Harboring EGFR Mutations

Terminated Phase 2 Astellas Started 2015 NCT02500927

ASP8273 CapsulesASP8273 Capsules A

Patients confirmed to have the deletion of exon 19 (del ex19), L858R, G719X, or L861Q mutation among the EGFR activating mutations (patients…

EGFR-TKI-naïve Patients With NSCLC Harboring EGFR Activating Mutations

Intermittent and Maintenance of Icotinib in Combination With Pemetrexed/Carboplatin Compared With Icotinib Single Drug in Ⅲb/IV Non Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Mutation

Unknown status Phase 2 Sun Yat-sen University Started 2015 NCT03151161

Icotinib,Pemetrexed,CarboplatinIcotinib

Confirmed activating mutation of EGFR-ie, an exon 19 deletion or an exon 21 L858R point mutation.

Lung, Carcinoma

Study For Patients With NSCLC EGFR Mutations (Del 19 or L858R +/- T790M)

Terminated Phase 1/2 Pfizer Started 2015 NCT02349633

PF-06747775PalbociclibAvelumab

…tologically or cytologically confirmed diagnosis of locally advanced or metastatic EGFRm (del 19 or L858R) NSCLC:

Non-Small Cell Lung Cancer

A Study of ASP2215 in Combination With Erlotinib in Subjects With Epidermal Growth Factor Receptor (EGFR) Activating Mutation-Positive (EGFRm+) Advanced Non-Small-Cell Lung Cancer (NSCLC) Who Have Acquired Resistance to an EGFR Tyrosine Kinase Inhibitor (TKI)

Terminated Phase 1/2 Astellas Started 2015 NCT02495233

GilteritinibErlotinib FDA EU

Participant had a documented exon 19 deletion or exon 21 L858R EGFR activating mutation.

Non-Small-Cell Lung Cancer

Third-line Treatment of Gefitinib in NSCLC Patients

Completed Phase 2 Guangdong Association of Clinical Trials Started 2014 NCT01933347

Gefitinib FDA EU

EGFR exon 19 deletion or exon 21 L858R substitution mutation confirmed;

Non Small Cell Lung Cancer

Trial of Erlotinib and BKM120 in Patients With Advanced Non Small Cell Lung Cancer Previously Sensitive to Erlotinib

Completed Phase 2 SCRI Development Innovations Started 2014 NCT01487265

BKM120 and Erlotinib FDA EU

Exon 19 deletion

Non Small Cell Lung Cancer

A Phase 2, Study of Ficlatuzumab Plus Erlotinib vs. Placebo Plus Erlotinib in Subjects With Previously Untreated Metastatic, EGFR-mutated NSCLC and BDX004 Positive Label

Terminated Phase 2 AVEO Pharmaceuticals Started 2014 NCT02318368

FiclatuzumabErlotinib FDA EU

An EGFR exon 19 deletion and/or an exon 21 (L858R) substitution mutation.

Non-small Cell Lung Cancer

Chemotherapy and Erlotinib for Lung Cancer With Low Abundance Epidermal Growth Factor Receptor Mutation

Terminated Phase 2 Guangdong Association of Clinical Trials Started 2014 NCT02095782

Intercalated combination of chemotherapy and erlotinib FDA EU

Low abundant activating EGFR mutation: EGFR exon 19 deletion or exon 21 L858R, which are positive by real-time PCR methods and negative by standard se…

Non-small-cell Lung Cancer

Itacitinib in Combination With Erlotinib in Non Small Cell Lung Cancer Patients With Epidermal Growth Factor Receptor (EGFR) Activating Mutations

Withdrawn Phase 2 Incyte Started 2014 NCT02355431

Itacitiniberlotinib FDA EU

Documented evidence of an activating mutation in EGFR in tumor samples (exon 19 deletions or point mutation L858R in exon 21 or point mutations at codon 719).

Solid Tumors and Hematologic Malignancy, NSCLC (Non-small Cell Lung Carcinoma)

Intermittent and Maintenance of Erlotinib in Combination With Pemetrexed/Carboplatin in Ⅲb/IV Non Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Mutation

Unknown status Phase 2 Sun Yat-sen University Started 2014 NCT02066038

Erlotinib FDA EU

Confirmed activating mutation of EGFR-ie, an exon 19 deletion or an exon 21 L858R point mutation.

Lung, Carcinoma

Pemetrexed Disodium and Carboplatin or Cisplatin With or Without Erlotinib Hydrochloride in Treating Patient With Stage IV Non-Small Cell Lung Cancer Resistant to First-Line Therapy With Erlotinib Hydrochloride or Gefitinib

Withdrawn Phase 2 Vanderbilt-Ingram Cancer Center Started 2014 NCT01928160

pemetrexed disodiumcarboplatincisplatinerlotinib hydrochloride FDA EU

Histologically- or cytologically-confirmed Stage IV NSCLC with an EGFR exon-19 deletion or L858R mutation

Recurrent Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer

A Study Comparing Pemetrexed Plus Cisplatin Versus Pemetrexed Alone in NSCLC Patients Who Have Progressed on First Line EGFR-TKI

Unknown status Phase 2 Samsung Medical Center Started 2013 NCT03050437

CisplatinPemetrexed

Histologically confirmed nonsquamous NSCLC with activating EGFR mutation (on exon 19 deletion or exon 21 L858R mutation)

Carcinoma, Non-Small-Cell Lung

Afatinib Plus Nimotuzumb for NSCLC

Unknown status Phase 1/2 Samsung Medical Center Started 2013 NCT01861223

afatinib (30 or 40mg) + nimotuzumab (100 or 200mg) FDA EU

Presence of EGFR sensitizing mutations (L858R mutation in exon 21 or exon 19 deletion) or response by RECIST on prior gefitinib or erlotinib or stable disease on prior gefitin…

NSCLC

ATOM_local Ablative Therapy

Completed Phase 2 Chinese University of Hong Kong Started 2013 NCT01941654

Oral TKI

Documented activating EGFR mutation (exon 19 deletion or exon 21 L858R only) in tumor tissues

NSCLC, Activating EGFR Mutation

Erlotinib Hydrochloride or Crizotinib and Chemoradiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer

Terminated Phase 2 National Cancer Institute (NCI) Started 2013 NCT01822496

CarboplatinCisplatinCrizotinibErlotinib FDA EUEtoposidePaclitaxel

…ensitive" mutations in epidermal growth factor receptor tyrosine kinase (EGFR TK) domain (exon 19 deletion, L858) and/or EML4-anaplastic lymphoma kinase (ALK) fusion arrangement

Stage III Non-Small Cell Lung Cancer AJCC v7, Stage IIIA Non-Small Cell Lung Cancer AJCC v7, Stage IIIB Non-Small Cell Lung Cancer AJCC v7

Preoperative Gefitinib for EGFR Mutant II-IIIa NSCLC (ECTOP-1001)

Completed Phase 2 Fudan University Started 2013 NCT01833572

Gefitinib FDA EU

Pathologically confirmed non-small cell lung cancer with EGFR exon 19 deletion or exon 21 L858 mutation.

Non-small-cell Lung Cancer

A Study of LY2875358 in Participants With Non-Small Cell Lung Cancer With Activating Epidermal Growth Factor Receptor Mutations

Completed Phase 2 Eli Lilly Started 2013 NCT01897480

LY2875358Erlotinib FDA EU

…known to be associated with EGFR tyrosine kinase inhibitor (TKI) drug sensitivity (G719X, exon 19 deletion, L858R, L861Q)

Carcinoma, Non-Small-Cell Lung

Erlotinib Monotherapy Versus Docetaxel and Cisplatin as Neoadjuvant Therapy in Patients of stageIIIA Lung ca

Unknown status Phase 2 National Taiwan University Hospital Started 2012 NCT02036359

erlotinib FDA EUdocetaxel

Tumor specimen with EGFR gene mutation of exon 19 deletion and L858R, G719X, L861Q mutation

Non-small Cell Lung Cancer(NSCLC)

A Clinical Study Conducted in Multiple Centers Comparing Veliparib in Combination With Carboplatin and Paclitaxel Versus a Placebo in Combination With Carboplatin and Paclitaxel in Patients With Advanced Non-small Cell Lung Cancer

Completed Phase 2 AbbVie Started 2012 NCT01560104

VeliparibCarboplatinpaclitaxel

Subjects with a known epidermal growth factor receptor (EGFR) mutation of exon 19 deletion or L858R mutation in exon 21. (Subjects with wild type epidermal growth factor receptor (…

Non-Small -Cell Lung Cancer

Efficacy and Safety Study of Afatinib to Treat Lung Cancer Patients

Completed Phase 2 University College, London Started 2012 NCT01415011

Afatinib (BIBW 2992) FDA EU

L858R, exon 19 deletions, exon 20 insertions, T790M, list is not exhaustive), and WHO PS 0-3 Or No tissue suitabl…

Carcinoma, Non-Small-Cell Lung

BELIEF (Bevacizumab and ErLotinib In EGFR Mut+ NSCLC)

Completed Phase 2 ETOP IBCSG Partners Foundation Started 2012 NCT01562028

Erlotinib FDA EUBevacizumab

Centrally confirmed EGFR exon 19 deletion (del19) or exon 21 mutation (L858R)

Lung Cancer

Erlotinib in Post Radical Operation NSCLC Patients With EGFR Mutation

Unknown status Phase 2 Tianjin Medical University Cancer Institute and Hospital Started 2012 NCT01683175

Erlotinib FDA EUcis-platinumVinorelbine

… 7 2009, confirmed by histopathology or cytology after radical operation, and having EGFR exon 19 deletion mutation or exon 21 L858R single base substitution;

Non-small Cell Lung Cancer Stage III

Study of Erlotinib (Tarceva®) in Combination With OSI-906 in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) With Activating Mutations of the Epidermal Growth Factor Receptor (EGFR) Gene

Completed Phase 2 Astellas Started 2011 NCT01221077

OSI-906Erlotinib FDA EU

Exon 19 deletion or exon 21 activating mutation in EGFR

NSCLC, Non Small Cell Lung Cancer

Study With Gefitinib in Combination With Olaparib (AZD2281) Versus Gefitinib Alone

Completed Phase 1/2 Spanish Lung Cancer Group Started 2011 NCT01513174

Gefitinib FDA EUOlaparib

…sessment: to be included in the study patients should present at least one EGFR mutation (exon 19 deletion or L858R with or without T790M).

Non Small Cell Lung Cancer

A Study to Assess the Incidence of EGFR Mutation in Patients With Newly Diagnosed Locally Advanced or Metastatic Non-Small Cell Lung Cancer in the UK, And of Tarceva (Erlotinib) as First-Line Therapy in EGFR Mutation Positive Patients.

Completed Phase 2 Roche Started 2011 NCT01250119

erlotinib [Tarceva] FDA EU

Treatment phase: histologically confirmed EGFR exon 19 deletion or exon 21 mutation in the diagnostic phase of the study

Non-Squamous Non-Small Cell Lung Cancer

Radiotherapy Combined With Iressa for EGFR Mutation Positive Patients With Locally Advanced Non-small Cell Lung Cancer (NSCLC)

Unknown status Phase 2 ZhuGuangYing Started 2011 NCT01391260

Patients with tumor EGFR mutation positive (exon 19 deletion mutation or exon 21 L858R substitution mutation);

Non-small Cell Lung Cancer

Hsp90 Inhibitor AUY922 and Erlotinib Hydrochloride in Treating Patients With Stage IIIB-IV Non-Small Cell Lung Cancer

Completed Phase 1/2 Northwestern University Started 2011 NCT01259089

erlotinib hydrochloride FDA EUHsp90 inhibitor AUY922mutation analysis

…or an investigational EGFR TK inhibitor OR a documented mutation in the EGFR gene (G719X, exon 19 deletion, L858R, L861Q)

Adenocarcinoma of the Lung, Non-small Cell Lung Cancer

LUX-Lung 7: A Phase IIb Trial of Afatinib(BIBW2992) Versus Gefitinib for the Treatment of 1st Line EGFR Mutation Positive Adenocarcinoma of the Lung

Completed Phase 2 Boehringer Ingelheim Started 2011 NCT01466660

Afatinib FDA EUgefitinib FDA EU

Documented activating epidermal growth factor receptor mutation (Del19 and/or L858R) with tumour tissues.

Lung Neoplasms

Erlotinib Re-Challenge for Recurrent EGFR-mutant Lung Cancer in Patients Who Previously Received Adjuvant Erlotinib or Gefitinib

Terminated Phase 2 Memorial Sloan Kettering Cancer Center Started 2010 NCT01189435

erlotinib FDA EU

…ancer, confirmed at MSKCC EGFR sensitizing mutation (point mutation in exons 18 or 21, or deletion in exon 19) must be documented in the primary or recurrent tumor

Lung Cancer

Erlotinib in Patients With Resected, Early Stage NSCLC With Confirmed Mutations in the EGFR

Completed Phase 2 Massachusetts General Hospital Started 2007 NCT00567359

Erlotinib FDA EU

Tumor samples must have either exon 19 deletion mutations or the exon 21 L858R point mutation

Non-small Cell Lung Cancer

Erlotinib and Chemotherapy for Patients With Stage IB-IIIA NSCLC With EGFR Mutations (ECON)

Completed Phase 2 Memorial Sloan Kettering Cancer Center Started 2007 NCT00577707

erlotinib FDA EUPemetrexedCisplatin

Patients must have lung cancer with a documented EGFR activating mutation (exon 19 deletion, L858R, L861Q)

Non Small Cell Lung Cancer, Lung Cancer

Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-1971 in Combination With Either Osimertinib in Participants With Unresectable, Locally Advanced, or Metastatic Non-Small Cell Lung Cancer, or With Cetuximab in Participants With Metastatic Colorectal Cancer

Completed Phase 1 Roche Started 2024 NCT05954871

GDC-1971Osimertinib FDA EUCetuximab

Positive for an EGFR exon 19 deletion or exon 21 L858R mutation

Colorectal Cancer, Non-Small Cell Lung Cancer

Tipifarnib and Osimertinib in EGFR-mutated Non-Small Cell Lung Cancer

Withdrawn Phase 1 Kura Oncology Started 2023 NCT05693090

TipifarnibOsimertinib FDA EU

The tumor harbors an Ex19del or Ex21-L858R substitution (based on tumor tissue or plasma \[ctDNA\] assessment).

NSCLC

To Evaluate the Efficacy of QLH11811 in Advanced NSCLC Patients With EGFR Mutation

Unknown status Phase 1 Qilu Pharmaceutical Started 2022 NCT05555212

QLH11811

…, unresectable or recurrent metastatic NSCLC who are naive to EGFR-TKI treatment and have 19del or 21L858R mutation among EGFR sensitive mutations.

Non-small Cell Lung Cancer

Study of HS-10241 in Combination With Almonertinib in Patients With Locally Advanced or Metastatic NSCLC

Unknown status Phase 1 Hansoh Pharma Started 2022 NCT05430386

HS-10241

…h disease progression during or after the last treatment: EGFR sensitive mutation (either exon 19 deletion or L858R mutation)

Non Small Cell Lung Cancer

(HARMONY) Study of BLU-701 in EGFR-mutant NSCLC

Terminated Phase 1 Blueprint Medicines Started 2022 NCT05153408

BLU-701osimertinib FDA EUcarboplatinpemetrexed

All Parts: activating EGFR mutation (Ex19Del or L858R)

Lung Neoplasm, Carcinoma, Non-Small-Cell Lung, Respiratory Tract Neoplasms, Neoplasms

VIC-1911 Combined With Osimertinib for EGFR -Mutant Non-small Cell Lung Cancer

Unknown status Phase 1 Jiesi Yingda Pharmaceutical Technology (Suzhou) Started 2022 NCT05489731

VIC-1911Osimertinib Mesylate Tablets FDA EU

NSCLC with advanced EGFR mutation positive \[exon 19 deletion (19del) and exon 21 L858R (21l858r) point mutation\] confirmed by cytology or histology A…

Advanced Non-small Cell Lung Cancer

A Study of Gentuximab in Combination With Almonertinib in EGFR Mutation-positive Metastatic NSCLC

Unknown status Phase 1 Changchun GeneScience Pharmaceutical Started 2021 NCT05223595

Gentuximab

…h erlotinib based on documented evidence of tumor harboring an activating EGFR mutation \[exon 19 deletion or exon 21 (L858R) substitution mutation\].

Metastatic Non-Small Cell Lung Cancer

Study of ONO-7475 in Combination With Osimertinib in EGFR Gene Mutation-positive Non-small Cell Lung Cancer

Completed Phase 1 Ono Pharmaceutical Started 2021 NCT06525246

ONO-7475Osimertinib Mesylate FDA EU

Patients with confirmed EGFR gene exon 19 deletion or EGFR gene exon 21 mutation(L858R)and who are scheduled to receive osimertinib

Stage IIIB Non-small Cell Lung Cancer, Stage IIIC Non-Small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer, Recurrent Non-Small Cell Lung Cancer

Osimertinib in Combination With Alisertib or Sapanisertib for the Treatment of Osimertinib-Resistant EGFR Mutant Stage IIIB or IV Non-Small Cell Lung Cancer

Completed Phase 1 M.D. Anderson Cancer Center Started 2020 NCT04479306

AlisertibOsimertinib FDA EUSapanisertib

EGFR exon 21 L858R or exon 19 deletion mutation, or T790M mutation that was acquired following treatment with first or second ge…

Recurrent Lung Non-Small Cell Carcinoma, Stage IIIB Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8

Temodar Plus Tyrosine Kinase Inhibitors for Progressive CNS Disease

Completed Phase 1 University of Colorado, Denver Started 2020 NCT04541407

Temozolomide plus Osimertinib FDA EUTemozolomide plus Lorlatinib

…e in the CNS on osimertinib 80 mg daily for patients with EGFR activating mutations (EGFR exon 19 deletions or EGFR L858R exon 21 point mutations) -OR- Stage IV NSCLC with progression of disease i…

Non Small Cell Lung Cancer, CNS Progression

A Study of BDTX-189, an Orally Available Allosteric ErbB Inhibitor, in Patients With Advanced Solid Tumors.

Terminated Phase 1 Black Diamond Therapeutics Started 2019 NCT04209465

BDTX-189

EGFR exon 19 deletion or L858R mutation

Solid Tumor

Safety and Efficacy of Genolimzumab (GB226) in Combination With Fruquintinib

Unknown status Phase 1 Genor Biopharma Started 2019 NCT03976856

GB226Fruquintinib

EGFR gene sensitive mutation is confirmed positive, any of following is met: exon 19 deletion (19DEL), exon 21 point mutation (L858R / L861Q), 18 exon point mutation (G719X), 20 exon …

Metastatic Non-small Cell Lung Cancer

Alisertib in Combination With Osimertinib in Metastatic EGFR-mutant Lung Cancer

Completed Phase 1 Collin Blakely Started 2019 NCT04085315

Osimertinib FDA EUAlisertib

Documented activating EGFR mutation (Exon 19 deletion, Exon 19 insertion, E709K, G719X, S768I, V769L, T790M, L833F, L833V, V834L, H835L, L858R,…

Lung Cancer Metastatic, EGFR Gene Mutation

EGF816 and Trametinib in Patients With Non-small Cell Lung Cancer Harboring Activating EGFR Mutations

Completed Phase 1 University of Cologne Started 2018 NCT03516214

EGF816Trametinib

Patients must have NSCLC harbouring EGFR p.L858R or EGFR del19 as assessed by local testing.

Bronchial Neoplasms

Safety, Tolerability and Pharmacokinetic Profile of BPI-15086 in EGFR T790M Mutation-positive NSCLC Patients

Completed Phase 1 Betta Pharmaceuticals Started 2016 NCT02914990

BPI-15086

Confirmation that the tumour harbours EGFR sensitivity mutation (exon 19 deletion, L858R and L861R, G719X)

Non-Small Cell Lung Cancer

Phase I/II Study of CK-101 in NSCLC Patients and Other Advanced Solid Tumors

Completed Phase 1 Checkpoint Therapeutics Started 2016 NCT02926768

CK-101

…R mutations known to be associated with EGFR tyrosine kinase inhibitor (TKI) sensitivity (exon 19 deletion, L858R), either alone or in combination with other EGFR mutations, determined by PCR-base…

Lung Neoplasms, Carcinoma, Non-Small-Cell Lung, Lung Diseases, Adenocarcinoma

Osimertinib and Navitoclax in Treating Patients With EGFR-Positive Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer

Completed Phase 1 National Cancer Institute (NCI) Started 2016 NCT02520778

NavitoclaxOsimertinib FDA EU

Prior genotyping positive for an EGFR activating mutation (L858R, exon 19 deletion, G719X, L861Q)

Advanced Lung Non-Squamous Non-Small Cell Carcinoma, Metastatic Lung Non-Squamous Non-Small Cell Carcinoma, Stage III Lung Non-Small Cell Cancer AJCC v7, Stage IIIA Lung Non-Small Cell Cancer AJCC v7

Pembrolizumab and Afatinib in Patients With Non-small Cell Lung Cancer With Resistance to Erlotinib

Completed Phase 1 Jonathan Riess Started 2015 NCT02364609

Afatinib Dimaleate FDA EUPembrolizumab

…vanced or metastatic/recurrent non-small cell lung cancer with EGFR activating mutations (exon 19 del, exon 21 L858R, L861Q, G718X)

Recurrent Non-Small Cell Lung Carcinoma, Stage IIIA Non-Small Cell Lung Cancer, Stage IIIB Non-Small Cell Lung Cancer, Stage IV Non-Small Cell Lung Cancer

A Safety and Efficacy Study of INC280 Alone, and in Combination With Erlotinib, Compared to Chemotherapy, in Advanced/Metastatic Non-small Cell Lung Cancer Patients With EGFR Mutation and cMET Amplification

Terminated Phase 1 Novartis Started 2015 NCT02468661

INC280 single agenterlotinib FDA EU

EGFR mutation (L858R and /or ex19del)

Non-Small Cell Lung Cancer

Phase I of Vorinostat-Iressa Combined Therapy on Resistance by BIM Polymorphysim in EGFR Mutant Lung Cancer

Unknown status Phase 1 Kanazawa University Started 2014 NCT02151721

Vorinostat, gefitinib FDA EU

EGFR mutations (deletion of exon 19 and L858R mutation of exon 21) for which the clinical benefits of an EGFR-TKI (gefitinib …

Non-Small-Cell Lung Carcinoma

Erlotinib and Momelotinib for the Treatment of Epidermal Growth Factor Receptor (EGFR) Mutated EGFR Tyrosine Kinase Inhibitor (TKI) Naive Metastatic Non-Small Cell Lung Cancer (NSCLC)

Terminated Phase 1 Sierra Oncology LLC - a GSK company Started 2014 NCT02206763

Momelotinib (MMB)Erlotinib FDA EU

Metastatic NSCLC with documented EGFR exon 19 deletion or exon 21 (L858R) substitution mutation

EGFR Mutated EGFR TKI Naive Metastatic NSCLC

Tolerability and Efficacy of Tremelimumab in Combination With Gefitinib in NSCLC Patients

Completed Phase 1 Gustave Roussy, Cancer Campus, Grand Paris Started 2014 NCT02040064

Gefitinib FDA EUTremelimumab

…tivating EGFR TK mutations known to be associated with EGFR TKI sensitivity (i.e., G719X, exon 19 deletion, L858R, L861Q) as determined locally using a well-validated and robust methodology ;

Non Small Cell Lung Cancer

A Dose Escalation Study of ASP8273 in Subjects With Non-Small-Cell Lung Cancer (NSCLC) Who Have Epidermal Growth Factor Receptor (EGFR) Mutations

Completed Phase 1 Astellas Started 2014 NCT02113813

naquotinibmidazolam

…dermal Growth Factor Receptor (EGFR) activating mutation by local testing: exon 18 G719X, exon 19 deletion, exon 21 L861Q, exon 21 L858R or exon 20 insertion

Non-Small-Cell Lung Cancer (NSCLC), Epidermal Growth Factor Receptor Mutations

Xentuzumab (BI 836845) Plus Afatinib in Patients With Epidermal Growth Factor Receptor (EGFR) Mutant Non-small Cell Lung Cancer (NSCLC)

Completed Phase 1 Boehringer Ingelheim Started 2014 NCT02191891

XentuzumabAfatinib FDA EU

Activating EGFR mutation (exon 19 deletion, L858R, G719X, L861X)

Carcinoma, Non-Small-Cell Lung

Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors, AZD3759 or AZD9291, in Patients Who Have Advanced Non-Small Cell Lung Cancer

Completed Phase 1 AstraZeneca Started 2014 NCT02228369

AZD3759AZD9291

…ytologically confirmed diagnosis of NSCLC with single activating EGFR mutations (L858R or Exon19Del).

EGFR Mutation Positive Advanced Non Small Cell Lung Cancer

INC280 and Erlotinib Hydrochloride in Treating Patients With Non-small Cell Lung Cancer

Completed Phase 1 University of California, Davis Started 2013 NCT01911507

INC280erlotinib hydrochloride FDA EU

G719X, exon 19 deletion, L858R, L861Q)

Recurrent Non-small Cell Lung Cancer

Erlotinib in Combination With Pralatrexate in Advanced Malignancies

Completed Phase 1 M.D. Anderson Cancer Center Started 2012 NCT01532011

Erlotinib FDA EUPralatrexate

Have an epidermal growth factor receptor (EGFR)-sensitive mutation (as G719C in exon 18, E746-A750 in exon 90, L858R in exon 21) and have been previously treated with EGFR inhibitor therap…

Advanced Cancers, Solid Tumors

A Study of DS-2248 in Participants With Advanced Solid Tumors

Terminated Phase 1 Daiichi Sankyo Started 2011 NCT01288430

DS-2248

… that harbors an EGFR mutation known to be associated with drug sensitivity (i.e., G719X, exon 19 deletion, L858R, L861Q) -OR- Prior objective clinical benefit from EGFR-TKI, as evidenced by compl…

Solid Tumors, Non-small Cell Lung Carcinoma

A Phase I Study of Epitinib(HMPL-813) in Patients With Advanced Solid Tumors

Completed Phase 1 HUTCHMED Started 2011 NCT02590952

Epitinib

EGFR sensitizing mutation in exon 19 deletion or exon 21(L858R).

Solid Tumor

Trial of BIBW 2992 (Afatinib) + Cetuximab in Non-Small Cell Lung Cancer

Completed Phase 1 Boehringer Ingelheim Started 2010 NCT01090011

CetuximabCetuximabBIBW 2992BIBW 2992

…ctor Receptor (EGFR) -mutation known to be associated with drug sensitivity (i.e., G719X, exon 19 deletion, L858R, L861Q) from previous tumor biopsy or surgery.

Carcinoma, Non-Small-Cell Lung

Safety/Tolerability Study of AV-412 in Subjects With Refractory or Relapsed Solid Tumor Malignancies

Terminated Phase 1 AVEO Pharmaceuticals Started 2006 NCT00381654

AV-412

Previously documented exon 19 deletion and/or exon 21 L858R mutations

Tumor

Camrelizumab Combined With Pemetrexed and Carboplatin for the Study of EGFR-mutated Lung Squamous NSCLC Treatment

Unknown status No phase Cancer Institute and Hospital, Chinese Academy of Medical Sciences Started 2021 NCT04970043

Camrelizumab+ pemetrexed + platinum

EGFR mutation (deletion of exon 19 and L858R mutation of exon 21) was confirmed by tumor histology, cytology or hematology b…

Lung Cancer Stage II

A Window of Opportunity Study for Investigating Drug Tolerant Persister (DTP) to Neoadjuvant Osimertinib in Resectable Non-small Cell Lung Cancer (NSCLC) Harbouring EGFR Mutations

Unknown status No phase Yonsei University Started 2021 NCT04816838

Osimertinib FDA EU

Documented activating EGFR mutation (Exon 19 deletion or L858R)

Non Small Cell Lung Cancer

ctDNA Guided Treatment of Early Resistance to Targeted Treatment

Completed No phase The Netherlands Cancer Institute Started 2019 NCT04148066

Histologically confirmed metastatic NSCLC, characterized by a sensitizing exon 19 deletion or exon 21 L858R EGFR mutation.

Carcinoma, Non-Small-Cell Lung

Anlotinib Hydrochloride Combined With EGFR TKIs in Advanced Non-small Cell Lung Cancer

Unknown status No phase The First Affiliated Hospital of Soochow University Started 2019 NCT03766490

Anlotinib HydrochlorideGefitinib FDA EUIcotinib

Previously, EGFR gene test showed EGFR exon 19 deletion or exon 21 (L858R) mutation, and the gene test showed no T790M mutation before enrollment…

Non-Small-Cell Lung

Gefitinib Combine Radiotherapy as Therapy for Patients With NSCLC Harbouring Sensitive Mutations of EGFR

Unknown status No phase Qilu Pharmaceutical Started 2018 NCT03381430

Gefitinib FDA EU

Target population is completely resected pathological stage IIIA-N2 NSCLC with EGFR exon 19 deletions and exon 21 L858R activating mutation.

Lung Cancer

Evaluation of EGFR TKI Resistance Mechanism Using Plasma DNA Analysis

Unknown status No phase Samsung Medical Center Started 2012 NCT01776684

EGFR TKIs (gefitinib, erlotinib, afatinib, et al) FDA EU

Patients with tumors harboring EGFR mutation (del 19 or L858R mutation) 6.

EGFR Mutation Positive Non-small Cell Lung Cancer

Improving Osimertinib Exposure and Cost-effectiveness Using Pharmacokinetic Boosting With Cobicistat

Unknown status Phase 4 Maastricht University Medical Center Started 2024 NCT05748093

Cobicistat

The patient has non-squamous advanced EGFR-mutated NSCLC with no signs of imminent progression (CT confirmed).

Broad match: EGFR mutation (unspecified)Non-small Cell Lung Cancer

Doxycycline vs Isotretinoin for Acneiform Eruptions of TKI

Unknown status Phase 4 Lady Davis Institute Started 2021 NCT04864717

Doxycycline 100mg po once daily x 6 monthsIsotretinoin 40 mg po once daily x 6 months

Participant has histologically- or pathologically-confirmed cancer with a known sensitizing EGFR mutation.

Broad match: EGFR sensitizing mutationAcneiform Eruptions, Cancer, Treatment-Related

Pembrolizumab for Metastatic NSCLC Patients Expressing PD-L1 Who Have Their Own PDX

Completed Phase 4 Samsung Medical Center Started 2018 NCT03134456

Pembrolizumab Injection

Patients with sensitive EGFR mutations should have disease progression on at least one of EGFR TKIs (including but not limited t…

Broad match: EGFR mutation (unspecified)Metastatic Non-Small Cell Lung Carcinoma

Endostar Treatment of Advanced Non-small Cell Lung Cancer Multi-center Clinical Research

Unknown status Phase 4 Nanjing NingQi Medicine Science and Technology Started 2015 NCT02513355

EndostarChangchun marinacisplatinTaxolparapl

… the preious untreated stage IIIB or IV non-small cell lung cancer (with the exception of EGFR/ALK mutations type);

Broad match: EGFR mutation (unspecified)Non-small Cell Lung Cancer

Intercalating and Maintenance Gefitinib in Combination With Chemotherapy for Advanced EGFR-mutant NSCLC

Terminated Phase 4 Sichuan University Started 2014 NCT02299765

Gefitinib FDA EUgemcitabinecarboplatin

Harboring activating mutation of EGFR,only including an exon 19 deletion or an exon 21 point mutation.

Broad match: EGFR exon 19 deletionNon-small Cell Lung Cancer Metastatic, EGFR Activating Mutation

Intercalated Combination of Chemotherapy and Tyrosine Kinase Inhibitors as First-line Treatment for Patients With Non-Small-Cell Lung Cancer

Unknown status Phase 4 Qilu Hospital of Shandong University Started 2014 NCT02031601

Erlotinib FDA EUGefitinib FDA EUIcotinibDocetaxelPemetrexedPlatinum (cisplatin or carboplatin)

EGFR mutation-positive (EGFR exon-18, exon-19 or exon-21);

Broad match: EGFR mutation (unspecified)Non-Small-Cell Lung Cancer

Sequential and Maintenance Icotinib Plus Chemotherapy Versus Icotinib Maintenance After Chemotherapy in Advanced NSCLC

Unknown status Phase 4 Betta Pharmaceuticals Started 2014 NCT02194556

Sequential and maintenance icotinibMaintenance icotinib

Positive EGFR Mutation

Broad match: EGFR mutation (unspecified)EGFR Positive Non-small Cell Lung Cancer, Adenocarcinoma

Icotinib as the Adjunctive Treatment After Surgery in Stage I-IIIB Lung Adenocarcinoma Patients With EGFR Gene Mutation

Unknown status Phase 4 Chinese PLA General Hospital Started 2014 NCT02283424

Icotinibchemotherapy (Carboplatin and Docetaxel)

Lung adenocarcinoma patients with epidermal growth factor receptor gene mutation,stage I-IIIB after surgery

Broad match: EGFR mutation (unspecified)Neoplasms, Therapy-Associated

A Study of Tarceva (Erlotinib) in First Line in Patients With Locally Advanced or Metastatic Lung Adenocarcinoma With EGFR Mutations

Completed Phase 4 Roche Started 2012 NCT01609543

erlotinib [Tarceva] FDA EU

Non-small cell lung cancer with an EGFR activating mutation

Broad match: EGFR sensitizing mutationNon-Squamous Non-Small Cell Lung Cancer

First-line Treatment With Icotinib in Elder NSCLC EGFR Mutated Patients

Unknown status Phase 4 Betta Pharmaceuticals Started 2012 NCT01646450

Icotinib

Positive EGFR Mutation.

Broad match: EGFR mutation (unspecified)Non-Small Cell Lung Cancer

A Study of Tarceva (Erlotinib) in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer Who Present EGFR Mutations

Completed Phase 4 Roche Started 2011 NCT01287754

erlotinib [Tarceva] FDA EU

Locally advanced or metastatic (stage III/IV) non-small cell lung cancer with EGFR mutations

Broad match: EGFR mutation (unspecified)Non-Small Cell Lung Cancer

Efficacy, Safety, Tolerability of Gefitinib as 1st Line in Caucasian Patients With EGFR Mutation Positive Advanced NSCLC

Completed Phase 4 AstraZeneca Started 2010 NCT01203917

Gefitinib FDA EU

…c non-small cell lung cancer (i.e. cancer that has spread from where it started) which is EGFR mutation positive

Broad match: EGFR mutation (unspecified)Caucasian Patients With EGFR Mutation Positive Advanced NSCLC

Experience of Erlotinib in Patients With Advanced Non-Small Cell Lung Cancer

Suspended Phase 4 National Guard Health Affairs Started 2009 NCT01320501

Erlotinib FDA EU

Positive EGFR mutation tested in certified lab (although EGFR test is not mandatory only if available).

Broad match: EGFR mutation (unspecified)Non-small Cell Lung Cancer Metastatic

SELINE: Second-Line Iressa Phase IV Study in NSCLC Patients

Completed Phase 4 AstraZeneca Started 2007 NCT00608868

Gefitinib FDA EU

Patient who can provide sample for EGFR mutation test

Broad match: EGFR mutation (unspecified)Non Small Cell Lung Carcinoma

Radiotherapy Combined With Almonertinib for Stage III EGFR-Mutated Lung Cancer

Unknown status Phase 2/3 Laibin People's Hospital Started 2023 NCT05994339

Almonertinib

Radiotherapy Combined With Almonertinib for Stage III EGFR-Mutated Lung Cancer

Broad match: EGFR mutation (unspecified)Lung Cancer Stage III

Utidelone Versus Docetaxel in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Unknown status Phase 3 Beijing Biostar Pharmaceuticals Started 2023 NCT05673590

Utidelone InjectionDocetaxel Injection

…FR-TKI (including Erlotinib, Gefitinib, Icotinib, Afatinib, Osimertinib, or other TKI for EGFR mutations, etc.), with disease progression or intolerance during or after treatment.

Broad match: EGFR mutation (unspecified)Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Alflutinib Versus Alflutinib Plus Chemotherapy for NSCLC

Unknown status Phase 2/3 The First Affiliated Hospital of Henan University of Science and Technology Started 2022 NCT05209256

ChemotherapyAlflutinib plus chemotherapy

an EGFR mutation, including an exon-19 deletion (Ex19del), L858R, or other (L861Q, G719A, G719C, or G719S), as well as the T790M mutation…

Broad match: EGFR exon 19 deletionNSCLC

A Study of BPI-7711 Capsule in Non-small Cell Lung Cancer Patients

Unknown status Phase 3 Beta Pharma Shanghai Started 2021 NCT03866499

BPI-7711Gefitinib FDA EU

…rollment, a central laboratory testing report has confirmed that the tumor has one of two common EGFR mutations positive that are sensitive to EGFR-TKI therapy, accompanied with or not accompanied with…

Broad match: EGFR sensitizing mutationNSCLC

Osimertinib Combined With Bevacizumab in Patients With Brain Metastasis Epidermal Growth Factor Receptor (EGFR) Mutation Positive Metastatic Non-Small Cell Lung Cancer

Unknown status Phase 3 Qingdao Central Hospital Started 2021 NCT05104281

osimertinib oral and bevazizumab intravenously FDA EU

…ined With Bevacizumab in Patients With Brain Metastasis Epidermal Growth Factor Receptor (EGFR) Mutation Positive Metastatic Non-Small Cell Lung Cancer

Broad match: EGFR mutation (unspecified)Carcinoma, Non-Small-Cell Lung

Study Evaluating Efficacy and Safety of Capmatinib in Combination With Osimertinib in Adult Subjects With Non-small Cell Lung Cancers as Second Line Therapy

Terminated Phase 3 Novartis Started 2021 NCT04816214

CapmatinibOsimertinib FDA EUPemetrexedCisplatinCarboplatin

…ased Doublet Chemotherapy in Patients With Locally Advanced or Metastatic NSCLC Harboring EGFR Activating Mutations Who Have Progressed on Prior Generation EGFR-TKI Therapy and Whose Tumors Are T790M Muta…

Broad match: EGFR sensitizing mutationCarcinoma, Non-Small-Cell Lung

A Study of SHR-1701 Plus Bevacizumab and Chemotherapy in Non-Small-Cell-Lung-Cancer

Unknown status Phase 3 Jiangsu Hengrui Started 2021 NCT05132413

SHR-1701 + Pemetrexed Disodium + cisplatin/carboplatin + bevacizumab

…b and Chemotherapy in Advanced or Metastatic Non-squamous Non-small-cell Lung Cancer With EGFR Mutation After Failure of TKIs

Broad match: EGFR mutation (unspecified)Advanced or Metastatic Non-squamous Non-small-cell Lung Cancer

A Phase III Study to Assess the Efficacy and Safety of Almonertinib Versus Platinum-based Chemotherapy as First-line Therapy in Patients With Locally Advanced or Metastatic NSCLC Harbouring Uncommon EGFR Mutation

Unknown status Phase 3 Hansoh Pharma Started 2021 NCT04951648

Almonertinibchemotherapy

The tumor harbors uncommon EGFR mutations (one of the following EGFR mutation: L861Q, G719X or S768I), assessed by Xiamen AmoyDx EG…

Broad match: EGFR sensitizing mutationNon-small Cell Lung Cancer

A Clinical Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsules Versus K Drug in the Treatment of First-line Non-small Cell Lung Cancer(NSCLC)

Unknown status Phase 3 Chia Tai Tianqing Started 2021 NCT04964479

TQB2450 injectionAnlotinib Hydrochloride CapsulesPembrolizumab injection

…factor receptor (EGFR) mutations and ALK fusions (for squamous NSCLC, patients with known EGFR mutations and anaplastic Lymphoma kinase (ALK) fusions need to be excluded, and those with unknown …

Broad match: EGFR mutation (unspecified)Non Small Cell Lung Cancer

A Study of Bevacizumab, Carboplatin, and Paclitaxel or Pemetrexed With or Without Atezolizumab in Chemotherapy-Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer (IMpower151)

Completed Phase 3 Roche Started 2020 NCT04194203

AtezolizumabBevacizumabPaclitaxelPemetrexedCarboplatin

…ecimen that is suitable for the determination of PD-L1 status, as well as the presence of EGFR mutations and ALK gene rearrangements, via central testing.

Broad match: EGFR mutation (unspecified)Carcinoma, Non-Small-Cell Lung

Efficacy of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Combined With Early Stereotactic Body Radiation Therapy to the Primary Tumor in Advanced Non-small Cell Lung Cancer

Unknown status Phase 3 Haihua Yang Started 2019 NCT03727867

Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor

…opathologically or cytologically as advanced non-small cell lung cancer and that harbored sensitizing EGFR mutation (e.g. exon 19 deletion or exon 21 L858R);

Broad match: EGFR sensitizing mutationAdvanced Non-small Cell Lung Cancer

Clinical Study of Combination Therapy With Ectiecinib, Pemetrexed and Platinum in Patients With Metastatic Non-squamous Non-small Cell Lung Cancer With EGFR Mutations.

Unknown status Phase 3 Tianjin Medical University Cancer Institute and Hospital Started 2019 NCT03992885

Icotinib

Metastatic non-squamous non-small cell lung cancer with EGFR mutations confirmed by histological or cytological examination;

Broad match: EGFR mutation (unspecified)Non-squamous Non-small Cell Lung Cancer

Toripalimab Plus Pemetrexed+Platinus in Advanced Non-small-cell Lungcancer Patients Previsouly Treated EGFR-TKI

Completed Phase 3 Shanghai Junshi Bioscience Started 2019 NCT03924050

TORIPALIMAB INJECTION(JS001 )

…ab (JS001) in Advanced Non-small Cell Lung Cancer (NSCLC) Participants With TKI-resistant EGFR-mutated Tumors

Broad match: EGFR mutation (unspecified)Non-small Cell Lung Cancer

Sintilimab ± IBI305 Plus Chemotherapy (Pemetrexed + Cisplatin) for EGFRm + Locally Advanced or Metastasis Non-Squamous NSCLC Patients After EGFR-TKI Treatment Failure

Completed Phase 3 Innovent Biologics Started 2019 NCT03802240

SintilimabIBI305PemetrexedCisplatinPlacebo1Placebo2

Patients with EGFR mutation confirmed by tumor histology or cytology or hematology prior to EGFR-TKI treatment

Broad match: EGFR mutation (unspecified)Non-Squamous Non-Small Cell Lung Cancer

A Study of Tislelizumab (BGB-A317) Plus Chemoradiotherapy Followed by Tislelizumab Monotherapy in Newly Diagnosed, Stage III Subjects With Locally Advanced, Unresectable Non-small Cell Lung Cancer

Terminated Phase 3 Bristol Myers Squibb Started 2019 NCT03745222

TislelizumabConcurrent chemoradiotherapy (cCRT)

Epidermal growth factor receptor (EGFR) mutation and anaplastic lymphoma kinase (ALK) gene translocation status available prior to randomi…

Broad match: EGFR mutation (unspecified)Carcinoma, Non-Small-Cell Lung

First Line Treatment in EGFR Mutation Positive Advanced NSCLC Patients With Central Nervous System (CNS) Metastases

Completed Phase 2/3 Alpha Biopharma (Jiangsu) Started 2018 NCT03653546

AZD3759Erlotinib FDA EUGefitinib FDA EU

Histologically or cytologically confirmed diagnosis of NSCLC with activating EGFR mutations including L858R and/or Exon19Del.

Broad match: EGFR sensitizing mutationNon-small Cell Lung Cancer, EGFR Gene Mutation, Brain Metastases

To Evaluate the Efficacy and Safety of Gefitinib in Adjuvant Chemotherapy for Lung Adenocarcinoma

Unknown status Phase 3 Shenzhen People's Hospital Started 2018 NCT03656393

Gefitinib FDA EUVinorelbineCarboplatin

The gene detects EGFR mutations is positive;

Broad match: EGFR mutation (unspecified)NSCLC, EGFR

A Study of Nivolumab + Chemotherapy or Nivolumab + Ipilimumab Versus Chemotherapy in Non-Small Cell Lung Cancer (NSCLC) Participants With Epidermal Growth Factor Receptor (EGFR) Mutation Who Failed 1L or 2L EGFR Tyrosine Kinase Inhibitor (TKI) Therapy

Completed Phase 3 Bristol Myers Squibb Started 2017 NCT02864251

NivolumabIpilimumabPemetrexedCisplatinCarboplatin

Confirmed stage IV or recurrent EGFR mutated NSCLC with disease progression on one or two prior lines of treatment with EGFR TKIs (all…

Broad match: EGFR mutation (unspecified)Non-Small-Cell Lung Carcinoma

Endostar Plus EGFR-TKI（Epidermal Growth Factor Receptor-Tyrosine-Kinase Inhibitor） as a Treatment of EGFR Mutation-positive NSCLC

Unknown status Phase 3 Zaiwen Fan Started 2017 NCT03008109

EGFR-TK Inhibitor

…us EGFR-TKI（Epidermal Growth Factor Receptor-Tyrosine-Kinase Inhibitor） as a Treatment of EGFR Mutation-positive NSCLC

Broad match: EGFR mutation (unspecified)Advanced Cancer, Lung Cancer, Nonsmall Cell

Comparison of Efficacy and Safety of Tislelizumab (BGB-A317) Versus Docetaxel as Treatment in the Second- or Third-line Setting in Participants With Non-Small Cell Lung Cancer (NSCLC)

Completed Phase 3 BeOne Medicines (BeiGene) Started 2017 NCT03358875

TislelizumabDocetaxel

…ous histology must provide evidence of not harboring sensitizing epidermal growth factor (EGFR) mutation tested by a histology-based method.

Broad match: EGFR mutation (unspecified)Non-small Cell Lung Cancer

Targeted Treatment With Intercalated Radiotherapy in EGFR-mutant IIIA/IIIB NSCLC

Unknown status Phase 2/3 Guangdong Provincial People's Hospital Started 2017 NCT03074864

Erlotinib Hydrochloride FDA EU

EGFR activating mutations in exon 18, 19 or 21were detected in tumor tissue or plasma.

Broad match: EGFR sensitizing mutationNon-small Cell Lung Cancer, Epidermal Growth Factor Receptor

Gefitinib With or Without Chemotherapy in Brain Metastases From Non-small Cell Lung Cancer

Unknown status Phase 3 Sun Yat-sen University Started 2016 NCT01951469

Gefitinib and Pemetrexed/platinum FDA EUGefitinib mono-therapy FDA EU

Patient who was confirmed stage IV NSCLC with EGFR activating mutation and brain metastases by pathologic histology or cytology

Broad match: EGFR sensitizing mutationNon-small Cell Lung Cancer, Brain Metastases, EGFR Mutation

Open Label, Prospective Study to Investigate Efficacy and Safety of AZD9291 in BM From NSCLC Patients With EGFR T790M

Unknown status Phase 3 Shandong Cancer Hospital and Institute Started 2016 NCT02972333

AZD9291 80mg oral each day

Metastatic (stage IV) EGFRm NSCLC, not amenable to curative surgery or radiotherapy, with confirmation of the presenc…

Broad match: EGFR mutation (unspecified)EGFR-TKI Resistant Mutation, Nonsmall Cell Lung Cancer, AZD9291, Brain Metastases

First-line Icotinib With Concurrent Radiotherapy for NSCLC With EGFR Mutation

Unknown status Phase 3 Daping Hospital and the Research Institute of Surgery of the Third Military Medical University Started 2016 NCT02883543

icotinibChemotherapy

…ncurrent Radiotherapy as First-line Treatment for Unresectable/Oligometastasis NSCLC With EGFR Activating Mutation: a Prospective, Multicentre, Open-label, Randomised Study

Broad match: EGFR sensitizing mutationNon-small Cell Lung Cancer

Study Comparing Bevacizumab + Erlotinib vs Erlotinib Alone as First Line Treatment of Patients With EGFR Mutated Advanced Non Squamous Non Small Cell Lung Cancer

Unknown status Phase 3 National Cancer Institute, Naples Started 2016 NCT02633189

Erlotinib FDA EUBevacizumab

Activating epidermal growth factor receptor mutation (exon19 deletion or exon 21 L858R mutation or other activating/sensitizing mutations, suc…

Broad match: EGFR sensitizing mutationNon-squamous Non-small Cell Lung Cancer

A Study of Atezolizumab Compared With Docetaxel in Non-Small Cell Lung Cancer (NSCLC) After Failure With Platinum-Containing Chemotherapy

Completed Phase 3 Roche Started 2016 NCT02813785

Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibodyDocetaxel

…ermal growth factor receptor (EGFR) mutation status prior to enrollment, except for known sensitizing EGFR mutations in which case 10 unstained slides are required and there is no need for central testing o…

Broad match: EGFR sensitizing mutationCarcinoma, Non-Small-Cell Lung

Study of Pembrolizumab Versus Docetaxel in Participants Previously Treated for Non-Small Cell Lung Cancer (MK-3475-033/KEYNOTE-033)

Completed Phase 3 MSD (Merck & Co.) Started 2016 NCT02864394

PembrolizumabDocetaxel

Has documentation of epidermal growth factor receptor (EGFR) mutation and anaplastic lymphoma kinase (ALK) translocation status

Broad match: EGFR mutation (unspecified)Carcinoma, Non-Small-Cell Lung

Prophylactic TCM for Mitigation of EGFR-TKI Related Dermatological Adverse Effect

Completed Phase 3 China Medical University Hospital Started 2016 NCT05204758

TCM Formula

…ologically confirmed diagnosis of locally advanced or metastatic lung adenocarcinoma with EGFR mutations,

Broad match: EGFR mutation (unspecified)Advanced Lung Adenocarcinoma

EGFR-TKI With Chemotherapy in NSCLC Patients With Both EGFR Mutation and BIM Deletion Polymorphism

Unknown status Phase 3 Shanghai Pulmonary Hospital, Shanghai, China Started 2016 NCT02859077

EGFR-TKI FDA EUChemotherapy（pemetrexed/gemcitabine）Chemotherapy（carboplatin）

EGFR-TKI With Chemotherapy in NSCLC Patients With Both EGFR Mutation and BIM Deletion Polymorphism

Broad match: EGFR mutation (unspecified)Non-Small-Cell Lung Cancer

Real World Treatment Study of AZD9291 for Advanced/Metastatic EGFR T790M Mutation NSCLC

Completed Phase 3 AstraZeneca Started 2015 NCT02474355

AZD9291 Dosing

Locally advanced (stage IIIB) or metastatic (stage IV) EGFRm NSCLC, not amenable to curative surgery or radiotherapy, with confirmation of the presenc…

Broad match: EGFR mutation (unspecified)Lung Cancer

TIGER-3: Open Label, Multicenter Study of Rociletinib (CO-1686) Mono Therapy Versus Single-agent Cytotoxic Chemotherapy in Patients With Mutant EGFR NSCLC Who Have Failed at Least One Previous EGFR-Directed TKI and Platinum-doublet Chemotherapy

Terminated Phase 3 Clovis Oncology Started 2015 NCT02322281

RociletinibPemetrexed or gemcitabine or paclitaxel or docetaxel

Documented evidence of a tumor with 1 or more EGFR activating mutations excluding exon 20 insertion

Broad match: EGFR sensitizing mutationNon-small Cell Lung Cancer

Gefitinib Combined With Thalidomide to Treat NSCLC

Unknown status Phase 2/3 Bai Jun Started 2015 NCT02387086

ThalidomideGefitinib FDA EUAspirin

The NSCLC harbors EGFR-mutation and are previously untreated

Broad match: EGFR mutation (unspecified)NSCLC

Hypofractionated Brain Radiation In EGFR Mutated Adenocarcinoma Cranial Disease (Hybrid)

Unknown status Phase 3 Sichuan Provincial People's Hospital Started 2015 NCT02882984

Gefitinib 250mg po qd or Tarceva 150mg po qd or Icotinib 125mg po tid Other Name: Gefitinib/Tarceva/Icotinib FDA EU

Positive EGFR mutation.

Broad match: EGFR mutation (unspecified)Stage IV EGFR Mutated NSCL With Brain Metastases

EGFR-TKI Concurrent With/Without WBRT in Brain Metastasis From NSCLC

Unknown status Phase 3 Sun Yat-sen University Started 2015 NCT02714010

EGFR-TKI FDA EU

… who was confirmed non-small cell lung cancer (NSCLC) by histology or cytology, harboring EGFR mutant type (19 and/or 21 exon mutation).

Broad match: EGFR mutation (unspecified)Non-Small Cell Lung Cancer

Pilot Trial of EGF Ointment for the Patients With EGFR-i Related Skin Side Effects

Completed Phase 2/3 Dong-A University Hospital Started 2015 NCT02284139

Arm EGF ointment 1ppmArm EGF ointment 20 ppmArm Placebos

EGFR mutation (+) NSCLC - adenocarcinoma for 1st line treatment

Broad match: EGFR mutation (unspecified)Non-small Cell Lung Cancer, Pancreatic Cancer, Colorectal Cancer

Icotinib as Adjuvant Therapy Compared With Standard Chemotherapy in Stage II-IIIA NSCLC With EGFR-mutation

Unknown status Phase 3 Betta Pharmaceuticals Started 2015 NCT02448797

IcotinibChemotherapy

Positive EGFR gene mutation (19/21)

Broad match: EGFR mutation (unspecified)Non-small Cell Lung Cancer

Study of AZD9291 Plus MEDI4736 Versus AZD9291 Monotherapy in NSCLC After Previous EGFR TKI Therapy in T790M Mutation Positive Tumours

Completed Phase 3 AstraZeneca Started 2015 NCT02454933

AZD9291MEDI4736

Confirmation from a previous archival sample that the tumour harbours an EGFR mutation known to be associated with EGFR TKI sensitivity

Broad match: EGFR mutation (unspecified)Locally Advanced or Metastatic EGFR T790M+ NSCLC

Induction Therapy With Intercalated Tyrosine Kinase Inhibitor (TKI) and Chemotherapy in NSCLC With Activating Epidermal Growth Factor Receptor (EGFR) Mutation in Stages II-IIIB

Terminated Phase 2/3 AIO-Studien-gGmbH Started 2015 NCT02326285

Gefitinib FDA EUdocetaxelcisplatin

…ng cancer (NSCLC) stage II, IIIA and IIIB detected preoperatively by adequate methods and activating EGFR mutation in exons 18-21 and deemed to be able to undergo curative surgery after induction therapy.

Broad match: EGFR sensitizing mutationNon-squamous Non-small Cell Lung Cancer Stage II, Non-squamous Non-small Cell Lung Cancer Stage IIIA, Non-squamous Non-small Cell Lung Cancer Stage IIIB, Activating EGFR Mutation

Icotinib Following Chemotherapy Versus Chemotherapy as Adjuvant Therapy in Stage IIA-IIIA NSCLC With EGFR Mutation

Terminated Phase 3 Sun Yat-sen University Started 2014 NCT01996098

6-month Icotinib12-month icotinib

EGFR activating mutation in exon 19 or 21.

Broad match: EGFR sensitizing mutationLung Cancer

TIGER-1: Safety and Efficacy Study of Rociletinib (CO-1686) or Erlotinib in Patients With EGFR-mutant/Metastatic NSCLC Who Have Not Had Any Previous EGFR Directed Therapy

Terminated Phase 2/3 Clovis Oncology Started 2014 NCT02186301

Rociletinib Mono-TherapyErlotinib Mono-Therapy FDA EU

Documented evidence of a tumor with activating EGFR mutations by local testing.

Broad match: EGFR sensitizing mutationNon-Small Cell Lung Cancer

Afatinib in Patients With Non Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR) Mutations

Completed Phase 3 Boehringer Ingelheim Started 2014 NCT02044380

Afatinib FDA EU

Epidermal Growth Factor Receptor (EGFR) mutation-positive results per the institution's testing methodology

Broad match: EGFR mutation (unspecified)Carcinoma, Non-Small-Cell Lung

Icotinib Versus Placebo as Adjuvant Therapy in EGFR-mutant Lung Adenocarcinoma

Unknown status Phase 3 Betta Pharmaceuticals Started 2014 NCT02125240

Icotinib

Patients must harbor sensitive EGFR gene mutation (19/21)

Broad match: EGFR mutation (unspecified)EGFR Positive Non-small Cell Lung Cancer, Adenocarcinoma

Erlotinib Intercalated With Chemotherapy Versus Erlotinib as First Line Treatment in Stage IIIB/IV NSCLC Patients With EGFR Mutation

Unknown status Phase 3 Xinjiang Medical University Started 2013 NCT02001896

gemcitabine; cisplatin or carboplatin; erlotinib FDA EUerlotinib FDA EU

…hemotherapy Versus Erlotinib as First Line Treatment in Stage IIIB/IV NSCLC Patients With EGFR Mutation

Broad match: EGFR mutation (unspecified)Non-Small Cell Lung Cancer

An Open Label Trial of Afatinib (Giotrif) in Treatment-naive (1st Line) or Chemotherapy Pre-treated Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Harboring EGFR Mutation(s)

Completed Phase 3 Boehringer Ingelheim Started 2013 NCT01853826

Afatinib FDA EU

Epidermal Growth Factor Receptor (EGFR) mutation-positive result per the institution's testing methodology.

Broad match: EGFR mutation (unspecified)Carcinoma, Non-Small-Cell Lung

Phase 3 Study of Bavituximab Plus Docetaxel Versus Docetaxel Alone in Patients With Late-stage Non-squamous Non-small-cell Lung Cancer

Completed Phase 3 Peregrine Pharmaceuticals Started 2013 NCT01999673

bavituximabDocetaxel

For patients with known epidermal growth factor receptor (EGFR) activating mutations or anaplastic lymphoma kinase (ALK) translocations, appropriate targeted treatment shoul…

Broad match: EGFR sensitizing mutationNon-Small-Cell Lung Cancer Stage IIIB, Non-Small-Cell Lung Cancer Stage IV, Non-Small-Cell Lung Cancer Metastatic, Carcinoma, Non-Small-Cell Lung

Afatinib (BIBW 2992) in Advanced Non-Small Cell Lung Cancer Patients With EGFR Mutation

Completed Phase 3 Boehringer Ingelheim Started 2013 NCT01953913

Afatinib FDA EU

presence of Epidermal Growth Factor Receptor (EGFR) mutations in tumor biopsy

Broad match: EGFR mutation (unspecified)Carcinoma, Non-Small-Cell Lung

Phase Ⅲ Trial of WBRT Versus Erlotinib Concurrent Whole-brain Radiation Therapy as ﬁrst-line Treatment for Patients With Multiple Brain Metastases From Non-small-cell Lung Cancer(ENTER): a Multicentre, Open-label, Randomised Study

Completed Phase 3 Daping Hospital and the Research Institute of Surgery of the Third Military Medical University Started 2013 NCT01887795

Erlotinib FDA EUWBRT

…gnosis of non-small cell lung cancer and detection of pulmonary primary ARMs / sequencing EGFR mutation;

Broad match: EGFR mutation (unspecified)Multiple Brain Metastases, Non-small-cell Lung Cancer

Paclitaxel-bevacizumab in Advanced Lung Cancer

Completed Phase 3 Intergroupe Francophone de Cancerologie Thoracique Started 2013 NCT01763671

DocetaxelPaclitaxelBevacizumab

Patient with active mutation of EGFR must have had on line of chemotherapy with platinum and one with Tyrosine kinase inhibito…

Broad match: EGFR mutation (unspecified)Non-squamous Non-small Cell Lung Cancer

Therapeutic Strategies in Patients With Non-squamous Non-small Cell Lung Cancer With Brain Metastases

Terminated Phase 3 Centre Hospitalier Intercommunal Creteil Started 2013 NCT02162537

CisplatinPemetrexedBevacizumab

…tologically or cytologically proven non-epidermoid, non-small cell lung cancer, non-EGFR (Epidermal Growth Factor Receptor)-mutated (or mutation test impracticable).

Broad match: EGFR mutation (unspecified)Non-small Cell Lung Cancer Metastatic, Non-small Cell Lung Cancer, Adenocarcinoma of Lung Metastatic to Brain, Cerebral Metastases

A Study of Onartuzumab in Combination With Erlotinib in Patients With MET-Positive Stage IIIB or IV Non-Small Cell Lung Cancer Carrying an Activating Epidermal Growth Factor Receptor (EGFR) Mutation

Completed Phase 3 Roche Started 2013 NCT01887886

erlotinib FDA EUonartuzumab

…MET-Positive Unresectable Stage IIIb or IV Non-Small Cell Lung Cancer (NSCLC) Carrying an Activating EGFR Mutation

Broad match: EGFR sensitizing mutationNon-Squamous Non-Small Cell Lung Cancer

A Study of IRESSA Treatment Beyond Progression in Addition to Chemotherapy Versus Chemotherapy Alone

Completed Phase 3 AstraZeneca Started 2012 NCT01544179

Gefitinib FDA EUPemetrexedCisplatin

…otherapy Versus Chemotherapy Alone in Patients Who Have Epidermal Growth Factor Receptor (EGFR) Mutation Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) and Have Progr…

Broad match: EGFR mutation (unspecified)Non-Small Cell Lung Cancer

Icotinib or Whole Brain Irradiation in EGFR-mutant Lung Cancer

Completed Phase 3 Guangdong Association of Clinical Trials Started 2012 NCT01724801

Icotinib

Patient who was confirmed stage IV NSCLC with EGFR activating mutation and brain metastases by pathologic histology or cytology.

Broad match: EGFR sensitizing mutationBrain Metastasis, Non Small Cell Lung Cancer

Icotinib Versus First-line Chemotherapy Plus Maintenance Treatment in EGFR Positive Lung Adenocarcinoma Patients

Completed Phase 3 Betta Pharmaceuticals Started 2012 NCT01719536

IcotinibChemotherapy

Positive EGFR Mutation.

Broad match: EGFR mutation (unspecified)NSCLC

Erlotinib Versus Gemcitabine/Cisplatin as (Neo)Adjuvant Treatment in Non-small Cell Lung Cancer

Unknown status Phase 2/3 Guangdong Association of Clinical Trials Started 2011 NCT01407822

Erlotinib FDA EUGemcitabine/cisplatin

EGFR activating mutation in exon 19 or 21 by the biopsy of primary tumor or N2 lymph node.

Broad match: EGFR sensitizing mutationNon-small Cell Lung Cancer

A Randomized, Open-label, Multicenter, Phase 3 Study to Compare the Efficacy and Safety of Eribulin With Treatment of Physician's Choice in Subjects With Advanced Non-Small Cell Lung Cancer

Completed Phase 3 Eisai Started 2011 NCT01454934

EribulinTPC -Vinorelbine,Gemcitabine,Docetaxel, and Pemetrexed

…should have included a platinum-based regimen and, in all subjects with tumors harbouring EGFR mutations, an EGFR TKI.

Broad match: EGFR mutation (unspecified)Non-Small Cell Lung Cancer (NSCLC)

A Study of Erlotinib (Tarceva) Versus Gemcitabine/Cisplatin as First-line Treatment in Patients With Non-small Cell Lung Cancer With EGFR Mutations

Completed Phase 3 Roche Started 2011 NCT01342965

Erlotinib FDA EUChemotherapy

Presence of epidermal growth factor receptor (EGFR) mutations in tumours.

Broad match: EGFR mutation (unspecified)Non-Small Cell Lung Cancer

BIBW 2992 (Afatinib) vs Gemcitabine-cisplatin in 1st Line Non-small Cell Lung Cancer (NSCLC)

Completed Phase 3 Boehringer Ingelheim Started 2010 NCT01121393

Gemcitabine+CisplatinBIBW 2992

…ine Treatment for Patients With Stage IIIB or IV Adenocarcinoma of the Lung Harbouring an EGFR Activating Mutation

Broad match: EGFR sensitizing mutationCarcinoma, Non-Small-Cell Lung, Adenocarcinoma

BIBW 2992 (Afatinib) Versus Chemotherapy as First Line Treatment in NSCLC With EGFR Mutation

Completed Phase 3 Boehringer Ingelheim Started 2009 NCT00949650

PemetrexedBIBW 2992Cisplatin

…ine Treatment for Patients With Stage IIIB or IV Adenocarcinoma of the Lung Harbouring an EGFR Activating Mutation

Broad match: EGFR sensitizing mutationCarcinoma, Non-Small-Cell Lung, Adenocarcinoma

Radiation Therapy to the Brain or Observation in Preventing Brain Metastases in Patients With Advanced Non-Small Cell Lung Cancer

Unknown status Phase 3 National Cancer Center, Korea Started 2009 NCT00955695

erlotinib hydrochloride FDA EUgefitinib FDA EU

EGFR mutation (exon 19 or 21)

Broad match: EGFR mutation (unspecified)Lung Cancer

PH009-1 in Patients With EGFR Mutation Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)

Unknown status Phase 1/2 Suzhou Puhe Pharmaceutical Technology Started 2024 NCT06590194

PH009-1 tablet

Subjects must have NSCLC harboring one or more active EGFR mutations.

Broad match: EGFR mutation (unspecified)Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)

Phase II Trial of Almonertinib Plus Lastet for EGFR+ Non-small Cell Lung Cancer

Unknown status Phase 2 Shanghai Pulmonary Hospital, Shanghai, China Started 2024 NCT06463171

Almonertinib

…he First-line Treatment of Locally Advanced or Metastatic Non-small Cell Lung Cancer With EGFR Mutations

Broad match: EGFR mutation (unspecified)Lung Cancer Non-small Cell Stage IV

Oral Iloprost for the Prevention of Lung Cancer In Former Smokers

Withdrawn Phase 2 National Cancer Institute (NCI) Started 2024 NCT05411107

Iloprost

Osimertinib for epidermal growth factor receptor (EGFR) mutation)\], if appropriate, provided they are \> 12 months from the last systemic adjuvant therap…

Broad match: EGFR mutation (unspecified)Bronchial Epithelial Dysplasia, Chronic Obstructive Pulmonary Disease, Lung Carcinoma, Stage I Lung Cancer AJCC v8

A Study to Investigate Safety, Tolerability, PK and Anti-tumor Activity of TRX-221 in EGFRm NSCLC Patients

Terminated Phase 1/2 Therapex Started 2024 NCT06186076

TRX-221

…of relapsed or refractory, locally unresectable advanced or metastatic NSCLC harboring an activating EGFR mutation

Broad match: EGFR sensitizing mutationCarcinoma, Non-Small-Cell Lung, EGFR Mutant Advanced Non-Small Cell Lung Cancer

Intrathecal Pemetrexed Combined With High-dose Furmonertinib and Beva for EGFR-m NSCLC With Leptomeningeal Metastases

Unknown status Phase 2 Hunan Province Tumor Hospital Started 2024 NCT06537297

Intrathecal Pemetrexed and high-dose Furmonertinib plus bevacizumab

…cy and Safety of Intrathecal Pemetrexed With High-dose Furmonertinib Plus Bevacizumab for EGFR-mutant NSCLC Patients With Leptomeningeal Metastases Resistant to Third-generation EGFR-TKIs: A …

Broad match: EGFR mutation (unspecified)Non-small Cell Lung Cancer

Radiotherapy Plus Anlotinib in LA-NSCLC Intolerable to cCRT

Completed Phase 2 JIANYANG WANG Started 2024 NCT07037680

Anlotinib

Patients with histologically or cytologically confirmed negative EGFR (including EGFR exon 19 deletion or L858R mutations) or ALK/ROS1-mutated locally advanced unresectable NSCLC were screened…

Broad match: EGFR exon 19 deletionLocally Advanced Non-Small Cell Lung Cancer, Thoracic Radiotherapy, Safety

High-dose Furmonertinib Combined With Bevacizumab and Intrathecal Pemetrexed Chemotherapy in Patients With EGFR-mutated Non-small Cell Lung Cancer and Meningeal Metastasis

Completed Phase 2 Sun Yat-sen University Started 2024 NCT06812871

furmonertinib

…rtinib Combined With Bevacizumab and Intrathecal Pemetrexed Chemotherapy in Patients With EGFR-mutated Non-small Cell Lung Cancer and Meningeal Metastasis

Broad match: EGFR mutation (unspecified)Non-small Cell Lung Cancer Metastatic

Lazertinib+Pemetrexed/Carboplatin in Patients With EGFR Sensitizing Mutation Positive Recurrent or Metastatic Non-Small Cell Lung Cancer Failed to Prior Lazertinib

Completed Phase 2 Yonsei University Started 2023 NCT05786430

Lazertinib/Pemetrexed/Carboplatin FDA EU

Lazertinib+Pemetrexed/Carboplatin in Patients With EGFR Sensitizing Mutation Positive Recurrent or Metastatic Non-Small Cell Lung Cancer Failed to Prior Lazertinib

Broad match: EGFR sensitizing mutationNon-small Cell Lung Cancer

Lazertinib 160mg in EGFR T790M NSCLC

Unknown status Phase 2 Samsung Medical Center Started 2023 NCT05701384

Lazertinib FDA EU

EGFR mutation positive patients who received previous 1st or 2nd generation EGFR TKI

Broad match: EGFR mutation (unspecified)Lung Cancer Stage IV, EGFR T790M

Disitamab Vedotin Combined Therapy for Locally Advanced or Metastatic NSCLC Patients With HER2 Alterations

Unknown status Phase 2 Sun Yat-sen University Started 2023 NCT05847764

RC48+Tislelizumab+carboplatinRC48+Furmonertinib, 1LRC48+Furmonertinib, 2L+

Arm 2: EGFR mutations accompanied by HER2 alterations;

Broad match: EGFR mutation (unspecified)Non Small Cell Lung Cancer, ERBB2 Mutation-Related Tumors, RC48, Disitamab Vedotin

A Phase II Clinical Trial of DZD9008 in Combination With AZD4205 in Standard Treatment Failed NSCLC Patients With EGFR Mutations (WU-KONG21)

Completed Phase 2 Dizal Pharmaceuticals Started 2023 NCT06295432

DZD9008+AZD4205

Subjects must have documented EGFR sensitizing mutation from a local certified laboratory.

Broad match: EGFR sensitizing mutationNon-small Cell Lung Cancer

Study of AK119 and AK112 With or Without Chemotherapy for NSCLC Patients

Terminated Phase 1/2 Akeso Started 2023 NCT05636267

AK119AK112PemetrexedCarboplatin

EGFR activating mutation confirmed by tumor histology, cytology or hematology.

Broad match: EGFR sensitizing mutationNSCLC

Serplulimab Plus Bevacizumab and Chemotherapy for EGFR-mutant Metastatic NSCLC Patients After EGFR-TKI Treatment Failure

Unknown status Phase 2 Henan Cancer Hospital Started 2023 NCT06334757

SerplulimabBevacizumab Biosimilar HLX04PemetrexedCarboplatin

Patients with EGFR mutation confirmed by tumor histology or cytology or hematology prior to EGFR-TKI treatment

Broad match: EGFR mutation (unspecified)Non-Squamous Non-Small Cell Lung Cancer

Neoadjuvant Aumolertinib in Patients With AI-diagnosed EGFR-mutant High-risk Pulmonary Ground-glass Opacity.

Unknown status Phase 2 The First Affiliated Hospital of Guangzhou Medical University Started 2023 NCT05946460

Aumolertinib

Presence of at least one resectable malignant EGFR-mutant pulmonary ground-glass nodule diagnosed by AI (CTR ≤ 0.5, EGFR mutation prediction value …

Broad match: EGFR mutation (unspecified)Lung Cancer

Aumolertinib Combined Intrathecal Chemotherapy for Leptomeningeal Metastasis From EGFR-Mutated NSCLC and Prognostic Value of Dynamic Changes in cfDNA Profiles

Completed Phase 2 Three Gorges Hospital of Chongqing University Started 2023 NCT05810350

Aumonertinib 165mg orally once daily and intrathecal chemotherapy with pemetrexed

…samples or blood samples were tested and confirmed as EGFR sensitive mutations (including exon 19 deletion or L858R, both alone or coexisting with other EGFR site mutations).

Broad match: EGFR exon 19 deletionNon-small Cell Lung Cancer

Hydroxychloroquine Combined With Gemcitabine in the Treatment of Advanced Non-small Cell Lung Cancer

Unknown status Phase 2 Henan Cancer Hospital Started 2022 NCT05647330

Hydroxychloroquine Combined With Gemcitabine

…gically proven advanced lung squamous cell carcinoma or lung adenocarcinoma with negative EGFR and ALK gene mutations.

Broad match: EGFR mutation (unspecified)Hydroxychloroquine, Gemcitabine, Lung Neoplasms

CNS Dose Escalation/Expansion of Tepotinib in MET-driven NSCLC

Terminated Phase 1/2 Criterium Started 2022 NCT04739358

Tepotinib

…histologic or cytologic confirmation of metastatic NSCLC with documented other driver (eg EGFR or ALK alterations) in which there is evidence of MET-driven acquired resistance (including any of the MET …

Broad match: EGFR mutation (unspecified)Advanced Non-Small Cell Lung Cancer With MET Mutations

Furmonertinib in EGFR-Mutant NSCLC With Brain Metastases (iFORCE)

Completed Phase 2 Peking Union Medical College Started 2022 NCT05465343

Furmonertinib 160 mg, Q.D.

Tumor tissue samples or blood samples are confirmed to be EGFR mutations (including 19del or 21L858R or T790M)

Broad match: EGFR exon 19 deletionFurmonertinib, EGFR-mutation, NSCLC, Brain Metastases

A Study of Lazertinib as Consolidation Therapy in Patients With Locally Advanced, Unresectable, EGFR-Mutant Non-Small Cell Lung Cancer (Stage III) Following Chemoradiation Therapy

Unknown status Phase 2 Sung Yong Lee Started 2022 NCT05338619

Lazertinib FDA EU

…y of Lazertinib as Consolidation Therapy in Patients With Locally Advanced, Unresectable, EGFR-Mutant Non-Small Cell Lung Cancer (Stage III) Following Chemoradiation Therapy

Broad match: EGFR mutation (unspecified)Non-small Cell Lung Cancer Stage III, EGFR Positive Non-small Cell Lung Cancer, Non-squamous Non-small-cell Lung Cancer

Adjuvant Furmonertinib in Stage IA With High Risk Factors and Stage IB Non-small Cell Lung Cancer

Unknown status Phase 2 Peking Union Medical College Hospital Started 2022 NCT05445310

Furmonertinib

EGFR mutation positive according to NGS testing by tissue, including deletions in exon 19, L858R, S768I, G719X, L861Q, T790M mutations et al.

Broad match: EGFR exon 19 deletionNon-small Cell Lung Cancer

Efficacy of Triplet Combination With Pembrolizumab, Neratinib, and Paclitaxel as a Second Line Treatment in Recurrent/Advanced Gastric Cancer Having Somatic Human Epidermal Growth Factor Receptor Family (EGFR, HER2, HER3, HER4) Mutations or HER2 Amplification/Overexpression

Withdrawn Phase 2 Yonsei University Started 2022 NCT05512182

Chemotherapy

Has tumors with known activating EGFR, ERBB2, ERBB3, ERBB4 mutations or HER2 amplification by NGS, or HER2 overexpression by IHC or SISH/FISH

Broad match: EGFR sensitizing mutationRecurrent/Advanced Gastric Cancer

Efficacy of SRT as Salvage Therapy in Patients With Brain Oligo-progression of EGFR-mutant Non-small Cell Lung Cancer After Failure of the Third-generation EGFR-TKIs

Unknown status Phase 2 Shanghai Cancer Hospital, China Started 2022 NCT04519983

Aumolertinib Oral Tablet

Efficacy of SRT as Salvage Therapy in Patients With Brain Oligo-progression of EGFR-mutant Non-small Cell Lung Cancer After Failure of the Third-generation EGFR-TKIs

Broad match: EGFR mutation (unspecified)Lung Cancer Stage IV

Envafolimab Immunotherapy After ctDNA EGFR Clearance by Treatment With Almonertinib in EGFR-Mutant, PD-LI Positive NSCLC

Unknown status Phase 2 The First Affiliated Hospital with Nanjing Medical University Started 2022 NCT05534113

Almonertinib Envafolimab

…ood samples were confirmed to contain EGFR-sensitive mutations by ctDNA testing(including exon 19 deletion or L858R, both alone or coexist with other EGFR mutations.Patients with EGFR20 exon inser…

Broad match: EGFR exon 19 deletionNon-small Cell Lung Cancer

Osimertinib With or Without Savolitinib as 1L in de Novo MET+, EGFR+ NSCLC

Unknown status Phase 2 Guangdong Association of Clinical Trials Started 2022 NCT05163249

Osimertinib FDA EUSavolitinib

…ally or cytologically confirmed locally advanced or metastatic EGFRm+ NSCLC harbouring an EGFR mutation known to be associated with EGFR TKI sensitivity.

Broad match: EGFR mutation (unspecified)Carcinoma, Non-Small-Cell Lung

Almonertinib Therapy in Patients With Abnormal Liver Function After EGFR-TKI Treatment, or Almonertinib First-line Therapy in Patients With Basic Hepatopathy

Unknown status Phase 2 West China Hospital Started 2022 NCT05662813

Almonertinib

…r tissue samples or blood samples are confirmed to be EGFR sensitive mutations (including exon 19 deletion or L858R, both alone or coexist with other EGFR mutations).

Broad match: EGFR exon 19 deletionNon-small Cell Lung Cancer

Study of TY-9591 in Patients With a Lung Cancer With Brain or Leptomeningeal Metastases With EGFR Mutation

Completed Phase 2 TYK Medicines Started 2022 NCT05146219

TY-9591 Tablets

Presence of an activating EGFR-sensitive mutations (including exon 19 deletions, L858R, the above mentioned mutations alone or co-existed with other EGFR-mutated sites)…

Broad match: EGFR exon 19 deletionNSCLC, EGFR Activating Mutation, Brain Metastases, Leptomeningeal Metastasis

Testing the Use of Targeted Treatment for RET Positive Advanced Non-small Cell Lung Cancer

Withdrawn Phase 2 SWOG Cancer Research Network Started 2022 NCT05364645

CarboplatinPemetrexedSelpercatinib

This includes EGFR sensitizing mutations, EGFR T790M mutations, ALK gene fusions, ROS1 gene fusion, KRAS activating mutations, BR…

Broad match: EGFR sensitizing mutationLung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8

Furmonertinib in Patients With Leptomeningeal Metastases Associated With EGFR Mutated NSCLC

Unknown status Phase 2 First Affiliated Hospital of Zhejiang University Started 2022 NCT05813522

Furmonertinib Mesilate Tablets

…ients with new neurological symptoms and signs or typical MRI findings, together with the EGFR mutations detected by CSF ctDNA, can also be enrolled even if CSF cytology is not positive.

Broad match: EGFR mutation (unspecified)Non Small Cell Lung Cancer

Neoadjuvant Immunotherapy in EGFR-mutant Localized NSCLC

Unknown status Phase 2 Guangdong Provincial People's Hospital Started 2022 NCT05244213

SintilimabCarboplatinNab paclitaxel

…ically confirmed diagnosis with Stage II-IIIB(N2) NSCLC which harbored sensitive and rare EGFR alteration.

Broad match: EGFR mutation (unspecified)Non-small Cell Lung Cancer, EGFR Activating Mutation

Almonertinib as First-line Treatment in Patients With EGFR Mutations Positive in Advanced NSCLC With Brain Metastases

Unknown status Phase 2 Zhejiang Cancer Hospital Started 2021 NCT04808752

Almonertinib

…r tissue samples or blood samples are confirmed to be EGFR sensitive mutations (including exon 19 deletion or L858R, both alone or coexist with other EGFR mutations).

Broad match: EGFR exon 19 deletionLung Cancer

A Study of Amivantamab and Lazertinib in People With Non-Small Cell Lung Cancer (NSCLC)

Completed Phase 2 Memorial Sloan Kettering Cancer Center Started 2021 NCT04965090

Amivantamab FDA EULazertinib FDA EU

Somatic activating mutation in EGFR in a prior tumor biopsy or cfDNA sample

Broad match: EGFR mutation (unspecified)Metastatic Non Small Cell Lung Cancer, Recurrent Non Small Cell Lung Cancer

Almonertinib as First-line Treatment in Patients With EGFR+ Positive Pulmonary Adenosquamous Carcinoma or Combined Adenocarcinoma and Squamous Cell Carcinoma

Unknown status Phase 2 Fujian Cancer Hospital Started 2021 NCT04354961

Almonertinib

Aumolertinib as First-line Treatment in EGFR-Mutant Pulmonary Adenosquamous Carcinoma: A Multicenter, Single-Arm, Prospective Study (ARISE)

Broad match: EGFR mutation (unspecified)Pulmonary Adenosquamous Carcinoma

Study of Pembrolizumab With Single Agent Chemotherapy in Elderly Patients With Advanced NSCLC

Withdrawn Phase 2 Shirish Gadgeel Started 2021 NCT04754815

PembrolizumabPemetrexedPaclitaxelNab-paclitaxel

…iagnosis of stage IV (AJCC version 8) NSCLC with tumor PD-L1 \< 50% and negative 'driver' alterations in EGFR, ALK and ROS1 will be enrolled in this study.

Broad match: EGFR mutation (unspecified)Non Small Cell Lung Cancer, Advanced Lung Non-Small Cell Carcinoma, PD-L1 Gene Mutation

Almonertinib Treats Advanced NSCLC Patients With EGFR Mutations Who Are Safety Intolerant After Osimertinib Treatment

Unknown status Phase 2 Shanghai Chest Hospital Started 2021 NCT04882345

Almonertinib

…ally advanced or metastatic NSCLC are confirmed to be EGFR sensitive mutations (including exon 19 deletion or L858R, both alone or coexist with other EGFR mutations).

Broad match: EGFR exon 19 deletionLung Cancer, EGFR Gene Mutation

Combination of Almonertinib and Concurrent Chemoradiotherapy in Unresectable Stage III NSCLC

Unknown status Phase 2 Yuan Chen Started 2021 NCT04952168

Almonertinib

Patients must has sensitizing EGFR mutation (e.g. exon 19 deletion or exon 21 L858R).

Broad match: EGFR sensitizing mutationNSCLC, Stage III

Pembrolizumab, Lenvatinib and Chemotherapy After TKIs in NSCLC

Unknown status Phase 2 Dr Joanne CHIU Started 2021 NCT04989322

PembrolizumabLenvatinibPemetrexedCarboplatin

Unresectable or metastatic NSCLC, including squamous cell carcinoma, harboring sensitizing EGFR, ALK, or ROS1 genetic aberrations who have received standard of care targeted therapy and have progressed on treatment.

Broad match: EGFR sensitizing mutationNsclc, EGFR Activating Mutation, EGF-R Positive Non-Small Cell Lung Cancer, ALK Gene Rearrangement Positive

Clinical Efficacy and Safety of EGFR-TKI Combined With Nimotuzumab in the Treatment of Leptomeningeal Metastases From Lung Cancer

Unknown status Phase 2 Hui Bu Started 2021 NCT04833205

Nimotuzumab

Detection results of cerebrospinal fluid, blood gene or lung tissue specimens showed EGFR mutation, and immunohistochemistry results of cerebrospinal fluid, blood gene or lung tissue showe…

Broad match: EGFR mutation (unspecified)Leptomeningeal Metastasis, Lung Cancer

ctDNA-MRD Based Adjuvant Targeted Therapy for EGFR Positive Stage I Lung Adenocarcinomas

Unknown status Phase 1/2 Peking University People's Hospital Started 2021 NCT05079022

Furmonertinib

…noma patients underwent complete surgical resection with negative margins (R0) and harbor sensitizing EGFR mutations (exon 19 and/or exon 21).

Broad match: EGFR sensitizing mutationAdenocarcinoma of Lung

Poziotinib and Ramucirumab for the Treatment of EGFR Exon 20 Mutant Stage IV Non-small Cell Lung Cancer

Withdrawn Phase 2 M.D. Anderson Cancer Center Started 2021 NCT05045404

Poziotinib Hydrochloride1429757-68-5, HM781-36B, NOV-1201 Hydrochloride, NOV120101 Hydrochloride, Poziotinib HCl, POZIOTINIB HYDROCHLORIDE

…n using a Food and Drug Administration (FDA)-approved in vitro diagnostic test (ie, cobas EGFR mutation test version \[v\] 2 or therascreen EGFR RGQ polymerase chain reaction \[PCR\] kit), a Cl…

Broad match: EGFR mutation (unspecified)Metastatic Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8

Durvalumab and Stereotactic Radiotherapy for Advanced NSCLC

Terminated Phase 2 University of Texas Southwestern Medical Center Started 2021 NCT04786093

Durvalumab

… on this study should not be on any targeted systemic therapies such as those directed at EGFR mutations, ALK or ROS1 gene rearrangements, BRAF V600E mutation, or NTRK gene fusions.

Broad match: EGFR mutation (unspecified)Non Small Cell Lung Cancer

AP-L1898 Capsule in Patients With Non-small Cell Lung Cancer

Terminated Phase 1/2 Suzhou Junjing BioSciences Started 2021 NCT04993391

JS111(AP-L1898 Capsules)JS111(AP-L1898 Capsules)JS111(AP-L1898 Capsules)JS111(AP-L1898 Capsules)JS111(AP-L1898 Capsules)

There is clear evidence showing carrying EGFR exon 20 insertion and other rare EGFR mutations (only applicable for dose-extension and efficacy-extension periods).

Broad match: EGFR mutation (unspecified)Lung Cancer

the Efficacy and Safety of Anlotinib Combined With Almonertinib in the First-line Treatment of Patients With Brain Metastases From EGFR Mutation-positive Non-small Cell Lung Cancer

Unknown status Phase 2 Li-kun Chen Started 2021 NCT04978753

Anlotinib

…ined With Almonertinib in the First-line Treatment of Patients With Brain Metastases From EGFR Mutation-positive Non-small Cell Lung Cancer

Broad match: EGFR mutation (unspecified)Non-small Cell Lung Cancer, Brain Metastases

Olaparib (LYNPARZA) Plus Durvalumab (IMFINZI) in EGFR-Mutated Adenocarcinomas That Transform to Small Cell Lung Cancer (SCLC) and Other Neuroendocrine Tumors

Terminated Phase 2 National Cancer Institute (NCI) Started 2021 NCT04538378

OlaparibDurvalumab

Subjects with initial diagnosis of epidermal growth factor receptor (EGFR)-mutated non-small-cell lung carcinoma (NSCLC) and histologically or cytologically confirmed trans…

Broad match: EGFR mutation (unspecified)EGFR-Mutated Non-Small-Cell Lung Carcinoma, Small Cell/Neuroendocrine

EMB-01 in Patients With Advanced/Metastatic Gastrointestinal Cancers

Unknown status Phase 1/2 Shanghai EpimAb Biotherapeutics Started 2021 NCT05176665

EMB-01

Other EGFR or cMET gene alteration in blood sample (circulating tumor DNA, ctDNA).

Broad match: EGFR mutation (unspecified)Neoplasms, Neoplasm Metastasis, Metastatic Gastrointestinal Carcinoid Tumor

Study to Assess AFM24 in Combination With Atezolizumab in Selected Advanced/Metastatic EGFR-expressing Cancers

Terminated Phase 1/2 Affimed Started 2021 NCT05109442

AFM24Atezolizumab 840 MG in 14 ML Injection

Subjects must have documentation of EGFR mutated NSCLC as assessed by an approved test using genomic sequencing of tumor or circulation fr…

Broad match: EGFR mutation (unspecified)Advanced Solid Tumor

Neo-DIANA: Neoadjuvant Treatment for EGFR Mutated Patients

Terminated Phase 2 Fundación GECP Started 2020 NCT04512430

AtezolizumabBevacizumabCarboplatinPemetrexed

Sensitizing EGFR mutation (Del Exon 19 and ins Exon 21).

Broad match: EGFR sensitizing mutationNon Small Cell Lung Cancer, EGFR Gene Mutation

Clinical Study of Camrelizumab Combined With APatinib and Albumin Paclitacxel in Patients With Advanced Lung Adenocarcinoma

Unknown status Phase 2 Hunan Cancer Hospital Started 2020 NCT04459078

CamrelizumabAlbumin PaclitacxelApatinib

Laboratory certified by CAP reported negative in EGFR and ALK mutation-sensitive mutations.

Broad match: EGFR mutation (unspecified)Adenocarcinoma of the Lung

Ramucirumab and Pembrolizumab for the Treatment of EGFR Mutant Recurrent or Metastatic Non-small Cell Lung Cancer

Completed Phase 2 Ohio State University Comprehensive Cancer Center Started 2020 NCT04120454

PembrolizumabRamucirumab FDA EU

…istologically confirmed recurrent or metastatic non-small cell carcinoma of the lung with sensitizing EGFR mutations.

Broad match: EGFR sensitizing mutationMetastatic Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8

Neoadjuvant Afatinib Therapy for Potentially Resectable Stage III EGFR Mutation-Positive Lung Adenocarcinoma

Completed Phase 2 Shanghai Pulmonary Hospital, Shanghai, China Started 2020 NCT04201756

Afatinib FDA EU

Neoadjuvant Afatinib Therapy for Potentially Resectable Stage III EGFR Mutation-Positive Lung Adenocarcinoma

Broad match: EGFR mutation (unspecified)Lung Adenocarcinoma Stage III, EGFR Gene Mutation

Camrelizumab With Apatinib as Neoadjuvant Therapy for Participants With Resectable Non-Small Cell Lung Cancer

Unknown status Phase 2 Cancer Institute and Hospital, Chinese Academy of Medical Sciences Started 2020 NCT04506242

SHR-1210Apatinib

Patients who need to obtain tumor tissue for EGFR mutation detection before operation, and no sensitive mutation was found in the EGFR detection res…

Broad match: EGFR mutation (unspecified)NSCLC

ABC-lung: Atezolizumab, Bevacizumab and Chemotherapy in EGFR-mutant Non-small Cell Lung Carcinoma

Completed Phase 2 ETOP IBCSG Partners Foundation Started 2020 NCT04245085

AtezolizumabBevacizumabCarboplatinPaclitaxelPemetrexed

…own EGFR mutations genotypes by tissue or ctDNA, patients with common mutations (L858R or Del19) and other rare mutations (e.g.

Broad match: EGFR exon 19 deletionEGFRmutant Stage IIIB/C or IV Non-squamous NSCLC

A Study to Evaluate the Impact of Management Strategies on Gastrointestinal-Related Adverse Events in Participants With Non-Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations Receiving TAK-788

Withdrawn Phase 2 Takeda Started 2020 NCT04576208

TAK-788Antidiarrheal prophylaxis

A documented epidermal growth factor receptor (EGFR) mutation with in-frame exon 20 insertion, confirmed as follows:

Broad match: EGFR mutation (unspecified)Non-Small Cell Lung Cancer (NSCLC)

Neoadjuvant Afatinib Combination With Chemotherapy for Stage Ⅱa-Ⅲb NSCLC With EGFR Activating Mutation

Unknown status Phase 2 Fifth Affiliated Hospital, Sun Yat-Sen University Started 2020 NCT04470076

Neoadjuvant treatment: Afatinib, pemetrexed, gemcitabine, cisplatin, carboplatin FDA EUAdjuvant treatment:afatinib FDA EU

Neoadjuvant Afatinib Combination With Chemotherapy for Stage Ⅱa-Ⅲb NSCLC With EGFR Activating Mutation

Broad match: EGFR sensitizing mutationNon Small Cell Lung Cancer, Surgery, EGFR Activating Mutation, Chemotherapy

Study to Assess AFM24 in Advanced Solid Cancers

Terminated Phase 1/2 Affimed Started 2020 NCT04259450

14 mg AFM2440 mg AFM2480 mg AFM24160 mg AFM24320 mg AFM24480 mg AFM24

metastatic NSCLC, EGFRmut: disease has progressed on/after after ≥ 1 prior lines of therapy for advanced disease in…

Broad match: EGFR mutation (unspecified)Advanced Solid Tumor

A Study of Atezolizumab in Combination With Bevacizumab in Patients With EGFR Mutation Positive Stage IIIB-IV Non-Squamous Non-Small Cell Lung Cancer

Completed Phase 2 Roche Started 2020 NCT04426825

AtezolizumabBevacizumab

A Study of Atezolizumab in Combination With Bevacizumab in Patients With EGFR Mutation Positive Stage IIIB-IV Non-Squamous Non-Small Cell Lung Cancer

Broad match: EGFR mutation (unspecified)Carcinoma, Non-Small-Cell Lung

Almonertinib Vs. Erlotinib/Chemotherapy for Neo-adjuVant Treatment of Stage IIIA-N2 EGFR-mutated NSCLC

Unknown status Phase 2 The First Affiliated Hospital of Guangzhou Medical University Started 2020 NCT04455594

AlmonertinibErlotinib FDA EUCisplatinCarboplatinPemetrexed

… samples are confirmed as EGFR sensitive mutations by central laboratory tests (including Ex19del or L858R, both alone or with other EGFR mutations).

Broad match: EGFR exon 19 deletionNon-Small Cell Lung Cancer Stage IIIA

Sasanlimab (PF-06801591, PD-1 Inhibitor) in Participants With Advanced Malignancies

Completed Phase 1/2 Pfizer Started 2020 NCT04181788

PF-06801591

EGFR mutation, BRAF mutation, and ALK or ROS1 translocation/rearrangement are not permitted

Broad match: EGFR mutation (unspecified)Advanced Malignancies, Non-small-cell Lung Cancer

Efficacy and Safety of Platinum-based Chemotherapy + Bevacizumab + Durvalumab, and Salvage SBRT for IV Non-Small Cell Lung Cancer Patients With EGFR Mutations After Failure of First Line Osimertinib: A Multicenter, Prospective, Phase II Clinical Study

Unknown status Phase 2 Shanghai Cancer Hospital, China Started 2020 NCT04517526

pemetrexed，cisplatin/carboplatin，bevacizumab，durvalumab，SBRT

…evacizumab + Durvalumab, and Salvage SBRT for IV Non-Small Cell Lung Cancer Patients With EGFR Mutations After Failure of First Line Osimertinib: A Multicenter, Prospective, Phase II Clinical St…

Broad match: EGFR mutation (unspecified)Lung Cancer Stage IV，EGFR-mutant，TKI，PD-L1，SBRT

A Trial of Anlotinib Combined With Docetaxel in EGFR Mutations Advanced Non Small Cell Lung Cancer Patients

Unknown status Phase 2 Shandong Cancer Hospital and Institute Started 2020 NCT04619563

Anlotinib Hydrochloride plus Docetaxel

EGFR mutation-positive、ALK mutation-negative；Patients have progressed after receiving EGFR targeted and…

Broad match: EGFR mutation (unspecified)Non Small Cell Lung Cancer

Tislelizumab Combined With Chemotherapy With or Without Bevacizumab in TKI-Resistant EGFR-Mutated Non-squamous NSCLC

Unknown status Phase 2 Shanghai Chest Hospital Started 2020 NCT04405674

TislelizumabCarboplatinPemetrexedBevacizumabNab paclitaxel

Documentation of tumor EGFR sensitizing mutation before EGFR TKI treatment, including 19del, L858R, G719X, S786I and L861Q.

Broad match: EGFR exon 19 deletionNon Small Cell Lung Cancer

Best EGFR-TKI Sequence in NSCLC Harboring EGFR Mutations

Unknown status Phase 2 Fondazione Ricerca Traslazionale Started 2020 NCT04811001

Osimertinib FDA EUDacomitinib FDA EU

Histologically/cytologically confirmed diagnosis of stage IIIB/IV NSCLC with evidence of activating EGFR mutations including exon 19 deletion, exon 21 L858R or other activating/sensitizing EGFR mutations …

Broad match: EGFR sensitizing mutationNSCLC

Apatinib Combined With Radiotherapy in Patient With BM From Drive Gene Negative NSCLC

Unknown status Phase 2 Hubei Cancer Hospital Started 2020 NCT03801200

Apatinib

All patients with non-small cell lung cancer brain metastases should be recommended for EGFR mutation and ALK gene rearrangement assay，exclusion of patients with NSCLC brain metastases with p…

Broad match: EGFR mutation (unspecified)NSCLC

Immunopheresis Alone or in Combination With Paclitaxel or Atezolizumab in Non-small Cell Lung Cancer (NSCLC).

Unknown status Phase 2 Immunicom Started 2020 NCT04690686

…tinum salt (Arm 3). \[Patients with adenocarcinoma must have confirmed negative status of EGFR gene mutation and ALK fusion gene and ROS1.\]

Broad match: EGFR mutation (unspecified)Non Small Cell Lung Cancer

Atezolizumab and Bevacizumab in EGFR Mutant NSCLC in Patients With Progressive Disease After Receiving Osimertinib

Terminated Phase 2 Duke University Started 2020 NCT04099836

AtezolizumabBevacizumab

Atezolizumab and Bevacizumab in EGFR Mutant NSCLC in Patients With Progressive Disease After Receiving Osimertinib

Broad match: EGFR mutation (unspecified)Non Small Cell Lung Cancer

Correlation Between Efficacy of Osimertinib and EGFR T790M Status and Ratio Via ddPCR in NSCLC

Unknown status Phase 2 Peking Union Medical College Started 2020 NCT05458726

Osimertinib FDA EU

histologically/cytologically confirmed stage IV NSCLC patients harboring sensitizing EGFR mutations;

Broad match: EGFR sensitizing mutationEGFR T790M, Osimertinib, Non-small Cell Lung Cancer, ddPCR

Keynatinib in Treated Patients With NSCLC and Brain Metastases

Completed Phase 2 Medolution Started 2020 NCT04824079

Keynatinib

…ly or cytologically documented locally advanced, metastatic NSCLC (including L858R and/or Exon19 del mutation positive).

Broad match: EGFR exon 19 deletionNon-Small Cell Lung Cancer With EGFR Mutation, Brain Metastases

A Study of Lazertinib in Participants With Epidermal Growth Factor Receptor (EGFR) Mutation Positive Advanced Non-Small Cell Lung Cancer (NSCLC)

Completed Phase 1/2 Johnson & Johnson Started 2019 NCT04075396

Lazertinib FDA EU

…reviously diagnosed epidermal growth factor receptor single activating mutation positive (EGFRm+), and who have had progressive disease on prior epidermal growth factor receptor- Tyrosin…

Broad match: EGFR mutation (unspecified)Carcinoma, Non-Small-Cell Lung

Targeted Stem Cells Expressing TRAIL as a Therapy for Lung Cancer

Unknown status Phase 1/2 University College, London Started 2019 NCT03298763

MSCTRAIL

EGFR mutation and EML4-ALK translocation negative

Broad match: EGFR mutation (unspecified)Adenocarcinoma of Lung

LMB-100 Followed by Pembrolizumab in the Treatment of Adults With Mesothelin-Expressing Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

Terminated Phase 2 National Cancer Institute (NCI) Started 2019 NCT04027946

LMB-100pembrolizumab

…ned modality approach) or targeted agents to actionable epidermal growth factor receptor (EGFR) mutations or Anaplastic lymphoma kinase (ALK) or ROS oncogene 1 (ROS1) gene rearrangement and exclu…

Broad match: EGFR mutation (unspecified)Lung Cancer, Non-Small Cell Lung Cancer, Adenocarcinoma of Lung

A Study of Poziotinib in Patients With Epidermal Growth Factor Receptor (EGFR) or Human Epidermal Growth Factor Receptor 2 (HER2) Activating Mutations in Advanced Malignancies

Terminated Phase 2 Spectrum Pharmaceuticals Started 2019 NCT04172597

Poziotinib HydrochlorideLoperamide

Cohorts 4-5: EGFR Activating Mutations (at least one of the following) Extracellular \& Transmembrane: EGFRvIII, R108K, R222C, …

Broad match: EGFR sensitizing mutationBreast Cancer, Colorectal Cancer, Solid Tumor, Glioblastome Multiforme

Osimertinib With or Without Bevacizumab for EGFR- Mutant Non-small Cell Lung Cancer With Leptomeningeal Metastasis

Unknown status Phase 2 Second Affiliated Hospital of Nanchang University Started 2019 NCT04148898

Osimertinib FDA EUBevacizumab

A Randomized Phase II Trial of Osimertinib Alone or in Combination With Bevacizumab for EGFR- Mutant Non-small Cell Lung Cancer With Leptomeningeal Metastasis

Broad match: EGFR mutation (unspecified)Leptomeningeal Metastasis, Non-small Cell Lung Cancer, EGFR Activating Mutation

D-0316 in Patients With EGFR Positive Non Small Cell Lung Cancer

Completed Phase 2 InventisBio Started 2019 NCT03861156

D-0316

… in Patients With Locally Advanced/Metastatic Non Small Cell Lung Cancer Whose Tumors Are Epidermal Growth Factor Receptor Mutation Positive

Broad match: EGFR mutation (unspecified)Solid Tumor, NSCLC, EGFR T790M

Nivolumab After Cyclophosphamide and Doxorubicin Induction Therapy in NSCLC With PD-L1<10%

Unknown status Phase 2 National Cancer Center, Korea Started 2019 NCT03808480

CA and Nivolumab

… is not known to have anaplastic lymphoma kinase(ALK) or epidermal growth factor receptor(EGFR) mutation and Previously treated with at least one platinum-based chemotherapy but less than 3 prio…

Broad match: EGFR mutation (unspecified)Non-small Cell Lung Cancer

Study of ADXS-503 With or Without Pembro in Subjects With Metastatic Non-Small Cell Lung Cancer

Completed Phase 1/2 Advaxis Started 2019 NCT03847519

ADXS-503Pembrolizumab

EGFR sensitizing mutations are mutations that are amenable to treatment with TKIs (e.g., erlotinib, gefitinib, afat…

Broad match: EGFR sensitizing mutationLung Cancer, Non-Small Cell, Metastatic Squamous Cell Carcinoma, Metastatic Non-Squamous Cell Carcinoma

Combination of Osimertinib and Aspirin to Treat EGFR Mutation NSCLC Patients

Completed Phase 2 Daping Hospital and the Research Institute of Surgery of the Third Military Medical University Started 2019 NCT04184921

Aspirin 100mgOsimertinib 80 MG FDA EU

Locally advanced (stage IIIB) or metastatic (stage IV) EGFR-mutant NSCLC.

Broad match: EGFR mutation (unspecified)Lung Cancer Non-small Cell Stage IV

Dose-Esc/Exp RMC4630 & Cobi in Relapsed/Refractory Solid Tumors & RMC4630& Osi in EGFR+ Locally Adv/Meta NSCLC

Completed Phase 1/2 Revolution Medicines Started 2019 NCT03989115

RMC-4630CobimetinibDrug: Osimertinib FDA EU

For RMC-4630 + Osimertinib only - Locally advanced or metastatic EGFR mutant NSCLC not amenable to curative surgery or radiotherapy

Broad match: EGFR mutation (unspecified)Solid Tumor

A Study of Tepotinib Plus Osimertinib in Osimertinib Relapsed MET Amplified NSCLC (INSIGHT 2)

Completed Phase 2 Merck KGaA Started 2019 NCT03940703

TepotinibOsimertinib FDA EU

…otinib Combined With Osimertinib in MET Amplified, Advanced or Metastatic NSCLC Harboring Activating EGFR Mutations and Having Acquired Resistance to Prior Osimertinib Therapy (INSIGHT 2)

Broad match: EGFR sensitizing mutationNon-small Cell Lung Cancer

Exploring the Theragnostic Value of Osimertinib in EGFR-mutated Lung Cancer (THEROS)

Completed Phase 2 University Hospital, Essen Started 2019 NCT03810066

Osimertinib FDA EU

EGFR-mutated NSCLC not amenable to curative treatment (surgery, curative radiochemotherapy).

Broad match: EGFR mutation (unspecified)NSCLC, EGFR T790M, FDG-PET

A Study to Evaluate the Safety and Efficacy of SH-1028 in Locally Advanced or Metastatic NSCLC

Unknown status Phase 2 Nanjing Sanhome Pharmaceutical Started 2019 NCT03823807

SH-1028

…umor harbors an EGFR mutation known to be associated with EGFR-TKI sensitivity (including exon 19 deletion, L858R, L861Q, G719X or dual mutation) for treatment-naive NSCLC patients (without system…

Broad match: EGFR exon 19 deletionNon-Small Cell Lung Cancer

First-in-Human Phase I/II Study of FHND-9041 in Patients With EGFR Mutated Advanced Non-Small Cell Lung Cancer

Completed Phase 1/2 Yongchang Zhang Started 2019 NCT06521034

FHND-9041

…a written test report should confirm the detection of EGFR sensitive mutations (including exon 19 deletion or L858R, both alone or co-existing with other EGFR site mutations).

Broad match: EGFR exon 19 deletionNon-small Cell Lung Cancer, EGFR Gene Mutation, EGFR-TKI Sensitizing Mutation

A Study of Famitinib in Combination With HS-10296 in Patients With EGFR-mutant NSCLC

Unknown status Phase 2 Jiangsu Hengrui Started 2019 NCT03904823

famitinib poHS-10296 po

A Study of Famitinib in Combination With HS-10296 in Patients With EGFR-mutant NSCLC

Broad match: EGFR mutation (unspecified)EGFR-mutant Non-Small Cell Lung Cancer

A Phase IIb Study of BPI-7711 Capsule in Non-small Cell Lung Cancer Patients With T790M Mutation Positive

Completed Phase 2 Beta Pharma Shanghai Started 2019 NCT03812809

BPI-7711

…al diagnosis of NSCLC) known to be associated with EGFR TKI sensitivity (including G719X, exon 19 deletion, L858R, L861Q).

Broad match: EGFR exon 19 deletionNSCLC

Precision Immuno-Oncology for Advanced Non-small Cell Lung Cancer Patients With PD-1 ICI Resistance

Unknown status Phase 2 Assistance Publique Hopitaux De Marseille Started 2019 NCT03833440

Durvalumab (MEDI4736)Monalizumab (IPH2201)Oleclumab (MEDI9447)Ceralasertib (AZD6738)DOCETAXELSavolitinib

Patients with known actionable molecular alteration (EGFR activating mutation, ALK rearrangement, ROS1 rearrangement) should have received a commercially available spe…

Broad match: EGFR sensitizing mutationNon-small Cell Lung Cancer

A Study Evaluating Platinum-Pemetrexed-Atezolizumab (+/-Bevacizumab) for Patients With Stage IIIB/IV Non-squamous Non-small Cell Lung Cancer With EGFR Mutations, ALK Rearrangement or ROS1 Fusion Progressing After Targeted Therapies

Completed Phase 2 Centre Francois Baclesse Started 2019 NCT04042558

Carboplatin + Pemetrexed + Atezolizumab + BevacizumabCarboplatin + Pemetrexed + Atezolizumab

…Bevacizumab) for Patients With Stage IIIB/IV Non-squamous Non-small Cell Lung Cancer With EGFR Mutations, ALK Rearrangement or ROS1 Fusion Progressing After Targeted Therapies

Broad match: EGFR mutation (unspecified)NSCLC Stage IIIB, NSCLC Stage IV, EGFR Gene Mutation, ALK Gene Rearrangement Positive

A Phase I Study of FCN-411 in Advanced Non-small Cell Lung Cancer Chinese Patients With EGFR Positive Mutation

Unknown status Phase 1/2 Ahon Pharmaceutical Started 2018 NCT03420079

FCN-411 Dose-escalationFCN-411 Dose-expansion

patients must have confirmation of tumor EGFR activating mutations (exon 19 del, or exon 21 ins) and T790M status by biopsy sample or optical microscopy.

Broad match: EGFR sensitizing mutationLung Cancer

Efficacy and Safety of Anlotinib Plus Platinum Plus Pemetrexed in T790M-negative NSCLC

Unknown status Phase 1/2 Sichuan Cancer Hospital and Research Institute Started 2018 NCT03706287

anlotinib 8mg + AP/PCanlotinib 10mg + AP/PCanlotinib 12mg + AP/PCanlotinib + AP/PC

Epidermal Growth Factor Receptor(EGFR)mutations confirmed by molecular detection (including, but not limited to 19 exon deletion and L858…

Broad match: EGFR mutation (unspecified)Lung Cancer Metastatic

Neo-adjuvant Trial With AZD9291 in EGFRm+ Stage IIIA/B NSCLC

Unknown status Phase 2 Shaare Zedek Medical Center Started 2018 NCT02824952

Tagrisso

Treatment-naïve stage IIIA/B NSCLC with an activating sensitizing EGFR mutation/T790M

Broad match: EGFR sensitizing mutationLung Cancer, Non-small Cell

Assessing an Oral Janus Kinase Inhibitor, AZD4205, in Combination With Osimertinib in Patients Who Have Advanced Non-small Cell Lung Cancer

Completed Phase 1/2 Dizal Pharmaceuticals Started 2018 NCT03450330

AZD4205

Patients must have histological or cytological confirmation of activating EGFR mutation positive NSCLC and have failed prior EGFR TKIs treatment.

Broad match: EGFR sensitizing mutationNonsmall Cell Lung Cancer

Depletion of Myeloid Derived Suppressor Cells to Enhance Anti PD-1 Therapy

Terminated Phase 2 Fox Chase Cancer Center Started 2018 NCT03302247

NivolumabNivolumab+Gemcitabine

EGFR del 19 mutation should have been treated with gefitinib, erlotinib or afatanib etc).

Broad match: EGFR exon 19 deletionNon Small Cell Lung Cancer Stage IIIB

A Molecular Profiling Study of Patients With EGFR Mutation-positive Locally Advanced or Metastatic NSCLC Treated With Osimertinib

Completed Phase 2 AstraZeneca Started 2018 NCT03239340

Osimertinib FDA EU

A Molecular Profiling Study of Patients With EGFR Mutation-positive Locally Advanced or Metastatic NSCLC Treated With Osimertinib

Broad match: EGFR mutation (unspecified)EGFR Mutation Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer

T-DM1 and Osimertinib Combination Treatment to Target HER2 Bypass Track Resistance in EGFR Mutation Positive NSCLC

Terminated Phase 2 The Netherlands Cancer Institute Started 2018 NCT03784599

Trastuzumab emtansineOsimertinib FDA EU

…istologically or cytologically confirmed stage IV non-squamous NSCLC, characterized by an activating EGFR mutation.

Broad match: EGFR sensitizing mutationCarcinoma, Non-Small-Cell Lung

Osimertinib as First-line Therapy for Patients With Late-stage Lung Cancer

Unknown status Phase 2 Sun Yat-sen University Started 2018 NCT03460275

Osimertinib Mesylate Tablets FDA EU

… IIIB，not amenable to definitive multi-modality therapy)、metastatic(Stage IV)or recurrent EGFR mutation-positive Non-squamous NSCLC.( Diagnosis of NSCLC based on sputum cytology alone is not ac…

Broad match: EGFR mutation (unspecified)Non-small Cell Lung Cancer

Anlotinib Plus Chemotherapy for Patients With Advanced Non-small Cell Lung Cancer

Unknown status Phase 2 The First People's Hospital of Lianyungang Started 2018 NCT03589950

anlotinib plus chemotherapychemotherapy

…who have previously received one lines chemotherapy, EGFR TKI or ALK inhibitor (whom with EGFR or ALK mutation but not with T790 M positive) treatment before participating；

Broad match: EGFR mutation (unspecified)Lung Neoplasms, Docetaxel, Pemetrexed, S-1

Atezolizumab in Combination With Bevacizumab, Carboplatin and Pemetrexed for EGFR-mutant Metastatic NSCLC Patients After Failure of EGFR Tyrosine Kinase Inhibitors

Unknown status Phase 2 The University of Hong Kong Started 2018 NCT03647956

AtezolizumabBevacizumabCarboplatinPemetrexed

Stage IIIB or IV NSCLC with known EGFR activating mutation not amenable to curative surgery or radiotherapy.

Broad match: EGFR sensitizing mutationNSCLC Stage IIIB, NSCLC Stage IV, EGFR Activating Mutation

Combination of Osimertinib and Aspirin to Treat 1st Generation EGFR-TKI Resistance in NSCLC

Completed Phase 2 Daping Hospital and the Research Institute of Surgery of the Third Military Medical University Started 2018 NCT03543683

Osimertinib FDA EUAspirin

…istologically or cytologically confirmed non small cell carcinoma of the lung who harbors EGFR-mutation and are previously disease progression to 1st generation EGFR-TKI.

Broad match: EGFR mutation (unspecified)Non-Small Cell Lung Cancer Stage IIIB, Non-small Cell Lung Cancer Stage IV, EGFR T790M

18F-FDG PET and Osimertinib in Evaluating Glucose Utilization in Patients with EGFR Activated Recurrent Glioblastoma

Completed Phase 2 Jonsson Comprehensive Cancer Center Started 2018 NCT03732352

Osimertinib FDA EU

…r sample must have evidence of EGFR activation as determined by EGFR amplification and/or EGFR mutations by fluorescent in situ hybridization (FISH) or sequencing approaches

Broad match: EGFR mutation (unspecified)EGFR Gene Amplification, EGFR Gene Mutation, Glioblastoma, Recurrent Glioblastoma

G1T38, a CDK 4/6 Inhibitor, in Combination With Osimertinib in EGFR-Mutant Non-Small Cell Lung Cancer

Completed Phase 1/2 G1 Therapeutics Started 2018 NCT03455829

G1T38Osimertinib FDA EU

Confirmed EGFR mutation for non-small cell lung cancer associated with EGFR TKI sensitivity

Broad match: EGFR mutation (unspecified)Carcinoma, Non-Small-Cell Lung, Lung Cancer, Non-small Cell Lung Cancer

A Study of RC48-ADC in Subjects With Advanced Non-small Cell Lung Cancer

Completed Phase 1/2 RemeGen Started 2018 NCT04311034

RC48

For EGFR gene mutation-positive patients, one of the following is met: 1) T790M gene mutation negative, c-Met ge…

Broad match: EGFR mutation (unspecified)Non Small Cell Lung Cancer

Study of Fruquintinib (HMPL-013) in High Risk Patients With Advanced NSCLC

Withdrawn Phase 2 HUTCHMED Started 2018 NCT03684967

Fruquintinib

or EGFR activating mutation and resistant / intolerant to related targeted therapies

Broad match: EGFR sensitizing mutationLung Cancer

Vitamin C and Tyrosine Kinase Inhibitor in Lung Cancer Patients With Epidermal Growth Factor Receptor Mutations

Unknown status Phase 1/2 Clifford Hospital, Guangzhou, China Started 2018 NCT03799094

Vitamin CTyrosine kinase inhibitor

Primary non-small cell lung cancer (adenocarcinoma) with EGFR mutations on exons 19 and 21.

Broad match: EGFR mutation (unspecified)Carcinoma, Non-Small-Cell Lung

A Dose Escalation With Expansion Study of EMB-01 in Participants With Advanced/Metastatic Solid Tumors

Unknown status Phase 1/2 Shanghai EpimAb Biotherapeutics Started 2018 NCT03797391

EMB-01

Phase II: Advanced/metastatic NSCLC Patients have confirmed EGFR mutant and/or cMET aberration, and have progressed after standard treatment (including platinum-…

Broad match: EGFR mutation (unspecified)Neoplasms, Neoplasm Metastasis, Non-Small-Cell Lung Cancer

Icotinib Combined With Radiation Therapy For NSCLC Patients With Brain Metastases and EGFR Mutation

Unknown status Phase 2 Betta Pharmaceuticals Started 2018 NCT03754530

Icotinib

Icotinib Combined With Radiation Therapy For NSCLC Patients With Brain Metastases and EGFR Mutation

Broad match: EGFR mutation (unspecified)Non-Small Cell Lung Cancer, Brain Metastases

First-line Treatment With Osimertinib in EGFR-mutated Non-small Cell Lung Cancer

Unknown status Phase 2 Vestre Viken Hospital Trust Started 2018 NCT03804580

osimertinib FDA EU

Documented EGFR mutation in exon 18-21, except insertions in exon 20, based on tissue analysis.

Broad match: EGFR mutation (unspecified)Lung Cancer

E GFR TKI and EGF-P TI C Ombination in EGFR mutA nt NSCL C

Completed Phase 1/2 Instituto Oncológico Dr Rosell Started 2018 NCT03623750

EGFR-TK InhibitorEGF-PTICyclophosphamide

Histological confirmation of locally advanced or metastatic, non-squamous NSCLC with an activating EGFR mutation who are not candidates for local curative treatment.

Broad match: EGFR sensitizing mutationCarcinoma, Non-Small-Cell Lung

Icotinib Combined With Dihydroaremisinin (DHA) Therapy in Patients With Advanced NSCLC

Unknown status Phase 2 Peking University Cancer Hospital & Institute Started 2018 NCT03402464

Icotinib combined dihydroaremisinin

Sensitive EGFR gene mutation(19/21)

Broad match: EGFR mutation (unspecified)EGFR Positive Non-Small Cell Lung Cancer,Adenocarcinoma

Retreatment With Epidermal Growth Factor Receptor(EGFR) Tyrosine Kinase Inhibitor in EGFR Mutation Positive Patients

Unknown status Phase 2 Korea University Guro Hospital Started 2018 NCT03382795

EGFR

…ore than 4 cycles and developed progressive disease, and then confirmed T790 negative and sensitizing EGFR mutation(E19Del, L858R, L861Q, G719X, E19insertion) positive in Histologic, cytologic specimen or …

Broad match: EGFR sensitizing mutationEGFR Positive Non-small Cell Lung Cancer

Anlotinib Plus Sintilimab for NSCLC Patients With First-generation EGFR-TKIs Drug Resistance Along With T790M Negative

Unknown status Phase 2 First Hospital of Shijiazhuang City Started 2018 NCT03765775

SintilimabAnlotinib Hydrochloride

Has confirmation that epidermal growth factor receptor (EGFR) mutation，with first-generation EGFR-TKIs drug resistance T790M negative .

Broad match: EGFR mutation (unspecified)Carcinoma, Non-small Cell Lung Cancer, Lung Neoplasm

Osimertinib With Bevacizumab for Leptomeningeal Metastasis From EGFR-mutation Non-Small Cell Lung Cancer

Unknown status Phase 2 Second Affiliated Hospital of Nanchang University Started 2017 NCT04425681

Osimertinib FDA EUBevacizumab

Osimertinib With Bevacizumab for Leptomeningeal Metastasis From EGFR-mutation Non-Small Cell Lung Cancer

Broad match: EGFR mutation (unspecified)Leptomeningeal Metastasis, Non-small Cell Lung Cancer, EGFR Activating Mutation

TAGRISSO (Osimertinib) in NSCLC Patients in Whom T790 Mutations Are Detected by Liquid Biopsy

Completed Phase 2 Asan Medical Center Started 2017 NCT03394118

Osimertinib FDA EU

Patients with EGFR sensitizing mutation (E19Del, L858R, L861Q, G719X) positive, who had shown clinical benefits (responders (CR o…

Broad match: EGFR sensitizing mutationNSCLC

Study of Nivolumab Verses Nivolumab and Ipilimumab Combination in EGFR Mutant Non-small Cell Lung Cancer

Terminated Phase 2 National Cancer Centre, Singapore Started 2017 NCT03091491

IpilimumabNivolumab

Study of Nivolumab Verses Nivolumab and Ipilimumab Combination in EGFR Mutant Non-small Cell Lung Cancer

Broad match: EGFR mutation (unspecified)Non-Small Cell Lung Cancer

Evaluate Safety, Tolerability, Pharmacokinetics and Anti-tumor Activity of AZD3759

Completed Phase 1/2 LYZZ Alpha Holding Started 2017 NCT03360929

AZD3759

…lly confirmed non-small cell lung cancer with activating mutation in EGFR gene (including Exon19Del and/or L858R).

Broad match: EGFR exon 19 deletionNon Small Cell Lung Cancer

Effectiveness and Safety of Adding Bevacizumab to First Line Chemotherapy in Lung Cancer Patients With Stable Disease

Unknown status Phase 2 Beijing Hospital Started 2017 NCT03240549

bevacizumab

… disease chemotherapy for patients with mutations associated with driving genes (eg, EGFR(epidermal growth factor receptor) mutations, ALK(anaplastic lymphoma kinase) gene fusion, etc.) could be included;

Broad match: EGFR mutation (unspecified)Non-small Cell Lung Cancer Metastatic

Olmutinib Trial in T790M (+) NSCLC Patients Detected by Liquid Biopsy Using BALF Extracellular Vesicular DNA

Completed Phase 2 Konkuk University Medical Center Started 2017 NCT03228277

Olmutinib

…bours an EGFR mutation known to be associated with EGFR TKI sensitivity (including G719X, exon 19 deletion, L858R, L861Q).

Broad match: EGFR exon 19 deletionNon Small Cell Lung Cancer

Icotinib Combined With SBRT for Patients With Metastatic Non-squamous NSCLC With EGFR Mutation

Unknown status Phase 2 Sichuan Cancer Hospital and Research Institute Started 2017 NCT03153358

Icotinib

Histologic documentation of primary lung carcinoma, non-squamous histology with EGFR mutation.

Broad match: EGFR mutation (unspecified)Lung Cancer Stage IV

A Study of EGF816 and Gefitinib in TKI-naïve EGFR-mutant Non-Small Cell Lung Cancer

Terminated Phase 2 Massachusetts General Hospital Started 2017 NCT03292133

EGF816Gefitinib FDA EU

An EGFR sensitizing mutation must be detected in tumor tissue.

Broad match: EGFR sensitizing mutationLung Cancer

Ipilimumab and Nivolumab in Patients With Anti-PD-1-axis Therapy-resistant Advanced Non-small Cell Lung Cancer.

Completed Phase 2 Yale University Started 2017 NCT03262779

combination nivolumab and ipilimumab

Patients with NSCLC known to harbor an ALK rearrangement, or EGFR mutation known to be sensitive to FDA-approved tyrosine kinase inhibitors (TKI), are only eligible…

Broad match: EGFR mutation (unspecified)Carcinoma, Non-Small-Cell Lung

Phase II Trial of Continuation Therapy in Advanced NSCLC

Completed Phase 2 Greg Durm, MD Started 2017 NCT03083808

Pembrolizumab

Subjects whose tumors harbor a mutation in EGFR exon 19 or 21 or have gene rearrangements in ALK or ROS1 must have already been treated w…

Broad match: EGFR mutation (unspecified)Non-Small-Cell Lung Cancer

Targeted Therapy in Treating Patients With Incurable Non-Small Cell Lung Cancer With Genetic Mutations

Terminated Phase 2 Wake Forest University Health Sciences Started 2017 NCT02949843

ChemotherapyImmunotherapyNivolumabPembrolizumabTargeted Molecular TherapyTyrosine Kinase Inhibitor

…r cytologically confirmed incurable non-small cell lung cancer that harbors an activating mutation in EGFR, MET, BRAF, V600E, RET, HER2, translocation in Alk, or translocation in ROS-1

Broad match: EGFR mutation (unspecified)EGFR Activating Mutation, Recurrent Non-Small Cell Lung Carcinoma, Stage IV Non-Small Cell Lung Cancer

Pembrolizumab Plus Chemotherapy in NSCLC With Targetable Genetic Alterations After Progression on Targeted Agents

Completed Phase 2 University of Michigan Rogel Cancer Center Started 2017 NCT03242915

PembrolizumabCarboplatinPemetrexed

Cohort 1- EGFR mutation positive NSCLC patients previously treated with appropriate targeted therapy with progres…

Broad match: EGFR mutation (unspecified)Non-small Cell Lung Cancer

Poziotinib in EGFR Exon 20 Mutant Advanced NSCLC

Terminated Phase 2 M.D. Anderson Cancer Center Started 2017 NCT03066206

Poziotinib

…oundationOne Assay or by a Food and Drug Administration (FDA) approved device using cobas EGFR mutation test version (v)2 or therascreen EGFR RGQ PCt kit

Broad match: EGFR mutation (unspecified)EGFR Exon 20 Mutation, ERBB2 Gene Mutation, Recurrent Lung Non-Small Cell Carcinoma, Stage IV Non-Small Cell Lung Cancer AJCC v7

Phase 2 Study of Poziotinib in Participants With NSCLC Having EGFR or HER2 Exon 20 Insertion Mutation

Terminated Phase 2 Spectrum Pharmaceuticals Started 2017 NCT03318939

Poziotinib

Cohort 6: Participant with EGFR mutation-positive NSCLC who progressed while on treatment with first-line osimertinib

Broad match: EGFR mutation (unspecified)NSCLC

VX15/2503 in Combination With Avelumab in Advanced Non-small Cell Lung Cancer

Completed Phase 1/2 Vaccinex Started 2017 NCT03268057

VX15/2503 + avelumab

Tumors lack activating epidermal growth factor receptor (EGFR) mutations, ROS-1, or ALK rearrangement (no EGFR or ALK testing is required if a subject has a KRAS …

Broad match: EGFR mutation (unspecified)Carcinoma, Non-Small-Cell Lung

Maintenance Targeted Therapy With or Without Stereotactic Body Radiation Therapy for Stage IV Non-small Cell Lung Cancer

Completed Phase 2 Tongji Hospital Started 2017 NCT03595644

TKI

Patients must has sensitizing EGFR mutation (e.g. exon 19 deletion or exon 21 L858R)

Broad match: EGFR sensitizing mutationStage IV Non-small Cell Lung Cancer

Clinical Trial of YH25448 in Patients with EGFR Mutation Positive Advanced NSCLC

Completed Phase 1/2 Yuhan Started 2017 NCT03046992

YH25448

Histologically or cytologically confirmed diagnosis of NSCLC with single activating EGFR mutations.

Broad match: EGFR sensitizing mutationEGFR Gene Mutation

Bemcentinib (BGB324) in Combination With Pembrolizumab in Patients With Advanced Non-small Cell Lung Cancer (NSCLC)

Completed Phase 2 BerGenBio ASA Started 2017 NCT03184571

PembrolizumabBemcentinib

Note: Patients with EGFR mutations or ALK genomic rearrangements had to have documented disease progression on at least 1 li…

Broad match: EGFR mutation (unspecified)Lung Cancer Metastatic, NSCLC Stage IV, Adenocarcinoma of Lung

Pembrolizumab + Imprime PGG for Metastatic Non-small Cell Lung Cancer After Progression on First-Line Therapy: Big Ten Cancer Research Consortium BTCRC-LUN15-017

Completed Phase 1/2 Lawrence Feldman, MD Started 2017 NCT03003468

Imprime PGGMK-3475Imprime PGG

Phase II: Subjects with an EGFR or ALK mutation who are no longer candidates for TKI therapy and have progressed on standard systemic the…

Broad match: EGFR mutation (unspecified)Non-Small Cell Lung Cancer

Oncolytic MG1-MAGEA3 With Ad-MAGEA3 Vaccine in Combination With Pembrolizumab for Non-Small Cell Lung Cancer Patients

Completed Phase 1/2 Turnstone Biologics Started 2017 NCT02879760

Ad-MAGEA3MG1-MAGEA3Pembrolizumab

…umors of non-squamous NSCLC histology that have a known epidermal growth factor receptor (EGFR) mutation and/or anaplastic lymphoma kinase (ALK) translocation can participate in the Phase 1 port…

Broad match: EGFR mutation (unspecified)Non-Small Cell Lung Cancer

Nivolumab in Combination With Chemotherapy, or Nivolumab in Combination With Ipilimumab, in Advanced EGFR-Mutant or ALK-Rearranged NSCLC

Completed Phase 2 Massachusetts General Hospital Started 2017 NCT03256136

CarboplatinNivolumabpemetrexedIpilimumab

EGFR-mutant NSCLC: EGFR activating gene mutation (e.g., L858R, exon 19 deletion) as well as a T790M mutation per local testing.

Broad match: EGFR exon 19 deletionLung Cancer

BPI-7711 Capsule in Patients With EGFR Mutation T790M Positive Non-small Cell Lung Cancer

Completed Phase 1/2 Beta Pharma Shanghai Started 2017 NCT03386955

BPI-7711 Capsule

BPI-7711 Capsule in Patients With EGFR Mutation T790M Positive Non-small Cell Lung Cancer

Broad match: EGFR mutation (unspecified)Non-small Cell Lung Cancer

A Phase 1/2 Trial of Trametinib and Erlotinib in Patients With EGFR-Mutant Lung Adenocarcinomas and Acquired Resistance to Erlotinib

Completed Phase 1/2 Memorial Sloan Kettering Cancer Center Started 2017 NCT03076164

TrametinibErlotinib FDA EU

Somatic activating mutation in EGFR Radiographic progression during treatment with erlotinib.

Broad match: EGFR mutation (unspecified)Lung Adenocarcinoma, Lung Cancer, Lung Cancer Metastatic, Lung Cancer Stage IV

Safety, Tolerability, Pharmacokinetics and Anti-tumour Activity of ASK120067 in Locally Advanced and Metastatic Non Small Cell Lung Cancer

Unknown status Phase 1/2 Jiangsu Aosaikang Pharmaceutical Started 2017 NCT03502850

ASK120067

…tation known to be associated with EGFR TKI sensitivity (including at least one of G719X, exon 19 deletion, L858R, L861Q mutation)

Broad match: EGFR exon 19 deletionLocally Advanced or Metastatic NSCLC

An Explorative Study of Afatinib in the Treatment of Advanced Cancer Carrying an EGFR, a HER2 or a HER3 Mutation

Unknown status Phase 2 Universitair Ziekenhuis Brussel Started 2017 NCT03810872

Afatinib FDA EUPaclitaxel

Women and men with locally advanced or metastatic cancers harboring either an activating EGFR mutation or a HER2 mutation or a HER3 mutation

Broad match: EGFR sensitizing mutationCancers Harbouring an EGFR Mutation, (Excluding Non-squamous Non- Small Cell Lung Cancer, a Registered Indication), a HER2 Mutation or a HER3 Mutation

Alternating Icotinib and Chemotherapy for Advanced Non-small Cell Lung Cancer With EGFR Mutation

Unknown status Phase 2 Henan Cancer Hospital Started 2016 NCT02737774

IcotinibPemetrexed/Carboplatin

Positive EGFR mutation(19 exon or 21 exon)。

Broad match: EGFR mutation (unspecified)Lung Adenocarcinoma

High-dose Icotinib Treatment Beyond Progression in EGFR Mutant NSCLC

Unknown status Phase 2 Chinese Academy of Medical Sciences Started 2016 NCT02960607

Icotinib

are EGFR mutation-positive or

Broad match: EGFR mutation (unspecified)Carcinoma, Non-Small-Cell Lung

Pemetrexed vs Pemetrexed Plus Cisplatin in EGFR-mutant NSCLC Patients After First Line EGFR-TKIs Failure

Unknown status Phase 2 Guangdong Association of Clinical Trials Started 2016 NCT02725918

PemetrexedCisplatin

Histologically confirmed stage IIIB/IV advanced NSCLC harboring activating EGFR mutation.

Broad match: EGFR sensitizing mutationNon-small Cell Lung Cancer

Deciphering Afatinib Response and Resistance With INtratumour Heterogeneity

Completed Phase 2 University College, London Started 2016 NCT02183883

Afatinib FDA EU

Patients must have tumours harbouring a sensitising EGFR mutation or HER2 mutation in at least one biopsy at recurrence, or region of the primary sample.

Broad match: EGFR sensitizing mutationNon-small Cell Lung Cancer

Combination of Anti-PD-1 and NK Immunotherapy for Recurrent Solid Tumors

Completed Phase 1/2 Fuda Cancer Hospital, Guangzhou Started 2016 NCT02843204

PembrolizumabNK immunotherapy

Progression after chemotherapy or appropriate TKI treatment for those patients with an EGFR-sensitizing mutation or ALK rearrangement

Broad match: EGFR sensitizing mutationMalignant Solid Tumour

Intracranial Activity of AZD9291 (TAGRISSO) in Advanced EGFRm NSCLC Patients With Asymptomatic Brain Metastases

Unknown status Phase 2 Soroka University Medical Center Started 2016 NCT02736513

AZD9291

Group A: treatment-naïve advanced NSCLC with an sensitizing EGFR mutation.

Broad match: EGFR sensitizing mutationLung Cancer

Osimertinib and Bevacizumab as Treatment for EGFR-mutant Lung Cancers

Completed Phase 1/2 Memorial Sloan Kettering Cancer Center Started 2016 NCT02803203

osimertinib FDA EUBevacizumab

Somatic activating mutation in EGFR

Broad match: EGFR mutation (unspecified)Non-small Cell Lung Cancer, EGFR-mutant Lung Cancers

Neoadjuvant Afatinib in Early Stage Non Small Cell Lung Cancer.

Suspended Phase 2 European Organisation for Research and Treatment of Cancer - EORTC Started 2016 NCT02470065

Afatinib FDA EU

Resectable EGFR Mutant NSCLC With (or Without) Afatinib as Neoadjuvant Treatment; REMNANT an Exploratory Study o…

Broad match: EGFR mutation (unspecified)Non Small Cell Lung Cancer

Tarceva With or Without Apatinib in the Advanced Lung Adenocarcinoma

Unknown status Phase 2 First Affiliated Hospital of Kunming Medical University Started 2016 NCT02704767

ApatinibTarceva

lung adenocarcinoma proved by histology;with mutant EGFR;ECOG PS 0-2;Clinical stage IIIb or IV;without other fatal disease;without hemorrhagic dis…

Broad match: EGFR mutation (unspecified)Lung Cancer

Thymosin Alpha 1 Plus Maintenance Therapy With the Standard of Care (SoC) in Patients With Metastatic Non-Small Cell Lung Cancer (NSCLC), EGFR Wild Type

Unknown status Phase 2 SciClone Pharmaceuticals Started 2016 NCT02906150

Thymalfasin (Thymosin alpha 1, Ta1)SoC (chemotherapy and platinum agent)

Activating mutations of EGFR diagnosis of Stage IIIB (with cytologically proven pleural effusion or pericardial effusi…

Broad match: EGFR mutation (unspecified)Non-Small Cell Lung Cancer

A Phase II Study of Fruquintinib in Combination With Gefitinib in Patients With Advanced Non-small Cell Lung Cancer

Completed Phase 2 HUTCHMED Started 2016 NCT02976116

FruquintinibGefitinib FDA EU

…-line Therapy in Patients With Advanced Non-squamous Non-small-cell Lung Cancer Harboring Activating EGFR Mutations : a Single-arm, Multicenter, Phase II Study

Broad match: EGFR sensitizing mutationNSCLC

Rapid Plasma Genotyping For Early Initiation Of Erlotinib In EGFR Mutant Lung Cancer

Terminated Phase 2 Dana-Farber Cancer Institute Started 2016 NCT02770014

Erlotinib FDA EU

…ants must possess at least two of the following clinical characteristics which enrich for EGFR mutations:

Broad match: EGFR mutation (unspecified)Epidermal Growth Factor Receptor, Non-Small Cell Lung Cancer

Ningetinib (CT053PTSA) Plus Gefitinib in Stage IIIB or IV NSCLC Patients With EGFR Mutation and T790M Negative

Completed Phase 1/2 Sunshine Lake Pharma Started 2016 NCT03758287

CT053PTSAGefitinib FDA EU

Histological or cytological evidence of EGFR mutation and T790M negative after progression on last EGFR TKI therapy

Broad match: EGFR mutation (unspecified)Non-small Cell Lung Cancer

NEoadjuvant Gefitinib fOllowed by Surgery and gefiTinib In unresectAble sTage III NSCLC With EGFR Mutations.

Withdrawn Phase 2 Sun Yat-sen University Started 2016 NCT02347839

Target population is unresectable stage III (III A-bulky N2, III B) NSCLC with EGFR activating mutation in exon 19 or 21

Broad match: EGFR sensitizing mutationLung Cancer

Atezolizumab With Stereotactic Ablative Radiotherapy in Patients With Metastatic Tumours

Completed Phase 2 Gustave Roussy, Cancer Campus, Grand Paris Started 2016 NCT02992912

Anti-PD-L1 antibody atezolizumab

Patients EGFR-mutant can be included only if they have been treated with, or developed toxicity with or refuse…

Broad match: EGFR mutation (unspecified)Patients With Metastatic Tumours (Colorectal Cancer, Non-small Lung Cancer, Renal Cell Carcinoma or Sarcoma )

Rociletinib Genomic Landscape in Non-small Cell Lung Cancer (NSCLC)

Withdrawn Phase 2 Washington University School of Medicine Started 2016 NCT02705339

Rociletinib

…B/IV lung adenocarcinoma with known activating mutations in the EGFR TK domain (including exon 19 deletion and L858R)

Broad match: EGFR exon 19 deletionCarcinoma, Non-Small-Cell Lung, Non-Small Cell Lung Cancer, Nonsmall Cell Lung Cancer

First Line Bio-immunotherapy With Thymosin Alpha 1 in Patients With Sensitizing EGFR Mutation Positive Non Small Cell Lung Cancer Who Are Taking Standard of Care Therapy

Unknown status Phase 1/2 SciClone Pharmaceuticals Started 2016 NCT02906163

Thymalfasin (Thymosin alpha 1, Ta1)SoC (tyrosine kinase inhibitor) FDA EU

First Line Bio-immunotherapy With Thymosin Alpha 1 in Patients With Sensitizing EGFR Mutation Positive Non Small Cell Lung Cancer Who Are Taking Standard of Care Therapy

Broad match: EGFR sensitizing mutationEGFR Mutation Positive Non Small Cell Lung Cancer

Pembrolizumab in Treating Patients With EGFR Mutant, Tyrosine Kinase Inhibitor Naive Advanced Non-Small Cell Lung Cancer

Completed Phase 2 Jonsson Comprehensive Cancer Center Started 2016 NCT02879994

Pembrolizumab

Have an EGFR mutation (sensitizing or non-sensitizing)

Broad match: EGFR mutation (unspecified)Stage IIIA Non-Small Cell Lung Cancer, Stage IIIB Non-Small Cell Lung Cancer, Stage IV Non-Small Cell Lung Cancer

Local Ablative Therapy for Treatment of Oligoprogressive, EGFR-Mutated, Non-Small Cell Lung Cancer After Treatment With Osimertinib

Completed Phase 2 National Cancer Institute (NCI) Started 2016 NCT02759835

osimertinib FDA EU

…certified Next Generation Sequencing or Cobas estimated Epidermal Growth Factor Receptor (EGFR) Mutation Test v1/2 at an outside institution, advanced lung adenocarcinoma with EGFR-sensitizing s…

Broad match: EGFR mutation (unspecified)Lung Adenocarcinoma, Lung Neoplasms

EGFR-TKI With/Without Chemotherapy in NSCLC Patients With Both EGFR Mutation and BIM Deletion Polymorphism

Unknown status Phase 2 Shanghai Pulmonary Hospital, Shanghai, China Started 2016 NCT03002844

EGFR-TK Inhibitor FDA EUEGFR-TKI FDA EUEGFR-TKI and Chemotherapy

EGFR-TKI With/Without Chemotherapy in NSCLC Patients With Both EGFR Mutation and BIM Deletion Polymorphism

Broad match: EGFR mutation (unspecified)Nonsmall Cell Lung Cancer, EGFR Gene Mutation

Osimertinib (AZD9291) in First-line Locally Advanced or Metastatic NSCLC Patients With EGFR and EGFR T790M

Completed Phase 2 MedSIR Started 2016 NCT02841579

Osimertinib FDA EU

…f locally advanced or metastatic, non-squamous non-small cell lung cancer (NSCLC) with an activating EGFR mutation and concomitant T790M mutation who are not candidates for local curative treatment.

Broad match: EGFR sensitizing mutationNon-Small Cell Lung Cancer

Genetically Modified T Cells in Treating Patients With Stage III-IV Non-small Cell Lung Cancer or Mesothelioma

Terminated Phase 1/2 Fred Hutchinson Cancer Center Started 2015 NCT02408016

AldesleukinAutologous WT1-TCRc4 Gene-transduced CD8-positive Tcm/Tn LymphocytesCyclophosphamide

ELIGIBILITY FOR TREATMENT ON ARM 1: NSCLC patients with a mutation in epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) must have demonstrated progression or intolerance to…

Broad match: EGFR mutation (unspecified)Advanced Pleural Malignant Mesothelioma, HLA-A*0201 Positive Cells Present, Recurrent Non-Small Cell Lung Carcinoma, Recurrent Pleural Malignant Mesothelioma

Phase II Trial of HM61713 for the Treatment of ≥2nd Line T790M Mutation Positive Adenocarcinoma of the Lung

Terminated Phase 2 Hanmi Pharmaceutical Company Limited Started 2015 NCT02485652

HM61713

… mutation which is known to be related with susceptibility to EGFR-TKIs (including G719X, exon 19 deletion, L858R, and L861Q)

Broad match: EGFR exon 19 deletionNon Small Cell Lung Cancer

Maintaining ERBB Blockade in EGFR-mutated Lung Cancer

Terminated Phase 2 AIO-Studien-gGmbH Started 2015 NCT02488694

Afatinib FDA EUPemetrexed

Documented somatic EGFR mutation as determined by medically accepted assay technology

Broad match: EGFR mutation (unspecified)Non-small-cell Lung Cancer With Somatic EGFR Mutations

Study of EGFR-TKI to Asymptomatic Brain Metastases of NSCLC

Unknown status Phase 2 Union Hospital, Tongji Medical College, Huazhong University of Science and Technology Started 2015 NCT02250846

EGFR-TKI

Phase II Study of EGFR-TKI in Patients With EGFR Mutation Non-Small Cell Lung Cancer With Asymptomatic Untreated Brain Metastasis

Broad match: EGFR mutation (unspecified)Asymptomatic Brain Metastases of Non Small Cell Lung Cancer

A Phase II, Single-Arm Trial of Poziotinib as Salvage Treatment in Patients With Metastatic Breast Cancer Who Has HER2 or EGFR Mutation or Activated AR or EGFR Pathway

Completed Phase 2 Samsung Medical Center Started 2015 NCT02544997

Poziotinib

HER2 mutation or EGFR mutation/gene amplification confirmed by CancerSCAN or Activated AR pathway confirmed by RNA seq \…

Broad match: EGFR mutation (unspecified)Metastatic Breast Cancer

Nintedanib (Vargatef®) Plus Docetaxel in Second Line of Treatment in Patients With Lung Cancer

Completed Phase 2 University Hospital, Limoges Started 2015 NCT02531737

vargatef®Docetaxel

Patients without activating epidermal growth factor receptor (EGFR) mutation

Broad match: EGFR mutation (unspecified)Lung Neoplasms

Trial of Topotecan With VX-970 (M6620), an ATR Kinase Inhibitor, in Small Cell Cancers and Extrapulmonary Small Cell Cancers

Completed Phase 1/2 National Cancer Institute (NCI) Started 2015 NCT02487095

TopotecanVX-970 (M6620)

NSCLC subjects with epidermal growth factor receptor (EGFR) mutations or anaplastic lymphoma kinase (ALK) translocations should have previously received approp…

Broad match: EGFR mutation (unspecified)Carcinoma, Non-Small -Cell Lung, Ovarian Neoplasms, Small Cell Lung Carcinoma, Uterine Cervical Neoplasms

Study of Efficacy and Safety of Nivolumab in Combination With EGF816 and of Nivolumab in Combination With INC280 in Patients With Previously Treated Non-small Cell Lung Cancer

Terminated Phase 2 Novartis Started 2015 NCT02323126

EGF816INC280Nivolumab

…ticenter, Open-label Study of EGF816 in Combination With Nivolumab in Adult Patients With EGFR Mutated Non-small Cell Lung Cancer and of INC280 in Combination With Nivolumab in Adult Patients …

Broad match: EGFR mutation (unspecified)Non Small Cell Lung Cancer

Nintedanib in Molecularly Selected Patients With Advanced Non-Small Cell Lung Cancer

Completed Phase 2 Washington University School of Medicine Started 2015 NCT02299141

Nintedanib

Patients with EGFR mutations or ALK rearrangements must have disease progression on appropriate FDA-approved therapy f…

Broad match: EGFR mutation (unspecified)Carcinoma, Non-Small-Cell Lung, Non-Small Cell Lung Cancer, Nonsmall Cell Lung Cancer

Rh-Endostatin in Combination With Icotinib for Advanced NSCLC With EGFR Mutations

Unknown status Phase 2 Zhejiang University Started 2015 NCT02375022

Endostar and icotinib

Rh-Endostatin in Combination With Icotinib for Advanced NSCLC With EGFR Mutations

Broad match: EGFR mutation (unspecified)Lung Cancer

Phase 1/2 Study of the Safety and Efficacy of Rociletinib in Combination With Trametinib in Patients With mEGFR-positive Advanced or Metastatic Non-small Cell Lung Cancer

Terminated Phase 1/2 Clovis Oncology Started 2015 NCT02580708

RociletinibTrametinib

…gically or cytologically confirmed metastatic or unresectable locally advanced NSCLC with EGFR activating mutation (excluding exon 20 insertion)

Broad match: EGFR sensitizing mutationNon-small Cell Lung Cancer

Chemotherapy Combined Autologous Cytokine-induced Killer Cells in Naive Stage IV EGFR-wild Type Lung Adenocarcinoma

Terminated Phase 2 Henan Cancer Hospital Started 2015 NCT02621333

CIKchemotherapy

The detection method of EGFR mutation is ARMS.

Broad match: EGFR mutation (unspecified)Lung Adenocarcinoma

AZD9291, an Irreversible EGFR-TKI, in Relapsed EGFR-mutated Non-small Cell Lung Cancer Patients Previously Treated With an EGFR-TKI, Coupled to Extensive Translational Studies

Unknown status Phase 2 Oslo University Hospital Started 2015 NCT02504346

AZD9291

Documented EGFR mutation known to be associated with EGFR TKI sensitivity (also including T790M).

Broad match: EGFR mutation (unspecified)Lung Cancer, Targeted Therapy

Pembrolizumab Alone and In Combination With Acalabrutinib (ACP-196) in Subjects With Advanced Non-small Cell Lung Cancer

Completed Phase 2 Acerta Pharma Started 2015 NCT02448303

PembrolizumabAcalabrutinib

Note: Subjects with EGFR mutations or ALK translocations are required to have received prior therapy with appropriate TKI

Broad match: EGFR mutation (unspecified)Carcinoma, Non-Small-Cell Lung

Phase II Trial to Evaluate the Efficacy and Safety of HM61713 as the 1st-line NSCLC Anticancer Therapy

Completed Phase 2 Hanmi Pharmaceutical Company Limited Started 2015 NCT02444819

HM61713

Documented EGFR mutations (excluding exon 20 insertion)

Broad match: EGFR mutation (unspecified)Non Small Cell Lung Cancer

Phase II Single Arm Study of AZD9291 to Treat NSCLC Patients in Asia Pacific

Completed Phase 2 AstraZeneca Started 2015 NCT02442349

AZD9291

…al diagnosis of NSCLC) known to be associated with EGFR TKI sensitivity (including G719X, exon 19 deletion, L858R, L861Q).

Broad match: EGFR exon 19 deletionNon-Small Cell Lung Cancer

PRe-Operative Gefitinib in Resectable EGFR Mutation Positive Lung Cancer With Sector Sequencing for Biomarker Discovery

Completed Phase 2 National Cancer Centre, Singapore Started 2015 NCT02804776

Gefitinib FDA EU

All patients must have histologically proven NSCLC, with known EGFR mutation

Broad match: EGFR mutation (unspecified)Non-small Cell Lung Cancer

Concurrent EGFR-TKIs and Thoracic Radiation Therapy in Active EGFR Mutation for 1st Line Treatment of Stage IV NSCLC

Terminated Phase 2 Xinqiao Hospital of Chongqing Started 2015 NCT02353741

EGFR-TKIs

Concurrent EGFR-TKIs and Thoracic Radiation Therapy in Active EGFR Mutation for 1st Line Treatment of Stage IV NSCLC

Broad match: EGFR mutation (unspecified)Non Small Cell Lung Cancer

Study for Treatment With TH-4000 (Tarloxotinib) in Epidermal Growth Factor Receptor (EGFR) Mutant, T790M-negative Non-small Cell Lung Cancer (NSCLC) Patients

Terminated Phase 2 Rain Oncology Started 2015 NCT02454842

TH-4000 (Tarloxotinib)

Documented evidence of an EGFR mutation known to be associated with an EGFR TKI sensitivity

Broad match: EGFR mutation (unspecified)Non-small Cell Lung Cancer, NSCLC, Non-squamous NSCLC

The Continuation of Gefitinib Treatment Beyond Progression in Non-small Cell Lung Cancer Patients With EGFR Mutation

Unknown status Phase 2 Samsung Medical Center Started 2015 NCT03399669

gefitinib FDA EU

Histologically confirmed stage IIIB/IV or recurrent NSCLC with activating EGFR mutation in exon 18 through exon 21 except T790M

Broad match: EGFR sensitizing mutationNon-small Cell Lung Cancer

Phase 2 Study of MPDL3280A Combined With CDX-1401 in NY-ESO 1 (+) IIIB, IV or Recurrent Non-Small Cell Lung Cancer

Withdrawn Phase 2 Yale University Started 2015 NCT02495636

CDX-1401MPDL3280A

Patients with NSCLC known to harbor an ALK rearrangement, or EGFR mutation known to be sensitive to FDA approved tyrosine kinase inhibitors (TKI), are only eligible…

Broad match: EGFR mutation (unspecified)Non-Small Cell Lung Cancer

A Study Of Avelumab In Combination With Other Cancer Immunotherapies In Advanced Malignancies (JAVELIN Medley)

Terminated Phase 1/2 Pfizer Started 2015 NCT02554812

AvelumabUtomilumabPF-04518600PD 0360324CMP-001

Activating EGFR mutation, ALK, ROS1 translocation/rearrangements are not permitted.

Broad match: EGFR sensitizing mutationAdvanced Cancer

Icotinib for Completed Resected IB NSCLC With EGFR Mutation

Completed Phase 2 Sun Yat-sen University Started 2015 NCT02264210

Icotinib

EGFR activating mutation in exon 19 or 21.

Broad match: EGFR sensitizing mutationLung Neoplasms, Squamous Cell Lung Cancer, Adenocarcinoma of the Lung, Adenosquamous Cell Lung Cancer

A Study of BGB324 (Bemcentinib) in Combination With Erlotinib in Patients With Non-Small Cell Lung Cancer

Completed Phase 1/2 BerGenBio ASA Started 2015 NCT02424617

Erlotinib FDA EUBemcentinibBemcentinibBemcentinib

Participants who have an activating EGFR mutation may have up to 4 lines of previous treatment in the advanced setting.

Broad match: EGFR sensitizing mutationNon-Small Cell Lung Cancer

A Phase I/II Study of Ibrutinib in Previously Treated Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer

Completed Phase 1/2 M.D. Anderson Cancer Center Started 2015 NCT02321540

Ibrutinib

For EGFR mutant cohort, patients must have: a) Documented EGFR mutation by Clinical Laboratory Improvemen…

Broad match: EGFR mutation (unspecified)Lung Cancer

An Open-label Phase Ib/II Study of BAY 1000394 (Roniciclib) in Combination With Docetaxel in Second- or Third-line Treatment of Patients With Advanced Non-small Cell Lung Cancer (NSCLC)

Withdrawn Phase 1/2 Yonsei University Started 2015 NCT02522910

BAY 1000394 (Roniciclib) in combination with docetaxel

For EGFR mutated or ALK rearranged patients, EGFR TKI or ALK inhibitor is also considered a line of system…

Broad match: EGFR mutation (unspecified)NSCLC (Non-Small Cell Lung Cancer)

RRx-001 in Lung Cancer, Ovarian Cancer and Neuroendocrine Tumors Prior to Re-administration of Platinum Based Doublet Regimens (QUADRUPLE THREAT)

Completed Phase 2 EpicentRx Started 2015 NCT02489903

RRx-001CisplatinEtoposideCarboplatinIrinotecanVinorelbine

EGFR mutated non-small cell lung cancer (NSCLC) that has previously received a first line platinum dou…

Broad match: EGFR mutation (unspecified)Small Cell Carcinoma, Carcinoma, Non-Small-Cell Lung, Neuroendocrine Tumors, Ovarian Epithelial Cancer

A Study of Famitinib in Patients With Advanced Non-squamous and Non-Small Cell Lung Cancer (NSCLC)

Suspended Phase 2 Jiangsu Hengrui Started 2014 NCT02356991

Famitinib

b.for EGFR mutation type, third line or above treatment failure(at least previously treated with Platinum-bas…

Broad match: EGFR mutation (unspecified)Non-Small Cell Lung Cancer (NSCLC)

Study of Chemotherapy Plus Icotinib to Treat EGFR Mutation-positive Non-small-cell Lung Cancer

Unknown status Phase 2 Nanfang Hospital, Southern Medical University Started 2014 NCT02272127

icotinib

Study of Chemotherapy Plus Icotinib to Treat EGFR Mutation-positive Non-small-cell Lung Cancer

Broad match: EGFR mutation (unspecified)NSCLC

Icotinib With Concurrent Radiotherapy vs. Chemoradiotherapy in Non-small Cell Lung Cancer

Unknown status Phase 2 People's Hospital of Guangxi Zhuang Autonomous Region Started 2014 NCT02407366

IcotinibPemetrexedCarboplatin

…Unresectable Stage III Non-small Cell Lung Cancer With Epidermal Growth Factor Receptor ( EGFR) Mutation

Broad match: EGFR mutation (unspecified)Non-small Cell Lung Cancer

Erlotinib Treatment Beyond Progression in EGFR Mutant NSCLC

Completed Phase 2 Finnish Lung Cancer Group Started 2014 NCT02064491

Erlotinib FDA EUChemotherapy

Erlotinib Treatment Beyond Progression in EGFR Mutant NSCLC

Broad match: EGFR mutation (unspecified)Non-small Cell Lung Cancer

Selumetinib in Combination With Gefitinib in NSCLC Patients

Completed Phase 1/2 National Taiwan University Hospital Started 2014 NCT02025114

selumetinib

A tumor harboring an EGFR mutation known to be associated with drug sensitivity (ie, exon 19 deletion , L858R, L861Q, G719X etc.).

Broad match: EGFR exon 19 deletionNon-small Cell Lung Cancer (NSCLC)

Multicenter Study of Rociletinib Administered to Patients With Previously Treated Mutant EGFR Non-small Cell Lung Cancer

Terminated Phase 2 Clovis Oncology Started 2014 NCT02147990

Rociletinib

Documented evidence of a tumor with 1 or more EGFR mutations excluding exon 20 insertion

Broad match: EGFR mutation (unspecified)Non-small Cell Lung Cancer

Safety, Tolerability, Pharmacokinetics and Anti-tumour Activity of AC0010 in Advanced Non Small Cell Lung Cancer

Unknown status Phase 1/2 Sun Yat-sen University Started 2014 NCT02274337

AC0010

Documented evidence of any activating EGFR mutation in the tumor tissue.

Broad match: EGFR sensitizing mutationNon-Small Cell Lung Cancer

Erlotinib Combined With Chemotherapy in TKI Resistant Non-Small Cell Lung Cancers

Unknown status Phase 2 Hunan Province Tumor Hospital Started 2014 NCT02098954

Gemcitabine platinum combined with erlotinib FDA EU

EGFR sensitive mutations, such as exon 19 del, or exon 21 L858R

Broad match: EGFR exon 19 deletionCarcinoma, Non-Small Cell Lung, EGFR Gene Mutation

Phase II AZD9291 Open Label Study in NSCLC After Previous EGFR TKI Therapy in EGFR and T790M Mutation Positive Tumours

Completed Phase 2 AstraZeneca Started 2014 NCT02094261

AZD9291

…bours an EGFR mutation known to be associated with EGFR TKI sensitivity (including G719X, exon 19 deletion, L858R, L861Q).

Broad match: EGFR exon 19 deletionNon Small Cell Lung Cancer

An Open Study of ASP8273 in Patients With Non-Small-Cell Lung Cancer (NSCLC) Who Have Epidermal Growth Factor Receptor (EGFR) Mutations

Terminated Phase 1/2 Astellas Started 2014 NCT02192697

ASP8273

Patients confirmed to have the del ex19, L858R, G719X, or L861Q mutation among the EGFR activating mutations (patients at the study site who are documented to have any of the above-stated EGFR acti…

Broad match: EGFR sensitizing mutationNon-small Cell Lung Cancer

A Study to Evaluate Foretinib in Subjects With Non-Small-Cell Lung Cancer

Withdrawn Phase 2 GSK Started 2014 NCT02034097

ForetinibErlotinib FDA EU

…the following: Evidence of Epidermal growth factor receptor activating mutation positive (EGFRm) or Epidermal growth factor receptor (EGFR)/ Wild Type (WT) genes in Deoxyribonucleic aci…

Broad match: EGFR mutation (unspecified)Cancer

A Phase II Study to Assess Efficacy of Combined Treatment With Erlotinib (Tarceva) and Silybin-phytosome (Siliphos) in Patients With EGFR Mutant Lung Adenocarcinoma

Unknown status Phase 2 MedicalLogic Started 2014 NCT02146118

Erlotinib FDA EU

Histological or cytologic diagnosis of stage IV lung adenocarcinoma and confirmed EGFR mutation

Broad match: EGFR mutation (unspecified)Carcinoma, Non-Small-Cell Lung

A Phase I/II, Multicenter, Open-label Study of EGFRmut-TKI EGF816, Administered Orally in Adult Patients With EGFRmut Solid Malignancies

Completed Phase 1/2 Novartis Started 2014 NCT02108964

EGF816

…amenable to definitive multi-modality therapy including surgery) or metastatic (stage IV) EGFR mutant NSCLC.

Broad match: EGFR mutation (unspecified)Advanced Non-small Cell Lung Cancer

Icotinib as an Adjuvant Therapy for Patients With Stage IIA-IIIA Adenocarcinoma With EGFR Mutation

Completed Phase 2 Betta Pharmaceuticals Started 2014 NCT02044328

Icotinib

Icotinib as an Adjuvant Therapy for Patients With Stage IIA-IIIA Adenocarcinoma With EGFR Mutation

Broad match: EGFR mutation (unspecified)Non-small Cell Lung Cancer

AUY922 in Patient With Stage IV NSCLC

Completed Phase 2 National Taiwan University Hospital Started 2014 NCT01922583

AUY922

EGFR mutations in exon 20 T790M.

Broad match: EGFR mutation (unspecified)Non-small Cell Lung Cancer (NSCLC)

Iressa Re-challenge in Advanced NSCLC EGFR-mutated Patients

Terminated Phase 2 Amsterdam UMC, location VUmc Started 2014 NCT02025218

Gefitinib standard dose FDA EU

Iressa Re-challenge in Advanced NSCLC EGFR-mutated Patients

Broad match: EGFR mutation (unspecified)Lung Cancer

NOV120101 (Poziotinib) for 1st Line Monotherapy in Patients With Lung Adenocarcinoma

Terminated Phase 2 National OncoVenture Started 2013 NCT01819428

NOV120101 (Poziotinib)

Documented EGFR mutation (e.g., exon 19 deletion, exon 21 L858R, etc.) with tumor tissue

Broad match: EGFR exon 19 deletionAdenocarcinoma of Lung Stage IIIB, Adenocarcinoma of Lung Stage IV

Cabozantinib-S-Malate and Erlotinib Hydrochloride in Treating Patients With Previously Treated Metastatic Non-Small Cell Lung Cancer

Completed Phase 2 National Cancer Institute (NCI) Started 2013 NCT01866410

Cabozantinib S-malateErlotinib Hydrochloride FDA EU

…st have histologically or cytologically confirmed non-small cell lung cancer harboring an EGFR mutation

Broad match: EGFR mutation (unspecified)Recurrent Non-Small Cell Lung Carcinoma, Stage IV Non-Small Cell Lung Cancer AJCC v7

Erlotinib 100mg qd Versus Gefitinib 250mg qd for EGFR Mutant Nsclc

Unknown status Phase 2 Sun Yat-sen University Started 2013 NCT01955421

Erlotinib 100mg qd FDA EUGefitinib 250mg qd FDA EU

Harboring a PCR-confirmed activating mutation of EGFR, including an exon 19 deletion or an exon 21 L858R point mutation.

Broad match: EGFR exon 19 deletionAdvanced Stage Non Small Cell Lung Cancer

An Open Label Study of BIBW 2992/Afatinib in Advanced Non-Small Cell Lung Cancer Patients Pre-treated With Erlotinib or Gefitinib

Unknown status Phase 2 Sheba Medical Center Started 2013 NCT01932229

Afatinib treatment FDA EU

EGFR mutation or six months or longer benefit from EGFR TKIs

Broad match: EGFR mutation (unspecified)NSCLC

NOV120101 Phase 2 Study in NSCLC Patients With Aquired Resistance to 1st Generation EGFR Tyrosine Kinase Inhibitors

Completed Phase 2 National OncoVenture Started 2013 NCT01718847

NOV120101 (Poziotinib)

Patients with EGFR mutation (e.g., G719X, exon 19 deletion, L858R, L861Q, etc) known to be associated with sensitivity to TKIs

Broad match: EGFR exon 19 deletionIncreased Drug Resistance

Erlotinib Hydrochloride Before Surgery in Treating Patients With Stage III Non-Small Cell Lung Cancer

Terminated Phase 2 Albert Einstein College of Medicine Started 2013 NCT01857271

Erlotinib Hydrochloride FDA EU

Activating mutation in EGFR

Broad match: EGFR mutation (unspecified)Stage IIIA Non-Small Cell Lung Cancer, Stage IIIB Non-Small Cell Lung Cancer

Evaluate Erlotinib Efficacy and Safety as the 2nd/3rd Treatment in NSCLC With EGFR M(-) and C-met(-)

Unknown status Phase 2 Li Zhang Started 2013 NCT02006043

Erlotinib 150mg FDA EU

Neither with EGFR mutation nor c-met expression on Ventana Benchmark instrument(Met negative expression definition: …

Broad match: EGFR mutation (unspecified)Non-small Cell Lung Cancer

Afatinib vs Erlotinib as 2nd TKI After Failure to 1st TKI and Chemotherapy for Metastatic NSCLC

Completed Phase 2 The University of Hong Kong Started 2013 NCT02625168

Afatinib FDA EUErlotinib FDA EU

Patients with stage IV epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer who were previously responsive to one line of EGFR tyrosine ki…

Broad match: EGFR mutation (unspecified)Lung Cancer

Neoadjuvant Therapy of Icotinib in Epidermal Growth Factor Receptor Mutated NSCLC Patients

Unknown status Phase 2 Betta Pharmaceuticals Started 2013 NCT01843647

IcotinibChemotherapy

Neoadjuvant Therapy of Icotinib in Epidermal Growth Factor Receptor Mutated NSCLC Patients

Broad match: EGFR mutation (unspecified)Non-small-cell Lung Cancer

Combination of Metformin With Gefitinib to Treat NSCLC

Completed Phase 2 Daping Hospital and the Research Institute of Surgery of the Third Military Medical University Started 2013 NCT01864681

Gefitinib and Metformin FDA EUGefitinib and placebo FDA EU

…istologically or cytologically confirmed non small cell carcinoma of the lung who harbors EGFR-mutation and are previously untreated

Broad match: EGFR mutation (unspecified)NSCLC, EGFR Gene Amplification, Advanced Cancer, Stage IIIB NSCLC

Icotinib as Adjuvant Therapy in Treating Non-small-cell Lung Cancer Patients With Positive EGFR Mutation

Unknown status Phase 2 Betta Pharmaceuticals Started 2013 NCT01929200

1-year treatment with icotinib2-year treatment with icotinib

…cotinib as Adjuvant Therapy in Treating Non-small-cell Lung Cancer Patients With Positive EGFR Mutation

Broad match: EGFR mutation (unspecified)Non-small-cell Lung Cancer

Phase 2 Study of AUY922 in NSCLC Patients With Exon 20 Insertion Mutations in EGFR

Completed Phase 2 Massachusetts General Hospital Started 2013 NCT01854034

AUY922

Phase 2 Study of AUY922 in NSCLC Patients With Exon 20 Insertion Mutations in EGFR

Broad match: EGFR mutation (unspecified)Non Small Cell Lung Cancer

Adjuvant Afatinib in Stage I-III NSCLC With EGFR Mutation

Unknown status Phase 2 Massachusetts General Hospital Started 2013 NCT01746251

Afatinib FDA EU

Pathologically confirmed diagnosis of non-small cell lung cancer with EGFR mutation

Broad match: EGFR mutation (unspecified)Non Small Cell Lung Cancer

AZD9291 First Time In Patients Ascending Dose Study

Completed Phase 1/2 AstraZeneca Started 2013 NCT01802632

AZD9291

…bours an EGFR mutation known to be associated with EGFR TKI sensitivity (including G719X, exon 19 deletion, L858R, L861Q) OR

Broad match: EGFR exon 19 deletionAdvanced Non Small Cell Lung Cancer, Advanced (Inoperable) Non Small Cell Lung Cancer

Tepotinib With Gefitinib in Participants With Locally Advanced or Metastatic NSCLC (INSIGHT)

Completed Phase 1/2 Merck KGaA Started 2013 NCT01982955

TepotinibGefitinib FDA EUPemetrexedCisplatinCarboplatin

…e Treatment in Subjects With MET Positive, Locally Advanced or Metastatic NSCLC Harboring EGFR Mutation and Having Acquired Resistance to Prior EGFR-TKI Therapy (INSIGHT)

Broad match: EGFR mutation (unspecified)Non-small Cell Lung Cancer

Safety and Effectiveness Study of Chemotherapy in Combination With Erlotinib,or Sequential Erlotinib for Treatment in Patients With NSCLC

Unknown status Phase 2 Fudan University Started 2013 NCT02037997

docetaxelpemetrexedErlotinib FDA EU

…avorable surgical locally advanced stage (stage IIIB) or metastatic NSCLC (IV), Sensitive EGFR gene mutation

Broad match: EGFR mutation (unspecified)Non Small Cell Lung Cancer

Erlotinib Hydrochloride in Treating Patients With Malignant Peritoneal Mesothelioma

Completed Phase 2 University of Chicago Started 2012 NCT01592383

erlotinib hydrochloride FDA EU

only those patients who have a mutation of the EGFR tyrosine kinase domain will be able to enroll in this study.

Broad match: EGFR mutation (unspecified)Malignant Peritoneal Mesothelioma

Lung Cancer in Women Treated With Anti-oestrogens anD Inhibitors of EGFR

Completed Phase 2 Intergroupe Francophone de Cancerologie Thoracique Started 2012 NCT01556191

Gefitinib FDA EUFulvestrantErlotinib FDA EU

The presence of analysable tissue for the research of EGFR activating mutation.

Broad match: EGFR sensitizing mutationStage IV Lung Cancer

GEfitinib Plus viNOrelbine in Advanced EGFR Mutated NSCLC. GENOA Trial

Unknown status Phase 2 IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy Started 2012 NCT02319577

oral vinorelbineGefitinib FDA EU

Evidence of activating mutations of EGFR

Broad match: EGFR mutation (unspecified)Non Small Cell Lung Cancer

Phase II Trial of Double Dose of Icotinib in Treating Brain Metastases From Non-small Cell Lung Cancer

Unknown status Phase 2 Zhejiang Cancer Hospital Started 2012 NCT01688713

Icotinib

Patients with EGFR mutation or the lesions that remains stable for more than 3 months after local treatment(WBRT and/…

Broad match: EGFR mutation (unspecified)Brain Metastases, Non-small Cell Lung Cancer

Neoadjuvant Erlotinib for Operable Stage II or IIIA NSCLC With EGFR Mutations

Unknown status Phase 2 National Cancer Center, Korea Started 2012 NCT01470716

Erlotinib FDA EU

Neoadjuvant Erlotinib for Operable Stage II or IIIA NSCLC With EGFR Mutations

Broad match: EGFR mutation (unspecified)NSCLC Stage II, NSCLC, Stage IIIA

A Study of Tarceva (Erlotinib) in Patients With Locally Advanced, Metastatic or Recurrent Non-Small Cell Cancer Who Present Epidermal Growth Factor Receptor Mutations

Completed Phase 2 Roche Started 2012 NCT01372384

erlotinib [Tarceva] FDA EU

…Patients With Locally Advanced, Metastatic or Recurrent Non-Small Cell Cancer Who Present Epidermal Growth Factor Receptor Mutations

Broad match: EGFR mutation (unspecified)Non-Squamous Non-Small Cell Lung Cancer

Phase I/II Trial to Evaluate Safety, Tolerability and Pharmacokinetic Profile of HM61713 in NSCLC Patients

Completed Phase 1/2 Hanmi Pharmaceutical Company Limited Started 2012 NCT01588145

HM61713

Patients with EGFR mutation-positive tumor

Broad match: EGFR mutation (unspecified)Non Small Cell Lung Cancer

Erlotinib With Concurrent Brain Radiotherapy and Secondary Brain Radiotherapy After Recurrence With Erlotinib in NSCLC Non-increased-intracranial-pressure Symptomatic Brain Metastases

Unknown status Phase 2 Wu Jieping Medical Foundation Started 2012 NCT01763385

Erlotinib FDA EU

Patients in initial treatment should be detected EGFR mutation;

Broad match: EGFR mutation (unspecified)Non-small-cell Lung Cancer, Brain Metastases

Phase II Study of Erlotinib With Concurrent Radiotherapy in Unresectable NSCLC With Activating Mutation of EGFR in Exon 19 or 21

Unknown status Phase 2 Jinming Yu Started 2012 NCT01714908

Has active mutation of EGFR in exon 19 or 21;

Broad match: EGFR mutation (unspecified)Non-small Cell Lung Cancer

A Study of Docetaxel and Ramucirumab Versus Docetaxel and Placebo in the Treatment of Stage IV Non-Small Cell Lung Cancer

Completed Phase 2 Eli Lilly Started 2012 NCT01703091

Ramucirumab FDA EUDocetaxel

For participants with activating epidermal growth factor receptor (EGFR) mutation only, prior epidermal growth factor receptor- tyrosine kinase inhibitor (EGFR-TKI) monoth…

Broad match: EGFR mutation (unspecified)Non-small Cell Lung Cancer Metastatic

A Safety and Efficacy Study of INC280 and Gefitinib in Patients With EGFR Mutated, c-MET-amplified NSCLC Who Have Progressed After EGFRi Treatment

Completed Phase 2 Novartis Started 2012 NCT01610336

INC280Gefitinib FDA EU

Documented EGFR mutation

Broad match: EGFR mutation (unspecified)Non-small Cell Lung Cancer

First Line Gefitinib by FDG-PET Metabolic Response

Unknown status Phase 2 Asan Medical Center Started 2012 NCT01510990

Gefitinib FDA EU

Patients with tissue for the detection of EGFR mutation

Broad match: EGFR mutation (unspecified)Non-small Cell Lung Cancer

Study to Evaluate Safety, Pharmacokinetics, and Efficacy of Rociletinib (CO-1686) in Previously Treated Mutant Epidermal Growth Factor Receptor (EGFR) in Non-Small Cell Lung Cancer (NSCLC) Patients

Terminated Phase 1/2 Clovis Oncology Started 2012 NCT01526928

RociletinibRociletinibRociletinibRociletinibRociletinibRociletinib

Evidence of a tumor with one or more EGFR mutations excluding exon 20 insertion

Broad match: EGFR mutation (unspecified)Locally Advanced or Metastatic Non Small Cell Lung Cancer

Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Previously Treated Advanced Non-small Cell Lung Cancer

Completed Phase 2 University of Washington Started 2012 NCT01620190

Paclitaxel Albumin-Stabilized Nanoparticle Formulation

Pathologically confirmed non-small cell lung cancer with documented EGFR mutation in tumor deoxyribonucleic acid (DNA) or complete/partial response to first line EGFR tyro…

Broad match: EGFR mutation (unspecified)Recurrent Non-Small Cell Lung Carcinoma, Stage IV Non-Small Cell Lung Cancer

A Study of Pemetrexed and Gefitinib Versus Gefitinib in Non-Small Cell Lung Cancer (NSCLC)

Completed Phase 2 Eli Lilly Started 2012 NCT01469000

Gefitinib FDA EUPemetrexed

…st Line Treatment for Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer With Activating Epidermal Growth Factor Receptor Mutations

Broad match: EGFR sensitizing mutationCarcinoma, Non Small Cell Lung

Iressa Re-Challenge in Advanced NSCLC EGFR M+ Patients Who Responded to Gefitinib USed as 1st Line or Previous Treatment

Completed Phase 2 AstraZeneca Started 2012 NCT01530334

Gefitinib 250mg FDA EU

…s 3rd Line Treatment Re-challenge in Patients, Who Have Epidermal Growth Factor Receptor (EGFR) Mutation Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) and Who Respon…

Broad match: EGFR mutation (unspecified)Lung Cancer

Stereotactic Radiosurgery or Other Local Ablation Then Erlotinib in Epidermal Growth Factor Receptor (EGFR)

Completed Phase 2 UNC Lineberger Comprehensive Cancer Center Started 2012 NCT01573702

Erlotinib FDA EU

Histologically or cytologically confirmed stge IV EGFR-mutant NSCLC

Broad match: EGFR mutation (unspecified)Non Small Cell Lung Cancer

ARQ 197 Plus Erlotinib in Patient With Locally Advanced or Metastatic EGFR Mutation-positive Non-small-cell Lung Cancer

Completed Phase 2 Kyowa Kirin Started 2012 NCT01580735

ARQ 197

…nfirmed surgically unresectable locally advanced or metastatic (stage IIIB/IV) NSCLC with EGFR activating mutation.

Broad match: EGFR sensitizing mutationNon-small-cell Lung Cancer

A Dose Escalation Trial of PR610 Treating Patients With Solid Tumors

Terminated Phase 1/2 Proacta, Incorporated Started 2012 NCT01631279

PR610

…Stage IIIB or IV, non-squamous, non-small cell lung cancer (NSCLC) with known sensitizing mutations in EGFR, and the T790M resistance mutation

Broad match: EGFR mutation (unspecified)Unspecified Adult Solid Tumor, Protocol Specific

Erlotinib Hydrochloride With or Without Bevacizumab in Treating Patients With Stage IV Non-small Cell Lung Cancer With Epidermal Growth Factor Receptor Mutations

Completed Phase 2 Academic and Community Cancer Research United Started 2012 NCT01532089

BevacizumabErlotinib FDA EUErlotinib Hydrochloride FDA EU

… Alone or in Combination With Bevacizumab in Patients With Non-Small Cell Lung Cancer and Activating Epidermal Growth Factor Receptor Mutations

Broad match: EGFR sensitizing mutationEGFR Exon 19 Deletion Mutation, EGFR NP_005219.2:p.L858R, Lung Non-Squamous Non-Small Cell Carcinoma, Stage IV Lung Non-Small Cell Cancer AJCC v7

An Open-label, Randomized Phase II Study to Evaluate the Efficacy of AUY922 vs Pemetrexed or Docetaxel in NSCLC Patients With EGFR Mutations

Terminated Phase 2 Novartis Started 2012 NCT01646125

AUY922DocetaxelPemetrexed

Provide a pathology report that indicates the patient's tumor had EGFR activating mutation in the past.

Broad match: EGFR sensitizing mutationAdvanced Non Small Cell Lung Cancer (NSCLC)

Treatment With BIBW 2992, Irreversible Inhibitor of EGFR and HER-2 in Non-small Cell Lung Cancer

Completed Phase 2 Instituto Nacional de Cancerologia de Mexico Started 2012 NCT01542437

BIBW 2992 FDA EU

…ll Cell Lung Cancer in Advanced Stage, Which Have Progressed to Chemotherapy. Analysis of Mutations in EGFR and Number of Copies of HER-2

Broad match: EGFR mutation (unspecified)Non-Small Cell Lung Cancer, EGFR, HER-2

A Study of Erlotinib in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor Mutations

Completed Phase 2 Roche Started 2011 NCT01260181

Erlotinib FDA EU

Locally advanced or metastatic NSCLC with EGFR mutations

Broad match: EGFR mutation (unspecified)Non-Squamous Non-Small Cell Lung Cancer

Erlotinib as Neoadjuvant Treatment in Patients With Stage ⅢA N2 NSCLC With Activating EGFR Mutation.

Completed Phase 2 Baohui Han Started 2011 NCT01217619

erlotinib FDA EU

Erlotinib as Neoadjuvant Treatment in Patients With Stage ⅢA N2 NSCLC With Activating EGFR Mutation.

Broad match: EGFR sensitizing mutationNon Small Cell Lung Cancer

Efficacy and Safety Study of Gefitinib in Squamous NSCLC Patients Who Failed First-Line Chemotherapy

Completed Phase 2 Seoul Veterans Hospital Started 2011 NCT01485809

Gefitinib FDA EU

NSCLC with an activating sensitizing EGFR mutation

Broad match: EGFR sensitizing mutationSquamous Cell Carcinoma of Bronchus

BATTLE-FL: Front-Line Biomarker-Integrated Treatment Study in Non Small Cell Lung Cancer

Completed Phase 2 M.D. Anderson Cancer Center Started 2011 NCT01263782

CarboplatinPemetrexedBevacizumabCixutumumab

The patient should have tumor available for epidermal growth factor receptor (EGFR) mutations, ALK fusions and other molecular analyses.

Broad match: EGFR mutation (unspecified)Lung Cancer

A Study to Assess Biomarkers Impact on Participants Response to Erlotinib Treatment for First-line Non-Small Cell Lung Cancer With Endothelial Growth Factor Receptor (EGFR) Activating Mutations

Completed Phase 2 Roche Started 2011 NCT01153984

Erlotinib FDA EU

…atment for First-line Non-Small Cell Lung Cancer With Endothelial Growth Factor Receptor (EGFR) Activating Mutations

Broad match: EGFR sensitizing mutationCarcinoma，Non-Small-Cell Lung

A Study of Tarceva (Erlotinib) as First Line Therapy in Participants With Non-Small Cell Lung Cancer Harbouring Epidermal Growth Factor Receptor (EGFR) Mutations

Completed Phase 2 Roche Started 2011 NCT01310036

Erlotinib FDA EU

…Participants With Non-Small Cell Lung Cancer Harbouring Epidermal Growth Factor Receptor (EGFR) Mutations

Broad match: EGFR mutation (unspecified)Non-Squamous Non-Small Cell Lung Cancer

SS1P and Pentostatin Plus Cyclophosphamide for Mesothelioma

Completed Phase 1/2 National Cancer Institute (NCI) Started 2011 NCT01362790

PentostatinCyclophosphamideSS1(dsFv)PE38 - lot 073I0809SS1(dsFv)PE38 - lot FIL129J01

… approved estimated glomerular filtration rate (EGFR) tyrosine kinase inhibitor (TKI) for EGFR mutant tumors or crizotinib and ceritinib for ALK translocated tumors)\].

Broad match: EGFR mutation (unspecified)Mesothelioma, Adenocarcinoma of Lung, Pancreatic Neoplasms

MK2206 and Erlotinib Hydrochloride in Treating Patients With Advanced Non-Small Cell Lung Cancer Who Have Progressed After Previous Response to Erlotinib Hydrochloride Therapy

Completed Phase 2 National Cancer Institute (NCI) Started 2011 NCT01294306

Akt Inhibitor MK2206Erlotinib Hydrochloride FDA EU

NOTE: a patient with an EGFR activating mutation who has received EGFR-TKI therapy as first line therapy, but has not received platinum-ba…

Broad match: EGFR sensitizing mutationAdenosquamous Lung Carcinoma, Bronchioloalveolar Carcinoma, Large Cell Lung Carcinoma, Lung Adenocarcinoma

A Study on the Correlation Between Tarceva (Erlotinib) - Induced Rash and Efficacy in EGFR Mutated Participants With Advanced Non-Small Cell Lung Cancer Receiving First-Line Therapy

Completed Phase 2 Roche Started 2011 NCT01174563

erlotinib [Tarceva] FDA EU

Presence of epidermal growth factor receptor (EGFR) mutations

Broad match: EGFR mutation (unspecified)Non-Squamous Non-Small Cell Lung Cancer

Erlotinib Versus Vinorelbine/Cisplatin as Adjuvant Treatment in Stage IIIA NSCLC Patients With EGFR Mutations

Unknown status Phase 2 Chinese Lung Cancer Surgical Group Started 2011 NCT01410214

Erlotinib FDA EUvinorelbine/cisplatin

EGFR activating mutation in exon 19 or 21 and KARS

Broad match: EGFR sensitizing mutationNon-small Cell Lung Cancer Stage IIIA

Icotinib Combined With WBRT For NSCLC Patients With Brain Metastases and EGFR Mutation

Completed Phase 1/2 Betta Pharmaceuticals Started 2011 NCT01516983

icotinib

Positive EGFR mutation.

Broad match: EGFR mutation (unspecified)Non-small Cell Lung Cancer, Brain Metastases

A Study of AUY922 in Non-small-cell Lung Cancer Patients Who Have Received Previous Two Lines of Chemotherapy.

Completed Phase 2 Novartis Started 2010 NCT01124864

AUY922

Patients enrolled to the fifth stratum, modified EGFR mutant, must have documented prior response to EGFR TKI as defined by CR, PR or SD for 6 months …

Broad match: EGFR mutation (unspecified)Non-small-cell Lung Cancer

Erlotinib Therapy and Subsequent Development of Mechanisms of Secondary Resistance in Patients With NSCLC

Completed Phase 2 David M. Jackman, MD Started 2010 NCT00997334

Erlotinib FDA EU

… Mechanisms of Secondary Resistance in Patients With Non-Small Cell Lung Cancer and Known Sensitizing EGFR Mutations

Broad match: EGFR sensitizing mutationNon-small Cell Lung Cancer

Trial of BMS-690514 in Non-Small Cell Lung Cancer Subjects Who Have Been Treated With Gefitinib or Erlotinib and Are Genotypically EGFR Mutation Positive or Who Have Had a Prior Response

Completed Phase 2 Bristol Myers Squibb Started 2010 NCT01167244

BMS-690514

A tumor that harbors an EGFR mutation

Broad match: EGFR mutation (unspecified)Non-Small-Cell Lung Carcinoma

Erlotinib Combined With Radiotherapy in Patients With Non-resectable Locally Advanced Non-small Cell Lung Cancer (LA-NSCLC)

Unknown status Phase 2 Zhejiang Cancer Hospital Started 2010 NCT01091376

Erlotinib FDA EU

Tumor EGFR mutation

Broad match: EGFR mutation (unspecified)Non-small Cell Lung Cancer

A Chinese Randomized Crossover Study of Erlotinib Versus Docetaxel/Cisplatin in Previously Untreated Stage IIIB/IV Lung Adenocarcinoma With EGFR Mutations

Unknown status Phase 2 Chinese PLA General Hospital Started 2010 NCT01131429

Erlotinib FDA EUDocetaxelCisplatinDocetaxelCisplatinErlotinib FDA EU

…Versus Docetaxel/Cisplatin in Previously Untreated Stage IIIB/IV Lung Adenocarcinoma With EGFR Mutations

Broad match: EGFR mutation (unspecified)Neoplasms, Lung, Carcinoma, Non-Small Cell Lung, Drug Therapy, Genes, EGFR

Erlotinib and AT-101 in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients With Epidermal Growth Factor Receptor (EGFR) Activating Mutations

Terminated Phase 2 Memorial Sloan Kettering Cancer Center Started 2009 NCT00988169

oral erlotinib and pulsed doses of oral AT-101 FDA EU

Presence of exon 19 or exon 21 EGFR activating mutation.

Broad match: EGFR sensitizing mutationLung Cancer

Phase 2 Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin for Non-Small Cell Lung Cancer With KRAS or EGFR Activation

Completed Phase 2 Oncolytics Biotech Started 2009 NCT00861627

REOLYSIN®CarboplatinPaclitaxel

…cell lung cancer with evidence of RAS- or EGFR- activation in their tumors, as defined by EGFR activating mutations in exons 18 to 21, EGFR FISH amplification, or K-ras mutations in exon 2 (codons 12,13,6…

Broad match: EGFR sensitizing mutationCarcinoma, Non-small Cell Lung

A Study to Assess the Efficacy of Erlotinib for Leptomeningeal Carcinomatosis in EGFR Mutation Positive Non-small Cell Lung Cancer

Terminated Phase 2 Clinical Research Center for Solid Tumor, Korea Started 2009 NCT00830245

Erlotinib FDA EU

A patients with EGFR mutation (including exon 19 deletion, L858R)

Broad match: EGFR exon 19 deletionLeptomeningeal Carcinomatosis, Non-small Cell Lung Cancer

Induction Chemotherapy Followed by CCRT According to EGFR Mutation Status in NSCLC III

Unknown status Phase 2 National Cancer Center, Korea Started 2008 NCT00620269

Erlotinib FDA EUInduction or consolidation IP chemotherapyCCRT with IP chemotherapy (Irinotecan + Cisplatin)

…or cytologically confirmed NSCLC: it is recommended to obtain adequate tissue samples for EGFR mutation analysis.

Broad match: EGFR mutation (unspecified)Lung Cancer, NSCLC

Phase II Trial of BIBW 2992 (Afatinib) in Genetically Pre-screened Cancers With EGFR and/or HER2 Gene Amplification.

Terminated Phase 2 Boehringer Ingelheim Started 2008 NCT00748709

BIBW 2992 (Afatinib) FDA EU

… and/or HER2 gene amplification by FISH testing or patients with tumors that harbor known activating EGFR mutations.

Broad match: EGFR sensitizing mutationNeoplasms

Cetuximab in Patients With Lung Adenocarcinoma Receiving Erlotinib That Have Developed "Acquired Resistance" to Erlotinib

Completed Phase 1/2 Memorial Sloan Kettering Cancer Center Started 2008 NCT00716456

erlotinib with cetuximab FDA EU

A documented mutation in EGFR exons 19 or 21.

Broad match: EGFR mutation (unspecified)Lung Adenocarcinoma

Phase I/II of Oral Vorinostat Combination With Erlotinib in NSCLC Patients With EGFR Mutations With DP After Erlotinib.

Terminated Phase 1/2 Spanish Lung Cancer Group Started 2008 NCT00503971

Vorinostat plus Erlotinib FDA EU

Phase I/II of Oral Vorinostat Combination With Erlotinib in NSCLC Patients With EGFR Mutations With DP After Erlotinib.

Broad match: EGFR mutation (unspecified)Non-small Cell Lung Cancer

LUX Lung 2 Phase II Single Arm BIBW 2992 "Afatinib" in NSCLC With EGFR Activating Mutations

Completed Phase 2 Boehringer Ingelheim Started 2007 NCT00525148

BIBW 2992

LUX Lung 2 Phase II Single Arm BIBW 2992 "Afatinib" in NSCLC With EGFR Activating Mutations

Broad match: EGFR sensitizing mutationCarcinoma, Non-Small-Cell Lung

Study of XL647 in Subjects With NSCLC Who Have Progressed After Responding to Treatment With Gefitinib or Erlotinib

Completed Phase 2 Kadmon Corporation Started 2007 NCT00522145

XL647

2. a documented T790M EGFR mutation

Broad match: EGFR mutation (unspecified)Carcinoma, Non-Small-Cell Lung

Gefitinib in Treating Patients With Stage IIIA Non-Small Cell Lung Cancer

Unknown status Phase 2 Yonsei University Started 2006 NCT00616499

gefitinib FDA EU

EGFR mutations (in exon 18, 19, or 21)

Broad match: EGFR mutation (unspecified)Lung Cancer

First-Line EGFR-1 Tyrosine Kinase Inhibition in Patients With NSCLC With Mutant EGFR Gene

Unknown status Phase 2 Universitair Ziekenhuis Brussel Started 2006 NCT00339586

Erlotinib FDA EU

First-Line EGFR-1 Tyrosine Kinase Inhibition in Patients With NSCLC With Mutant EGFR Gene

Broad match: EGFR mutation (unspecified)Lung Neoplasms, Non-Small Cell Lung Cancer, Adenocarcinoma, Bronchiolo-Alveolar

First-line Treatment for Adenocarcinoma Patients With Epidermal Growth Factor Receptor (EGFR) Mutation

Completed Phase 2 AstraZeneca Started 2006 NCT00344773

Gefitinib FDA EU

First-line Treatment for Adenocarcinoma Patients With Epidermal Growth Factor Receptor (EGFR) Mutation

Broad match: EGFR mutation (unspecified)Pulmonary Cancer

The Role of EGFR Mutations in Pancreatic Cancer Patients Receiving Gemcitabine With or Without Erlotinib

Unknown status Phase 2 Taipei Veterans General Hospital, Taiwan Started 2005 NCT01608841

Erlotinib FDA EU

The Role of EGFR Mutations in Pancreatic Cancer Patients Receiving Gemcitabine With or Without Erlotinib

Broad match: EGFR mutation (unspecified)Metastatic Pancreatic Cancer

A Study With BPI-1178 and Osimertinib in Advanced Non-small Cell Lung Cancer Patients With EGFR Mutations

Unknown status Phase 1 National Cancer Center, China Started 2024 NCT06362980

BPI-1178Osimertinib FDA EU

…, demonstrating an EGFR-positive gene mutation sensitive to EGFR TKI treatment (including exon 19 deletion, 21 L858R mutation, etc.), with or without T790M mutation.

Broad match: EGFR exon 19 deletionNSCLC

A Study Investigating BG-60366 in Adults With Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer

Terminated Phase 1 BeOne Medicines (BeiGene) Started 2024 NCT06685718

BG-60366

Histologically or cytologically confirmed diagnosis of NSCLC, carrying an EGFR activating mutation prior to receiving standard EGFR-tyrosine kinase inhibitor (EGFR-TKI)

Broad match: EGFR sensitizing mutationNon-Small Cell Lung Cancer, Lung Cancer, NSCLC, NSCLC (Non-small Cell Lung Carcinoma)

Clinical Study of Antibody-Drug Conjugate MYTX-011 in Subjects With Non-Small Cell Lung Cancer

Terminated Phase 1 Mythic Therapeutics Started 2023 NCT05652868

MYTX-011

…current (and not a candidate for a curative therapy), or metastatic NSCLC with actionable EGFR mutations.

Broad match: EGFR mutation (unspecified)NSCLC, NSCLC Stage IV, NSCLC Stage IIIB, Non-Small Cell Lung Cancer

Assessing the Effect of DZD9008 on the Pharmacokinetics of the Cocktail Probes Representative for CYP3A4, P-gp, BCRP and OATP1B1 in Patients with EGFR or HER2 Mutant Advanced Non-small Cell Lung Cancer (WU-KONG19)

Completed Phase 1 Dizal Pharmaceuticals Started 2023 NCT05926180

DZD9008 and Probe drugs (midazolam, digoxin, rosuvastatin)

…of the Cocktail Probes Representative for CYP3A4, P-gp, BCRP and OATP1B1 in Patients with EGFR or HER2 Mutant Advanced Non-small Cell Lung Cancer (WU-KONG19)

Broad match: EGFR mutation (unspecified)Non-small Cell Lung Cancer

A Study of TAS3351 in NSCLC Patients With EGFRmt

Terminated Phase 1 Taiho Oncology Started 2023 NCT05765734

TAS3351

A Phase 1/2 Study of TAS3351 in Patients With Advanced Non-Small Cell Lung Cancer and EGFR Mutations

Broad match: EGFR mutation (unspecified)Non-Small Cell Lung Cancer

A Phase 1 Study of MRTX0902 in Solid Tumors With Mutations in the KRAS MAPK Pathway

Terminated Phase 1 Bristol Myers Squibb Started 2022 NCT05578092

MRTX0902MRTX849

…own KRAS mutations, known annotated recurrent activating SOS1, PTPN11, class III BRAF, or EGFR mutation, or known annotated recurrent inactivating NF1 mutation;

Broad match: EGFR mutation (unspecified)Solid Tumor, Advanced Solid Tumor, Non Small Cell Lung Cancer, Colo-rectal Cancer

Oral TEAD Inhibitor Targeting the Hippo Pathway in Subjects with Advanced Solid Tumors

Terminated Phase 1 Ikena Oncology Started 2022 NCT05228015

IK-930Osimertinib FDA EU

… proven, incurable, locally advanced or metastatic NSCLC expressing osimertinib-sensitive EGFR mutations

Broad match: EGFR mutation (unspecified)Solid Tumors, Adult, Solid Tumor, Malignant Pleural Mesothelioma (MPM), Epithelioid Hemangioendothelioma (EHE)

A Study Evaluating the Safety, Pharmacokinetic and Anti-tumor Activity of RO7428731 in Participants With Glioblastoma

Completed Phase 1 Roche Started 2022 NCT05187624

RO7428731

…minary Clinical Activity of RO7428731 in Participants With Glioblastoma Expressing Mutant Epidermal Growth Factor Receptor Variant III

Broad match: EGFR mutation (unspecified)Glioblastoma

Almonertinib in the First-line Treatment of Patients of NSCLC With Poor Performance Status

Unknown status Phase 1 Guangzhou Institute of Respiratory Disease Started 2022 NCT05826483

Almonertinib

NSCLC patients with EGFR mutation (19 deletion/21 L858R point mutation) or primary T790M mutation in pre-enrollment genetic…

Broad match: EGFR mutation (unspecified)Malignant Tumor of Lung, Poor Performance Status

Phase I Study of the BBP-398 in Patients With Advance Solid Tumors

Terminated Phase 1 LianBio Started 2022 NCT05621525

BBP-398

…ation: locally advanced or metastatic solid tumors Dose expansion: Advanced or metastatic EGFR-mutant NSCLC 5.

Broad match: EGFR mutation (unspecified)Advanced Solid Tumor, Advanced or Metastatic Non-small Cell Lung Cancer

(Concerto) Study of BLU-451 in Advanced Cancers With EGFR Exon 20 Insertion Mutations

Terminated Phase 1 Blueprint Medicines Started 2022 NCT05241873

BLU-451CarboplatinPemetrexed

Documented EGFR mutation, based on Next-generation sequencing (NGS) testing of tumor or liquid biopsy analyzed in …

Broad match: EGFR mutation (unspecified)Lung Neoplasm Malignant, Carcinoma, Non-Small-Cell Lung, Respiratory Tract Neoplasms, Neoplasms

Phase I Study of Repotrectinib and Osimertinib in NSCLC Patients

Unknown status Phase 1 Instituto Oncológico Dr Rosell Started 2022 NCT04772235

RepotrectinibOsimertinib FDA EU

Patients must have been locally diagnosed with EGFR activating mutation (including exon 18, exon 19, exon 21 and mutation T790M) based on FDA approved test (or a…

Broad match: EGFR sensitizing mutationNsclc

A Study of Anti-Cancer Therapies Targeting the MAPK Pathway in Patients With Advanced NSCLC

Completed Phase 1 Erasca Started 2021 NCT04959981

ERAS-007ERAS-601Osimertinib FDA EUSotorasib

Have histologically or cytologically confirmed NSCLC, with presence of EGFR mutation(s) sensitive to EGFR inhibitors, or KRAS G12C mutation.

Broad match: EGFR mutation (unspecified)Advanced Non-squamous Non-small-cell Lung Cancer

(SYMPHONY) Phase 1/2 Study Targeting EGFR Resistance Mechanisms in NSCLC

Terminated Phase 1 Blueprint Medicines Started 2021 NCT04862780

BLU-945osimertinib FDA EU

Pathologically confirmed, definitively diagnosed, metastatic NSCLC harboring an activating EGFR mutation.

Broad match: EGFR sensitizing mutationLung Neoplasms, Carcinoma, Non-Small-Cell Lung, Respiratory Tract Neoplasms, Neoplasms

Assessing the Safety and Efficacy of PLB1004 in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)

Unknown status Phase 1 Avistone Biotechnology Started 2020 NCT05347628

PLB1004

Patients with EGFR or HER2 mutations;

Broad match: EGFR mutation (unspecified)Non-Small-Cell Lung Cancer

First-in-Human Study of the SHP2 Inhibitor BBP-398 in Patients With Advanced Solid Tumors

Terminated Phase 1 Navire Pharma Inc., a BridgeBio company Started 2020 NCT04528836

BBP-398 (Formerly known as IACS-15509)

…are or curative therapies (MAPK-pathway alterations include, for example KRASG12C mutant, EGFR-mutant).

Broad match: EGFR mutation (unspecified)Tumor, Solid

A Phase 1 Open Label Trial of Intravenous Administration of MVA-BN-Brachyury Vaccine in Patients With Advanced Cancer

Completed Phase 1 Bavarian Nordic Started 2020 NCT04134312

MVA-BN-Brachyury

Disease progression after indicated targeted therapy (EGFR-mut, ALK-fusion, BRAF-mut).

Broad match: EGFR mutation (unspecified)Solid Metastatic Tumor

Phase I Study of Individualized Neoantigen Peptides in the Treatment of EGFR Mutant Non-small Cell Lung Cancer

Unknown status Phase 1 Sun Yat-sen University Started 2020 NCT04397926

Individualized neoantigen peptides vaccine

Available tumor specimen for sequencing and EGFR gene mutation frequency\>5%.

Broad match: EGFR mutation (unspecified)Non Small Cell Lung Cancer

A Study of TY-9591 in Advanced Non-small Cell Lung Cancer(NSCLC) Patients With EGFR Positive Mutation

Completed Phase 1 TYK Medicines Started 2020 NCT04204473

TY-9591(10mg,40mg) qd. po

patients must have confirmation of tumor EGFR activating mutations (exon 19 del, or exon 21 ) and T790M mutation status

Broad match: EGFR sensitizing mutationNSCLC

DS-1205c With Osimertinib for Metastatic or Unresectable Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer

Terminated Phase 1 Daiichi Sankyo Started 2019 NCT03255083

DS-1205cOsimertinib FDA EU

…rbors an EGFR mutation known to be associated with EGFR TKI sensitivity (including G719X, exon 19 deletion, L858R, L861Q) or

Broad match: EGFR exon 19 deletionNon-small Cell Lung Cancer (NSCLC)

A Study to Evaluate the Tolerance and Pharmacokinetics of TQB3804 in Subjects With Advanced Malignant Tumors

Unknown status Phase 1 Chia Tai Tianqing Started 2019 NCT04128085

TQB3804

Has EGFR mutations. 5.

Broad match: EGFR mutation (unspecified)Advanced Malignant Tumors

Niraparib in Combination With Osimertinib in EGFR-Mutated Advanced Lung Cancer

Terminated Phase 1 Massachusetts General Hospital Started 2019 NCT03891615

NiraparibOsimertinib FDA EU

…must have histologically or cytologically confirmed stage IV (AJCC 8th ed.) NSCLC with an activating EGFR mutation as identified in a CLIA-approved laboratory.

Broad match: EGFR sensitizing mutationLung Cancer

A Study to Evaluate Immunotherapy Combinations in Participants With Lung Cancer

Completed Phase 1 Arcus Biosciences Started 2019 NCT03846310

EtrumadenantZimberelimabCarboplatinPemetrexedPembrolizumab

Arm 1 and Arm 2 participants must have a sensitizing epidermal growth factor receptor (EGFR) mutation with disease progression or treatment intolerance after one or more approved TKIs.

Broad match: EGFR mutation (unspecified)Non Small Cell Lung Cancer Metastatic, Non Small Cell Lung Cancer, Nonsquamous Nonsmall Cell Neoplasm of Lung, Sensitizing EGFR Gene Mutation

Dry Pleurodesis With Talcum and Afatinib is Used to Treat Patients With Non-Small Cell Lung Carcinoma

Unknown status Phase 1 Center Trials & Treatment Europe Started 2019 NCT03827070

Afatinib FDA EUTalcum powder

Non-small cell lung cancer with positive mutation of EGFR verified

Broad match: EGFR mutation (unspecified)Non Small Cell Lung Cancer

Study of Dacomitinib and Osimertinib for Patients With Advanced EGFR Mutant Lung Cancer

Completed Phase 1 Memorial Sloan Kettering Cancer Center Started 2019 NCT03810807

Dacomitinib FDA EUOsimertinib FDA EU

Somatic activating mutation in EGFR in a tumor biopsy

Broad match: EGFR mutation (unspecified)Metastatic Non-small Cell Lung Cancer

Study Evaluating CMP-001 in Combination With Atezolizumab in Participants With Non-Small Cell Lung Cancer

Completed Phase 1 Regeneron Started 2018 NCT03438318

CMP-001Atezolizumab

Participants with epidermal growth factor (EGFR) activating mutations, EGFR T790M or anaplastic lymphoma kinase (ALK) gene re-arrangement must have received p…

Broad match: EGFR sensitizing mutationNon Small Cell Lung Cancer

Safety and Tolerability of SH-1028 in Patients With Advanced Solid Cancer

Unknown status Phase 1 Nanjing Sanhome Pharmaceutical Started 2018 NCT03618043

SH-1028

Confirmation that the tumor harbors an EGFR mutation known to be associated with EGFR TKI sensitivity :

Broad match: EGFR mutation (unspecified)Advanced Solid Cancer

Osimertinib With Stereotactic Radiosurgery (SRS) in Brain Metastases From EGFR Positive NSCLC

Completed Phase 1 Case Comprehensive Cancer Center Started 2018 NCT03535363

Osimertinib FDA EU

Confirmed pathology of EGFR mutation positive NSCLC with new brain metastases.

Broad match: EGFR mutation (unspecified)NSCLC, Non-small Cell Lung Cancer

Epacadostat (INCB24360) in Combination With Sirolimus in Advanced Malignancy

Unknown status Phase 1 Chao Huang Started 2018 NCT03217669

Epacadostatsirolimus

Those with activating EGFR mutation or ALK gene arrangement must have progressed on at least one kinase inhibitor.

Broad match: EGFR sensitizing mutationAdvanced Solid Tumor, Non-small Cell Lung Cancer (NSCLC)

An Autologous NK/CIK Cell Product (PB101) in Combination With EGFR-TKI for Treating Lung Cancer

Completed Phase 1 Precision Biotech Taiwan Started 2018 NCT07271446

PB101 plus EGFR-TKI including gefitinib, erlotinib, afatinib, or osimertinib FDA EU

EGFR sensitizing mutation must be detected in tumor tissue.

Broad match: EGFR sensitizing mutationNon-small Cell Lung Cancer

Olmutinib 600 mg QD in Patients With T790M-positive NSCLC After Treatment With an EGFR-TKI

Terminated Phase 1 Hanmi Pharmaceutical Company Limited Started 2018 NCT04510415

Olmutinib

… mutation which is known to be related with susceptibility to EGFR-TKIs (including G719X, exon 19 deletion, L858R, and L861Q).

Broad match: EGFR exon 19 deletionNon Small Cell Lung Cancer

DS-1205c With Gefitinib for Metastatic or Unresectable Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer

Terminated Phase 1 Daiichi Sankyo Started 2018 NCT03599518

DS-1205cGefitinib FDA EU

…rbors an EGFR mutation known to be associated with EGFR TKI sensitivity (including G719X, exon 19 deletion, L858R, L861Q) OR

Broad match: EGFR exon 19 deletionNon Small Cell Lung Cancer

Study of AMG 596 in Patients With EGFRvIII Positive Glioblastoma

Terminated Phase 1 Amgen Started 2018 NCT03296696

AMG 596AMG 404

…rld Health Organization (WHO) grade 4, glioblastoma or lower grade malignant gliomas with epidermal growth factor receptor variant III (EGFRvIII) positive tumor

Broad match: EGFR mutation (unspecified)Glioblastoma or Malignant Glioma

Phase Ib Study of Stereotactic Body Radiotherapy (SBRT) in Oligometastatic Non-small Lung Cancer (NSCLC) With Dual Immune Checkpoint Inhibition

Terminated Phase 1 University of Wisconsin, Madison Started 2018 NCT03275597

DurvalumabTremelimumab

Participants must have tumors that lack sensitizing EGFR mutation (e.g. exon 19 deletion or exon 21 L858R) or ALK rearrangement.

Broad match: EGFR exon 19 deletionNon-small Cell Lung Cancer, Non-small Cell Lung Cancer Stage IV

Afatinib on CNS Metastases and LMD in EGFR Mutation Positive NSCLC

Terminated Phase 1 National Cancer Centre, Singapore Started 2018 NCT03711422

Afatinib FDA EUAfatinib FDA EU

Afatinib on CNS Metastases and LMD in EGFR Mutation Positive NSCLC

Broad match: EGFR mutation (unspecified)Non-small Cell Lung Cancer, Leptomeningeal Disease, Central Nervous System Metastases

Study in Patients With Tumours Requiring Arginine to Assess ADI-PEG 20 With Atezolizumab, Pemetrexed and Carboplatin

Withdrawn Phase 1 Queen Mary University of London Started 2018 NCT03498222

AtezolizumabPemetrexedCarboplatinADI PEG20

Patients with EGFR mutant or ALK positive NSCLC must have had an EGFR tyrosine kinase inhibitor (TKI) or ALK inhibi…

Broad match: EGFR mutation (unspecified)Carcinoma, Non-Small-Cell Lung

MP0250 DARPin® Protein Plus Osimertinib in Patients With EGFR-mutated NSCLC

Terminated Phase 1 Molecular Partners Started 2018 NCT03418532

MP0250 DARPin® drug candidate, Osimertinib FDA EU

… confirmed metastatic or unresectable locally advanced non-squamous NSCLC with documented EGFR mutation-positive disease

Broad match: EGFR mutation (unspecified)EGFR-mutated NSCLC (Disorder)

APX005M With Nivolumab and Cabiralizumab in Advanced Melanoma, Non-small Cell Lung Cancer or Renal Cell Carcinoma

Completed Phase 1 Yale University Started 2018 NCT03502330

APX005MCabiralizumabNivolumab

Patients known to harbor an ALK rearrangement or EGFR mutation known to be sensitive to FDA-approved tyrosine kinase inhibitors (TKI), are only eligible…

Broad match: EGFR mutation (unspecified)Advanced Melanoma, Non-small Cell Lung Cancer, Renal Cell Carcinoma

Open-label PET Study With [11C]Osimertinib in Patients With EGFRm NSCLC and Brain Metastases

Completed Phase 1 AstraZeneca Started 2018 NCT03463525

Osimertinib FDA EU[11C]osimertinib FDA EU

…bours an EGFR mutation known to be associated with EGFR-TKI sensitivity (including G719X, exon 19 deletion, L858R, L861Q) or T790M EGFR resistance mutation as assessed by local laboratory/or centr…

Broad match: EGFR exon 19 deletionNon-small Cell Lung Cancer

A Study of TAS-116 in Patients With Solid Tumors

Completed Phase 1 Taiho Oncology Started 2017 NCT02965885

TAS-116

…lecular/genetic alterations will be enrolled: HER2 positive MBC Advanced NSCLC, harboring EGFR mutations after progression on osimertinib Advanced NSCLC, harboring ALK translocations after treat…

Broad match: EGFR mutation (unspecified)Advanced Solid Tumors

LZM009 to Treat Patients With Advanced Solid Tumors

Completed Phase 1 Livzon Pharmaceutical Group Started 2017 NCT03286296

LZM009,recombinant humanized anti-PD-1 monoclonal antibody for injection

…dard therapy \[note for patients with NSCLC patients with activating ALK translocation or EGFR mutations must have been treated and failed appropriate therapy\], or for which there is no standar…

Broad match: EGFR mutation (unspecified)Solid Tumor

Study to Evaluate the Safety and Anti-tumor Activity of SCC244

Completed Phase 1 Haihe Biopharma Started 2017 NCT03466268

Gumarontinib Tablets

In Phase Ia/Ib, all NSCLC subjects with EGFR mutation must have progressive disease after 1 or 2 lines of prior therapy including at least an E…

Broad match: EGFR mutation (unspecified)Advanced Solid Tumor

This Study in Patients With Different Types of Cancer (Solid Tumours) Aims to Find a Safe Dose of Xentuzumab in Combination With Abemaciclib With or Without Hormonal Therapies. The Study Also Tests How Effective These Medicines Are in Patients With Lung and Breast Cancer

Completed Phase 1 Boehringer Ingelheim Started 2017 NCT03099174

XentuzumabAbemaciclibLetrozoleAnastrozoleFulvestrantAbemaciclib

…anaplastic lymphoma kinase (ALK) inhibitors is mandatory in participants whose tumour has EGFR-activating mutations or ALK translocations.

Broad match: EGFR sensitizing mutationNeoplasms, Breast Neoplasms

A Phase I Study of SCC244 in Patients with Advanced MET Alterations Solid Tumors

Completed Phase 1 Haihe Biopharma Started 2017 NCT03457532

Gumarontinib Tablets

Known druggable molecular alterations such as EGFR mutation, ALK rearrangement, ROS1 rearrangement, BRAF mutation, or NTRK fusion which might be a ca…

Broad match: EGFR mutation (unspecified)Advanced Solid Tumor

Neratinib and Everolimus, Palbociclib, or Trametinib in Treating Participants With Refractory and Advanced or Metastatic Solid Tumors With EGFR Mutation/Amplification, HER2 Mutation/Amplification, or HER3/4 Mutation or KRAS Mutation

Terminated Phase 1 M.D. Anderson Cancer Center Started 2017 NCT03065387

EverolimusNeratinibPalbociclibTrametinib

…nib in Treating Participants With Refractory and Advanced or Metastatic Solid Tumors With EGFR Mutation/Amplification, HER2 Mutation/Amplification, or HER3/4 Mutation or KRAS Mutation

Broad match: EGFR mutation (unspecified)Advanced Malignant Solid Neoplasm, EGFR Gene Amplification, EGFR Gene Mutation, ERBB2 Gene Amplification

A Study of DBPR112 in Patients With Head and Neck Cancer and EGFR Mutated Lung Cancer

Terminated Phase 1 National Health Research Institutes, Taiwan Started 2017 NCT03246854

DBPR112

…f head and neck that has failed prior standard therapy for metastatic disease or advanced EGFR-mutated NSCLC that has failed prior standard therapy including at least one anti EGFR TK inhibito…

Broad match: EGFR mutation (unspecified)Head and Neck Cancer, NSCLC

A Study of ASP8273 in Subjects With Non-small Cell Lung Cancer (NSCLC) Harboring Epidermal Growth Factor Receptor (EGFR) Mutations

Terminated Phase 1 Astellas Started 2017 NCT03082300

naquotinib

…jects With Non-small Cell Lung Cancer (NSCLC) Harboring Epidermal Growth Factor Receptor (EGFR) Mutations

Broad match: EGFR mutation (unspecified)Non-small Cell Lung Cancer (NSCLC), Epidermal Growth Factor Receptor (EGFR) Mutations

Study to Assess the Effect of Osimertinib (TAGRISSO™ ) on Blood Levels of Fexofenadine in Patients With EGFRm+ NSCLC

Completed Phase 1 AstraZeneca Started 2017 NCT02908750

Fexofenadine tablet dosingOsimertininb tablet dosing

Confirmation that the tumour harbours an EGFR mutation known to be associated with EGFR-TKI sensitivity

Broad match: EGFR mutation (unspecified)Non Small Cell Lung Cancer

Afatinib and Necitumumab in Patients With EGFR Mutation Positive Advanced or Metastatic Non-small Cell Lung Cancer

Terminated Phase 1 Vanderbilt-Ingram Cancer Center Started 2017 NCT03054038

Afatinib FDA EUNecitumumab

…cytologically-confirmed advanced or metastatic non-small cell lung cancer (NSCLC) that is EGFR mutation positive

Broad match: EGFR mutation (unspecified)Non-Small Cell Lung Carcinoma

A Trial of CV301 in Combination With Anti-PD-1 Therapy in Subjects With Non-Small Cell Lung Cancer

Completed Phase 1 Bavarian Nordic Started 2016 NCT02840994

CV301PembrolizumabNivolumab

…FISH+), maintenance therapy for colorectal or pancreatic cancer, and erlotinib therapy in EGFR-mutated lung cancer under the condition that subjects are on these therapies for at least two mon…

Broad match: EGFR mutation (unspecified)Non-small Cell Lung Cancer (NSCLC)

Safety, Tolerability, Pharmacokinetics and Anti-tumour Activity of Alflutinib in Advanced Non Small Cell Lung Cancer

Terminated Phase 1 Allist Pharmaceuticals Started 2016 NCT02973763

Alflutinib

…tation known to be associated with EGFR TKI sensitivity (including at least one of G719X, exon 19 deletion, L858R, L861Q mutation)

Broad match: EGFR exon 19 deletionNSCLC

A Dose Escalation Study Of PF-06801591 In Melanoma, Head And Neck Cancer (SCCHN), Ovarian, Sarcoma, Non-Small Cell Lung Cancer, Urothelial Carcinoma or Other Solid Tumors

Completed Phase 1 Pfizer Started 2016 NCT02573259

PF-06801591PF-06801591

NSCLC patients whose tumor is known to have ALK or EGFR mutation must have received prior systemic therapies that only include 1 or more lines of ALK or E…

Broad match: EGFR mutation (unspecified)Part 1, MELANOMA, SCCHN, OVCA

First in Human Study of IBI308 in Chinese Subjects With Advanced Solid Tumors

Completed Phase 1 Innovent Biologics Started 2016 NCT02937116

IBI308IBI308\Cisplatinum\PemetrexedIBI308\cisplatin\gemcitabineIBI308\oxaliplatin\capecitabineIBI308\etoposide\cisplatinIBI308\irinotecan\5-FU

… histologically confirmed advanced NSCLC without known epithelial growth factor receptor (EGFR) mutation and anaplastic lymphoma kinase (ALK) rearrangement after failure of 1st line standard the…

Broad match: EGFR mutation (unspecified)Cancer, Solid Tumor

A Study to Investigate the Absorption, Metabolism and Excretion of [14C]ASP8273 in Subjects With Solid Tumors

Withdrawn Phase 1 Astellas Started 2016 NCT02674555

radio-labeled naquotinibnaquotinib

…tologically confirmed metastatic or locally advanced, unresectable solid tumors harboring EGFR mutations.

Broad match: EGFR mutation (unspecified)Epidermal Growth Factor Receptor (EGFR) Mutations, Solid Tumors

A Study of Ramucirumab (LY3009806) or Necitumumab (LY3012211) Plus Osimertinib in Participants With Lung Cancer

Completed Phase 1 Eli Lilly Started 2016 NCT02789345

Ramucirumab FDA EUNecitumumabOsimertinib FDA EU

…b or Necitumumab in Combination With Osimertinib in Patients With Advanced T790M-Positive EGFR-Mutant Non-Small Cell Lung Cancer After Progression on First-Line EGFR TKI Therapy

Broad match: EGFR mutation (unspecified)Non-small Cell Lung Cancer

A Study of Atezolizumab in Combination With Epacadostat in Subjects With Previously Treated Stage IIIB or Stage IV Non-Small Cell Lung Cancer and Previously Treated Stage IV Urothelial Carcinoma

Terminated Phase 1 Incyte Started 2015 NCT02298153

EpacadostatAtezolizumab

Tumors with driver mutations (epidermal growth factor receptor mutation positive or anaplastic lymphoma kinase fusion oncogene positive) should have had disease …

Broad match: EGFR mutation (unspecified)NSCLC (Non-small Cell Lung Carcinoma), UC (Urothelial Cancer)

Safety, Immunogenicity and Pharmacokinetics of SYN004 in Patients With Solid Tumors

Completed Phase 1 Synermore Biologics Started 2015 NCT02391727

SYN004

…uximab or panitumumab or other anti-EGFR antibodies OR Tumor progression in patients with EGFR-mutated non-small cell lung cancer (NSCLC) who have refused therapy.

Broad match: EGFR mutation (unspecified)Colon Cancer, Breast Cancer, Cancer of the Head and Neck

MEDI9447 Alone and in Combination With MEDI4736 in Adult Participants With Select Advanced Solid Tumors.

Completed Phase 1 AstraZeneca Started 2015 NCT02503774

OleclumabDurvalumab

Have histologic or cytologic documentation of solid tumor including EGFRm NSCLC

Broad match: EGFR mutation (unspecified)Solid Tumors

Phase I, Study in Chinese NSCLC Patients

Completed Phase 1 AstraZeneca Started 2015 NCT02529995

AZD9291 40 mgAZD9291 80 mg

…al diagnosis of NSCLC) known to be associated with EGFR TKI sensitivity (including G719X, exon 19 deletion, L858R, L861Q)

Broad match: EGFR exon 19 deletionCarcinoma, Non-Small-Cell Lung With EGFR Mutation Positive

A Open-label Prospective Cohort Trial of Curcumin Plus Tyrosine Kinase Inhibitors (TKI) for EGFR -Mutant Advanced NSCLC

Unknown status Phase 1 Lady Davis Institute Started 2015 NCT02321293

Tyrosine Kinase Inhibitor gefitinib (Iressa) FDA EUTyrosine Kinase Inhibitor erlotinib (Tarceva) FDA EU

Newly diagnosed or patients on treatment for histologically confirmed advanced EGFR-mutant NSCLC defined as unresectable stage 3A, stage 3B or stage 4.

Broad match: EGFR mutation (unspecified)Lung Cancer

A Study of Necitumumab and Abemaciclib in Participants With Non-Small Cell Lung Cancer (NSCLC)

Completed Phase 1 Eli Lilly Started 2015 NCT02411591

NecitumumabAbemaciclib

… anaplastic lymphoma kinase (ALK) inhibitors is mandatory in participants whose tumor has EGFR-activating mutations or ALK translocations.

Broad match: EGFR sensitizing mutationCarcinoma, Non-Small-Cell Lung, Neoplasm Metastasis

A Phase 1b Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) Combined With Docetaxel in Subjects With Recurrent Previously Treated Locally Advanced or Metastatic NSCLC

Terminated Phase 1 Halozyme Therapeutics Started 2015 NCT02346370

PEGylated recombinant human hyaluronidase PH20Docetaxel

Participants that are known to be epidermal growth factor (EGFR)-activating mutation positive must have received an EGFR inhibitor.

Broad match: EGFR sensitizing mutationNon-small Cell Lung Cancer

Study of the Safety, Pharmacokinetics and Antitumor Activities of BGB-A317 in Participants With Advanced Tumors

Completed Phase 1 BeOne Medicines (BeiGene) Started 2015 NCT02407990

BGB-A317BGB-A317

i. non-small cell lung cancer (participants with documented epidermal growth factor receptor mutation or anaplastic lymphoma kinase rearrangement should have been excluded) ii. ovarian cancer…

Broad match: EGFR mutation (unspecified)Advanced Cancer

Safety, Pharmacokinetic and Preliminary Efficacy Study of AC0010MA in Advanced Non Small Cell Lung Cancer

Terminated Phase 1 ACEA Therapeutics Started 2015 NCT02448251

AC0010MA

Has documented evidence of an activating EGFR mutation in the tumor tissue determined by either sequencing or PCR-based technique (Part 1).

Broad match: EGFR sensitizing mutationNon Small Cell Lung Cancer

A Dose Escalation Study of L-DOS47 in Recurrent or Metastatic Non-Squamous NSCLC

Terminated Phase 1 Helix BioPharma Started 2015 NCT02309892

L-DOS47

EGFR-mutation positive patients must have progressed on or had intolerance to an EGFR small molecule ty…

Broad match: EGFR mutation (unspecified)Non-Small Cell Lung Cancer

A Study of the Combination of Necitumumab (LY3012211) and Pembrolizumab (MK3475) in Participants With NSCLC

Completed Phase 1 Eli Lilly Started 2015 NCT02451930

NecitumumabPembrolizumab

… with EGFR-TKI and ALK inhibitors is mandatory in participants with NSCLC whose tumor has EGFR-activating mutations or ALK translocations, respectively.

Broad match: EGFR sensitizing mutationStage IV Non-Small Cell Lung Cancer

Pacritinib in Patients With Endothelial Growth Factor (EGFR) Mutant Non-small Cell Lung Cancer (NSCLC) After EGFR Tyrosine Kinase Inhibitor (TKI)

Terminated Phase 1 Washington University School of Medicine Started 2015 NCT02342353

PacritinibErlotinib FDA EU

…ogically confirmed metastatic or unresectable locally advanced NSCLC with known sensitive EGFR mutations.

Broad match: EGFR mutation (unspecified)Non-Small Cell Lung Cancer, Nonsmall Cell Lung Cancer, Carcinoma, Non-Small-Cell Lung

A Study of Famitinib Plus Docetaxel in Patients With Advanced Non-squamous and Non-Small Cell Lung Cancer (NSCLC)

Completed Phase 1 Jiangsu Hengrui Started 2015 NCT02364362

famitinib L + docetaxelfamitinib M + docetaxelfamitinib H + docetaxel

Relapse or failure of one first line prior platinum-based chemotherapy;EGFR mutation type previously treated with platinum-based chemotherapy and EGFR inhibitors;

Broad match: EGFR mutation (unspecified)Non-Small Cell Lung Cancer (NSCLC)

Trial of PBF-509 and PDR001 in Patients With Advanced Non-small Cell Lung Cancer (NSCLC)

Completed Phase 1 Palobiofarma SL Started 2015 NCT02403193

PBF-509_80 mgPBF-509_160 mgPBF-509_320 mgPBF-509_640 mgCombo PBF-509 (160 mg) + PDR001Combo PBF-509 (320 mg) + PDR001

EGFR mutation with exon 19 deletion or L858R mutation (Exon 21) or ALK rearrangement positive must have…

Broad match: EGFR mutation (unspecified)Non-small Cell Lung Cancer (NSCLC)

A Phase I Study of Safety and Pharmacokinetics of Volitinib in Combination With Gefitinib in EGFR(+) NSCLC

Completed Phase 1 HUTCHMED Started 2015 NCT02374645

Volitinibgefitinib FDA EU

…e harbouring an EGFR mutation known to be associated with EGFR-TKI sensitivity (including exon 19 deletion, L858R, L861Q, G719X).

Broad match: EGFR exon 19 deletionNon-Small Cell Lung Cancer

Study Evaluating Hemay020 In Subjects With Advanced Solid Cancer

Terminated Phase 1 Tianjin Hemay Pharmaceutical Started 2015 NCT02467569

Hemay020

or advanced or metastatic patients with EGFR mutation after receiving EGFR-TKI and one chemotherapy.

Broad match: EGFR mutation (unspecified)Neoplasms，Non-Small Cell Lung Cancer

Study to Assess the Effect of AZD9291 on the Blood Levels of Rosuvastatin, in Patients With EGFRm+ Non-small Cell Lung Cancer

Completed Phase 1 AstraZeneca Started 2015 NCT02317016

AZD9291 tablet dosingRosuvastatin

…bours an EGFR mutation known to be associated with EGFR TKI sensitivity (including G719X, exon 19 deletion, L858R, L861Q).

Broad match: EGFR exon 19 deletionNon Small Cell Lung Cancer

Study of CLR457 Administered Orally in Adult Patients With Advanced Solid Malignancies

Terminated Phase 1 Novartis Started 2014 NCT02189174

CLR457

… one of the following: confirmed PIK3CA mutation or amplification, PTEN loss of function, EGFR mutation, cMET activation and/or HER2 overexpression.

Broad match: EGFR mutation (unspecified)Advanced Solid Tumor

Erlotinib Hydrochloride in Treating Non-Small Cell Lung Cancer That is Metastatic or Cannot be Removed by Surgery in Patients With HIV Infection

Terminated Phase 1 National Cancer Institute (NCI) Started 2014 NCT02134886

Erlotinib Hydrochloride FDA EU

…CER: trial eligibility will be restricted to those participants whose tumors harbor known EGFR activating mutations

Broad match: EGFR sensitizing mutationHIV Infection, Recurrent Non-Small Cell Lung Carcinoma, Stage IIIA Non-Small Cell Lung Cancer, Stage IIIB Non-Small Cell Lung Cancer

Study to Determine the Effect of Food on the Blood Levels of AZD9291 Following Oral Dosing of a Tablet Formulation in Patients With Non-Small Cell Lung Cancer

Completed Phase 1 AstraZeneca Started 2014 NCT02163733

AZD9291 tablets

…bours an EGFR mutation known to be associated with EGFR TKI sensitivity (including G719X, exon 19 deletion, L858R, L861Q).

Broad match: EGFR exon 19 deletionAdvanced Non Small Cell Lung Cancer, Advanced (Inoperable) Non Small Cell Lung Cancer

Study to Assess the Effect of Itraconazole (a CYP3A4 Inhibitor) on the Pharmacokinetics of AZD9291, in Patients With EGFR Positive Non-small Cell Lung Cancer. Patients Will be Chosen From Those Who Have Already Been Prescribed an EGFR TKI Medicine (Such as Iressa or Tarceva)

Completed Phase 1 AstraZeneca Started 2014 NCT02157883

AZD9291Itraconazole

…bours an EGFR mutation known to be associated with EGFR TKI sensitivity (including G719X, exon 19 deletion, L858R, L861Q).

Broad match: EGFR exon 19 deletionAdvanced Non Small Cell Lung Cancer, Advanced (Inoperable) Non Small Cell Lung Cancer

Icotinib and Arsenic Trioxide in Treating Non-small-cell Lung Cancer Patients With Resistance to EGFR-TKI

Unknown status Phase 1 Betta Pharmaceuticals Started 2014 NCT02066870

IcotinibArsenic trioxide

Histologically or cytologically confirmed stage IIIB/IV lung cancer with EGFR mutation

Broad match: EGFR mutation (unspecified)Non-small Cell Lung Cancer

Study to Assess the Effect of Rifampicin on Blood Levels and Safety of AZD9291, in Patients With EGFRm+ NSCLC

Completed Phase 1 AstraZeneca Started 2014 NCT02197247

RifampicinAZD9291 tablet dosing

…bours an EGFR mutation known to be associated with EGFR TKI sensitivity (including G719X, exon 19 deletion, L858R, L861Q).

Broad match: EGFR exon 19 deletionNon Small Cell Lung Cancer

Study to Assess the Effect of AZD9291 on the Blood Levels of Simvastatin in Patients With EGFRm+ NSCLC

Completed Phase 1 AstraZeneca Started 2014 NCT02197234

SimvastatinAZD9291 tablet dosing

…bours an EGFR mutation known to be associated with EGFR TKI sensitivity (including G719X, exon 19 deletion, L858R, L861Q).

Broad match: EGFR exon 19 deletionNon Small Cell Lung Cancer

Ph 1 Study in Subjects With Tumors Requiring Arginine to Assess ADI-PEG 20 With Pemetrexed and Cisplatin

Terminated Phase 1 Polaris Group Started 2014 NCT02029690

ADI-PEG 20

…ot been treated with prior chemotherapy or immunotherapy, except that NSCLC subjects with EGFR mutant or ALK positive must have had an EGFR tyrosine kinase inhibitor (TKI) or ALK inhibitor an…

Broad match: EGFR mutation (unspecified)Pleural Mesothelioma Malignant Advanced, Peritoneal Mesothelioma Malignant Advanced, Non-squamous Non-small Cell Lung Carcinoma, Uveal Melanoma

A Phase 1b Study of Atezolizumab in Combination With Erlotinib or Alectinib in Participants With Non-Small Cell Lung Cancer (NSCLC)

Completed Phase 1 Roche Started 2014 NCT02013219

AlectinibAtezolizumabErlotinib FDA EU

Participants in Stage 2 (Expansion) receiving erlotinib: i) sensitizing mutation in the EGFR gene and ii) consent to collection of tumor tissue samples before, during, and after trea…

Broad match: EGFR mutation (unspecified)Non-Small Cell Lung Cancer

MEDI4736 (Anti PD-L1) Combined With Gefitinib in Subjects With Non-Small Cell Lung Cancer(NSCLC).

Completed Phase 1 AstraZeneca Started 2014 NCT02088112

Gefitinib FDA EUMEDI4736

…e, histologically or cytologically confirmed locally advanced or metastatic NSCLC that is EGFR mutation positive, naïve to EGFR TKI therapy, and sensitive to EGFR TKIs therapy

Broad match: EGFR mutation (unspecified)Carcinoma, Non-Small-Cell Lung

Safety and Tolerability of a Modified Vaccinia Ankara (MVA)-Based Vaccine Modified to Express Brachyury and T-cell Costimulatory Molecules (MVA-Brachyury-TRICOM)

Completed Phase 1 National Cancer Institute (NCI) Started 2014 NCT02179515

MVA-brachyury- TRICOM

…escence in situ hybridization (FISH+), and erlotinib in epidermal growth factor receptor (EGFR)-mutated lung cancer in the expansion cohort as detailed in section.

Broad match: EGFR mutation (unspecified)Lung Cancer, Breast Cancer, Prostate Cancer, Tumors (Others)

Trial of RNActive®-Derived Cancer Vaccine and Local Radiation in in Stage IV Non Small Cell Lung Cancer (NSCLC)

Terminated Phase 1 CureVac Started 2013 NCT01915524

CV9202

Stratum 3: Non-squamous NSCLC harboring an activating EGFR mutation

Broad match: EGFR sensitizing mutationNon-Small Cell Lung Carcinoma

Low Dose Daily Erlotinib in Combination With High Dose Twice Weekly Erlotinib in Patients With EGFR-Mutant Lung Cancer

Completed Phase 1 Memorial Sloan Kettering Cancer Center Started 2013 NCT01967095

erlotinib FDA EU

Documented presence of EGFR mutation confirmed by MSKCC or a local facility.

Broad match: EGFR mutation (unspecified)EGFR-Mutant Lung Cancer

Phase I Trial of Afatinib (BIBW 2992) and Dasatinib in Non-small Cell Lung Cancer (NSCLC)

Completed Phase 1 H. Lee Moffitt Cancer Center and Research Institute Started 2013 NCT01999985

Dasatinib - 1AAfatinib - 1A FDA EUDasatinib - 1BAfatinib - 1B FDA EU

…h of the following: A tumor which harbors an activating Epidermal Growth Factor Receptor (EGFR) - mutation

Broad match: EGFR mutation (unspecified)Lung Cancer, Non-small Cell Lung Cancer (NSCLC)

Afatinib In Combination With Cisplatin Or Carboplatin + Pemetrexed In Patients With EGFR-Mutant Lung Cancers Undergoing Definitive Chemoradiation

Withdrawn Phase 1 Memorial Sloan Kettering Cancer Center Started 2013 NCT01836341

Afatinib FDA EUCisplatinCarboplatinPemetrexed

Documentation of a sensitizing EGFR mutation

Broad match: EGFR sensitizing mutationNon-small Cell Lung Cancer

A Phase I/IB Trial of MEK162 in Combination With Erlotinib in NSCLC Harboring KRAS or EGFR Mutation

Completed Phase 1 H. Lee Moffitt Cancer Center and Research Institute Started 2013 NCT01859026

MEK162Erlotinib FDA EU

Have a tissue or blood proven KRAS or EGFR mutation confirmed in a Clinical Laboratory Improvement Amendments (CLIA)certified lab (only requi…

Broad match: EGFR mutation (unspecified)Lung Cancer, Non-Small Cell Lung Cancer

Combination Checkpoint Inhibitor Plus Erlotinib or Crizotinib for EGFR or ALK Mutated Stage IV Non-small Cell Lung Cancer

Completed Phase 1 University of Utah Started 2013 NCT01998126

IpilimumabErlotinib FDA EUCrizotinibNivolumab

Non-Small Cell Lung Cancer (NSCLC) that is either EGFR or ALK mutated.

Broad match: EGFR mutation (unspecified)Non-small Cell Lung Cancer

Erlotinib Hydrochloride and Quinacrine Dihydrochloride in Stage IIIB-IV Non-Small Cell Lung Cancer

Completed Phase 1 Neelesh Sharma MD PhD Started 2013 NCT01839955

erlotinib hydrochloride FDA EUquinacrine dihydrochloride - Escalation dosequinacrine dihydrochloride - Extension dose

…atinum-containing regimen for the treatment of advanced or metastatic disease (except for EGFR-mutant patients).

Broad match: EGFR mutation (unspecified)Recurrent Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer

Avelumab in Metastatic or Locally Advanced Solid Tumors (JAVELIN Solid Tumor)

Completed Phase 1 Merck KGaA Started 2013 NCT01772004

Avelumab

No activating epidermal growth factor receptor (EGFR) mutation nor ALK translocation/re-arrangement

Broad match: EGFR mutation (unspecified)Solid Tumors

Safety, Tolerability, and Pharmacokinetics of Multiple Ascending Doses of Simotinib Hydrochloride in Patients With Advanced NSCLC

Unknown status Phase 1 Jiangsu Simcere Pharmaceutical Started 2012 NCT01772732

Simotinib Hydrochloride

EGFR mutation positive (such as E19del、L858R、L861Q、G719X, etc.);

Broad match: EGFR mutation (unspecified)Non-small Cell Lung Cancer

A Study of LY2875358 in Japanese Participants With Advanced Cancer

Completed Phase 1 Eli Lilly Started 2012 NCT01602289

LY2875358Erlotinib FDA EUGefitinib FDA EU

…istologic or cytologic diagnosis of advanced NSCLC with epidermal growth factor receptor (EGFR) activating mutation, Stage IV per the 7th edition of the AJCC Staging Criteria for NSCLC.

Broad match: EGFR sensitizing mutationSolid Tumors, Lymphoma, Carcinoma, Non-Small-Cell Lung

Study of 18F-Fluoro-PEG6-IPQA

Completed Phase 1 M.D. Anderson Cancer Center Started 2012 NCT01320059

18F-PEG6-IPQA

Specifically, they should have known EGFR mutations or high gene copy number.

Broad match: EGFR mutation (unspecified)Lung Cancer

A Clinical Study on the Safety and Efficacy of Debio 0932 in Combination With Standard of Care in Patients With Non-small Cell Lung Cancer [NSCLC]

Terminated Phase 1 Debiopharm International Started 2012 NCT01714037

Debio 0932CisplatinPemetrexedGemcitabineDocetaxel

…quamous or non-squamous tumour histology, without known epidermal growth factor receptor (EGFR) mutation

Broad match: EGFR mutation (unspecified)Non-small Cell Lung Cancer

AMG 595 First-in-Human in Recurrent Gliomas

Completed Phase 1 Amgen Started 2012 NCT01475006

AMG 595

…Pharmacodynamics of AMG 595 in Subjects With Recurrent Malignant Glioma Expressing Mutant Epidermal Growth Factor Receptor Variant III (EGFRvIII)

Broad match: EGFR mutation (unspecified)Advanced Malignant Glioma, Anaplastic Astrocytomas, Glioblastoma Multiforme

Pazopanib, Lapatinib or Trastuzumab in Subjects With Solid Tumors

Completed Phase 1 M.D. Anderson Cancer Center Started 2011 NCT01454804

PazopanibLapatinibTrastuzumab (Herceptin®)Pazopanib

…plification, c-Met mutation, EML4-ALK translocation, or epidermal growth factor receptor (EGFR) mutation.

Broad match: EGFR mutation (unspecified)Advanced Cancers

EGFR Inhibition Using Weekly Erlotinib for Recurrent Malignant Gliomas

Completed Phase 1 Andrew B Lassman, MD Started 2011 NCT01257594

erlotinib FDA EU

…n Using High Dose Administration of Erlotinib Weekly for Recurrent Malignant Gliomas With EGFR Variant III Mutation

Broad match: EGFR mutation (unspecified)Brain Cancer

An Evaluation of the Biodistribution and Imaging Characteristics of ABT-806i (111In-ABT-806) in Subjects With Advanced Solid Tumor Types

Completed Phase 1 AbbVie Started 2011 NCT01472003

ABT-806ABT-806i

…r overexpress wild-type Epidermal Growth Factor Receptor (EGFR) or to express variant III mutant EGFR (e.g., head and neck squamous cell carcinoma, Non-small Cell Lung Carcinoma (NSCLC), and …

Broad match: EGFR mutation (unspecified)Advanced Solid Tumors

Study to Assess Safety, Tolerability and PK of AZD1480 in Patients With Solid Tumours

Terminated Phase 1 AstraZeneca Started 2010 NCT01112397

AZD1480

…Oral Monotherapy in Patients With Advanced Solid Malignancies in the Escalation Phase and EGFR or ROS Mutant NSCLC or Non-Smokers With Lung Metastasis in the Expansion Phase.

Broad match: EGFR mutation (unspecified)Solid Malignancies

A Phase Ib Expansion Study Investigating the Safety, Efficacy, and Pharmacokinetics of Intravenous CUDC-101 in Subjects With Advanced Head and Neck, Gastric, Breast, Liver and Non-small Cell Lung Cancer Tumors

Completed Phase 1 Curis Started 2010 NCT01171924

CUDC-101CUDC-101

A documented mutation in EGFR exons 19 or 21

Broad match: EGFR mutation (unspecified)Head and Neck Cancer, Liver Cancer, Breast Cancer, Gastric Cancer

Trial of Continuous Once Daily Oral Treatment Using BIBW 2992 (Afatinib) Plus Sirolimus (Rapamune®) in Patients With Non-small Cell Lung Cancer Harbouring an EGFR Mutation and/or Disease Progression Following Prior Erlotinib or Gefitinib

Completed Phase 1 Boehringer Ingelheim Started 2009 NCT00993499

BIBW 2992Sirolimus (rapamycin)

are EGFR mutation-positive or

Broad match: EGFR mutation (unspecified)Carcinoma, Non-Small-Cell Lung

Erlotinib and Temsirolimus for Solid Tumors

Completed Phase 1 Washington University School of Medicine Started 2009 NCT00770263

Erlotinib FDA EUTemsirolimus

…sion Phase ONLY): Patients must have tumor harboring PTEN loss, PIK3CA mutation, , and/or EGFR mutation.

Broad match: EGFR mutation (unspecified)Solid Tumors

High Dose Gefitinib for the Treatment of Carcinomatous Meningitis in Adult Patients With Non-Small Cell Lung Cancer and Known or Suspected EGFR Mutations

Completed Phase 1 David M. Jackman, MD Started 2006 NCT00372515

Gefitinib FDA EU

known somatic mutation of the EGFR tyrosine kinase

Broad match: EGFR mutation (unspecified)Non-Small Cell Lung Cancer

A Study to Evaluate the Safety, Tolerance and Initial Efficacy of EGFRvIII CAR-T on Glioblastoma

Unknown status Early Phase 1 Beijing Tsinghua Chang Gung Hospital Started 2023 NCT05802693

Targeted Epidermal Growth Factor Receptor Variant III(EGFRvIII) autochimeric antigen receptor T cell injection

An Open Clinical Study to Evaluate the Safety, Tolerance and Initial Efficacy of Epidermal Growth Factor Receptor Variant III Chimeric Antigen Receptor T(EGFRvIII CAR-T) in the Treatment of Recurrent Glioblastom…

Broad match: EGFR mutation (unspecified)Recurrent Glioblastoma

Pharmacokinetic Boosting of Osimertinib

Completed Early Phase 1 Academisch Ziekenhuis Maastricht Started 2020 NCT03858491

Cobicistat

Patients with EGFR-mutated NSCLC receiving standard treatment with osimertinib for at least 2 months (steady state),…

Broad match: EGFR mutation (unspecified)Non Small Cell Lung Cancer

Effect of NK Cell Immunotherapy on Advanced Lung Adenocarcinoma Adenocarcinoma With EGFR Mutation

Unknown status Early Phase 1 Shenzhen Fifth People's Hospital Started 2018 NCT03662477

NK cells

Effect of NK Cell Immunotherapy on Advanced Lung Adenocarcinoma Adenocarcinoma With EGFR Mutation

Broad match: EGFR mutation (unspecified)NK Cell Mediated Immunity

A Pilot Study of Dacomitinib With or Without Osimertinib for Patients With Metastatic EGFR Mutant Lung Cancers With Disease Progression on Osimertinib.

Completed Early Phase 1 Memorial Sloan Kettering Cancer Center Started 2018 NCT03755102

Dacomitinib FDA EUOsimertinib FDA EU

Somatic activating mutation in EGFR in a tumor biopsy or plasma cfDNA liquid biopsy

Broad match: EGFR mutation (unspecified)EGFR Gene Mutation, Lung Cancer, Lung Cancer Metastatic

Personalized Adaptive Radiation Therapy With Individualized Systemic Targeted Therapy (PARTIST) for Locally Advanced, Non-small Cell Lung Cancer With Genomic Driver Mutations

Withdrawn Early Phase 1 University of Michigan Rogel Cancer Center Started 2015 NCT02277457

Erlotinib FDA EUCrizotinib

Patients with tumors that harbor either EGFR sensitizing mutations or ALK rearrangement.

Broad match: EGFR sensitizing mutationNon-Small Cell Lung Cancer

Feasibility of the Research for Mutation of K-ras and EGFR in CTCs From Metastatic Non Small Cells Bronchial Carcinomas

Terminated Early Phase 1 Centre Georges Francois Leclerc Started 2011 NCT01380795

CTC

Research for mutation of EGFR and Kras made on the primitive tumor

Broad match: EGFR mutation (unspecified)Non-small Cell Lung Cancer Metastatic

Efficacy and Safety of Almonertinib Combined With Stereotactic Body Radiotherapy (SBRT) in the Treatment of Non-small Cell Lung Cancer With EGFR Sensitive Mutation: a Single-arm, Open-label Clinical Trial

Unknown status No phase Chongqing University Cancer Hospital Started 2024 NCT06481566

…agnosed with NSCLC are tested and confirmed to have an EGFR-sensitive mutation (including exon 19 deletion or L858R, either alone or coexisting with mutations in other EGFR loci).

Broad match: EGFR exon 19 deletionNon-small Cell Lung Cancer

Next Generation Sequencing Method for the Detection of EGFR Gene Mutations in the Plasma of Patients With Lung Cancer

Completed No phase Istituto Oncologico Veneto IRCCS Started 2024 NCT06595498

…non-small cell lung cancer at diagnosis or progression who have previously had the cobas® EGFR Mutation Test v2 (Roche) performed on a liquid biopsy with a valid result (positive or negative);

Broad match: EGFR mutation (unspecified)Carcinoma, Non-small Cell Lung Cancer (NSCLC)

SBRT Combined With Osimertinib Compared With Osimertinib for Stage IV NSCLC

Unknown status No phase Li Zhang Started 2023 NCT05583409

Osimertinib 80 MG FDA EU

Patients must has sensitizing EGFR mutation (e.g. exon 19 deletion or exon 21 L858R) 9.

Broad match: EGFR sensitizing mutationStage IV Non-small Cell Lung Cancer

Feasibility of Intratumoral Washing Fluid for Detecting EGFR Mutations in Lung Cancer

Completed No phase Pusan National University Hospital Started 2022 NCT05517083

Patients with the following EGFR gene mutations: E19Del, L858R alone or concurrent rare EGFR gene mutations (T790M, G719X, exon 20 insert…

Broad match: EGFR mutation (unspecified)Non Small Cell Lung Cancer, EGFR Gene Mutation

A Single-arm Exploratory Study of Neoadjuvant Therapy

Unknown status No phase Jun Liu Started 2022 NCT05527808

Tislelizumabpemetrexedcis-platemumor carboplatin

EGFR gene mutation positive (can be tested by tissue or blood samples);

Broad match: EGFR mutation (unspecified)Lung Adenocarcinoma

A Dose Exploration Study of Almonertinib for EGFRm NSCLC Patients With Brain/Leptomeningeal Metastasis (ARTISTRY)

Unknown status No phase Henan Cancer Hospital Started 2021 NCT04778800

almonertinibLM-first line treatmentLM-second line treatment

Tumor tissue samples or blood are confirmed to be EGFR sensitive mutations (including exon 19 deletion or L858R) by ARMS;

Broad match: EGFR exon 19 deletionNSCLC, Brain Metastases, Leptomeningeal Metastasis

Almonertinib With Bevacizumab for EGFR-Mutant NSCLC Patients With Leptomeningeal Metastasis

Unknown status No phase Second Affiliated Hospital of Nanchang University Started 2021 NCT04944069

AlmonertinibBevacizumab

Tumor tissue samples or blood are confirmed to be EGFR sensitive mutations (including exon 19 deletion or L858R).

Broad match: EGFR exon 19 deletionNSCLC, Leptomeningeal Metastasis, EGFR Activating Mutation

Understanding and Overcoming the Early Adaptive Resistance to EGFR Tyrosine-kinase Inhibitors in Lung Cancer Patients

Completed No phase University Hospital, Toulouse Started 2021 NCT04222335

Pathological diagnosis of NSCLC carrying an EGFR activating mutation associated with sensitivity to the tyrosine kinase inhibitors (TKI) (exons 18, 19 and 21)…

Broad match: EGFR sensitizing mutationLung Cancer, Nonsmall Cell

Osimertinib Resistance in Patients With Non-small-cell Lung Carcinoma That Have Progressed.

Unknown status No phase The Netherlands Cancer Institute Started 2019 NCT04737382

Histologically confirmed metastatic NSCLC, characterized by a sensitizing EGFR mutation.

Broad match: EGFR sensitizing mutationNon-small-cell Lung Carcinoma

Adjuvant Chemotherapy With or Without Intercalated Icotinib

Unknown status No phase Nanfang Hospital, Southern Medical University Started 2019 NCT03983811

Icotinib

Adjuvant Chemotherapy of EGFR-Mutated Non-Small Cell Lung Cancer Patients With or Without Intercalated Icotinib Therapy: a Rand…

Broad match: EGFR mutation (unspecified)Carcinoma, Non-Small-Cell Lung

TKI Followed by Thoracic Radiotherapy for Stage IV EGFR Mutant NSCLC

Unknown status No phase Chinese Academy of Medical Sciences Started 2019 NCT03916913

TKI Followed by Thoracic Radiotherapy for Stage IV EGFR Mutant NSCLC

Broad match: EGFR mutation (unspecified)Non-Small Cell Lung Cancer Metastatic

Anlotinib Hydrochloride Combined With EGFR-Tyrosine Kinase Inhibitor (TKI) in Treating Advanced NSCLC Patients With Acquired Resistance to EGFR-TKI

Unknown status No phase Guangdong Association of Clinical Trials Started 2019 NCT04007835

Anlotinib Hydrochloride FDA EU

The patients should be confirmed with EGFR mutation \[e.g., T 790 M , exon 19 deletion, L 858 R, etc\],

Broad match: EGFR exon 19 deletionNSCLC

Satisfaction and Quality of Life Comparison Between Patients Using Cicaplast Baume B5 Versus Dexeryl for the Management of Cutaneous Toxicities Induced by Epidermal Growth Factor Receptor Inhibitors (iEGFR)

Completed No phase Centre Leon Berard Started 2018 NCT03421912

…l cancer with non-mutated RAS gene (wild-type) OR non-small cell lung cancer (NSCLC) with EGFR activating mutations.

Broad match: EGFR sensitizing mutationHead and Neck Squamous Cell Carcinoma, Colorectal Cancer, Non Small Cell Lung Cancer, Epidermal Growth Factor Receptor Inhibitor

Phase I Study of the Combination of Anlotinib With Gefitinib

Unknown status No phase Second Affiliated Hospital of Nanchang University Started 2018 NCT03602027

AnlotinibGefitinib FDA EU

Epidermal Growth Factor Receptor(EGFR)mutations confirmed by molecular detection (including, but not limited to, 20 exon, 19 exon deletio…

Broad match: EGFR mutation (unspecified)Non-squamous Non-small Cell Lung Cancer

Precision Immuno-Oncology for Advanced Non-small Cell Lung Cancer Patients With PD-1 ICI Resistance (PIONeeR-BioMarkers (BM) Profiling)

Unknown status No phase Assistance Publique Hopitaux De Marseille Started 2018 NCT03493581

…ients registered for a 2nd or 3rd line, those with known actionable molecular alteration (EGFR activating mutation, ALK rearrangement, ROS1 rearrangement) should have received a specific inhibitor

Broad match: EGFR sensitizing mutationNon-small Cell Lung Cancer Patients

Non Squamous NSCLC Patients With Anlotinib Combined With Pemetrexed and Cisplatin

Unknown status No phase Lingyu Luo Started 2018 NCT03671538

AnlotinibpemetrexedCisplatin

EGFR mutations confirmed by molecular detection (including, but not limited to, T790M, 19 exon deletion …

Broad match: EGFR mutation (unspecified)Non-squamous Non-small Cell Lung Cancer

Optimizing the Therapeutic Dose of Apatinib Mesylate Tablets in Patients With Lung Cancer by Dose Titration：A Real World Exploratory Study

Unknown status No phase Beijing Chest Hospital Started 2018 NCT03594682

… wild type EGFR/ALK must received two kinds of systemic chemotherapy before；Patients with EGFR mutation positive had experienced treatment failure with TKI in first line and Chemotherapy in sec…

Broad match: EGFR mutation (unspecified)NSCLC Stage IV, NSCLC Stage IIIB

Consistency Analysis of PD-L1s in Advanced NSCLC Tissues and in Plasma Exosomes Before and After Radiotherapy

Completed No phase Xinqiao Hospital of Chongqing Started 2017 NCT02869685

Sensitive mutant EGFR, but refused to targeted therapy;

Broad match: EGFR mutation (unspecified)NSCLC

IMRT and Timing in Combination With EGFRTKI for Stage IV Non-small-cell Lung Cancer

Unknown status No phase LuBing Started 2017 NCT03258671

EGFR-TK Inhibitor

…y or cytologically confirmed stage IV NSCLC\[UICC 2017 8th edition\] with known sensitive EGFR mutations(confirmed by tissue or blood).

Broad match: EGFR mutation (unspecified)Non-Small Cell Lung Cancer, Nonsmall Cell Lung Cancer, Carcinoma, Non-Small-Cell Lung

AST2818 in Advanced Non-Small Cell Lung Cancer With EGFR Mutations

Terminated No phase Allist Pharmaceuticals Started 2017 NCT03127449

Alflutinib

…tation known to be associated with EGFR TKI sensitivity (including at least one of G719X, exon 19 deletion, L858R, L861Q mutation)

Broad match: EGFR exon 19 deletionAdvanced NSCLC

Analysis of Re-biopsy Specimens in Advanced NSCLC With Acquired Resistance of EGFR-TKI Targeted Therapy

Completed No phase Shanghai Chest Hospital Started 2017 NCT03309462

EGFR mutations were confirmed by molecular pathology.

Broad match: EGFR mutation (unspecified)Lung Cancer

A Positron Emission Tomography (PET) Imaging Agent [18F]-ODS2004436 as a Marker of EGFR Mutation in Subjects With NSCLC

Completed No phase Centre Georges Francois Leclerc Started 2016 NCT02847377

EGFR activating mutation (All mutations: 719, 790, 861, 858 or del exon 19 and exon 20),

Broad match: EGFR sensitizing mutationCarcinoma, Non-Small-Cell Lung

Metformin Plus TKI Use in Patients With Non-Small Cell Lung Carcinoma

Unknown status No phase Instituto Nacional de Cancerologia de Mexico Started 2016 NCT03071705

MetforminTKI FDA EU

NSCLC EGFR mutation-positive

Broad match: EGFR mutation (unspecified)Non-Small Cell Adenocarcinoma, Tyrosine Kinase Mutation, EGFR Gene Mutation

Correlation Between Tissue and Plasmatic EGFR in CBNPC With EGFR Mutation or Predictive Factor of EGFR Mutation

Terminated No phase Centre Oscar Lambret Started 2016 NCT03265496

1st line treatmentBiopsy

With: - EGFR gene mutation

Broad match: EGFR mutation (unspecified)Nsclc

Local Therapies for Oligometastatic Non-Small Cell Lung Cancer Harboring Sensitizing EGFR Mutations

Completed No phase Memorial Sloan Kettering Cancer Center Started 2015 NCT02450591

Erlotinib FDA EU

Local Therapies for Oligometastatic Non-Small Cell Lung Cancer Harboring Sensitizing EGFR Mutations

Broad match: EGFR sensitizing mutationOligometastatic Lung Adenocarcinoma

NGS Genome Analysis in Personalisation of Lung Cancer Treatment

Completed No phase Centre Georges Francois Leclerc Started 2014 NCT02281214

… benefit from first-line therapy - targeted therapy by tyrosine kinase inhibitor(TKI) for EGFR mutation and chemotherapy for non EGFR mutation)

Broad match: EGFR mutation (unspecified)Lung Cancer

Blood Detection of EGFR Mutation For Iressa Treatment

Unknown status No phase Peking University Cancer Hospital & Institute Started 2014 NCT02282267

Gefitinib FDA EU

EGFR sensitive mutation (including exon 19 del and/or exon 21 L858R) in plasma cf-DNA by ddPCR.

Broad match: EGFR exon 19 deletionLung Adenocarcinoma

Combination of Chemotherapy and Gefitinib as First-line Treatment

Completed No phase Baohui Han Started 2014 NCT02148380

pemetrexed plus carboplatingefitinib FDA EU

…tinib as First-line Treatment of Patients With Advanced Lung Adenocarcinoma and Sensitive EGFR Mutations: a Randomised Controlled Trial

Broad match: EGFR mutation (unspecified)Non-Small-Cell Lung Cancer

Assess the Efficacy of Whole Brain Radiation Therapy in Lung Cancer Patients With Brain Metastasis

Terminated No phase Assistance Publique - Hôpitaux de Paris Started 2012 NCT01363557

Gefitinib (IRESSA) FDA EU

Activating mutation of EGFR

Broad match: EGFR mutation (unspecified)EGFR-mutated Lung Adenocarcinoma, Brain Metastasis

Understanding Mechanisms of Acquired Resistance to BIBW2992

Completed No phase Massachusetts General Hospital Started 2011 NCT01074177

BIBW 2992 FDA EU

A somatic mutation in epidermal growth factor receptor (EGFR) must be present as documented by a CLIA-certified laboratory

Broad match: EGFR mutation (unspecified)Non-small Cell Lung Cancer, EGFR Mutations

e- Ab Sensor-based Real-time Detection of Mutant EGFR in Clinical Specimens From Patients of Non-small Cell Lung Cancer

Unknown status No phase National Taiwan University Hospital Started 2010 NCT01359436

e- Ab Sensor-based Real-time Detection of Mutant EGFR in Clinical Specimens From Patients of Non-small Cell Lung Cancer

Broad match: EGFR mutation (unspecified)Non-small Cell Lung Cancer (NSCLC)

Tailored Second Line Treatment by Epidermal Growth Factor Receptor (EGFR) Mutation in Patients With Advanced Lung Adenocarcinoma

Unknown status No phase National Cheng-Kung University Hospital Started 2009 NCT00903292

erlotinib (Tarceva) FDA EUpemetrexed (Alimta)

Tailored Second Line Treatment by Epidermal Growth Factor Receptor (EGFR) Mutation in Patients With Advanced Lung Adenocarcinoma

Broad match: EGFR mutation (unspecified)Non-Small Cell Lung Cancer

Bone Metastasis on the Survival of Gefitinib Effective Patients

Completed No phase Qilu Hospital of Shandong University Started 2009 NCT03157310

Gefitinib FDA EU

4. whether patient was detected for EGFR gene mutation was not restricted.

Broad match: EGFR mutation (unspecified)Overal Survival, Non-small Cell Lung Cancer

Detection of EGFR Mutation in Malignant Pleural Effusion of Lung Cancer Patients and Cancer Cell Lines Establishment

Unknown status No phase National Taiwan University Hospital Started 2008 NCT00752076

Detection of EGFR Mutation in Malignant Pleural Effusion of Lung Cancer Patients and Cancer Cell Lines Establishment

Broad match: EGFR mutation (unspecified)NSCLC

Individualized Treatment Based on Epidermal Growth Factor Receptor Mutations and Level of BRCA1 Expression in Advanced Adenocarcinoma

Completed No phase Spanish Lung Cancer Group Started 2005 NCT00883480

DocetaxelCisplatinGemcitabineErlotinib FDA EU

Individualized Treatment Based on Epidermal Growth Factor Receptor Mutations and Level of BRCA1 Expression in Advanced Adenocarcinoma

Broad match: EGFR mutation (unspecified)Non-small Cell Lung Cancer

Approved therapies

Companies

Trials